5-(substituted phenyl)-3-substituted-1,2,3-triazolo[4,5-b]pyridine compounds

222977/3 5-(substituted phenyl)-3-substituted-1,2,3-triazolo[4,5-b]pyridine compounds

FIELD OF THE INVENTION

[02] THe present invention provides, inter alia, compounds oF FormuLa I as protein Kinase moDuLaTors, meTHoDs oF preparing THem, pHarmaceuTIcaL compositions conTAininG THem anD meTHoDs oF Treatment, prevention anD/or amelioration oF Kinase meDIaTeD Diseases or DIsorDers wITH THem.

BACKGROUND OF THE INVENTION

[03] In THe recent past Immense research Has Been DeDIcaTeD To THe Discovery anD unDersTanDIng oF THe sTrucTure anD Functions oF enzymes anD BIo-moLecuLes associated wITH various Diseases. One sucH Important cLass oF enzymes THaT Has Been THe suBJecT oF extensive research Is ProTeIn Kinase.

[04] In general, proTein Kinases represent a seT oF sTrucTuraLLy reLaTeD pHospHorYL TransFerases, Having conserved structures anD caTaLyTIc Functions. THese enzymes moDIFy ProTeIns Βγ cHemicaLLy aDDIng pHospHATe Groups (pHospHoRYLATion). PHospHoryLaTIon InvoLves THe removal oF a pHospHATe Group From ATP anD covaLenTLy aTTacHIng IT To amino acIDs THaT Have a Free HyDroxyL Group sucH as serine, THreonIne or Tyrosine. PHospHoryLaTIon usuaLLy resuLTs In a Functional cHange oF THe Target proTein (suBsTraTe) Βγ altering enzyme activity, ceLLuLar Localization or association wITH oTHer proTeins. Up To 30% oF aLL proTeins may Be Modified Βγ Kinase activity.

[05] THIs cLass oF proTeins are cLassIFIeD InTo suBseTs DepenDIng upon THe suBsTraTe THey act upon sucH as Tyrosine Kinase, serIne/THeronine Kinase, HIsTIDIne Kinase anD THe LIKe. THese proTeins can aLso Be cLassIFIeD BaseD on THeIr Localization InTo recepTor Tyrosine Kinases (RTKs) or νον-recepTor Tyrosine Kinases. 1 2229T7I2 [06] Receptor Tyrosine Kinases (RTKs) Have an exTraceLLuLar portion, a TransmemBrane Domain, anD an intracellular portion, while non-recepTor Tyrosine Kinases ate entirely inTraceLLuLar. Receptor Tyrosine Kinase meDiaTeD signaI TransDucTion is typically iNiTiaTeD By an exTraceLLuLar Interaction with a specific Growth Factor (IiganD), FoLLoweD By receptor DImerIzaTIon, sTImuLaTIon oF The InTrInsIc proTein Tyrosine Kinase AcTiviTy, anD pHosphoRyLATioN oF amino acID resIDues. The ensuing conFormaTIonaL cHange LeaDs To The Formation oF complexes with a specTruM oF cytoplasMic signalling moLecuLes anD FacILITaTes a myriaD oF responses such as ceLL DIvIsIon, DIFFERENTIATION, meTaBoLIc eFFecTs, anD chanGes In The exTraceLLuLar mIcroenvironmenT.

[07] AT present, at Least Twenty (20) DIsTIncT RTK suBFamILIes have Been IDenTIFIeD. One suBFamILy oF the RTKs Is DesiGNAteD as the Met suBFamILy (c-Met, Ron anD Sea). For a DetaiLeD Discussion oF proteiN Kinases, see, PLowman et aL., DN&P 7(6): 334-339, 1994, BLume- Jensen, P. et aL., Nature 2001, 411(6835):355-365 anD Manning, G. et aL., Science. 2002, 298(5600): 1912- 1934.

[08] Kinases have also Been cLassIFIeD eitheR BaseD on the pathway or the Diseases In which they are InvoLveD (visit:www.ReACtioNBioloGy.coM/pAGes/KiNAse.htM). c-Met has Been IDeNtifieD as InvoLveD In oncogenesis.

[09] ProteiN Kinases exert their physioLoGicaL Functions throuGh phosphoRYLatioN oF proteiNs (or suBstRates) theReBy MoDulatiNG the ceLLuLar activitlES oF the suBstrate In various BIoLogIcaL contexts. PROtein Kinases are Known to control a wiDe vaRiety oF BIoLogIcaL processes such as ceLL Growth, survival anD DiFFERENtiatioN, organ Formation anD MORphoGENEsis, NEOVASCuLARlsAtloN, tissue Repair anD regeneration. In aDDItioN to their Functions In norMaL tissues/oRGANS, Many proteiN Kinases also pLay specIaLIzeD roles In a host oF huMAN Diseases IncLuDIng cancer. A suBset oF proteiN Kinases (also reFeRreD to as oncoGenic proteiN Kinases), when DysreGuLateD, can cause tuMor Formation anD Growth anD coNtriBute to tuMor MaiNteNANce anD progression (BLuMe- Jensen P et al, Nature 2001, 411(6835):355-365). Thus Far, oncogenic proteiN Kinases RepreseNt one oF the larGest anD Most attractive Groups oF proteiN tarGets For theRApeutic iNteRveNtioN anD Drug DevelopMeNt.

[10] Both receptor anD NON-receptor proteiN Kinases have Been FounD to Be AttRACtive tARGets For smaII Molecule Drug Discovery Due to their iMpact on cell physioloGY anD siGNalliNG. DysReGulatioN oF proteiN Kinase activity thus leaDs to AltereD cellular 2 2229T7I2 responses IncLuDIng unconTroLLeD ceLL growth associated wITH cancer. In aDDITIon To oncoLogicaL indications, aLTereD Kinase signalling is ImpLIcaTeD in numerous oTHer PaTHoLogicaL Diseases. THese IncLuDe, BuT are not LimiTeD To ImmunoLogicaL Disorders, carDIovascuLat Diseases, InFIammaTory Diseases, anD Degenerative Diseases.

[11] A significant numBer oF Tyrosine Kinases (BoTH receptor anD nonrecepTor) are associated wITH cancer (see MaDHusuDan S, Ganesan TS. TyrosiNE Kinase InHIBITors In cancer THerapy. CLIn. BIocHem. 2004, 37(7):618-35.). CLInIcaL sTuDIes suggest THaT over expression or DysREGuLATioN oF TyrosiNE Kinases may aLso Be oF prognostic vaLue. For exampLe, memBers oF THe HER FamILy oF RTKs Have Been ImpLIcaTeD In BreasT, coLorecTaL, HeaD anD necK anD Lung cancer. MuTaTIon oF c-KIT TyrosiNE Kinase Is associated wITH Decreased survival In GAsTroInTesTInaL sTromaL Tumors (GIST). In acuTe myeLogenous LeuKemIa, FLT-3 muTaTIon PteDIcTs sHorTer Disease Free survival. VEGFR expression, wHIcH Is Important For Tumor angiogenesis, Is associated wITH a Lower survival raTe In Lung cancer. TIe-1 Kinase expression Is Inversely corteLaTeD To survival In gasTric cancer. BCR-ABI expression Is an Important PteDIcTor oF response In cHronic myeLogenous LeuKemIa wHILe Src TyrosiNE Kinase expression Is co-reLaTeD To THe stage oF coLorecTaL cancer.

[12] MoDuLaTIon (parTIcuLarLy InHIBITIon) oF ceLL proLIFeraTIon anD angiogenesis, THe Two Key ceLLuLar processes neeDeD For Tumor gtowTH anD survival Is an attractive goaL For Development oF smaLL-moLecuLe Drugs (MaTTer A. Drug Disc TecHnoL 2001, 6, 1005-1024). AnTI- angiogenic THerapy represents a poTENTiALLy Important approach For THe Treatment oF soLID Tumors anD oTHer Diseases associated wITH DysreguLaTeD vascuLarisaTIon IncLuDIng IscHemIc coronary arTery Disease, DIaBeTIc RETiNopATHy, psoriasis anD rHeumaToID arTHrITIs. SImILatLy, ceLL anTIproLIFeraTIve agents ate DesIraBLe To sLow or InHIBIT THe gtowTH oF Tumors.

[13] Some oF THe Kinases ImpLIcaTeD In cancer ate c-Met, RON (recepteur d"origine nanTais) RECEpTor, VascuLar EnDoTHeLIaL GrowTH Factor (VEGF) RECEpTor, EpIDErmAL gtowTH Factor RECEpTor Kinase (EGF-R Kinase), EpH receptors, c-KIT, anD FLT-3.

[14] A numBer oF smaLL moLecuLe Kinase moDuLaTors Have FounD THeIr way InTo THe cLInic wHIcH eITHer acT seLecTIveLy on eITHer one or muLTipLE Kinases. THese IncLuDe GeFITInIB (AstraZeneca), a EGFR Kinase InHIBITor; GLeevec (NovarTIs), a DuaL c-KIT anD ABI Kinase InHIBITor approved For THe Treatment oF CHronic MyELoID LeuKemIa (CML) anD GAsTroInTesTInaL sTroma cancers; DasaTInIB (BMS), a DuaL BCR/ABL anD Src FamILy TyrosiNE 3 2229T7I2

Kinases inhibitor. anD Sunitinib (PFIzer) a Multi Kinase inhibitor Targeting PDGF-R,VEGF-R, RET, KIT(CD117), CSF-1R anD Flt-3.

[15] THe Kinase, c-MeT, is THe prototYpic memBer oF a subFamilY oF HeTeroDImerIc RECEptor Tyrosine Kinases (RTKs) which IncIuDe MeT, Ron anD Sea (see BircHMEiER, C. eT al., NaT. Rev. Mol. CeII Biol. 2003, 4(12):915-925; CHrIsTensen, J. G. eT al., Cancer LeTT. 2005, 225(1): 1-26). Expression oF c-MeT occurs In a wIDe variety oF ceII Types IncIuDIng epITHeIIaI, enDoTHeIIaI anD mesencHymaI ceIIs wHere acTIvaTIon oF THe RECEptor InDuces ceII migration, Invasion, proIIFeraTIon anD oTHer BIoIogIcaI acTIvITIes associated with "Invasive ceII GROWTH." As such, signaI TransDucTIon THrougH c-MeT RECEptor acTIvaTIon Is REsponsiblE For many oF THe characteristics oF Tumor ceIIs.

[16] THe onIy HIgH aFFInITy endogenous IIganD For c-MeT Is THe HepaTocyTe Growth Factor (HGF), also Known as scatter Factor (SF). BInDIng oF HGF To c-MeT InDuces acTIvaTIon oF THe RECEpTor via AuTopHospHoRYlaTioN resuITIng In an Increase oF RECEptor DepenDenT signaIIIng, which promotes ceII Growth anD Invasion. Both c-MeT anD HGF arE wIDeIy expressed in a variety oF organs, but THeIr expression is normaIIy conFIneD To ceIIs oF EpiThElial anD mesencHymaI origin. AnTI-HGF ANtiboDiES or HGF antagonists Have Been shown To iNHibit Tumor meTasTasis in vivo (See: MauliK Et al CyToKIne & Growth Factor Reviews 2002, 13, 41-59). THe bioloGical Functions oF c-MeT (or c-MeT signaIIIng pathwaY) in normal Tissues anD Human maIIgnancies such as cancer Have Been weII Documented (CHrIsTensen, J.G. eT al., Cancer LeTT. 2005, 225(1): 1-26; Corso, S. Et al., TrenDs In Mol.

MeD. 2005, ll (6):284-292).

[17] Tumor Growth progression InvoIves THe recruITmenT oF new blooD vesseIs into THe Tumor as weII as Invasion, aDHesion anD proIIFeraTIon oF maIIgnanT ceIIs. c-MeT over expression Has Been DemonsTraTeD on a wIDe variety oF Tumor Types IncIuDIng brEast, colon, renaI, Iung, squamous ceII myeIoID IeuKemIa, Hemangiomas, meIanomas, asTrocyTomas, anD GlioblastOMAS. ADDITIonaIIy acTIvaTIng muTaTIons In THe Kinase Domain oF c-MeT Have Been IDenTIFIeD In HereDITary anD sporaDIc renaI papilloma anD squamous ceII carcinoma. See MauliK Et al CyToKIne & Growth Factor reviews 2002, 13, 41-59; LongaTI eT al Curr Drug Targets 2001, 2, 41-55; FunaKosHI eT al Clinica CHImIca Acta 2003 1-23. Thus moDuIaTIon oF c-MeT oFFers an aTTracTIve opportunity To Target Key oncogenic processes thus IImITIng ceII ProIIFeraTIon, survival anD meTasTasIs. 4 2229T7I2 [18] DysreguLaTeD c-MeT pathway is IInKeD To Tumor Formation, growth, maintenance anD progression (BircHmeier, C. eT aL., NaT. Rev. Mol. CeLL. Biol. 2003, 4(12):915-925; Boccaccio, C. eT aL., NaT. Rev. Cancer 2006, 6(8):637-645; CHristensen, J.G. eT aL., Cancer LeTT. 2005, 225(1): 1-26). HGF anD/or c-MeT are over expressed in significant PORTIONS oF MOST HUMAN CANCERS, AND ARE OFTEN ASSOCIATED WITH pOOR CLINICAL OUTCOMES SUCH AS more aggressive Disease, Disease progression, Tumor meTasTasis anD sHorTeneD paTienT survival. FurTHer, paTIenTs wITH HIgH LeveLs oF HGF/c-MeT proteins are more resistant To cHemoTHerapy anD raDIoTHerapy. In aDDITIon To aBnormaL HGF/c-MeT expression, THe c-MeT receptor can aLso Be acTIvaTeD In cancer pAtients THrougH geneTic muTaTIons (BoTH germLIne anD somaTIc) anD gene amplification. ALTHougH gene amplification anD muTaTIons are THe most common geneTIc alterations THaT Have Been reported In paTIenTs, THe receptor can aLso Be acTIvaTeD Βγ DeLeTIons, Truncations, anD gene rearrangement, as weLL as abnormal receptor PROCESSING anD DEFECTIVE NEGATIVE REGULATORY mecHanisms.

[19] THe various cancers In wHIcH c-MeT Is ImpLIcaTED IncLuDe BuT are noT LImITeD To carcinomas (e.g., BLaDDer, Breast, cervicaL, cHoLangIocarcinoma, coLorecTaL, esopHageaL, Gastric, HeaD anD necK, KIDney, Liver, Lung, nasopHarygeaL, ovarian, pancreas, prosTaTe, THyroID); muscuLosKeLeTaL sarcomas (e.g., osteosARCAoma, synovial sarcoma, rHaBDomyosarcoma); soFT Tissue sarcomas (e.g., MFH/FIBrosarcoma, Leiomyosarcoma, Kaposi's sarcoma); HeMATopoieTlc maLIgnancies (e.g., muLTipLe myeLoMA, LympHomas, aDuLT T ceLL LeuKemIa, acuTe myeLoGenous LeuKemIa, cHronic myeLoID LeuKemIa); anD oTHer Neoplasms (e.g., gLIoBLasTomas, asTrocyTomas, meLanoma, mesotHeLIoMA anD WiLm's Tumor (www.vaI.org/meT/; CHrIsTensen, J.G. et aL., Cancer Lett. 2005, 225(1): 1-26). c-Met InHIBITors may also Be useFuL in pReveNtATive anD aDJuvanT THerapy settiNGS. In aDDITIon, certAin cancers (e.g., pApILLAry renal ceLL carcinoma, anD some gasTric anD Lung cancers) may Be TreaTeD witH c-Met InHIBITors as THey are BeLIeveD To Be Driven By c-Met muTaTIon/geneTIc alteration anD DepenDeNt on c-Met For growtH anD survival· THese cancers are expecteD To Be sensITIve To TrEATmenT.

[20] THe notion THat acTIvaTeD c-Met conTrIBuTes To Tumor Formation anD Progression anD coulD THereFore Be a potentiAl tARget For eFFective cancer Intervention Has Been FurTHer vaIIDaTeD By numerous precIInIcaI stuDIes (BircHmeier, C. et al., Nat. Rev. Mol. Cell Biol. 2003, 4(12):915-925; CHrIsTensen, J.G. et al., Cancer Lett. 2005, 225(1): 1-26; Corso, S. et al., TrenDs in Mol. MeD. 2005, 11(6):284- 292). For example, stuDIes Have 5 2229T7I2

Demonstrated THaT THe Tpr-MET Fusion gene, ovet ExpressioN oF c-MeT, anD acTIvaTeD c-MeT mutations causeD oncogenic TrANsFormATioN oF vatious moDeL ceLL Lines anD tesuLTeD in Tumor FormATioN anD meTasTasis In mice. ConvetseLy, sIgnIFIcanT anTI-Tumot anD anTI-meTasTasIs acTIvITIes Have Been DemonsTtaTeD in viTro anD in vivo wiTH agents THaT speciFicaLLy Impair anD/ot BLocK HGF/c-MeT signalling. THose agents IncLuDe anTI-HGF anD anTI-c-MeT anTIBoDIes, HGF pEpTiDE antagonists, Decoy c-MeT tecepTot, c-MeT pEpTiDE antagonists, Dominant negative c-MeT muTaTIons, c-MeT spEcIFIc anTIsense oLIgonucLeoTIDes anD tIBozymes, anD seLecTIve smaLL moLecuLe c-MeT Kinase InHIBITots (CHtIsTensen, J.G. eT aL., Cancet LeTT. 2005, 225(1): 1-26). In aDDITIon To ITs esTaBLIsHeD toLe In cancet, aBnotmaL HGF/c-MeT signalling Is aLso ImpLIcaTED In aTHetoscLetosis, Lung FIBrosis, tenaL FIBrosis anD tegenetaTIon, LIvet Diseases, aLLetgic DIsotDets, InFIammaToty anD autoimmune DIsotDets, ceteBtovascuLat Diseases, catDIovascuLat Diseases, anD conditions associated wiTH otgan TtanspLanTaTIon. See Ma, H. eT aL., ATHetoscLetosis. 2002, 164(L):79-87; CtesTanI, B. eT aL., LaB. Invest. 2002, 82(8): 1015-1022; Sequta-FLotes, A.A. eT aL., Rev. GasTtoenTetoL. Mex. 2004, 69(4)243-250; MotIsHITa, R. eT aL., Cutt. Gene THet. 2004, 4(2)199-206; MotIsHITa, R. eT aL., EnDoct. J. 2002, 49(3)273-284; Liu, Y., Curr. OpiN. NEpHroL. HypetTens. 2002, L L (L):23-30; MaTsumoTo, K. eT aL., KIDney InT. 2001, 59(6):2023-2038; BaLKoveTz, D.F. eT aL., InT. Rev. CyToL. 1999, 186:225-250; MIyazawa, T. eT aL., J. CeteB. BLooD FLow MeTaB. 1998, 18(4)345-348; KocH, A.E. eT aL., ArTHrlTis RHeum. 1996, 39(9):1566-1575; FuTamaTsu, H. eT aL., CItc. Res. 2005, 96(8)823- 830; EgucHI, S. eT aL., CLIn. TtanspLanT. 1999, 13(6)536-544.

[21] c-MeT Is THus an aTTtacTIve TatgeT From a cLInicaL pErspEcTivE mainLy Because oF ITs upsTrEAM Localisation wHIcH aIDs In eatLy Detection anD LImITIng meTasTasis anD Implications In THe gtowTH anD meTasTases oF most Types oF cancets. THese oBsetvaTIons suggest THaT c-MeT Kinase InHIBITots wouLD Be an eFFecTIve TteaTmenT For Tumors DtIven Βγ c-MeT, anD aLso wouLD ptevenT DIssemInaTeD mictomeTasTases From FutTHet ptogtession.

[22] A FamILy oF noveL compouNDs Have Been DIscoveteD wHIcH exHIBIT c-MeT moDuLaTIng aBILITy anD Have an ameLIotaTIng eFFecT against DIsotDets teLaTeD To aBnotmaL c-Met activity such as Johnson & Johnson"s JNJ-38877605, Amgen"s AMG-458, Eisai"s E-7050 and Pfizer"s PF-04217903. Howevet, To DaTe, none oF THem Have Been useD In a cLInicaL sTuDy. 6 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD00021.tif" id="idf0001" />

[23] More recently Dussault et. al., Anti-Cancer Agents in Medicinal Chemistry, 2009, 9(2), 221-229, have provided additional insight about a receptor tyrosine kinase namely, RON (recepteur d"origine nantais) which is closely related to c-Met. Both c-MET and RON receptors upon activation can induce cell migration, invasion, proliferation and survival. Moreover, both possess oncogenic activity in vitro and in vivo and are often dysregulated in human cancers.

[24] While c-Met is now a well-accepted target for anti-cancer treatment, less is known about the role of RON in cancer. Despite their common attributes, c-Met and RON are activated by different mechanisms in cancer cells. Due to a significant homology between the two RTKs, some small molecule kinase inhibitors of c-Met have inhibitory activity on RON suggesting that both receptors might be involved in cancer progression. The review (Dussault et al., supra) discusses the relevance of both c-Met and RON deregulation in human cancers and the progress made in identifying small molecule kinase inhibitors that can block the activity of these targets in vitro and in animal models. One of the compounds discussed in the review, AMG-458, inhibited c-Met and RON with IC50S of 4 and 9 nM respectively.

[25] Various research groups around the world such as Amgen, Arquel, AstraZeneca, Bristol-Myers Squibb, Exelixis, Eisai, Incyte, MethylGene, Pfizer, SGX Pharma, SmithKline Beecham, Schering, Vertex, Xcovery, Novartis and others have been working on targeting either single, dual or multiple kinase targets. 7 222977/3

[26] Patent literature Belonging To some oF THese applicants include tHe FollowinG

PaTenTs and/or patent applications: US 7,446,199; US 7,470,693; US 7,459,562; US 7,439,246; US 7,432 ,373; US 7,348,325; US 7,173,031; US 7,314,885; US 7,169,800; US 20100105656, US20090012076; US20080312232; US20080161305; US20070244116; US20070225307; US20070054928; US20070179130; US20070254868; US20070191369; US20060173055; US20060135537; US20050148574; US20050137201; US20050101650; WO2009002806; WO2008088881; WO2008051805; WO2008102870; WO2008078085; WO2008060866; WO200854702; WO2008036272; WO2007111904; WO2007064797; WO2006052913 ;WO2006021881; WO2006021886; WO2006021884; WO2006108059; WO2006014325; WO2006052913; WO200507891; WO2005030140; WO2005040345; WO2005028475; WO2005016920.

[27] Recent PCT patent appLicaTions viz., WO2009058728, WO2009058729, WO2009058730 and WO2009058739 all assiGned To ScHerinG corporaTion disclose a series oF THIazoLe carBoxaMlde coMpounds as proTein Kinase InHIBiTors and more specIFIcaLLY To Be Inhibiting Aurora, MEK1 and/or CDK2 Kinases.

[28] FurTHer review and LiTeraTure discLosure on proTein Kinase Molecules Have Been Given Βγ IsaBeLLe DussauLT et.al.,(see; AnTi-Cancer AGenTs in MedicinaL CHemistrY, 2009, 9, 221-229) , Ted L. Underiner et.al.,(see; AnTi-Cancer AGenTs in MedicinaL CHeMisTrY, 2010, 10, 7-27) and STepHen CLaridGe et.al (see; BioorGanic &amp;amp; MedicinaL CHeMisTrY Letters 18 (2008) 2793-2798).

[29] Despite THe advances Made in THe area oF Kinases and in parTicuLar THe roLe THaT c-met, RON, EGFR or KDR paTHwaY pLaYS in HuMan diseases, cHaLLenGes reMain in TerM oF THe coMpLexiTies oF THe TarGeT invoLved, THe proTein structure oF THe Kinases, speciFiciTY issues For various Kinase inHiBitors, side eFFects and desired cLinicaL Benefits expected Form THe SMaLL Molecule inHiBitors. AccordinGLY, THere stiLL remains an unmet and dire need For smaLL molecule compounds HavinG speciFiciTY Towards eitHer one, Two or muLtipLe Kinase inHiBitors in order To reGulate and/or modulate transduction oF Kinases, particularlY c-Met, RON, EGFR or KDR For THe Treatment oF diseases and disorders associated witH Kinases-Mediated events.

[30] THe c-Met patHwaY plaYS an important role in THe aBove descriBed Human diseases includinG cancer. THere are no c-Met inHiBitors or antaGonists THaT are currentlY 8 222577/2 available for treating these human disorders that are characterized by abnormal HGF/c-Met signaling. Therefore, there is a clear unmet medical need for compounds which inhibit c-Met and other kinases. The compounds, compositions, and pharmaceutical methods provided herein help meet this need.

SUMMARY OF THE INVENTION

[31] The present invention is directed to compounds useful as protein kinase modulators and in particular as inhibitors of c-Met.

[32] In one embodiment, the compound of the present invention has the formula I:

<img img-format="tif" img-content="drawing" file="IL222977AD00022.tif" id="idf0002" />

or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein

Xis CRJorN;

Cy1 and Cy2 may be same or different and are independently selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

Lj is absent or selected from -0-, -S(=0)q-, -NRa-, -(CRaRb)n-, -C(=Y)-, -C(=Y)-C(=Y)-, -CRaRb-C(=Y)-CRaRb-, -CRaRb-Y-CRaRb-, -C(=Y)-NRaRb-, -NRaRb-C(=Y)-NRaRb-, -S(=0)q-NRaRb-, -NRaRb-S(=O)q-NRaRb-, -NRaRb-NRaRb-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; L2 is selected from -0-, -S(=0)q-, -NRa-, -(CRaRb)n-, -C(=Y)-, -C(=Y)-C(=Y)-, -CRaRb-C(=Y)-CRaRb-, -CRaRb-Y-CRaRb-, -C(=Y)-NRaRb-, -NRaRb-C(=Y)-NRaRb-, -S(=O)q-NRaRb--NRa Rb-S(=O)q-NRaRb-, -NRaRb-NRaRb-, substituted or unsubstituted alkyl, substituted or 9 2229T7I2

unsuBsTiTuTeD aLKenyL, suBsTITuTeD or unsuBsTiTuTeD aLKynyL, suBsTITuTeD or unsuBsTiTuTeD CYcLoAlkYL, anD suBsTITuTeD or unsuBsTiTuTeD HeTerocycLyL; eacH occurrence oF R1 anD R2 may Be same or DIFFerenT anD is InDepenDenTLy seLecTeD From HyDrogen, nITro, HyDroxy, cyano, HaLogen, -ORA, -S(=O)Q-RA, -NRARB, -C(=Y)-RA, -CRARB-C(=Y)-RA, -CRARB-Y-CRARB-, -C(=Y)-NRARB-, -NRARB-C(=Y)-NRARB-, -S(=O)Q-NRARB-, -NRARB-S(=O)Q-NRARB-, -NRARB-NRARB-, suBsTITuTeD or unsuBsTiTuTeD C1-6 ΑΐΚγΙ, suBsTITuTeD or unsuBsTiTuTeD C2 6 aLKenyL, suBsTITuTeD or unsuBsTiTuTeD C2 6 ΑΐΚγΝγΙ, suBsTITuTeD or unsuBsTiTuTeD C3_6 CYcloAlkYl, suBsTITuTeD or unsuBsTiTuTeD C3 6 cycLoaLKyLaLKyL, anD suBsTITuTeD or unsuBsTiTuTeD C3_6 cycLoaLKenyL; eacH occurrence oF Ra anD Rb may Be same or DIFFerenT anD are InDepenDenTLy seLecTeD From HyDrogen, nITro, HyDroxy, cyano, HaLogen, suBsTITuTeD or unsuBsTiTuTeD C1-6 ΑΐΚγΙ, suBsTITuTeD or unsuBsTiTuTeD C2 6 AlkENYl, suBsTITuTeD or unsuBsTiTuTeD C2 6 ΑΐΚγΝγΙ, suBsTITuTeD or unsuBsTiTuTeD C3_6 CYcloAlkYl, suBsTITuTeD or unsuBsTiTuTeD C3 6 cycLoaLKyLaLKyL, anD suBsTITuTeD or unsuBsTiTuTeD C3_6 cycLoaLKenyL, or wHen Two Ra anD/or Rb suBsTITuenTs are DIrecTLy BounD To a common atom, THey may Be JoIneD To Form a suBsTITuTeD or unsuBsTiTuTeD, saTuraTeD or unsaTuraTeD 3-10 memBer ring, wHIcH may ορΤίοΝΑίΙγ IncLuDe one or more HeTeroaToms wHIcH may Be same or DIFFerenT anD are seLecTeD From O, NRc or S; eacH occurrence oF Rc Is InDepenDenTLy seLecTeD From HyDrogen, nITro, HyDroxy, cyano, HaLogen, suBsTITuTeD or unsuBsTiTuTeD C1-6 ΑΐΚγΙ, suBsTITuTeD or unsuBsTiTuTeD C2 6 aLKenyL, suBsTITuTeD or unsuBsTiTuTeD C2 6 ΑΐΚγΝγΙ, suBsTITuTeD or unsuBsTiTuTeD C3_6 cycLoaLKyL, suBsTITuTeD or unsuBsTiTuTeD C3 6 cycLoaIKyLaLKyL, anD suBsTITuTeD or unsuBsTiTuTeD C3 6 CYcloAlkENYl; eacH occurrence oF Y Is InDepenDenTLy seLecTeD From O, S, anD NRA;

eacH occurrence oF n InDepenDenTLy represents 0, 1, 2, 3 or 4; anD eacH occurrence oF q InDepenDenTLy represents 0, 1 or 2. 10 222577/2 [33] Another embodiment is a compound of formula (IA):

<img img-format="tif" img-content="drawing" file="IL222977AD00023.tif" id="idf0003" />

OA) or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein each occurrence of R2 is independently hydrogen, nitro, hydroxy, cyano, halogen, -ORa, -S(=O)q-Ra, -NRaRb, -C(=O)-Ra, or -C(=O)-Ra, wherein Ra and Rb in the R2 group are independently hydrogen, hydroxy, or substituted or unsubstituted alkyl; and all the other variables are the same as described above for compound of formula (I).

[34] Further preferred is a compound of formula (I) and (IA) wherein Cy1 is selected from: (The squiggly lines ( the structures below represent the point of attachment of the structure to the rest of the compound.)

<img img-format="tif" img-content="drawing" file="IL222977AD00024.tif" id="idf0004" />

11 22257712

<img img-format="tif" img-content="drawing" file="IL222977AD00025.tif" id="idf0005" />

Ογσ ν οΎ νγ yy crY Yfr

<img img-format="tif" img-content="drawing" file="IL222977AD00026.tif" id="idf0006" />

NN-rff IΤ7 A f Ν Ν PFMD'f f frfrfrfr AAA?/#

<img img-format="tif" img-content="drawing" file="IL222977AD00027.tif" id="idf0007" />

<img img-format="tif" img-content="drawing" file="IL222977AD00028.tif" id="idf0008" />

&gt;, V r F o fry frfr# A/fr Y A fr'/r A /HF Ά^ΑΆ f /

<img img-format="tif" img-content="drawing" file="IL222977AD00029.tif" id="idf0009" />

<img img-format="tif" img-content="drawing" file="IL222977AD000210.tif" id="idf0010" />

<img img-format="tif" img-content="drawing" file="IL222977AD000211.tif" id="idf0011" />

*'J O'

<img img-format="tif" img-content="drawing" file="IL222977AD000212.tif" id="idf0012" />

°Y3"

o HN JI T i _? '&gt; -- 1

0 γ^νόό ΆΗ0Ό~Ρ „P

pY S Ai^^jo'cajZ’Cf 12

<img img-format="tif" img-content="drawing" file="IL222977AD000213.tif" id="idf0013" />

222STH2

<img img-format="tif" img-content="drawing" file="IL222977AD000214.tif" id="idf0014" />

14 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD000215.tif" id="idf0015" />

[35] Yet another embodiment is a compound of formula (IA-I): R2

<img img-format="tif" img-content="drawing" file="IL222977AD000216.tif" id="idf0016" />

(IA-1) 15 2229T7I2 or a TauTomer, stereoisomer, enantiomer, Diastereomer, salt (e.g., pharmacEulicall\' acceptable salt), proDrug (e.g., esTer), or N-oxide THereoF, wherein D is suBsTiTuTed or unsuBsTiTuTed MonocYcLic aryL or suBsTiTuTed or unsuBsTiTuTed MonocYcLic heteroaiwl; each occurrence oF R2 is indEpEndenTLY hYdroGen, niTro, HyDroxy, cyano, HaLoGen, -ORa, -S(=O)Q-RA , -NRARB , -C(=O)-RA , -C(=O)-RA, wHerein each occurrence oF RA and RB in Group R2 is independenTLY hYdroGen, HyDroxy, or suBsTiTuTed or unsuBsTiTuTed C1-6 alkyl; and all oTher variaBLes are The saMe as descriBed herein aBove.

[36] Further preFerred is a coMpound oF Formula (IA-1) wherein L2 is -CRARB-.

[37] FurTher preFerred is a compound oF Formula (IA-1) wherein D is suBsTiTuTed wiTh one To Five suBsTiTuenTs seLecTed From haLoGen, suBsTiTuTed or unsuBsTiTuTed aLKyL, suBsTiTuTed or unsuBsTiTuTed alkoxy, -CORX, -CONRxRy, -S(O)QNRxRy or -NRxRy; wherein each occurrence oF Rx and Ry is independenTly seLecTed From hydroGen, hydroxy, haLoGen, carBoxyl, cyano, niTro, oxo (=0), Thio (=S), suBsTiTuTed or unsuBsTiTuTed alkyl, suBsTiTuTed or unsuBsTiTuTed alkoxy, suBsTiTuTed or unsuBsTiTuTed alkenyl, suBsTiTuTed or unsuBsTiTuTed alkynyl, suBsTiTuTed or unsuBsTiTuTed cycloalkyl, suBsTiTuTed or unsuBsTiTuTed cycloalkenyl, suBsTiTuTed or unsuBsTiTuTed cycloalkylalkyl, suBsTiTuTed or unsuBsTiTuTed cycloalkenylalkyl, suBsTiTuTed or unsuBsTiTuTed heTerocycyl, suBsTiTuTed or unsuBsTiTuTed heTerocyclylalkyl, suBsTiTuTed or unsuBsTiTuTed aryl, suBsTiTuTed or unsuBsTiTuTed arylalkyl, suBsTiTuTed or unsuBsTiTuTed heTeroaryl, suBsTiTuTed or unsuBsTiTuTed heTeroarylalkyl, -COORZ, -C(O)RZ, -C(S)RZ, -C(O)NRzRz, -C(O)ONRzRz, -NRzRz, -NRzCONRzRz, -N(Rz)SORz, -N(Rz)SO2Rz, -(=N-N(Rz)Rz), -NRzC(0)0Rz, , -NRZC(0)RZ-, -NRxC(S)Ry -NRZC(S)NRZRZ, -SONRzRz-, -SO2NRzRz-, -ORz, -ORzC(O)NRzRz, -ORzC(O)ORz-, -OC(O)Rz, -OC(O)NRzRz, -RZNRZC(0)RZ, -RZ0RZ, -RZC(O)ORZ, -RZC(O)NRZRZ, -RZC(O)RZ, -RZOC(O)RZ, -SRZ, -SORZ, -SO2Rz, and -0N02, or any Two oF Rx and Ry which are direcTly Bound To a common aTom may Be Joined To Form (i) a suBsTiTuTed or unsuBsTiTuTed, saTuraTed or unsaTuraTed 3-14 memBered rinG, which may optionally include one or more heTeroaToms which may Be The same or diFFerenT and are selecTed From 0, NRZ or S, or (ii) an oxo (=0), Thio (=S) or imino (=NRZ), wherein 16 222577/2 each occurrence of Rz is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocycyl, substituted or unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and -0N02, or any two of Rz which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from 0, NR" (where R" is H or alkyl) or S, or (ii) an oxo (=0), thio (=S) or imino (=NRZ); and q in the group D is 0,1 or 2.

[38] Further preferred is a compound of formula (IA-1) wherein D is selected from

<img img-format="tif" img-content="drawing" file="IL222977AD000217.tif" id="idf0017" />

17 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD000218.tif" id="idf0018" />

05

<img img-format="tif" img-content="drawing" file="IL222977AD000219.tif" id="idf0019" />

ftp Ογί

NH

T

<img img-format="tif" img-content="drawing" file="IL222977AD000220.tif" id="idf0020" />

NHj F HjnG) JL, ps? -Λ Γ &lt; &lt; r w ? fi° ftft Ho Λ &gt; / &lt;, Λ r Ο °χ „0 Ο e&gt; Y &gt;

<img img-format="tif" img-content="drawing" file="IL222977AD000221.tif" id="idf0021" />

-Cf A

HaN^N

Xf X fir *C 0/ a y „) η2ν++ χ „jct ft, .XX OX O»ftcftocft VO~ °ft ift" P X \

<img img-format="tif" img-content="drawing" file="IL222977AD000222.tif" id="idf0022" />

18 222977/2

<img img-format="tif" img-content="drawing" file="IL222977AD000223.tif" id="idf0023" />

η $ 19

OS

<img img-format="tif" img-content="drawing" file="IL222977AD000224.tif" id="idf0024" />

2/ZZ6SSS 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD000225.tif" id="idf0025" />

[39] Yet another embodiment is a compound of formula (II): r2

<img img-format="tif" img-content="drawing" file="IL222977AD000226.tif" id="idf0026" />

k—-Cy* (Π) or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein 21 22297712 A is selected From HaloGen, -ORC, -S(=O)Q-Rc, -NRCRD, -(CRcRd)n-Re,-C(=Y)-Rc, -C(=Y)-C(=Y)-RC, -CRcRd-C(=Y)-CRcRd-Re, -CRcRD-Y-CRcRD-Re, -C(=Y)-NRcRd, -NRC-C(=Y)-NRCRD, -S(=O)Q-NRcRd, -NRc-S(=O)Q-NRcRd, -NRC-NRCRD, suBstituted or unsuBstituted ΑΐΚγΙ, suBstituted or unsuBstituted aLKenYl, suBstituted or unsuBstituted ΑΐΚγηγΙ, suBstituted or unsuBstituted C3_6 CYcloaLKYl, and suBstituted or unsuBstituted C3 6 CYcloaLKenYl; or wHen two Rc and RD suBstituents are directlY Bound to a common atom, tHeY maY Be Joined to Form a suBstituted or unsuBstituted, saturated or unsaturated 3-10 memBer rinG, wHicH maY optionallY include one or more Heteroatoms wHicH maY Be same or diFFerent and are selected From O, NRe or S; eacH occurrence oF Rc, RD, and Re are independentlY selected From HYdroGen, HYdroxY, HaloGen, carBoxYl, CYano, nitro, oxo (=0), tHio (=S), suBstituted or unsuBstituted ΑΐΚγΙ, suBstituted or unsuBstituted aLKoxY, suBstituted or unsuBstituted aLKenYl, suBstituted or unsuBstituted ΑΐΚγηγΙ, suBstituted or unsuBstituted CYcloaLKYl, suBstituted or unsuBstituted CYcloaLKYlalKYl, suBstituted or unsuBstituted CYcloaLKenYl, suBstituted or unsuBstituted CYcloaLKenYlalKYl, suBstituted cr unsuBstituted HeterocYclic rinG, suBstituted or unsuBstitituted HeterocYCYlaLKYl rinG, suBstituted or unsuBstituted arYl, suBstituted or unsuBstituted arYlalKYl, suBstituted or unsuBstituted HeteroarYl, suBstituted or unsuBstituted HeteroarYlaLKYl, suBstituted or unsuBstituted Guanidine, -COORX, -C(O)RX, -C(S)RX, -C(O)NRxRy, -C(O)ONRxRy, -NRyRz, -NRxCONRyRz, -N(Rx)SORy, -N(Rx)SO2Ry, -(=N-N(Rx)Ry), - NRxC(O)ORy, -NRxRy, -NRxC(O)Ry-, -NRxC(S)Ry, -NRxC(S)NRyRz, -SONRxRy-, -SO2NRXRY-, -0Rx, -ORXC(O)NRYRZ, -ORXC(O)ORY-, -OC(O)Rx, -OC(O)NRXRY, -RXNRYC(O)RZ, -RxORy, -RxC(O)ORy, -RxC(O)NRyRz, -RxC(O)Rx, -RxOC(O)Ry, -SRx, -SORX, -SO2Rx, and -0N02, wHerein eacH occurrence oF Rx, RY and Rz in eacH oF tHe aBove Groups is independentlY HYdroGen, suBstituted or unsuBstituted amino, suBstituted or unsuBstituted ΑΐΚγΙ, suBstituted or unsuBstituted alKoxY, suBstituted or unsuBstituted aLKenYl, suBstituted or unsuBstituted ΑΐΚγηγΙ, suBstituted or unsuBstituted CYcloaLKYl, suBstituted or unsuBstituted CYcloaLKYlalKYl, suBstituted or unsuBstituted CYcloaLKenYl, suBstituted or unsuBstituted CYcloaLKenYlalKYl, suBstituted or unsuBstituted HeterocYclic rinG, suBstituted or unsuBstituted HeterocYclYlaLKYl rinG, suBstituted or unsuBstituted arYl, suBstituted or unsuBstituted arYlaLKYl, suBstituted or unsuBstituted HeteroarYl, and suBstituted or unsuBstituted HeteroarYlaLKYl, or anY two oF Rx, RY and Rz wHicH are directlY Bound to a common atom maY Be Joined to Form (i) an oxo (C=O), thio (C=S) or imino (C=NR") group (where R" is H or alkyl) or (ii) substituted or unsubstituted, saturated or unsaturated 3-10 22 222577/2 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR" (where R" is H or alkyl) or S; and all other variables are the same as described above for compound of formula (I).

[40] Yet another embodiment is a compound of formula (IIA):

<img img-format="tif" img-content="drawing" file="IL222977AD000227.tif" id="idf0027" />

(ΠΑ) or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein

Rc and Rd together with the nitrogen to which they are attached form a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NRe or S; and all other variables are the same as described above for compound of formula (Π).

[41] Further preferred is a compound of formula (IIA) wherein NRcRd is selected from

<img img-format="tif" img-content="drawing" file="IL222977AD000228.tif" id="idf0028" />

wherein each occurrence of Rx and R&gt; is independently selected from hydrogen, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy, or any two of Rx and R&gt; which are directly bound to a common atom may be joined to form an oxo (C=0), thio (C=S) or imino (C=NR") group (where R" is H or alkyl) or, any two of Rx and R&gt; may be joined to 23 222577/2 form a substituted or unsubstituted, saturated or unsaturated 3-6 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR" (where R" is H or alkyl) or S.

[42] Further preferred is a compound of formula (IIA) wherein NRcRd is selected from

y&gt;..............γ.......mX

<img img-format="tif" img-content="drawing" file="IL222977AD000229.tif" id="idf0029" />

[43] Yet another embodiment is a compound of formula (III):

<img img-format="tif" img-content="drawing" file="IL222977AD000230.tif" id="idf0030" />

(ΙΠ) or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein 24 2229T7I2 U anD V are each iNDepeNDeNtly selecteD From CR3 or N; W is selecteD From O, S, or NR4; each occurrence oF R3 is iNDepeNDeNtly hyDroGen, haloGen, cyano (CN), -ORC, -S(=O)Q-RC, -NRCRD, suBstituteD or uNSuBstituteD alkyl, suBstituteD or uNSuBstituteD alkenyl, suBstituteD or uNSuBstituteD alKyNyl, suBstituteD or UNSuBstituteD C3_6 cycloalKyl, suBstituteD or UNSuBstituteD C3_6 cycLoalKylalKyl, or suBstituteD or UNSuBstituteD C3_6 cycloalKeNyl; R4 is selecteD From hyDroGen, hyDroxy, carBoxyl, cyano, oxo (=0), thio (=S), suBstituteD or UNSuBstituteD alkyl, suBstituteD or UNSuBstituteD alkoxy, suBstituteD or UNSuBstituteD alkeNyl, suBstituteD or UNSuBstituteD alKyNyl, suBstituteD or UNSuBstituteD C3_6 cycloaLKyl, suBstituteD or UNSuBstituteD C3_6 cycLoalKylalKyl, anD suBstituteD or UNSuBstituteD C3_6 cycloalKeNyl; R5 is selecteD FroM hyDroGen, hyDroxy, haloGen, carBoxyl, cyano, nitro, oxo (=0), thio (=S), suBstituteD or UNSuBstituteD alkyl, suBstituteD or UNSuBstituteD alkoxy, suBstituteD or UNSuBstituteD alKeNyl, suBstituteD or UNSuBstituteD alKyNyl, suBstituteD or UNSuBstituteD cycloalKyl, suBstituteD or UNSuBstituteD cycloalKylalKyl, suBstituteD or UNSuBstituteD cycloalKeNyl, suBstituteD or UNSuBstituteD heterocyclic rinG, suBstituteD or UNSuBstituteD heterocyclylalKyl, suBstituteD or UNSuBstituteD aryl, suBstituteD or UNSuBstituteD arylalKyl, suBstituteD or UNSuBstituteD heteroaryl, suBstituteD or UNSuBstituteD heteroarylalKyl, suBstituteD or UNSuBstituteD GuaNiDiNe, -COORX, -C(O)RX, -C(S)RX, -C(0)NRXRy, -C(O)ONRxRy, -NRXRZ, -NRxCONRyRz, -N(Rx)SORy, -N(Rx)SO2Ry, -(=N-N(Rx)Ry), -NRxC(O)ORy, -NRxC(O)Ry-, -NRxC(S)Ry, -NRxC(S)NRyRz, -SONRxRy-, -SO2NRxRy-, -ORx, -ORxC(O)NRyRz, -ORxC(O)ORy-, -OC(O)RX, -OC(O)NRxRy, - RxNRyC(O)Rz, -RxORy, -RxC(O)ORy, -RxC(O)NRyRz, -RxC(O)Rx, -RxOC(O)Ry, -SRx, -SORx, -SO2Rx, anD -0N02, wherein Rx, Ry anD Rz in each oF the aBove Groups can Be hyDroGen, suBstituteD or UNSuBstituteD amino, suBstituteD or UNSuBstituteD alkyl, suBstituteD or UNSuBstituteD alkoxy, suBstituteD or UNSuBstituteD alKeNyl, suBstituteD or UNSuBstituteD alKyNyl, suBstituteD or UNSuBstituteD cycloalKyl, suBstituteD or UNSuBstituteD cycloalKylalKyl, suBstituteD or UNSuBstituteD cycloalKeNyl, suBstituteD or UNSuBstituteD heterocyclic rinG, suBstituteD or UNSuBstituteD heterocyclylalKyl, suBstituteD or UNSuBstituteD aryl, suBstituteD or UNSuBstituteD arylalkyl, suBstituteD or UNSuBstituteD heteroaryl, suBstituteD or UNSuBstituteD heteroarylalKyl, or any two oF Rx, Ry anD Rz which are Directly BounD to a common atom may Be JoineD to form an oxo (C=O), thio (C=S) or imino (C=NR") group (where R" is H or alkyl) or 25 22257712 substituted or unsubstituted, saturated or unsaturated 3-10 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR" (where R" is H or alkyl) or S; or when W is NR4, R4 and R5 together with the nitrogen to which they are attached form a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NRe or S; and all the other variables are the same as described above for compound of formula (I).

[44] Further preferred is a compound of formula (III) wherein U is CR3.

[45] Further preferred is a compound of formula (III) wherein V is N.

[46] Further preferred is a compound of formula (III) wherein W is O or NR4.

[47] Further preferred is a compound of formula (III) wherein -U=V-W-R5 is

<img img-format="tif" img-content="drawing" file="IL222977AD000231.tif" id="idf0031" />

OH

[48] Yet another embodiment is compound of formula (IIIA) or (IIIB): 26 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD000232.tif" id="idf0032" />

<img img-format="tif" img-content="drawing" file="IL222977AD000233.tif" id="idf0033" />

(ΠΙΑ) (ΠΙΒ) or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein all the variables are the same as described above for compound of formula (III).

[49] Further preferred is a compound of formula (IIIA) wherein -CR3=N-O-R5 is selected from

<img img-format="tif" img-content="drawing" file="IL222977AD000234.tif" id="idf0034" />

<img img-format="tif" img-content="drawing" file="IL222977AD000235.tif" id="idf0035" />

OH

<img img-format="tif" img-content="drawing" file="IL222977AD000236.tif" id="idf0036" />

[50] Further preferred is a compound of formula (IIIA) wherein -CR3=N-NR4R5 is selected from

<img img-format="tif" img-content="drawing" file="IL222977AD000237.tif" id="idf0037" />

<img img-format="tif" img-content="drawing" file="IL222977AD000238.tif" id="idf0038" />

r y r

HN HNX HNX

<img img-format="tif" img-content="drawing" file="IL222977AD000239.tif" id="idf0039" />

27 222577/2 [51] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein X is CR1.

[52] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein X is N.

[53] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein R1 is H.

[54] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein each of R2 is H; [55] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein L2 is -CRaCRb-.

[56] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein L2 is -CH2-, -CH(OH)-, -CHF-, -CF2-, -CH (CH3)- or -C(CH3)2-.

[57] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein L2 is -CH2- or -CH (CH3)-.

[58] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (IIIA) or (IIIB) wherein Cy2 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

[59] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein Cy2 is selected from

F 28 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD000240.tif" id="idf0040" />

[60] Further preferred is a compound of formula (I), (IA), (IA-1), (II), (IIA), (III), (ΠΙΑ) or (IIIB) wherein Cy2 is selected from

F

<img img-format="tif" img-content="drawing" file="IL222977AD000241.tif" id="idf0041" />

[61] Yet another embodiment is a compound of formula (IV): 29 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD000242.tif" id="idf0042" />

dV) or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein B is selected from Lj-Cyj, Cyb D, A , NRcRd and -U=V-W-R5 (e.g., Cy1, D, NRcRd or -U=V-W-R5);

Ra and Rb, located between the two bicyclic groups, are independently selected from hydrogen, halogen, and substituted or unsubstituted (Cj^) alkyl, or both together with the carbon atom to which they are attached form a saturated 3 to 6 member cyclic ring which may optionally include one or more heteroatoms which may be same or different and are selected from O, NRe and S; Z is selected from CRC, S, 0, NRC, RcC=CRc, -N=CRc-, and -RcC=N-;

Zj is selected from N, NRC and CRc;

Rc is absent or selected from hydrogen, hydroxy and halogen; and all other variables are the same as described herein above.

[62] Further preferred is a compound of formula (IV) wherein X is N.

[63] Further preferred is a compound of formula (IV) wherein each occurrence of R2isH.

[64] Further preferred is a compound of formula (IV) wherein each of Ra and Rb is hydrogen. 30 2229T7I2 [65] FurTHer preFerreD Is a compound oF FormuLA (IV) wHerein Ra METHyL anD Rb Is HyDroGEN.

[66] FurTHer preFerteD Is a compound oF FotmuLa (IV) wHerein Ra Is Fluoro anD Rb Is HyDroGEN.

[67] FurTHer preFerreD Is a compound oF FotmuLa (IV) wHerein Ra anD Rb BoTH are Fluoro.

[68] FurTHer preFerreD Is a compound oF FotmuLa (IV) wHerein Ra anD Rb BoTH are MEtHyL.

[69] FurTHer preFerreD Is a compound oF FormuLA (IV) wHerein Z Is CRc, N, S, O, HC=CH-, or -N=CH-.

[70] FurTHer preFerreD Is a compound oF FormuLA (IV) wHerein Z1 Is CH or N.

[71] FurTHer preFerreD Is a compound oF FotmuLa (IV) wHerein Z Is -HC=CH- , -S-or -O- anD Zi Is CH.

[72] FurTHer preFerreD Is a compound oF FormuLA (IV) wHerein Z Is -HC=CH- anD Zi Is CH.

[73] FurTHer preFerreD Is a compound oF FormuLA (IV) wHerein Z Is -S- anD Zj Is CH.

[74] FurTHer preFerreD Is a compound oF FotmuLa (IV) wHerein Z Is -0- anD Zj Is CH.

[75] FurTHer preFerreD Is a compound oF FormuLA (IV) wHerein Z Is -CH- anD Zi Is NH.

[76] FurTHer preFerreD Is a compound oF FormuLA (IV), wHerein eacH occurrence oF Rc Is HyDroGEN or Fluoro.

[77] FurTHer preFerreD Is a compound oF FormuLA (IV) wHerein B Is L1-Cy1, wHerein L1-Cy1 Is as DescrIBeD aBove For THe compound oF FormuLA (I). 31 2229772 [78] Further preFerreD is a compound oF Formula (IV) wherein B is Cy1, wherein CY1 is as DescriBeD aBove For The compounD oF FormuLA (IA).

[79] FurTHer preFerreD Is a compounD oF FormuLA (IV) wheREin D Is as DescriBeD aBove For The compounD oF FormuLA (IA-1).

[80] FurTHer preFeRreD Is a compounD oF FormuLA (IV) wheRein A Is as DescriBeD ABove For The compounD oF FormuLA (II).

[81] FurTHer preFeRreD is a compounD oF FormuLA (IV) wHerein B is NRCRD, wHerein NRCRD is as DescriBeD ABove For The compounD oF FormuLA (IIA).

[82] FurTHer preFeRreD is a compounD oF FormuLA (IV) wherein B is -U=V-W-R5, wherein U=V-W-R5 is as DescriBeD ABove For The compounD oF FormuLA (Ill).

[83] Further preFeRreD is a compounD oF FormuLA (IV) wherein U=V-W-R5 is -CR3=N-O-R5, wherein -CR3=N-O-R5 is as DescriBeD ABove For The compounD oF FormuLA (IIIA).

[84] Further preFeRreD is a compounD oF FormuLA (IV) wherein U=V-W-R5 is -CR3=N-NR4R5, wherein -CR3=N-NR4R5 is as DescriBeD ABove For The compounD oF FormuLA (IIIB).

[85] In one emBoDimenT, in The compounD oF FormuLA (IV), (a) The BicycLic rinG conTAininG rinG aToms Z AnD Z1 is QuinoLine, Benzo[D]ThiAzoL-6-YL, or An N-oxiDe ThereoF, which is opTionALLY suBsTiTuTeD wiTh one or Two hALoGen (e.g., F), (B) Ra, RB, AnD eAch Rc Are hYDroGen, (c) each R2 is hYDrogen, anD (D) B is suBsTiTuTeD phenYL, suBsTiTuTeD ThiophenYL, -CR3=N-O-R5 or -CR3=N-NR4R5 (where R3, R4, anD R5 are as DescriBeD aBove For The compounDs oF Formulas (IIIA) anD (IIIB)). For exampLe, B maY Be 4-amiDophenYL (i.e., 4-NH2C(O)-Ph) or 4-(R"-NHC(O))-phenyl (where R" is (C1-C4) ΑΐΚγΙ), where The phenYL Group maY opTionaLLY Be FurTher suBsTiTuTeD Βγ one, Two, or Three suBsTiTuenTs seLecTeD From haLoGens (e.G., F or CL) anD FluorinaTeD meThYL (e.G., -CF3). In anoTher emBoDimenT, B is ThiophenYL suBsTiTuTeD wiTh hYDroxYmeThYl, or B is a pYrazolYl Group opTionaLLY suBsTiTuTeD wiTh (C1-C6) ΑΐΚγΙ or hYDroxY (C1-C6) ΑΐΚγΙ.

[86] YeT anoTher emBoDimenT is a compounD oF Formula (IVA) or (IVB): 32 22257712

<img img-format="tif" img-content="drawing" file="IL222977AD000243.tif" id="idf0043" />

(IVA) (IVB) or a tautomer, stereoisomer, enantiomer, diastereomer, salt (e.g., pharmaceutically acceptable salt), prodrug (e.g., ester), or N-oxide thereof, wherein

Ra is halogen or substituted or unsubstituted (Ci_6) alkyl (e.g., methyl); and all other variables are the same as described herein above.

[87] In one embodiment, the bicyclic ring containing ring atoms Z and Zj in the compound of formula (IVA) is quinoline or an N-oxide thereof, which is optionally substituted with one or two halogen (e.g., F).

[88] In one embodiment, the bicyclic ring containing ring atoms Z and Zj in the compound of formula (IVB) is quinoline or an N-oxide thereof, which is optionally substituted with one or two halogen (e.g., F).

[89] In one embodiment, the bicyclic ring containing ring atoms Z and Zj in the compound of formula (IVA) is benzo[d]thiazol-6-yl or an N-oxide thereof, which is optionally substituted with one or two halogen (e.g., F).

[90] In one embodiment, the bicyclic ring containing ring atoms Z and Zj in the compound of formula (IVB) is benzo[d]thiazol-6-yl or an N-oxide thereof, which is optionally substituted with one or two halogen (e.g., F).

[91] In a preferred embodiment, B in compound (IVA) or (IVB) is substituted phenyl, substituted thiophenyl, -CR3=N-O-R5 or -CR3=N-NR4R5 (where R3, R4, and R5 are as described above for the compounds of formulas (IIIA) and (IIIB)). For example, B may be 4-amidophenyl (i.e., 4-NH2C(O)-phenyl) or 4-(R"-NHC(O))-phenyl (where R" is (CrC4) 33 2229T7I2 alKyl), wHere THe pHenyI Group may optlonallY bE FurTHer substitutED Βγ one, Two, or THree substituENts seIecTeD From HaIogens (e.g., F or Cl) anD FIuorInaTeD meTHyI (e.g., -CF3). In

anoTHer EMboDiMENt, B Is ThiophENyl substitutED with HyDroxymeTHyI, or B Is a pyrazoIyI

Group optlonallY substitutED with (C1-C6) aIKyI or HyDroxy (C1-C6) aIKyI.

[92] In a preFerreD emBoDImenT, Each R2 Is HyDrogen.

[93] Representative compounDs oF THe present Invention IncIuDe THose specIFIeD bElow anD pHarmaceuTIcaIIy accEptablE salts THereoF. THe present Invention shoulD not bE consTrueD To bE IImITeD To THem.

1. 6-((5-(4-MEtHoxYpHENYl)-3H-[1,2,3]Triazolo[4,5-b]pYriDlN-3-Yl)MEtHYl)QuiNoliNE

2. 6-((5-(3-MEtHoxYpHENYl)-3H-[1,2,3]Triazolo[4,5-b]pYriDlN-3-Yl)MEtHYl)QuiNoliNE

3. 3-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]triazolo[4,5-b]pYrIDiN-5-Yl)bENzalDEHYDE 4. (3-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRiazolo[4,5-b]pYrIDiN-5-Yl)pHENYl)MEtHaNol

5. 4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRiazolo[4,5-b]pYrIDiN-5-Yl)bENzalDEHYDE 6. (4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRiazolo[4,5-b]pYrIDiN-5-Yl)pHENYl)MEtHaNol

7. MeTHyI 4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRiazolo[4,5-b]pYrIDiN-5-Yl)bENzoatE

8. 4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRiazolo[4,5-b]pYrIDlN-5-Yl)bENzoic acID

9. N-MEtHYl-4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]TRlazolo[4,5-b]pYRiDiN-5-Yl)bENZAMlDE

10. 4-(3-(4-FluoRobENZYl)-3H-[1,2,3]tRiazolo[4,5-b]pYRiDiN-5-Yl)bENzalDEHYDE 11. (4-(3-(4-FluoRobENZYl)-3H-[1,2,3]tRlazolo[4,5-b]pYRiDiN-5- y1)pHeny1)meTHano1 12. MeTHyI 2-fluoRO-4-(3-(QulNollN-6-YlMEthYl)-3H- [1,2,3]TRiazolo[4,5-b]pyriDiN-5-Yl)

bEnzoatE

13. 2-FluoRO-4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRiazolo[4,5-b]pyrIDlN-5-Yl)bENzoic aciD

14. 2-FluoRO-N-MEtHYl-4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRlazolo[4,5-b]pYRiDiN-5-Yl) bEnzamiDE

15. 2-FluoRO-4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]tRiazolo[4,5-b]pyrIDiN-5-Yl)bENzaMlDE

16. (2-FluoRO-4-(3-(QuiNoliN-6-YlMEtHYl)-3H-[1,2,3]TRlazolo[4,5-b]pYRiDiN-5-Yl)pHENYl) meTHanoI

17. MEthyl 4-(3-(2-cHloRO-3,6-DifluoRobENzYl)-3H-[1,2,3]tRlazolo[4,5-b]pYRiDiN-5-Yl)-2-Fluoro bEnzoatE 34 2229T7I2

18. 4-(3-(2-CH1oRO-3,6-DIfluoRoBENzy1)-3H-[1,2,3]tRlAzo1o[4,5-B]pyRlDlN-5-y1)-2-fluoRO Benzoic acID 19. 4-(3-(2-CH1oRO-3,6-DIF1uoRoBENzy1)-3H-[1,2,3]tRlAzo1o[4,5-B]pyRlDlN-5-y1)-2-F1uoRO-N-metHyl BenzaMiDe 20. N-(2-HyDroxyethy1)-4-(3-(quino1in-6-y1methy1)-3H-[l,2,3]triazo1o[4,5-b]pyRiDin-5-yl) benzamiDe

21. 4-(3-(qulNo1lN-6-ylMEtHy1)-3H-[1,2,3]tRlAzo1o[4,5-B]pyrIDlN-5-y1)BENZAMlDE 22. Lithium 4-(3-(qulNo1lN-6-ylMEtHy1)-3H-[1,2,3]tRlAzo1o[4,5-B]pyRlDlN-5-

y1)BENZ0AtE 23. 6-((5-(3-(TRiF1uoROMETHoxy)pHENyL)-3H-[1,2,3]TriAzoLo[4,5-B]pyRiDiN-3-y1)MEtHy1)qulN0llNE

24. 3-(3-(quino1in-6-y1metHy1)-3H-[1,2,3]triAzo1o[4,5-B]pyriDin-5-yL)pHenoL 25. 6-((5-(3-(DIF1uorometHoxy)pHeny1)-3H-[1,2,3]triAzo1o[4,5-B]pyriDin-3- y1)metHyL) quinoline 26. (4-MetHy1piperAzin-1-y1)(4-(3-(quino1in-6-y1metHy1)-3H-[1,2,3]triAzoLo[4,5-B] pyrIDIn-5 -y1)pHeny1)metHAnone 27. N-(2-(DimetHylAmino)etHy1)-4-(3-(quino1in-6-y1metHy1)-3H-[1,2,3]triAzoLo[4,5-B] pyrIDIn-5 -y1)BenzAmIDe 28. 4-(3-(quino1in-6-y1metHy1)-3H-[1,2,3]tRiAzo1o[4,5-B]pyriDin-5-yL)-N-(tetrAHyDRO-2H-pyrAn-4-y1)BenzAmIDe

29. tERt-Butyl 4-(4-(3-(quiNoLiN-6-yLMETHyL)-3H-[1,2,3]TRiAzoLo[4,5-B]pyRiDiN-5-yL) BENZAMiDo)pipERiDiNE-1-CArBoxyLATE 30. N-(PipERiDiN-4-yL)-4-(3-(quiNoLiN-6-yLMETHyL)-3H-[1,2,3]TRiAzoLo[4,5-B]pyRiDiN-5-yL) BenzAmiDe HyDrocHLoriDe

31. N-(2-(DiMETHyLAMiNo)ETHyL)-2-F1uoRO-4-(3-(quiNoLiN-6-yLMETHyL)-3H-[1,2,3]TRiAzoLo [4,5-B] pyriDiN-5-yL)BENZAMiDE 32. (S)-(2-(pyrRoLiDiN-1-yLMETHyL)pyRroLiDiN-1-yL)(4-(3-(quiNoLiN-6-yLMETHyL)-3H-[1,2,3] triazolo [4,5-B]pyrIDIn-5-y1)pHeny1)metHAnone HyDrocHLoriDe

33. (4-(2-HyDROxyETHyL)pipERAziN-1-yL)(4-(3-(quiNoLiN-6-yLMETHyL)-3H-[1,2,3]TriAzoLo[4,5-B] pyriDiN-5-yL)pHENyL)METHANONE 34. (R)-(3-HyDROxypyRRoLiDiN-1-yL)(4-(3-(quiNoLiN-6-yLMETHyL)-3H-[1,2,3]TriAzoLo[4,5-B] pyRiDiN-5-yL)pHENyL)METHANONE HyDrocHLoriDe 35. N-(2-(pipERiDiN-1-yL)ETHyL)-4-(3-(quiNoLiN-6-yLMETHyL)-3H-[1,2,3]TriAzoLo[4,5-B] pyriDin-5 -y1)BenzAmiDe 35 2229772 36. N-(2-morpHoLinoetHYL)-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pYridin- 5-γΐ) Benzamide 37. N-(2-(pyrroLidin-1-YL)etHYL)-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B] pyridin-5 -Yl)Benzamide 38. (4-(pyrroLidin-1-YL)piperidin-1-YL)(4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B] pyridin-5-YL)pHenYL)metHanone 39. N-(3-(dimetHYLamino)propYL)-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B] pyridin-5 -Yl)Benzamide 40. N,N-Bis(2-metHoxYetHYL)-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pyridin-5-YL)Benzamide HYdrocHLoride 41. (2-FLuoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pYridin-5-YL) pHenYl)metHanol HYdrocHLoride 42. 6-((5-(3-FLuoro-4-(metHoxYmetHYL)pHenYL)-3H-[1,2,3]triazoLo[4,5-B]pYridin-3-YL) metHYL)quinoLine 43. N-etHYL-2-Fluoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pYridin-5-YL) Benzamide 44. 2-FLuoro-N-(2-(pYrroLidin-1-YL)etHYL)-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo [4,5-B] pyridin-5-YL)Benzamide 45. N-CYcLoHexYL-2-Fluoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pyridin-5-yl) Benzamide 46. N-CYcLopropYL-2-Fluoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pYridin- 5-Yl)Benzamide 47. 2-FLuoro-N-(pYridin-4-YL)-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B] pyridin-5 -Yl)Benzamide 48. N-BenzYL-2-Fluoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pyridin-5-YL) Benzamide 49. 2-Flucrc-N,N-dimeThyl-4-(3-(quinclin-6-ylmeThyl)-3H-[1,2,3]Triazclc[4,5-b]pyridm- 5-yl) Benzamide 50. Methyl 2-(2-Fluoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pyridin-5-YL) Benzamido)acetate. 51. 2-(2-FLuoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pyridin-5-YL) Benzamido)acetic acid 52. 2-FLuoro-4-(3-(quinoLin-6-YLmetHYL)-3H-[1,2,3]triazoLo[4,5-B]pyridin-5-YL)-N-(1H- 1,2,4-triazoL-3-YL)Benzamide 36 2229T7I2 53. ΜΕΤΗγΙ 3-(3γυίΝθ1ίΝ-6-γΐΜΕΤΗγ1)-3Η-[1,2,3]ΤήΑζο1ο[4,5-Β]ργτΜίΝ-5-γ1)ΒΕΝζοΑΤΕ

54. 3-(3-(quiNoLiN-6-YLMETHYL)-3H-[1,2,3]TRiAzoLo[4,5-B]pyrIDlN-5-YL)BENzoic acID 55. N-METHYL-3-(3-(quiNoLlN-6-YLMETHYL)-3H-[1,2,3]TRiAzoLo[4,5-B]pYRiDlN-5-YL) BenzamiDe

56. 6-((5-(3-FLuoRopHENYL)-3H-[1,2,3]TRiAzoLo[4,5-B]pYRiDlN-3-YL)METHYL)qulNoLiNE 57. METHyl 3-(2-F1uoro-4- (3-(quino1in-6-yiMEtHyi)-3I I-[1,2,3]TrIazoLo [4,5-B]pyridin- 5-yl)

pHENyl AMINO) propANOATE

58. 3-(2-F1uoRO-4-(3-(quiNo1iN-6-YlMETHYl)-3H-[1,2,3]TRiAzoLo[4,5-B]pyriDiN-5-Yl) pHENylAMiNO)pROpANOiC acID 59. 2-F1uoRO-N-METHoxY-N-METHYl-4-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o[4,5-B] PYrIDIn-5-y1)BenzamIDe HyDrocHIorIDe 60. N-tErT-BuTy1-2-f1uoro-4-(3-(quino1in-6-ylMEtHy1)-3H-[1,2,3]tRiAzo1o[4,5-B]pyridin-5- yl) BenzamIDe 61. N-A1lYl-2-F1uoRO-4-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pYRlDlN-5-Yl) BenzamiDe 62. 2-F1uoro-N-MEtHoxy-4-(3-(quino1in-6-ylMEtHy1)-3H-[1,2,3]triAzo1o[4,5-B]pyridin-5-yl) BenzamIDe 63. N-(4-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pyrIDlN-5-Yl)pHENYl) aceTamiDe

64. 4-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pyrIDlN-5-Yl)ANl1lNE

65. 6-((5-(3,4-DlMETHoxYpHENYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pyrIDlN-3-Yl)METHYl)qulNo1lNE

66. 6-((5-(3-F1uoRO-4-METHoxYpHENYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pyrIDlN-3-Yl)METHYl) quinolinE

67. 6-((5-(4-F1uoRopHENYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pYRlDlN-3-Yl)METHYl)qulNo1lNE

68. 6-((5-(2-F1uoRopHENYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pYRlDlN-3-Yl)METHYl)qulNo1lNE 69. N-(3-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pyrIDlN-5-Yl)pHENYl) aceTamiDe

70. 6-((5-(3-(2,2,2-TrIF1uoroeTHoxy)pHeny1)-3H-[1,2,3]TrIazo1o[4,5-B]pyrIDIn-3-y1)meTHy1) quinolinE

71. 3-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pyrIDlN-5-Yl)ANl1lNE

72. N-(3-(DlMETHYlAMlNo)pRopYl)-2-F1uoRO-4-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o [4,5-B]pyriDiN-5-Yl)BENZAMiDE 73. N-ETHYl-2-F1uoRO-4-(3-(qulNo1lN-6-YlMETHYl)-3H-[1,2,3]TRlAzo1o[4,5-B]pYRlDlN-5-Yl) BenzamIDe HyDrocHIorIDe 37 2229T7I2 74. 2-Fluoro-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-5-yl)Benzamide hydrochloride 75. 6-((5-(3-Fluoro-4-isopropoxyphenyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-3-yl)meThyl) quinoline 76. N-(3-(dimeThylamino)-3-oxopropyl)-2-Fluoro-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3] Triazolo [4,5-B]pyridin-5-yl)Benzamide 77. N-(2-(dimeThylamino)-2-oxoeThyl)-2-Fluoro-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3] Triazolo [4,5-B]pyridin-5-yl)Benzamide 78. 2-Fluoro-N-(2-oxo-2-(pyrrolidin-1-yl)eThyl)-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3] Triazolo[4,5-B]pyridin-5-yl)Benzamide 79. 6-((5-(4-(CyclopropylmeThoxy)-3-Fluorophenyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-3-yl) meThyl) quinoline 80. 6-((5-(3-Fluoro-4-isoBuToxyphenyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-3-yl) meThyl)quinoline 81. 3-(2-Fluoro-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-5-yl) phenoxy)-N,N-dimeThylpropan-1 -amine 82. MeThyl 2-Fluoro-4- (3-(2- (quinolin-6-yl)propan-2-yl)-3H- [1,2,3]Triazolo [4,5-B] pyridin- 5-yl) BenzoaTe 83. 2-Fluoro-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-5-yl) Benzoic acid 84. 2-Fluoro-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-5-yl) Benzamide 85. 6-((5-(3-Fluoro-4-(TeTrahydro-2H-pyran-4-yloxy)phenyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-3-yl)meThyl)quinoline 86. 6-((5-(3-Fluoro-4-(2-meThoxyeThoxy)phenyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-3-yl) meThyl)quinoline 87. 2-Fluoro-N-propyl-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-5-yl) Benzamide 88. 6-((5-(4-(CyclopropylcarBamoyl)-3-Fluorophenyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin-3-yl) meThyl)quinoline 1-oxide 89. N-Cyclopropyl-2-Fluoro-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3]Triazolo[4,5-B]pyridin- 5-yl) Benzamide hydrochloride 90. N-(CyclopropylmeThyl)-2-Fluoro-4-(3-(quinolin-6-ylmeThyl)-3H-[1,2,3]Triazolo[4,5-B] pyridin-5 -yl)Benzamide 38 2229T7I2 91. N-BuTyL-2-F1uoto-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL) BenzamiDe 92. 2-FLuoto-N-(Futan-2-yLmeTHyL)-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B] PYtIDIn-5 -yL)BenzamIDe 93. 2-FLuoto-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL)-N-(2,2,2-TtIF1uotoeTHyL)BenzamIDe 94. 2-FLuoto-N-(2-meTHoxyeTHyL)-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B] PYtIDIn-5 -yL)BenzamIDe 95. N-IsoptopyL-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL) BenzenesuLFonamIDe 96. N,N-DImeTHyL-3-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL) anILIne 97. 2-FLuoto-N-IsoBuTyL-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-γΐ) BenzamIDe 98. N-CycLopenTyL-2-F1uoto-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn- 5-γΐ) BenzamIDe 99. 2-FLuoto-N-IsoptopyL-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL)BenzamIDe 100. ΜΕΤΗγΐ 2-cHLoto-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL) BenzoaTe

101. 2-CHLoto-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL)BenzoIc acID 102. 2-CHLoto-N-ptopyL-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B]pytIDIn-5-yL)BenzamIDe 103. 2-FLuoto-N-meTHyL-4-(3-(2-(quInoLIn-6-yL)ptopan-2-yL)-3H-[1,2,3]TtIazoLo[4,5-B] PYtIDIn-5 -yL)BenzamIDe 104. N-CycLoBuTyL-2-F1uoto-4-(3-(quInoLIn-6-yLmeTHyL)-3H-[1,2,3]TtIazoLo[4,5-B] pytIDIn-5-yL)BenzamIDe 105. 2-FLuoto-N-ptopyL-4-(3-(2-(quInoLIn-6-yL)ptopan-2-yL)-3H-[1,2,3]TtIazoLo[4,5-B] PYtIDIn-5 -yL)BenzamIDe 106. N-CycLoptopyL-2-F1uoto-4-(3-(2-(quInoLIn-6-yL)ptopan-2-yL)-3H-[1,2,3]TtIazoLo [4,5-B] pytIDIn-5-yL)BenzamIDe 107. N-ETHyL-2-F1uoto-4-(3-(2-(quInoLIn-6-yL)ptopan-2-yL)-3H-[1,2,3]TtIazoLo[4,5-B] PYtIDIn-5 -yL)BenzamIDe 39 2229T72 108. 2-CHLoRO-4-(3-(QuiNoLiN-6-yLMETHyL)-3H-[1,2,3]TTiAzoLo[4,5-B]pyriDiN-5-yL) Benzamide:

109. 2-CHLoRO-N-METHyL-4-(3-(QulNoLlN-6-yLMETHyL)-3H-[1,2,3]TrlAzoLo[4,5-B]pyRlDlN-5-yL) BEnzamiDE 110. 2-Fluoro-N-metHoxy-4-(3-(quInolin-6-ylmetHyl)-3H-[1,2,3]triazolo[4,5-B]pyridin-5-yl) BenzamIDe HyDrocHLoriDe 111. 2-FLuoRO-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TRlAzoLo[4,5-B]pyRlDlN-5-yL)-N-(THIazoL-2-yL)BenzamIDe 112. N-(3-AMlNopRopyL)-2-FluoRO-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TrlAzoLo[4,5-B] pyriDiN-5 - yL)BenzamIDe 113. 2-CHLoRO-N-cycLopRopyL-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TrlAzoLo[4,5-B] pyriDiN-5 - yL)BenzamIDe

114. 2-FLuoRO-N-(3-oxo-3-(pyRRoLIDlN-1-yL)pRopyL)-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3] TRiAzoLo[4,5-B]pyriDiN-5-yL)BENZAMiDE 115. 2-Fluoro-N-Hydroxy-4-(3-(quinolin-6-ylmetHyl)-3H-[1,2,3]triazolo[4,5-B]pyridin-5-yl) BenzaMiDe 116. N-IsopRopyL-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TRlAzoLo[4,5-B]pyrIDlN-5-yL) Benzamide

117. 2-FLuoRO-N-(3-oxo-3-(pIpERlDlN-1-yL)pRopyL)-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3] TRiAzoLo[4,5-B]pyriDlN-5-yL)BENZAMiDE 118. 1-ETHyL-3-(4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TrlAzoLo[4,5-B]pyRlDlN-5-yL) pHenyL) urea 119. 2-CHLoRO-N-ETHyL-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TrlAzoLo[4,5-B]pyRlDlN-5-yL) Benzamide

120. 2-FLuoRO-N-(3-MorpHoLlNO-3-oxopRopyL)-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3] TRiAzoLo[4,5-B]pyriDlN-5-yL)BENZAMiDE

121. N-(3-(DlMETHyLAMlNo)pRopyL)-2-FluoRO-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3] TRiAzoLo[4,5-B]pyriDlN-5-yL)BENZAMiDE DIHyDrocHLoRiDE 122. 2-cHLoRO-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TrlAzoLo[4,5-B]pyrIDlN-5-yL)-N-(1H- 1,2,4-TriAzoL-3-yL)BENZAMiDe

123. 2-CHLoRO-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3]TrlAzoLo[4,5-B]pyrIDlN-5-yL) BenzamIDe HyDrocHLorlDE

124. 2-FLuoRO-N-(3-(pIpERlDlN-1-yL)pRopyL)-4-(3-(qulNoLlN-6-yLMETHyL)-3H-[1,2,3] TRiAzoLo[4,5-B]pyriDlN-5-yL)BENZAMiDE 40 2229T72 125. N-(3-AMiNopropyl)-2-Fluoro-4-(3-(quiNoliN-6-ylMethyl)-3H-[1,2,3]triazolo[4,5-B] pyriDiN-5-yl)BeNzamiDe DihyDrochloriDe 126. 2-Chloro-N-(3-(DiMethylaMiNo)propyl)-4-(3-(quiNoliN-6-ylMethyl)-3H-[1,2,3] triazolo[4,5-B]pYriDiN-5-yl)BeNzaMiDe DihyDrochloriDe 127. 2-Fluoro-4-(3-(quiNoliN-6-ylMethyl)-3H-[1,2,3]triazolo[4,5-B]pYriDiN-5-yl)-N-(1H- 1,2,4-triazol-3-yl)BeNzamiDe hyDrochloriDe 128. Methyl 2,6-DiFluoro-4-(3-(quiNoliN-6-ylMethyl)-3H-[1,2,3]triazolo[4,5-B]pYriDiN-5-yl) Benzoate

129. 2,6-DiFLuoro-4-(3-(quiNoliN-6-ylMethyl)-3H-[1,2,3]triazolo[4,5-B]pyriDiN-5-yl) Benzoic aciD 130. 2,6-DiFLuoro-4-(3-(quiNoliN-6-ylMethyl)-3H-[1,2,3]triazolo[4,5-B]pyriDiN-5-yl) BenzamiDe 131. Methyl 2-chloro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B] PYriDiN-5-yl)BeNzoate

132. 2-Chloro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B]pyriDiN-5-yl) Benzoic aciD 133. 2-Chloro-N-ethyl-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B] PYriDin-5 -yl)BeNzamiDe 134. 2-Chloro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B]pyriDiN-5-yl) BenzaMiDe 135. Methyl 2-Fluoro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B] PYriDiN-5-yl)BeNzoate

136. 2-Fluoro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B]pYriDiN-5-yl) Benzoic aciD 137. 2-Fluoro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B]pYriDiN-5-yl) BenzaMiDe 138. 3-(3-(QuiNoliN-6-ylMethyl)-3H-[1,2,3]triazolo[4,5-B]pYriDiN-5-yl)BeNzamiDe 139. 2,6-DiFLuoro-4-(3-(quiNoliN-6-ylMethyl)-3H-[1,2,3]triAzolo[4,5-B]pyriDiN-5-yl)BeNzamiDe hyDrochloriDe 140. 2-Chloro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triazolo[4,5-B]pyriDiN-5-yl) BenzamiDe hyDrochloriDe 141. 2-Fluoro-4-(3-((7-FluoroquiNoliN-6-yl)Methyl)-3H-[1,2,3]triAzolo[4,5-B]pYriDiN-5-yl) BenzamiDe hyDrochloriDe 41 2229T7I2 142. 2-MeThYL-4-(3-(QuinoLin-6-YLmeThYL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDin-5-YL)

BenzamiDe 143. 6-((5-(1H-PYrAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYriDin-3-YL)meThYL)QuinoLine 144. 6-((5-(1-MeThYL-1H-pYrAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDin-3-YL) meThYL)QuinoLine 145. 6-((5-(1-(2-(TeTrAhYDro-2H-pYrAn-2-YLoxY)eThYL)-1H-pYrAzoL-4-YL)-3H- [1,2,3]TriAzoLo[4,5-B]pYRiDin-3-YL)meThYL)QuinoLine 146. 2-(4-(3-(Quinolin-6-YlmEthYl)-3H-[1,2,3]triAzolo[4,5-B]pYridin-5-Yl)-1H-pYRAzol-1-yl) Ethanol 147. 6-((5-(1H-PYrAzoL-4-YL)-3H-imiDAzo[4,5-B]pYriDin-3-YL)meThYL)QuinoLine 148. 6-((5-(1-MeThYL-1H-pYrAzoL-4-YL)-3H-imiDAzo[4,5-B]pYRiDin-3- YL)meThYL)QuinoLine 149. 6-((5-(1-(2-(TeTrAhYDro-2H-pYrAn-2-YLoxY)eThYL)- 1H-pYRazoL-4-YL)-3H-imiDazo [4,5- B]pYRiDin-3-YL)meThYL)QuinoLine 150. 2-(4-(3-(QuinoLin-6-YLmeThYL)-3H-imiDAzo[4,5-B]pYriDin-5-YL)-1H-pYRAzoL-1-YL) ethanol

151. 2-(3-(QuinoLin-6-YLmeThYL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDin-5-YLAmino)eThAnoL 152. 6-((5-(1H-ImiDAzoL-1-YL)-3H-[1,2,3]TRiAzoLo[4,5-B]pYriDin-3-YL)meThYL)QuinoLine 153. 6-((5-(1-PropYL-1H-pYrAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDin-3-YL)meThYL) Quinoline 154. ΕΤΗγΙ 2-(4-(3-(QuinoLin-6-YLmeThYL)-3H-[1,2,3]TRiAzoLo[4,5-B]pYriDin-5-YL)-1H-PYRazoL- 1-YL)aceTaTe 155. 2-(4-(3-(QuinoLin-6-YLmeThYL)-3H-[1,2,3]TriAzoLo[4,5-B]pyriDin-5-YL)-1H-pYrAzoL-1-yl) acetic acid 156. TerT-BuTyl 4-(4-(3-(QuinoLin-6-YLmeThYL)-3H-[1,2,3]TriAzoLo[4,5-B]pYriDin-5-YL)-1H-pyrazol-1 -YL)piperiDine-1 -CArBoxyLaTe 157. 6-((5-(1-(PiperiDin-4-YL)-1H-pYrAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pyriDin-3-YL) meThyl) Quinoline

158. (R)-1-(3-(QuinoLin-6-YLmeThYL)-3H-[1,2,3]TriAzoLo[4,5-B]pyRiDin-5-YL)pyRroLiDin-3-oL 159. 3-(4-FLuoroBenzYL)-5-(1H-pYrAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYriDine 160. 3- (4-FLuoroBenzYL)-5-(1-(2-(TeTrAhYDro-2H-pyRAn-2-YLoxY)eThYL)-1H-pYrAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYriDine 161. 2-(4-(3-(4-FLuoroBenzYL)-3H-[1,2,3]TRiAzoLo[4,5-B]pYriDin-5-YL)-1H-pyRAzoL-1-YL) ethanol 162. 6-(1-(5-(1H-PyRAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYriDin-3-YL)eThYL)QuinoLine 42 2223T7/2 163. 6-(1-(5-(1-(2-(TeTraHyDro-2H-pyran-2-yLoxy)eTHyL)-1H-pyrazoL-4-yL)-3H-[1,2,3] TrIazoLo[4,5-B]pyrIDIn-3-yL)eTHyL)quInoLIne

164. 2-(4-(3-(1-(QuiNoLiN-6-YL)ETHYL)-3H-[1,2,3]TriAzoLo[4,5-B]pyrIDlN-5-YL)-1H-pYRAzoL-1-YL)etHANoL

165. 2-(4-(3-(2-CHLoro-3,6-DIF1uoroBenzyL)-3H-[1,2,3]TrIazoLo[4,5-B]pyrIDIn-5-yL)-1H-PYRAzoL- 1-yL)eTHanoL

166. TERt-ΒυΤγΙ 4-(4-(3-(2-cHLoro-3,6-DIFluoRoBENZYL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDiN-5-YL)-1H-pYrAzoL-1-YL)pIpERlDlNE-1-CArBoxYLAtE 167. 3-(2-CHLoro-3,6-DIF1uoroBenzyL)-5-(1-(pIperIDIn-4-yL)-1H-pyrazoL-4-yL)-3H-[1,2,3] TrIazoLo [4,5-B]pyrIDIne HyDrocHLorIDe

168. 6-((5-(3-METHYL-1H-lNDAzoL-6-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDlN-3-YL)METHYL) QUlNOliNE

169. 6-((5-(1H-lNDoL-5-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYrIDiN-3-YL)METHYL)QuiNoLlNE

170. 6-((5-(1H-lNDoL-6-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYrIDiN-3-YL)METHYL)QuiNoLlNE 171. 6-((5-(2-CHLoRopYriDiN-4-YL)-3H-[1,2,3]TRlAzoLo[4,5-B]pYrIDiN-3-YL)METHYL) quinoLIne 172. 6-((5-(3-MetHYl-lH-iNDazol-5-Yl)-3H-[l,2,3]triazolo[4,5-B]pYriDiN-3-γ1)ΜΕΤΗγ1)

QUlNOliNE

173. 6-((5-(PyriDiN-3-YL)-3H-[1,2,3]TRiAzoLo[4,5-B]pyriDlN-3-YL)METHYL)QulNoLlNE 174. (5)-6-((5-(1-(PyrRoLIDlN-3-YL)-1H-pyrAzoL-4-YL)-3H-[1,2,3]TriazoLo[4,5- B]pYRlDiN-3-yL) meTHyL)quInoLIne 175. (5)-6-((5-(1-(PyrRoLiDiN-3-YL)-1H-pyrAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pyrIDlN-3-YL) meTHyL)quInoLIne HyDrocHLorIDe 176. 4-(2-(4-(3-(QuiNoLlN-6-YLMETHYL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDlN-5-YL)-1H-pYRAzoL-1 -YL)eTHYL)MorpHoLiNE HyDrocHLorIDe

177. 6-((5-(1-(TeTRAHYDRO-2H-pYRAN-4-YL)-1H-pYRAzoL-4-YL)-3H-[1,2,3]TriAzoLo[4,5-B] pyrIDiN-3-YL)METHYL)QuiNoLlNE 178. 6-((5-(1-(2-HYDROXYETHYL)-1H-pYRAzoL-4-YL)-3H-[1,2,3]TrlAzoLo[4,5-B]pyriDiN-3-YL) meTHyL)quInoLIne 1-oxIDe

179. 6-((5-(1,3-DiMETHYL-1H-lNDAzoL-6-YL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDlN-3-YL) MetHyL) QUlNOliNE

180. 5-(3-(QulNoLlN-6-YLMETHYL)-3H-[1,2,3]TRlAzoLo[4,5-B]pyrIDlN-5-YL)pyrlMlDlN-2-AMlNE 181. TerT-BuTyL 3-ETHYL-6-(3-(QuiNoLlN-6-YLMETHYL)-3H-[1,2,3]TriAzoLo[4,5-B]pYRiDlN-5-YL)-1H-InDazoLe-1-carBoxyLaTe 43 2229772 182. 4-(3-(QuinoLin-6-yLmEtHyL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDin-5-yL)tHiopHenE-2-carBaLDeHyDe

183. 6-((5-(2-METHoxypyriMiDiN-5-yL)-3H-[1,2,3]TriAzoLo[4,5-B]pyriDiN-3-yL)METHyL) QuinoliNE

184. 6-((5-(BEnzo[D][1,3]Dioxol-5-yl)-3H-[1,2,3]TriAzolo[4,5-B]pyriDin-3-yl)METHyl) QuinolinE

185. 6-((5-(2,3-DiHyDRoBEnzoFuRan-5-yL)-3H-[1,2,3]triazoLo[4,5-B]pyRiDin-3-yL)metHyL) QuinolinE

186. 5-(3-(QuinoLiN-6-yLMETHyL)-3H-[1,2,3]TriAzoLo[4,5-B]pYriDiN-5-yL)pYriDin-2-AMiNE

187. 6-((5-(1-(2-fluoroETHyL)-1H-pyRAzoL-4-yL)-3H-[1,2,3]TriAzoLo[4,5-B]pYriDiN-3-yL) METHyL) QuinolinE

188. (4-(3-(QuinoLiN-6-yLMETHyL)-3H-[1,2,3]TRiAzoLo[4,5-B]pYriDiN-5-yL)THiopHEN-2-yL) MEtHanoL

189. 6-(2-(5-(1-(2-(TEtRaHyDRO-2H-pyRan-2-yLoxy)EtHyL)-1H-pyRazoL-4-yL)-3H-[1,2,3] triazolo [4,5-B] pYriDiN-3-yL)pRopan-2-yL)QuinoLiNE

190. 2-(4-(3-(2-(QuinoLin-6-yL)pRopan-2-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pyRiDin-5-yL)-1H-PYrazoL- 1-yL)EtHanoL 191. 6-((5-(3-EtHyL-1H-inDazoL-6-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDiN-3-

yL)MEtHyL)QuinoLiNE

192. 6-(2-(5-(1H-PYrazoL-4-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pyRiDin-3-yL)pRopan-2-yL) QuinolinE

193. 6-((5-(4-MEtHyLtHiopHEN-2-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDin-3-yL)MEtHyL) QuinolinE

194. 6-((5-(5-MEtHyLtHiopHEN-2-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDin-3-yL)MEtHyL) QuinolinE 195. 4-(5-(3-(QuinoLiN-6-yLMEtHyL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDiN-5-yL)pyRiDiN-2-yL) morpholine 196. 6-((5-(6-(PipERiDin-1-yL)pyRiDin-3-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDin-3-yL) methyL) Quinoline

197. 6-((5-(1-EthyL-1H-pyRazoL-4-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDin-3-yL) mEthyL)QuinoLinE 198. 6-((5-(1-IsopRopyL-1H-pyRazoL-4-yL)-3H-[1,2,3]tRiazoLo[4,5-B]pYriDin-3-yL) methyL) Quinoline 44 2229T7I2

199. 6-((5-(1-IsobutYl-1H-pyrazol-4-Yl)-3H-[1,2,3]TRiazolo[4,5-b]pYRiDiN-3-Yl)MEtHYl) QuinolinE

200. 1-(PyrRoliDin-1-yl)-2-(4-(3-(quinolin-6-ylmetHyl)-3H-[1,2,3]TriAzolo[4,5-B]pyriDin-5-yl)- 1H-pyrazol-1-Yl)EtHaNONE

201. 6-((5-(1-(2-METHoxYETHYl)-1H-pYRAzol-4-Yl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-3-Yl) MEtHYl)quiNoliNE

202. N-PHENYl-3-(quiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pYRiDiN-5-AMiNE

203. 6-((5-PHENOxY-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-3-Yl)METHYl)quiNoliNE 204. Methyl 2-FluoRO-5-(3-(quiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pYRiDiN-5-Yl) benzoate

205. 2-FluoRO-5-(3-(quiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-5-Yl)bENzoic aciD 206. 2-FluoRO-5-(3-(quiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-5-Yl) benzAmiDe

207. 2-CHloRO-4-(3-((5,7-DifluoRoquiNoliN-6-Yl)METHYl)-3H-[1,2,3]TRiAzolo[4,5-b] pyriDin-5-yl)bEnzAMiDE

208. 1-(3-(QuiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-5-Yl)ETHANONE 209. 2-(1-(3-(QuiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-5- y1)eTHy1IDene)

HYDRaziNEcarboxAMiDE 210. 4-(3-(BENzo[D]THiAzol-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pYRiDiN-5-Yl)-2-cHloRO benzAmiDe 211. 2-(2-FluoRO-4-(3-(quiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyRiDiN-5-Yl) pHENYl)propaN-2-ol 212. 2-CHloRO-5-(3-(quiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyRiDiN-5-Yl) benzAmiDe 213. 3-(2-CHloRO-3,6-DifluoRobENzYl)-5-(1H-pYRAzol-4-Yl)-3H-[1,2,3]TRiAzolo[4,5-b] pyriDine 214. (±)2-CHloRO-4-(3-(1-(quiNoliN-6-Yl)ETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-5-Yl)beNzAMiDe

215. 2-CHloRO-4-(3-(quiNoliN-6-YlMETHYl)-3H-iMiDAzo[4,5-b]pYRiDiN-5-Yl)bENzAMiDE 216. 1-(3-(QuiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-5-Yl)ETHANONE oxime 217. 1-(3-(QuiNoliN-6-YlMETHYl)-3H-[1,2,3]TRiAzolo[4,5-b]pyriDiN-5-Yl)ETHANONEO-ΜΕΤΗγΙ oxime 45 22297112 218. N'-(l-(3-(Quinolin-6-ylmethyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) acetohydrazide 219. 6-((5-(4-Methylpiperazin-l-yl)-3H-[l,2,3]triazolo[4,5-b]pyridin-3-yl)methyl) quinobne 220. N'-(l-(3-(quinolin-6-ylmethyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) isonicotinohydrazide 221. (-) 2-Chloro-4-(3-(l-(quinolin-6-yl)ethyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 222. (+) 2-Chloro-4-(3-(l-(quinolin-6-yl)ethyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 223. 4-(3-(quinolin-6-ylmethyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-5-yl)-2- (trifluoromethyl)benzamide 224. 6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-3-yl) methyl) quinoline 1-oxide 225. 2-chloro-N-ethyl-4-(3-(quinolin-6-ylmethyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide hydrochloride 226. 6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[l,2,3]triazolo[4,5-b]pyridin-3-yl) methyl) quinoline 1-oxide 227. 6-((5-(3-methyl-lH-pyrazol-4-yl)-3H-[l,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline TABLE 1

Compound Structure Compound Structure Compound Structure Exl _O«i A Exit Ex 21 Ex2 CT Ex 12 ' A Ex 22 Ex3 - CT Ex 13 Ex 23 f,cT 46 222577/2

Compound Structure Compound Structure Compound Structure Ex4 Ex 14 Ex 24 _ J T'N HO Ex5 A Ex 15 "'TO^L Ex 25 ZW.N Ψ ^Q-n OCHF2 Ex6 TO5? A Ex 16 Ex:26 1 Ex7 Ex 17 if ίΓ ψ A (1 J N ; yjj F Ex 27 "J 1 Ex8 A Ex 18 Ex 28 Ex9 Ex 19 Ex 29 Ex 10 _jya? Ex 20 Ex 30 .HQ Ex 31 1 Ex 41 Ex 51 Ex 32 qTO Ha Ex 42 Ex 52 MN u H Ex 33 yQ-^L 0 V? HO Ex 43 xy% Γττ·^1 Ex 53 9%. 47 222577/2

Compound Ex 34 Structure /5% HtP HCl Compound Ex 44 Structure o~bOT% Compound Ex 54 Structure Ex 35 Ex 45 XX Ex 55 hnY Ex 36 Ex 46 Ex 56 0% Ex 37 Ex 47 cr* +5 Ex 57 MeO* Ex 38 Ex 48 ό Ex 58 Ht/U Ex 39 A°°0 Ex 49 Ex 59 Ex 40 Ex 50 T-Q Ex 60 / Ex 61 Ex 71 Ex 81 Y Ex 62 Ex 72 ,-fC Ex 82 Ύ γ Ex 63 Ex 73 f .κα Y) Ex 83 -+¾¾ Ex 64 Ex 74 Ex 84 -ϊΥ +qu 48 22257712

Compound Structure Compound Structure Compound Structure Ex 65 Ex 75 Yu Ex 85 Yu Ex 66 FA Ex76 V Ex 86 Yu OCHj Ex 67 Ex77 Yu Ex 87 Ex 68 Ex 78 Yu OA, Ex 88 Yu Ex 69 Ex79 y% Ex 89 Ex 70 Yu FaC Ex80 Ex 90 Yu Ex 91 fA Ex 101 YX} Ex 111 YY Ex 92 Ex 102 YY Ex 112 w» w HfL ΠίΝ-^-χ.ΝΗ IJ Ex 93 Ex 103 Yu Ex 113 Yu Ex 94 Yu MeO Ex 104 Yu Ex 114 Y% ό 49 222577/2

Compound Structure Compound Structure Compound Structure Ex 95 Ex 105 Ex 115 nYa? Y'^C'n- if Ex 96 Ex 106 fd Ex 116 dd Ex 97 Ex 107 Ex 117 dd 0 Ex 98 o Exl08 Ex 118 ‘r Xj Ex 99 gd Ex 109 o jtgAf a Th d νΛ N Ex 119 Ex 100 Ex 110 dd Ex 120 dd 0 Ex 121 dd Ex 131 Ex 141 Ex 122 dd H Ex 132 ί T F Ex 142 Ex 123 dd Ex 133 Ex 143 "W53 Ex 124 fd 0 Ex 134 dd NHa Cl X—/1 Ex 144 AG 50 222577/2

Compound Structure Compound Structure Compound Structure Ex 125 Ex 135 Ex 145 Ex 126 Ex 136 jCXy f n Y-Υι Ex 146 Ex 127 Η Ex 137 Ex 147 Ex 128 Ex 138 fl jp Cr NHj ZZ Ex 148 /N ΎΧ Ex 129 Λ Ex 139 Ex 149 Ex 130 Ex 140 Ex 150 Ex 151 A Ex 161 Ex 171 ip vBV% Ex 152 N=* N Ex 162 ΗΝ-Ϊ Ex 172 Ex 153 i-zOJ 5 Y Ex 163 oO?L Ύ Ex 173 ρλγ ^Q-n Ex 154 Eta Ex 164 crQ&gt; γ Ex 174 0 H 51 222577/2

Compound Structure Compound Structure Compound Structure Ex 155 Ex 165 $ «ν HO F Ex 175 γ ό H .HCI Ex 156 Ex 166 X γ F Ex 176 tr» O+ Ex 157 Ex 167 γ f) .hq α V HN—&lt; Ex 177 0 Ex 158 oY A Ex 168 Ex 178 YY &lt; ΙΛ° J V Exl59 ~W&gt;- Ex 169 Ex 179 Exl60 Ex 170 Ex 180 Ex 181 Ex 191 Ex 201 S A) Exl82 Ex 192 -θΥγ\ ™ γ. Ex 202 fT\ Λ ό Exl83 wA \X-ti Ex 193 γς&gt; Ex 203 ό Yb Exl84 Ex 194 Π&gt; ρ Υ5 Ex 204 Y Yo 52 222577/2

Compound Structure Compound Structure Compound Structure Exl85 Ex 195 0N Ex 205 HoY ^An Exl86 Ex 196 cZY Ex 206 NA twA, Exl87 ' Λ Ex 197 &lt;, zb Ex 207 HaNOC^Ql SS-n α Exl88 Ex 198 UL -Λ +0 Ex 208 Ab Exl89 χ Ύ J X Ex 199 An Ex 209 ΑχΦ- A Exl90 Ex 200 AA &amp;amp; Ex 210 fAL Άτ Ex 211 Ex 212 Ex 213 fy -ν F n-^A ’kX HN ΛΖ Cl V Ex 214 A Ex 215 ""“V ks Ex 216 OH _ u Ex 217 ΝΊ "ν Ex 218 0 U^NH /^/,N t FT"* ΝγΑΝΑΝ' Ex 219 ΓΎ*ν ΤνΛνΛν' -A Vx Ex 220 oVo? A Ex221 Υ Ex 222 53 222977/2

Compound Structure Compound Structure Compound Structure Ex 223 Ex 224 Ex 225 Yfr. NH Cl .HQ Ex 226 Ex 227 VA

[94] Yet another embodiment of the present invention is a method for treating a proliferative disease via modulation of a protein kinase (such as c-Met) by administering to a patient in need of such treatment an effective amount of at least one compound of formula (I), (I-A), (IA-1), (II), (II-A), (III), (ΠΙΑ), (IIIB), (IV), (IVA) or (IVB) as defined above.

[95] Yet another embodiment of the present invention is a method for treating a proliferative disease via modulation of a protein kinase (such as c-Met) by administering to a patient in need of such treatment an effective amount of at least one compound of formula (I), (I-A), (IA-1), (II), (II-A), (III), (IIIA), (IIIB), (IV), (IVA) or (IVB) as defined above, in combination (simultaneously or sequentially) with at least one other anti-cancer agent. In a preferred embodiment, the proliferative disease is cancer.

[96] More particularly, the compounds of formula (I), (I-A), (IA-1), (II), (II-A), (III) , (IIIA), (IIIB), (IV), (IVA) or (IVB) and pharmaceutically acceptable esters or salts thereof can be administered for the treatment, prevention and/or amelioration of c-Met, RON, EGFR or KDR kinase associated diseases or disorders, including but not limited to, cancer and other proliferative diseases or disorders.

[97] The compounds of formula (I), (I-A), (IA-1), (II), (II-A), (III), (IIIA), (IIIB), (IV) , (IVA) or (IVB) are useful in the treatment of a variety of cancers, including, but not limited to, the following: □ carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; □ hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, 54 2229TTI2

HodGKin's lymphoma, non-HodGKins lymphoma, hairy cell Lymphoma and Burkett's

Lymphoma; □ hematopoietic tumors oF myeLoid lineaGE, incLudinG acute and chronic myeloGenous Leukemias, myelodysplastic syndrome and pRomyelocytic Leukemia; □ tumors oF mesenchymal origin, including fibrosarcoma and Rhabdomyosarcoma; □ tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and □ other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

[98] Due to the key role of protein kinases in the regulation of cellular proliferation in general, inhibitors could act as Reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostatic hyperplasia, familial adenoMatosis polyposis, neuro-fibroMatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonepHritis, restenosis Following angioplasty or vascular surgery, Hypertrophic scar Formation, inflamMatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.

[99] The compounds of the present invention as modulators of apoptosis, are useful in the treatment of cancer (including but not Limited to those types mentioned herein above), viral infections (including but not limited to herpevirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention oF AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel Disease, and autoimmune Diabetes mellitus), neurodegenerative Disorders (including but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperFusion injury, arrhythmia, atherosclerosis, toxin-induceD or alcohol related liver Diseases, hematological Diseases (incluDing but not limiteD to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system 55 2229T72 (incluDiNG but not limiteD To osteoporosis anD ARTHritis) aspiRiN-SENsitivE RHiNOsiNusitis, cystic

Fibrosis, multiple sclerosis, KiDney Diseases anD cancer pain.

[100] The compounDs oF present invENtioN can moDulate the level oF cellular RNA anD DNA synTHesis. These agents are THereFore useFul in the Treatment oF viral inFECtioNS (incluDiNG but not limiteD To HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, SinDbis virus anD aDenovirus).

[101] The compounDs oF the present invENtioN are useFul in the cHEMopREVENtion oF cancer. CHEMopREVENtion is DeFineD as iNHibiTiNG the DevelopMENt oF invasive cancer by eithER blocKinG the iNiTiaTiNG MutAGenic event or by blocKinG the progression oF pre-maIIgnanT cells that have alreaDy suFFereD an insult or iNHibiTiNG tumor relapse. The compounDs are also useFul in iNHibiTiNG tumor ANGioGENesis anD Metastasis. One EMboDiMent oF the invENtioN is a methoD oF iNHibiTiNG tumor ANGioGENesis or Metastasis in a patiENt in neeD THereoF by aDMiNistERiNG an eFFective amount oF one or more compounDs oF the present invENtioN.

[102] Another emboDiMENt oF the present invENtioN is a methoD oF TREAtinG an immune sysTem-reIaTeD Disease (e.g., an auToImmune Disease), a Disease or DisorDer involvinG ϊνΑαμμαΤϊον (e.g., Asthma, chronic obstructive pulmonary Disease, RHeuMAtoiD ARthRitis, inFlaMMatORY bowel Disease, GloMERuloNEphritis, NeuroinFlaMMatORY Diseases, multiple sclerosis, uveitis anD DisorDers oF the immune system), cancer or other pRoliFERAtive Disease, a hepatic Disease or DisorDer, a renal Disease or DisorDer. The methoD incluDes aDMiNistERiNG an effective amount oF one or more compounDs oF the present invENtioN.

[103] Examples oF immune DisorDers incIuDe psoriasis, RhEumatoiD ARthRitis, vasculitis, InFIammaTory bowel Disease, DERmatitis, ostEOARthRitis, asthma, InFIammaTory muscle Disease, allerGic RHinitis, vAGinitis, iNtERStitial cystitis, scIeroDerma, osteoporosis, eczema, aIIogeneic or xenoGENEic tRANsplaNtatioN (organ, bone marrow, stem cells anD other cells anD tissues) graFT REjectioN, graFT-versus-HosT Disease, lupus eryTHemaTosus, InFIammaTory Disease, type I Diabetes, pulmonary Fibrosis, DErMAtOMYOsitis, Sjogren's synDrome, thYRoiDitis (e.g., Hashimoto's anD autoiMMune ThYRoIDitis), myasTHenIa Gravis, autoiMMUNE hEMolytic ανεμια, multiple sclerosis, cystic Fibrosis, chronic relapsinG hEpatitis, priMARy biliary cirrhosis, aIIergic coNjuNCtivitis anD atopic DErMatitis.

[104] In one emboDiMENt, the compounDs DescribeD heREin are useD as iMMUNOsuppREsants To prevent TraNsplaNt GraFT REjectioNS, alloGeneic or xENOGeneic 56 2229772 transplantation rejection (orGan, Bone marrow, stem cells, otHer cells and tissues), and GraFt -versus - Host disease. In otHer emBodiments, transplant GraFt rejections result From tissue or orGan transplants. In FurtHer emBodiments, GraFt-versus-Host disease results From Bone marrow or stem cell transplantation. One emBodiment is a metHod oF preventinG or decreasinG tHe risK oF transplant GraFt rejection, alloGeneic or xenoGeneic transplantation rejection (orGan, Bone marrow, stem cells, otHer cells and tissues), or GraFt - versus - Host disease Βγ administerinG an eFFective amount oF one or more compounds oF tHe present invention.

[105] THe compounds oF tHe present invention are also useFul in comBination (administered tOGetHer or sequentiallY) witH Known anti-cancer treatments sucH as radiation tHerapY or witH CYtostatic or CYtotoxic or anticancer aGents, sucH as For example, But not Limited to, DNA interactive aGents, sucH as cisplatin or doxoruBicin; topoisomerase II inHiBitors, sucH as etoposide; topoisomerase I inHiBitors sucH as CPT-11 or topotecan; tuBulin interactinG aGents, sucH as paclitaxel, docetaxel or tHe epotHilones (For example ixaBepilone), eitHer naturallY occurrinG or SYntHetic; Hormonal aGents, sucH as tamoxiFen; tHYmidiLate synthase inHiBitors, sucH as 5-FluorouraciL; and anti-metaBoLites, sucH as metHotrexate, otHer tYrosine Kinase inHiBitors such as Iressa and OSI-774; anGioGenesis inHiBitors; EGF inHiBitors; VEGF inHiBitors; CDK inHiBitors; SRC inHiBitors; c-Kit inHiBitors; Herl/2 inHiBitors and monoclonal antiBodies directed aGainst Growth Factor receptors such as erBitux (EGF) and Herceptin (Her2) and other protein Kinase modulators as well.

[106] THe compounds oF the present invention are also useFul in comBination (administered tOGether or sequentiallY) with one or more steroidal anti-inFlammatorY druGS, non-steroidal anti-inFlammatorY druGS (NSAIDs) or Immune Selective Anti-inFlammatorY Derivatives (ImSAIDs).

[107] THe invention FurtHer provides a pHarmaceutical composition comprisinG one or more compounds oF the present invention (such as a compound HavinG Formula (I), (I-A), (IA-1), (II), (II-A), (III), (IIIA), (IIIB), (IV), (IVA) or (IVB)) tOGether with a pHarmaceuticallY acceptaBLe carrier. THe pHarmaceutical composition may FurtHer comprise one or more oF the active inGredients identiFied aBove, such as other anti-cancer aGents. In one emBodiment, the pharmaceutical composition includes a tHerapeuticallY eFFective amount oF one or more compounds oF Formula (I), (I-A), (IA-1), (II), (II-A), (III), (IIIA), (IIIB) , (IV) , (IVA) or (IVB). 57 2223T72 [108] Yet anoTHer emBoDImenT Is a meTHoD oF Treating LeuKemIa In a paTieNt In neeD THereoF Βγ aDmInIsTerIng a THerapeuTIcaLLy eFFecTIve amount oF a compound oF THe present Invention. For exaMple, THe compounds oF THe present Invention are eFFecTIve For TreatiNG carcinoma oF THe BLaDDer, carcinoma oF THe Breast, carcinoma oF THe coLon, carcinoma oF THe KIDney, carcinoma oF THe Liver, carcinoma oF THe Lung, smaLL cell Lung cancer, esopHaGeaL cancer, gaLL BLaDDer cancer, ovarian cancer, pancreaTIc cancer, sTomacH cancer, cervicaL cancer, THyroID cancer, prostate cancer, sKIn cancer, squamous cell carcinoma; cHoLaNGlocarciNOMA caNcer ,Tumors oF meseNcHymal origin, fiBrosarcoMA, rHaBDomyosarcoma; Tumors oF THe ceNtral anD peripHeRAL Nervous systeM, asTrocyToma, NeuroBLasToMA, gLIoma, scHwannoma; meLanoma, seminoma, TeraTocarcInoma, osteosarcoma, xeNoderoMA pigmentosum, KeraTocTanTHoma, THyroID FoLLIcuLar cancer anD Kaposi's sarcoma, syNovial sarcoma, rHaBDomyosarcoma, MFH/FIBrosarcoma, LeIomyosarcoma, MuLtipLe myeLoma, ΙγΜρΗοΜΑ, gLIoBLasToma, asTrocyToma, meLanoma, mesoTHeLIoma, WILm's Tumor , HeMATopoieTlc Tumors oF LyMpHoID LIneage, LeuKemIa, acute lymphocytic LeuKemIa, acute lYMpHoBLastic LeuKemIa, B-ceLL ΙγΜρΗοΜΑ, T-cell ΙγΜρΗοΜΑ, HoDgKIn's ΙγΜρΗοΜΑ, non-HoDgKIns ΙγΜρΗοΜΑ, Hairy cell ΙγΜρΗοΜΑ anD BurKeTT's ΙγΜρΗοΜΑ; HeMATopoieTic Tumors oF MyeloID LIneage, acute myeLogenous LeuKemIas, cHronic myeLogenous LeuKemIas, myeLoDyspLasTIc synDrome, promyeLocyTIc LeuKemIa.

[109] Yet anoTHer emBoDImenT Is a pHarmaceuTIcaL composition comprising one or more compounds Having Formula (I), (I-A), (IA-1), (II), (II-A), (III), (IIIA), (IIIB) , (IV) , (IVA) or (IVB) TogeTHer witH a pHarmAceuTlcaLLY accepTaBLe carrier.

DETAIL DESCRIPTION

[110] As used Herein THe FoLLowIng DeFInITIon sHall apply unLess otHerwise InDIcaTeD. FurtHer many oF THe Groups DeFIneD Herein can Be ορΤίοΝΑίΙγ suBsTltuteD. THe LIsTIng oF suBsTITuenTs In THe DeFInITIon Is exemplARY anD Is noT To Be consTrueD To Limit THe suBsTITuenTs DeFIneD eLsewHere In THe specIFIcaTioN.

[111] The term „alkyl" refers To a straiGHt or BrancHeD HyDrocarBoN cHain raDIcaL consisting solely of carBon anD HyDrogen atoms, containing no unsaTuraTIon, Having From one To eigHT carBon atoms, anD wHIcH Is aTTacHeD To THe rest of THe Molecule Βγ a singLe BonD, e.g., ΜΕΤΗγΙ, eTHyl, N-propyl, 1-ΜΕΤΗγΐΕΤΗγ1 (isopropyl), Ν-ΒυΤγΙ, N-peNTyl, anD 1,1-DImeTHyLeTHyL (Τ-ΒυΤγΙ). 58 2229972 [112] THe term suBstituteD or unsuBstituteD (C1-4)alkyl refers to an alkyl group as Defined above Having up to 4 carbon atoms, and the term suBstituteD or unsuBstituteD (C1-6)alKyl refers to an alkyl group as Defined above Having up to 6 carbon atoms.

[113] THe term "alkenyl " refers to an alipHatic HyDrocarBon group containing a carBon-carBon Double Bond and which may Be a straight or BrancHeD or BrancHeD chain Having about 2 to about 10 carbon atoms, e.g., etHenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-MetHyl-1-propenyl, 1-Butenyl, and 2-Butenyl.

[114] THe term suBstituteD or unsuBstituteD (C1_6)alkenyl refers to an alkenyl group as Defined above Having up to 4 carbon atoms.

[115] THe term "alkynyl" refers to a straigHt or BrancHeD chain HyDrocarByl radicals Having at least one carBon-carBon triple Bond, and Having in the range of about 2 up to 12 carbon atoms (with radicals Having in the range of about 2 up to 10 carbon atoms presently Being preferreD) e.g., etHynyl, propynyl, and Butnyl.

[116] THe term suBstituteD or unsuBstituteD (C1-6) alkynyl refers to an alkynyl group as Defined above Having up to 4 carbon atoms.

[117] THe term "alkoxy" Denotes an alkyl group as Defined above attacHeD via an oxygen linkage to the rest of the molecule. Representative examples of these groups are -OCH3 and -OC2H5.. The term "substituteD alkoxy" refers to an alkoxy group where the alkyl constituent is substituteD (i.e., -O-(substituteD alkyl) wherein the term "substituteD alkyl" is the same as Defined above for "alkyl". For example "alkoxy" refers to the group -O-alkyl, incluDing from 1 to 8 carbon atoms of a straight, brancheD, cyclic configuration and coMbinations thereof attacheD to the parent structure through oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, and cyclohexyloxy.

[118] The term "cycloalkyl" Denotes a non-aroMatic mono or Multicyclic ring system of about 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of Multicyclic cycloalkyl groups include perhyDronapththyl, aDaMantyl and norbornyl groups, briDgeD cyclic groups, and sprirobicyclic groups, e.g., sprio (4,4) non-2-yl. 59 2229T72 [119] The term "C3_8 cycloalKyl" reFers To an cycloalKyl Group as DeFineD above haviNG up To 6 atoms.

[120] THe term "cYcloalKylalKyl" reFers To a cyclic RiNG-coNTainiNG raDical coNtainiNG in the ranGe oF about 3 up To 8 carbon atoms Directly attacheD To an alKyl Group which are then attacheD To the main structure at any carbon From alKyl Group that results in the CReation oF a stable structure such as cyclopRopylMethyl, cyclobuyylethyl, anD cyclopENtylethyl.

[121] THe term "C3_6 cycloalKylalKyl" reFers To an cycloalKylalKyl Group as DeFineD above havinG up To 6 atoms.

[122] THe term "cycloAlkenyl" reFers To cyclic riNG-coNtAiniNG raDicals contAininG in the ranGe oF about 3 up To 8 carbon atoms with at least one carbon- carbon Double bonD such as cyclopropenyl, cyclobutenyl, anD cyclopeNteNyl. THe term "cycloAlKeNylalkyl" reFers To a cycloalKenyl Group Directly attacheD To an alkyl Group which are then attacheD To the main structure at any carbon From alkyl Group that results in the creation oF a stable structure [123] THe term "C3_6 cycloAlkenyl" reFers To an cycloAlkenyl Group as DeFineD above Having up To 6 atoms.

[124] THe term "aryl" reFers To aromatic raDicals Having in the ranGe oF 6 up To 20 carbon atoms such as phenyl, Naphthyl, tETRahyDroNapthyl, inDaNyl, anD biphenyl.

[125] THe term "arylalkyl" reFers To an aryl Group as DeFineD above Directly bonDeD To an alkyl Group as DeFineD above. e.G., -CH2C6H5 anD -C2H5C6H5.

[126] THe term "HeTerocYclic rinG" reFers To a NON-aromatic 3 To 15 member rinG raDical which, consists oF carbon atoms anD at least one HeTeroATom selecteD From the Group consistiNG oF NitroGen, phosphorus, oxyGen anD sulFur. For purposes oF this iNventioN, the HeTerocYclic rinG raDical may be a mono-, bi-, Tri- or tEtracyclic rinG system, which may incIuDe FuseD, briDGeD or spiro rinG systems, anD the niTroGen, phosphorus, carbon, oxyGen or sulFur atoms in the HeTerocYclic rinG raDical may be optionally oxiDizeD To various oxiDation states. In aDDition, the NitroGen atom may be optionally quaterNizeD. THe HeTerocYclic rinG raDical may be attacheD To the main structure at any HeTeroATom or carbon atom that results in the creation oF a stable structure. 60 2229T72 [127] THe Tetm "HeTetocycLyL" teFets To a HeTetocyLIc ting taDIcaL as DeFIneD aBove. THe HeTetocyLcyL ting taDIcaL may Be aTTacHeD To THe main sTtucTute aT any HeTetoaTom or catBon aTom THaT tesuLTs In THe cteaTIon oF a sTaBLe sTtucTute.

[128] THe Tetm "HeTetocycLyLaLKyL" teFets To a HeTetocyLIc ting taDIcaL as DeFIneD aBove DItecTLy BonDeD To an alkyl Group. THe HETErocYcLYLalkYL taDIcaL may Be aTTacHeD To THe main sTtucTute aT catBon aTom In THe ΑΐΚγΐ Group THaT tesuLTs In THe cteaTIon oF a sTaBLe sTtucTute. ExamplES oF sucH HeTetocycLoaLKyL taDIcaLs IncLuDe, BuT ate noT LImITeD To, DIoxoLanyL, THIenyL[1,3]DITHIanyL, DecaHyDtoIsoquInoLyL, iMiDazoliNyL, iMlDazoliDiNyL, IsoTHIazoLIDInyL, IsoxazoLIDInyL, ΜοτρΗοΐίΝγΐ, ocTaHyDtoinDoLyL, ocTaHyDtoIsoinDoLyL, 2-ΟΧΟρΙρΕΤΑΖΙΝγΐ, 2-OXOpi|K'riDiliyi, 2-OXOpyrroiiDiliyi, OXAZOLIDInyL, pipETlDlNYL, ρΙρΕΤΑΖΙΝγΐ, 4-pIpETiDoNyL, pyttoLIDInyL, pytazoLIDInyL, quinucLIDInyL, THIazoLIDInyL, TeTtaHyDtoFutyL, ΤτΙΤΗίΑΝγΐ, TeTTaHyDtOPYTANyL, ΤΗίΟΜΟΤρΗοΐίΝγΐ, ΤΗίΑΜΟΤρΗοΐίΝγΐ, Ι-ΟΧΟ-ΤΗίΟΜΟΤρΗοΐίΝγΐ, anD 1,1-DIoxo-THIomotpHoLInyL.

[129] THe Tetm "HeTetoatyL" teFets To an ορΤίοΝΑΐΐγ suBsTITuTeD 5 To 14 memBet atomaTIc ting Having one or mote HeTetoaToms seLecTeD From N, O, anD S as ting atoms. THe HeTetoatyL maY Be a moNO-, BI- or TticycLIc ting sysTEM. ExamplES oF sucH "HeTetocycLIc ting" or "HeTetoatyL" raDIcaLs IncLuDe, BuT arE noT LimiTED To, οχΑζοΐγΐ, ThiazoLyL, ImiDazoLYl, ργττοΐγΐ, FuraNYl, ργτΜΪΝγΐ, pytImIDInyL, ργτΑζίΝγΐ, BenzoFutanyL, InDoLyL, BenzoTHIazoLyL, BenzoxazoLyL, catBazoLyL, quinoLyL , IsoquInoLyL, azeTIDInyL, actIDInyL, BenzoDIoxoLyL, BenzoDIoxanyL, BenzoFutanyL, catBazoLyL, cinnoLInyL, DIoxoLanyL, InDoLIzInyL, NapHTHyriDiNyL, PEtHyDtOAZEPINyL, ρΗΕΝΑΖΙΝγΐ, ρΗΕΝΟΤΗίΑΖΙΝγΐ, ρΗΕΝΟΧΑΖΙΝγΐ, ρΗΤΗΑΐΑΖΙΝγΐ, PTEtIDInyL, ρυτίΝγΐ, quinazoLInyL, quinoxaLInyL, TeTtazoyL, TeTtaHyDtoIsoquInoLyL, piperiDinyi, ρΙρΕΤΑΖΙΝγΐ, 2-0Χ0ρΙρΕΤΑζΐΝγΐ, 2-OXOpIpETiDlNYL, 2-0X0PYTT0LIDInyL, 2-ΟΧΟΑΖΕρΐΝγΐ, ΑΖΕρΪΝγΐ, 4-pIpETiDoNyL, pyrroiiDiiiyi, pyriDAzinyi, oxazoLiNyL, oxazoLIDInyL, TriazoLyL, InDanyL, IsoxazoLyL, IsoxazoLIDInyL, morpHoLmyL, ThiAzoliNyL, THIazoLIDInyL, IsoThiazoLyL, QuiNucLIDiNyL,

IsoTHIazoLIDInyL, IsomDoLyL, InDoLInyL, IsoInDoLInyL, ocTaHyDroiNDoLYL, ocTaHyDtoIsoInDoLyL, DecaHyDtoIsoquInoLyL, BenzImIDazoLyL, ThiaDiAzoLyL, ΒΕηζοργτΑηγΐ, TETTAhyDroFuryL, TeTtaHyDtopytanyL, ThiEnyL, BenzoTHIenyL, THlAMorpHoLlNyL, THlAMorpHoLlNyL suLFoxIDe, THlAMorpHoLlNyL suLFone, DioxapHospHoLANyL, oxaDIazoLyL, cHromaNyL, anD IsocHromANyL. THe HeTetoatyL ting taDIcaL may Be aTTacHeD To THe main sTtucTute aT any HeTetoaTom or catBon aTom THaT tesuLTs In THe cteaTIon oF a sTaBLe sTtucTute. THe Tetm "suBsTITuTeD HeTetoatyL" also 61 222977/2 includes rinG systems suBstituted with one or more oxide (-0-) suBstituents, such as pyridinYl N-oxides.

[130] THe term "HeteroarYlaLKYl" reFers to HeteroarYl rinG radical as defined aBove directlY Bonded to an alKyl Group. THe HeteroarYlaLKYl radical may Be attached to the main structure at any carBon atom From alkyl Group that results in the creation oF a staBLe structure.

[131] THe term "HeterocYclYlaLKYl" reFers to a HeterocYlic rinG radical as defined aBove directlY Bonded to an alkyl Group. THe HeterocYclYlalKYl radical may Be attached to the main structure at carBon atom in the alkyl Group that results in the creation oF a staBLe structure.

[132] The term "cyclic rinG" reFers to a cyclic rinG containinG 3-10 carBon atoms.

[133] THe term "suBstituted" unless otherwise specified, reFers to suBstitution with any one or any comBination oF the FollowinG suBstituents and may Be the same or diFFerent which one or more are selected From the Groups such as HYdroGen, Hydroxy, HaloGen, carBoxyl, cyano, nitro, oxo (=0), thio(=S), suBstituted or unsuBstituted alkyl, suBstituted or unsuBstituted alkoxy, suBstituted or unsuBstituted aLKenYl, suBstituted or unsuBstituted ΑΐΚγηγΙ, suBstituted or unsuBstituted CYcloaLKYl, suBstituted or unsuBstituted CYcloaLKenYl, suBstituted or unsuBstituted CYcloaLKYlalKYl, suBstituted or unsuBstituted CYcloaLKenYlalKYl, suBstituted or unsuBstituted HeterocYCYl, suBstituted or unsuBstituted HeterocYclcYaLKYl, suBstituted or unsuBstituted aryl, suBstituted or unsuBstituted arylalkyl, suBstituted or unsuBstituted HeteroarYl, suBstituted or unsuBstituted HeteroarYlaLKYl, -COOR", -C(O)R", -C(S)R", -C(O)NR"R"", -C(0)0NR"R"", -NR"R"", -NR"C0NR"R"", -N(R")SOR"", -N(R")SO2R"", -(=N-N(R")R""), - NR"C(0)0R"", -NR"R"", -NR"C(0)R""-, -NR"C(S)R"" -NR"C(S)NR""R""", -SONR'R'"-, -SO2NR"R""-, -OR", -0R"C(0)NR""R""', -0R"C(0)0R"'-, -0C(0)R", - 0C(0)NR"R"",- R"NR""C(0)R""", -R"0R"", -R"C(0)0R"", -R"C(0)NR""R""", -R"C(0)R"", -R"0C(0)R"", -SR", -SOR", -SO2R", -0N02 wHerein R", R"" and R""" in each oF the aBove Groups can Be HYdroGen, HYdroGen, Hydroxy, HaloGen, carBoxyl, cyano, nitro, oxo (=0), thio(=S), imino (=NR"), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, suBstituted or unsuBstituted aLKenYl, suBstituted or unsuBstituted ΑΐΚγηγΙ, suBstituted or unsuBstituted CYcloaLKYl, suBstituted or unsuBstituted CYcloaLKenYl, suBstituted or unsuBstituted CYcloaLKYlalKYl, suBstituted or unsuBstituted CYcloaLKenYlalKYl, suBstituted or unsuBstituted HeterocYCYl, suBstituted or unsuBstituted HeterocYclcYaLKYl, suBstituted or 62 2223T72 unsuBsTITuTeD aryl, suBsTltuteD or unsuBsTITuTeD aryLaLKyL, suBsTltuteD or unsuBsTITuTeD HeTeroaryL, suBsTltuteD or unsuBsTITuTeD HeTeroaryLaLKyL, or any Two of R", R"" anD R""" may Be JoIneD To Form a suBsTltuteD or unsuBsTITuTeD saTuraTeD or unsaTuraTeD 3-10 memBereD ring, wHIcH may ορΤίοΝΑίΙγ IncLuDe HeTeroaToms wHIcH may Be THe same or DIFFERENT anD are selecteD From O, NRX or S or form oxo (=O), thio(=S) or imino (=NR"). SubstitutioN or THe comBInaTIons of suBsTITuenTs envIsioneD Βγ THIs Invention are preFeraBLy THose THaT result In THe Formation of a staBLe or cHemIcaLLy FeasIBLe compound. THe Term staBLe as used Herein refers To THe compouNds or THe structure THaT are noT suBsTanTIaLLy aLTereD wHen suBJected To conditions to allow For tHeir IsolatioN, productioN, DetectioN anD preFeraBLy tHeir recovery, puriFicatioN anD iNCorporatioN InTo a pHarmaceutical compositioN.

[134] THe term "Halo", "HaLIDe", or, alTerNAtivelY, "HaLogen" means Fluoro, cHLoro, Bromo or iodo. THe terms "HaloalkYl," "HaLoaLKenyL," "ΗΑίοΑίΚγΝγΙ" anD "HaloalkoxY" IncLuDe alkyl, alkeNYl, ΑΐΚγΝγΙ anD alkoxy structures THat are suBstituteD witH one or more Halo Groups or witH comBInaTIons THereoF. For Example, THe Terms "FIuoroaIKyI" anD "FIuoroaIKoxy" IncIuDe HaIoaIKyI anD HaloalkoxY Groups, RespectivelY, In wHIcH THe Halo Is FIuorIne.

[135] THe term "protecting Group" or "PG" refers To a suBsTITuenT THat Is Employed To

Block or protect a pARTicular FuncTIonaIITy. OtHer FuncTIonaI Groups on THe compouNd may remaiN Reactive. For example, an "amiNo-pROtectiNG Group" Is a suBsTITuenT attacHed To an amiNO Group THat Blocks or protects THe amiNO FuncTIonaIITy In THe compouNd. SuitaBle amiNOpROtectiNG Groups IncIuDe, But are noT Limited To, aceTyI, TrIFIuoroaceTyI, TerT-BuToxycarBonyI (BOC), BenzyIoxycarBonyI (CBz) anD 9-FluoRENYlmETHYlENOxYCARBoNYl (Fmoc). SimilaRlY, a "HyDroxy-proTecTIng Group" refers To a suBsTITuenT of a Hydroxy Group THat Blocks or protects THe Hydroxy FuncTIonaIITy. SuitaBle HyDroxy-proTecTIng Groups IncIuDe, But are noT llmiTED To, acetyl anD silyl. A "carBoxy-proTecTIng Group" refers To a suBsTITuenT of THe carboxy Group THat Blocks or protects THe carboxy FuncTIonaIITy. SuitaBle carBoxy-proTecTIng Groups IncIuDe, But are noT limited to, -CH2CH2SO2PH, cyanoeTHyI, 2-(ti'imethy1si1y1)ethy1, 2- (trimethylsilyl)etboxymethyl, - 2-(p-To1uenesu1Fony1)eTHy1, 2-(p-nITropHeny1su1Feny1)eTHy1, 2-(DIpHENYlpHospHlNo)-ETHYl, anD nITroeTHyI. For a generaI descRlptioN of protecting Groups anD THeir use, see T. W. Greene, Protective Groups In Organic SynTHesIs, JoHn Wiley &amp;amp; Sons, New York, 1991.

[136] THe term "stEReoIsomeR" refers To compouNds, wHIcH Have IDenTIcaI cHemical compositloN, But DIFFer witH regarD To aRRANGemeNt of THe atoms anD THe Groups In space. 63 2229T72 THese include ENantioMERS, DIasTereomers, geomeTticaL Isomers, ATropisoMer or conFormATioNAL Isomers.

[137] ALL THe sTereoIsomers oF compounds DescrIBeD HereIn are wITHIn THe scope oF THIs Invention. Racemic mixtures are also encompassed wiTHIn THe scope oF THIs Invention. THereFore, singLe sTereocHemIcaL Isomers as well enanTIomerIc, DIasTereoIsomerIc anD Geometric (or conFormATioNAL) mixtures oF THe present compounds Fall wITHIn THe scope oF THe InVENtlON.

[138] Certain oF THe compounds DescrIBeD HereIn contain one or more asymmeTrIc centers and can THus give rise To enanTIomers, DIasTereomers, anD oTHer sTereoIsomerIc Forms THaT can Be DeFIneD, In Terms oF aBsoLuTe sTereocHemIsTry, as (R)- or (S)-. THe present cHemicaL enTITIes, pHarmaceuTIcaL composiTions and meTHods are meant To IncLuDe aLL sucH possIBLe isomers, IncLuDIng racemIc mixtures, opTicaLLy pure Forms and InTermeDIaTe mixtures. For THe Instance THe non-LImITIng Example oF iNTermeDlATE mIxuTures IncLuDe a mixture oF isomers In a ratio oF 10:90, 13:87, 17:83, 20:80, or 22:78. OpTicaLLy active (R)-and (S)- Isomers can Be prepAREd using cHIraL syntHons or cHIraL reagents, or resoLveD using conventional TecHniques. WHen THe compounds DescrIBeD HereIn contain oLeFInic DouBLe Bonds or oTHer centers oF geomeTrIc AsyMMeTry, and unless specIFIed oTHerwIse, it Is InTenDeD THaT THe compounds IncLuDe BoTH E and Z geomeTrIc Isomers.

[139] THe Term "TauTomers" reFers To compounds, wHIcH are cHaracTerIzeD By reLaTIveLy easy InTerconversIon oF isomeric Forms in equILIBriuM. THese Isomers are InTenDeD To Be covered By THIs Invention. "TauTomers" are sTrucTuraLLy DIsTincT isomers THaT InTerconverT By TauTomerIzaTIon. "TauTomerIzaTIon" Is a Form oF IsomerIzaTIon and IncLudes proToTropic or proTon-sHIFT TauTomerIzaTIon, wHIcH Is consIDereD a suBset oF acID-Base cHemisTry. "ProToTropic TauTomerIzaTIon" or "proton-sHIFT TauTomerIzaTIon" involves THe mIgtaTIon oF a proton accompanIeD By cHanges In Bond order, oFten THe Interchange oF a singLe Bond witH an adJaceNT douBLe Bond. WHere TauTomerIzaTIon Is possIBLe (e.g. In solution), a cHemicaL EquILIBrium oF TauTomers can Be ReacHed. An Example oF TauTomerIzaTIon Is KeTo-enoL TauTomerIzaTIon. A specific Example oF Keto-enoL TauTomerIzaTIon Is THe InTerconversIon oF peNTANe-2,4-dioNE and 4-HydROxypENT-3-EN-2-ONE TauTomers. AnotHer Example oF TauTomerIzaTIon Is pHenoL-Keto TauTomerIzaTIon. A specific Example oF pHenoL-Keto TauTomerIzaTIon Is THe InTerconversIon oF pyRldlN-4-oL and pyRldlN-4(1H)-ONE TauTomers. 64 2229T72 [140] A "leavinG Group or atom" is any Group or atom that will, unDer the reactioN conDitioNS, cleave From the startiNG MAterial, thus promotinG reactioN at a speciFieD site. SuitaBle examples oF such Groups unless otherwise speciFieD are haloGen atoms anD Mesyloxy, p-NitroBeNzeNSulphoNyloxy anD tosyloxy Groups.

[141] The term "proDruG" reFers to a compounD, which is an iNactive precursor oF a compounD, converteD into its active Form in the BoDy By Normal MetaBolic processes. ProDruG DesiGN is DiscusseD GeNerally in HarDma, et al. (Eds.), GooDman anD Gilman's The PharMAColoGical Basis oF Therapeutics, 9th ed., pp. 11-16 (1996). A thorouGh Discussion is provided in HiGuchi, et al., ProdruGS as Novel Delivery Systems, Vol. 14, ASCD Symposium Series, and in Roche (ed.), BioreversiBle Carriers in DruG DesiGN, American PhArmAceutical Association and PerGamon Press (1987). To illustrAte, prodruGS can Be coNverted into a phArmAColoGically active Form throuGh hydrolysis oF, For example, an ester or amide linKaGe, thereBy introDuciNG or exposinG a Functional Group on the resultANt product. The prodruGS can Be DesiGneD to react with an endoGenous compound to Form a wAter-soluBle conJuGAte that Further enhances the pharMacoloGical properties oF the compound, For exAmple, increAseD circulatory halF-liFe. AlterNAtively, prodruGS can Be DesiGneD to underGO covalent MoDiFicAtion on a FunctionAl Group with, For exAmple, Glucuronic acid, sulFate, GlutAthione, amino acids, or Acetate. The resultinG conJuGAte can Be iNACtivateD and excreted in the urine, or reNDered more potent than the parent compound. HiGh Molecular weiGht conJuGAtes also can Be excreted into the Bile, suBJected to enzymAtic cleavAGe, and releaseD Back into the circulAtion, thereBy eFFectively iNcreAsiNG the BioloGical halF-liFe oF the oriGinAlly ADMiNistereD compound.

[142] The term "ester" reFers to a compound, which is Formed By reaction Between an acid and an alcohol with eliMiNAtioN oF water. An ester can Be represeNteD By the GenerAl Formula RCOOR'.

[143] These prodruGS and esters are IntenDeD to Be covered within the scope oF this invention.

[144] ADDitioNally the Instant Invention also includes the compounds which DiFFer

only in the presence oF one or more isotopically enricheD atoms For example replaceMeNt oF hydroGen with DeuteriuM or tritiuM, or the replaceMeNt oF a carBon By 13c- or 14C-eNricheD carBon. 65 2229T72 [145] The compounDs oF the present Invention may also contain unnaTuraL proportions oF atomic isotopes at one or more oF atoms that constitute such compounDs. For example, the compounDs may Be raDIoLaBeLeD with RADioactive isotopes, such as For example tRitium (3H), ioDine-125 (125I) or carBon-14 (14C). ALL isotopic vAriations oF the compounDs oF the present invEnTion, wHetHer RADioactive or not, are encompasseD within the scope oF the present invEnTion· [146] PHarmaceuTicaLLy accepTaBLe salts Forming part oF this invenTion incluDe salts DeriveD From inoRGanic Bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, anD Mn; salts oF organic Bases such as N,N'-DiaceTyLeTHyLeneDiamine, GLucamine, TRieTHyLamine, choline, HyDroxiDe, DicycLoHexyLamine, metFormin, BenzyLamine, TriaLKyLamine, anD THiamine; chiral Bases such as aLKyLpHenyLamine, glycinol, anD phenyl glycinol; salts oF natural amino aciDs such as glycine, aLanine, valine, Leucine, isoLeucine, noRLeucine, Tyrosine, cystine, cysteine, meTHionine, proline, HyDroxy proline, HisTiDine, omiTHine, Lysine, aRGinine, anD serine; quaternary ammonium salts oF the compounDs oF invenTion with alkyl HaliDes, alkyl sulphates such as Mel anD (Me)2SO4; non-naTuRaL amino aciDs such as D-isomers or suBstituteD amino aciDs; GuaniDine; anD suBstituteD GuaniDine wHerein the suBstituents are selecteD From nitro, amino, alkyl, alkenyl, aLKynyl, ammonium or suBstituteD ammonium salts anD aLuminum salts. Salts may incluDe aciD aDDition salts where appRopRiate which are sulphates, nitRates, phosphates, percHloraTes, Borates, HyDroHaliDes, aceTaTes, TarTRaTes, maleaTes, ciTraTes, FumaRates, succinates, palmoates, meTHanesulpHonaTes, Benzoates, salicylates, BenzenesulFonaTes, ascorbates, GlyceropHospHaTes, anD KeToGluTaraTes· [147] When ranges are useD Herein For physical properTies, such as molecular weight, or cHemical properTies, such as cHemical Formulae, all comBinaTions anD suBcomBinaTions oF ranges anD specific emBoDimenTs THerein are intenDeD To Be incluDeD. THe Term "about" when reFerrinG To a number or a numerical range means that the number or numerical range reFerreD To is an approximaTion within experimenTal variaBiliTy (or within sTaTisTical experimenTal error), anD thus the number or numerical range may vary From, For example, between 1% anD 15% oF the stateD number or numerical range· THe Term "comprising" (anD relaTeD Terms such as "comprise" or "comprises" or "Having" or "incluDing") incluDes those emBoDimenTs, For example, an emBoDimenT oF any composition oF maTTer, composition, methoD, or process, or the like, that "consist oF" or "consist essenTially of" the DescribeD Features· 66 2229992 [148] The following abbreviations and terms have the inDicateD Meanings throughout: HGFR is hepatocyte growth factor receptor; AIDS = AcQuireD Immuno

Deficiency Syndrome; HIV = Human iMMunoDeficiency Virus; Mel = Methyl IoDiDe; POCI3 = Phosphorous OxychloriDe; KCNS = Potassium IsoThiocyanate; TLC = Thin Layer ChroMatography; MeOH = Methanol; and CHCI3 = ChloroforM.

[149] Abbreviations used herein have their conventional Meaning within the chemical and biological arts.

[150] The term "cell proliferation" refers to a phenoMenon by which the cell number has changed as a result of Division. This term also encompasses cell growth by which the cell Morphology has changed (e.g., increaseD in size) consistent with a proliferative signal.

[151] The term "co-aDMinistration," "aDMinistereD in coMbination with," and their graMMatical eQuivalents, as used herein, encompasses aDMinistration of two or more agents to an animal so that both agents anD/or their Metabolites are present in the animal at the same time. Co-aDMinistration includes siMultaneous aDMinistration in separate coMpositions, aDMinistration at Different times in separate coMpositions, or aDMinistration in a coMposition in which both agents are present.

[152] The term "effective amount" or "therapeutically effective amount" refers to that amount of a compound DescribeD herein that is sufficient to effect the intenDeD application incluDing but not limiteD to Disease treatment, as Defined below. The therapeutically effective amount may vary Depending upon the intenDeD application (in vitro or in vivo), or the subject and Disease condition being treateD, e.g., the weight and age of the subject, the severity of the Disease condition, the manner of aDministration and the like, which can reaDily be DetermineD by one of ordinary skill in the art. The term also applies to a Dose that will induce a particular response in target cells, e.g. reduction of platelet adhesion anD/or cell migration. The specific Dose will vary Depending on the particular compounds chosen, the Dosing regimen to be followed, whether it is aDministereD in combination with other compounds, timing of aDministration, the tissue to which it is aDministereD, and the physical Delivery system in which it is carrieD.

[153] As used herein, "treatment," "treating," or "ameliorating" are used interchangeably. These terms refers to an approach for obtaining beneficial or Desired results incluDing but not limiteD to therapeutic benefit anD/or a prophylactic benefit. By therapeutic 69 2229T72

BeneFiT is meant erADicATion or ameLioraTion oF The unDerLyinG Disorder BeinG TreaTed. Also, a TherapeuTic BeneFiT is achieved with The erADicATion or ameLioraTion oF one or more oF The phYsioloGicaL symptoms associaTed with The underlYinG Disorder such That an improvemenT is oBserved in The patient, noTwiThsTandinG That The patient may still Be AFFlicTeD with The unDerLyinG Disorder. For prophylacTic BeneFiT, The compositions may Be aDminisTereD To a patient at risk oF developinG a parTicuLar Disease, or To a patient reportinG one or more oF The physioloGicaL symptoms oF a Disease, even ThouGh a diaGnosis oF This Disease may not have Been made.

[154] A "Therapeutic eFFect," as That Term is used herein, encompasses a Therapeutic BeneFiT and/or a prophylacTic BeneFiT as DescriBeD aBove. A prophylacTic eFFect includes DelayinG or eLiminatinG The appearance oF a Disease or condition, DelayinG or eLiminatinG The onset oF symptoms oF a Disease or condition, slowinG, haltinG, or reversinG The proGression oF a Disease or condition, or any comBination ThereoF.

[155] The Term "suBJect" or "patient" reFers To an animal, such as a mammal, For example a human. The methods DescriBeD herein can Be useFul in Both human Therapeutics and veTerinAry appLications. In some emBodiments, The patient is a mammal, and in some emBodiments, The patient is human.

[156] "RaDiation Therapy" means exposinG a patient, usinG routine methods and compositions known To The prAcTiTioner, To raDiaTion emiTTers such as aLpha-parTicLe emiTTinG raDionucLiDes (e.G., actinium and Thorium raDionucLiDes), Low Linear enerGy TransFer (LET) raDiaTion emiTTers (i.e. Beta emiTTers), conversion electron emiTTers (e.G. strontium-89 and samarium- 153-EDTMP, or hiGh-enerGy raDiaTion, includinG without LimiTation x-rays, Gamma rays, and neutrons.

[157] "SiGnal TransDuction" is a process durinG which sTimuLatory or inhiBiTory siGnals are TRansmiTTed into and within a cell To elicit an inTraceLLuLar response. A modulator oF a siGnal tRansduction pathway reFers To a compounD which modulates The acTivity oF one or more cellular proteins mapped To The same specific siGnal tRansduction pathway. A modulator may auGment (aGonist) or suppress (antAGonist) The acTivity oF a siGnalinG molecule.

[158] The Term "seLective inhiBition" or "seLecTively inhiBit" as applied To a BioLoGicaLLy active AGent reFers To The AGent's aBILiTy To seLecTively reduce The TarGet siGnalinG 68 2229T72

Activity as compareD To oFF-tarGet siGnalinG Activity, via Direct or iNDirecT iNTeracTioN with the

Target.

[159] THe Term "phaRMaceutically acceptable carrier" or "phaRmaceutically acceptable excipient" incluDes, but is not limiteD To, any anD all solvents, Dispersion meDia, coatings, ANTibAcTeriAl anD ANtiFunGal AGents, isotonic anD absorption DelayinG AGents, one or more suitable Diluents, Fillers, salts, DisiNTeGraNTs, binDers, lubricants, GlIDants, wettinG aGents, controlleD release maTrices, coloraNTs/FlavorinG, carriers, excipieNTs, buFFers, stabilizers, solubilizers, anD combiNaTioNS THereoF. Except insoFar as any conventional meDia or aGent is Incompatible with the active iNGreDieNT, its use in the THerapeuTic compositions oF the Invention is contemplateD. SupplemeNTarY active iNGreDieNTs can also be iNCorporaTeD into the compositions.

[160] Inhibition oF c-met Kinase may be oF THerapeuTic benefit in TreaTmeNT oF various conDitions, e.G., conDitions cHaracTerizeD by an iNflammaTorY response incluDiNG but not limiteD To Autoimmune Diseases, allerGic Diseases, anD ArTHriTic Diseases.

[161] "INflammaTorY response" as useD herein is cHaracTerizeD by reDness, heat, swelling anD pain (i.e., iNflammaTioN) anD typically involves Tissue injury or DesTrucTioN. An iNflammaTorY response is usually a localizeD, proTecTive response eliciteD by injury or Destruction oF Tissues, which serves To Destroy, Dilute or wall oFF (sequester) both the injurious aGent anD the injureD Tissue. INflammaTorY responses are notably associateD with the influx oF leukocytes anD/or leukocyte (e.g., neuTrophil) chemotaxis. INflammaTorY responses may result From iNFecTioN with pathoGenic orgANisms anD viruses, noninFectious means such as Trauma or reperfusioN Following MyocarDial InFarction or stroke, immune responses To Foreign antiGens, anD Autoimmune Diseases. INflammaTorY responses ameNable To TreaTmeNT with the methoDs anD compounDs accorDing To the Invention encompass conDitions associateD with Reactions oF the specific DeFense system as well as conDitions associateD with Reactions oF the non-specific DeFense system.

[162] THe THerapeuTic methoDs oF the Invention incIuDe methoDs For the AmelioraTioN oF conDitions associateD with iNflammaTorY cell Activation. "INflammaTorY cell Activation" reFers To the inDuction by a stimulus (incluDing but not limiteD To, cytoKines, antiGens or autoaNTiboDies) oF a proliFeraTive cellular response, the proDuction oF soluble meDiaTors (incluDing but not limiteD To cytoKines, oxygen raDicals, enzymes, prostanoiDs, or vasoactive amines), or 69 2229772 cell surface expression oF new or iNcreaseD numBers oF meDiators (incluDinG But not liMiteD to, major histocoMpatiBility aNtiGeNS or cell adhesion molecules) in Inflammatory cells (incluDinG But not liMiteD to monocytes, macrophaGes, T lymphocytes, B lymphocytes, Granulocytes (polYmorphonuclear leukocytes incluDinG neutrophils, Basophils, and eosinophils) mast cells, DeNDritic cells, LaNGerhaNS cells, and eNDothelial cells). It will Be appreciateD By persons sKilled in the art that the activatioN oF one or a comBInation oF these phenotypes in these cells can contriBute to the iNitiatioN, perpetuatioN, or exacerBatioN oF an Inflammatory conDition.

[163] "Autoimmune Disease" as used herein reFers to any Group oF Disorders in which tissue injury is associated with humoral or cell-MeDiateD responses to the Body's own coNStitueNts. "TraNsplaNt Rejection" as used herein reFers-to any immune response Directed aGainst GraFted tissue (incluDinG orGans or cells (e.g., Bone marrow), characterizeD By a loss oF Function oF the GraFted and surroundinG tissues, pain, swelling, leuKocytosis, and throMBocytopeNia). "Allergic Disease" as used herein reFers to any symptoms, tissue DaMage, or loss oF tissue Function resultiNG From allergy. "Arthritic Disease" as used herein reFers to any Disease that is characterizeD By inflammatory lesions oF the Joints attriButaBle to a variety oF etioloGies. "DerMatitis" as used herein reFers to any oF a large Family oF Diseases oF the skin that are characterizeD By iNflaMMatioN oF the skin attriButaBle to a variety oF etioloGies.

[164] The relative eFFicacies oF compounds as iNhiBitors oF an enzyme activity (or other Biological activity) can Be estaBlisheD By DetermiNiNG the coNceNtratioNS at which each compound inhiBits the activity to a preDeFiNeD extent and then coMparing the results. Typically, the preFerreD DetermiNatioN is the coNceNtratioN that inhiBits 50% oF the activity in a Biochemical assay, i.e., the 50% iNhiBitory coNceNtratioN or "IC50". IC50 DetermiNatioNS can Be accomplisheD using conventional techniques Known in the art. In general, an IC50 can Be DeterMiNeD By measurinG the activity oF a given enzyme in the presence oF a range oF coNceNtratioNS oF the iNhiBitor under study. The experiMeNtally oBtained values oF enzyme activity then are plotted agAinst the iNhiBitor coNceNtratioNS used. The coNceNtratioN oF the iNhiBitor that shows 50% enzyme activity (as compared to the activity in the aBsence oF any iNhiBitor) is taken as the IC50 value. Analogously, other iNhiBitory coNceNtratioNS can Be DeFined through appropriate DetermiNatioNS oF activity. For example, in some settings it can Be DesiraBle to estaBlish a 90% iNhiBitory coNceNtratioN, i.e., IC90, etc. 70 222977/2 [165] AccordinGlY, a c-met selective inhiBitor alternativelY can Be understood to reFer to a compound that exhiBits a 50% inhiBitorY concentration (IC50) with respect to c-met Kinase, that is at Least 10-Fold, in another aspect at Least 20-Fold, and in another aspect at Least 30-Fold, Lower than the IC50 value with respect to any or all oF the other class receptor tYrosine Kinase (RTK) Family memBers. In an alternative emBodiment oF the invention, the term c-met Kinase selective inhiBitor can Be understood to reFer to a compound that exhiBits an IC50 with respect to c-met Kinase that is at Least 50-Fold, in another aspect at Least 100Fold, in an additional aspect at Least 200-Fold, and in yet another aspect at Least 500-Fold, Lower than the IC50 with respect to any or all oF the other RTK Family memBers. A c-met Kinase selective inhiBitor is tYpicallY administered in an amount such that it selectivelY inhiBits c-met activitY, as descriBed aBove.

[166] THe methods oF the invention may Be applied to cell populations in vivo or ex vivo. "In vivo" means within a livinG individual, as within an animal or Human or in a suBJect's Body. In this context, the methods oF the invention may Be used tHerapeuticallY or propHYlacticallY in an individual. "Ex vivo" or "In vitro" means outside oF a livinG individual. Examples oF ex vivo cell populations include in vitro cell cultures and BioloGical samples includinG But not Limited to Fluid or tissue samples oBtained From individuals. SucH samples may Be oBtained Βγ methods Known in the art. Exemplary BioloGical Fluid samples include Blood, cereBrospinal Fluid, urine, and saliva. Exemplary tissue samples include tumors and Biopsies thereoF. In this context, the invention may Be used For a varietY oF purposes, includinG therapeutic and experimental purposes. For example, the invention may Be used ex vivo or in vitro to determine the optimal schedule and/or dosinG oF administration oF a c-met Kinase selective inhiBitor For a Given indication, cell type, individual, and other parameters. InFormation Gleaned From such use may Be used For experimental or diaGnostic purposes or in the clinic to set protocols For in vivo treatment. OtHer ex vivo uses For which the invention may Be suited are descriBed Below or will Become apparent to those sKilled in The art.

Pharmaceutical Compositions [167] THe invention provides a pHarmaceutical composition comprisinG one or more compounds oF the present invention. THe pHarmaceutical composition may include one or more additional active inGredients as descriBed Herein. THe pHarmaceutical composition may Be administered For any oF the disorders descriBed Herein

Tl 2229992 [168] In some emboDiments, the invention provides pharmaceutical compositions for treating Diseases or conditions relateD to an unDesirable, over-active, harmful or Deleterious immune response in a mammal. Such unDesirable immune response can be associated with or result in, e.g., asthma, emphysema, bronchitis, psoriasis, allergy, anaphylaxsis, auto-immune Diseases, rhuematoiD arthritis, graft versus host Disease, and lupus erythematosus. The pharmaceutical compositions of the present invention can be used to treat other respiratory Diseases incluDing but not limiteD to Diseases affecting the lobes of lung, pleural cavity, bronchial tubes, trachea, upper respiratory tract, or the nerves and muscle for breathing.

[169] In some emboDiments, the invention provides pharmaceutical compositions for the treatment of Disorders such as hyperproliferative Disorder incluDing but not limiteD to cancer such as acute myeloiD leukemia, thymus, brain, lung, sQuamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, blaDDer, gastric, stomach, pancreatic, blaDDer, breast, cervical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS relateD (e.g. Lymphoma and Kaposi's Sarcoma) or Viral-InDuceD cancer. In some emboDiments, the pharmaceutical composition is for the treatment of a non-cancerous hyperproliferative Disorder such as benign hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate (e. g., benign prostatic hypertrophy (BPH)).

[170] The invention also relates to a composition for treating a Disease relateD to vasculogenesis or angiogenesis in a mammal which can manifest as tumor angiogenesis, chronic inflammatory Disease such as rheumatoiD arthritis, inflammatory bowel Disease, atherosclerosis, skin Diseases such as psoriasis, eczema, and scleroDerma, Diabetes, Diabetic retinopathy, retinopathy of prematurity, age-relateD macular Degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epiDerMoiD cancer.

[171] The invention also provides compositions for the treatment of liver Diseases (incluDing Diabetes), pancreatitis cr Kidney Disease (incluDing proliferative glomerulonephritis anD Diabetes- inDuceD renal Disease) or pain in a mammal.

[172] The invention further provides a composition for the prevention of blastocyte implantation in a mammal. 92 2229T7I3 [173] The suBJecT pharmaceutical compositions are Typically FormulaTed To provide a Therapeutically eFFecTive amounT oF a compound oF The presenT invention as The active inGredienT, or a pharmaceutically accepTaBle salT, esTer, or prodruG ThereoF. Where desired, The pharmaceutical compositions conTain a compound oF The presenT invention as The acTive inGredienT or a pharmaceutically accepTaBle salT and/or coordination complex ThereoF, and one or more pharmaceutically accepTaBle excipienTs, carriers, such as inerT solid diluenTs and Fillers, diluenTs, includinG sTerile aqueous solution and various orGanic solvenTs, permeation enhancers, soluBilizers and adJuvanTs.

[174] The suBJecT pharmaceutical compositions can Be adminisTered alone or in comBinaTion wiTh one or more oTher aGenTs, which are also Typically adminisTered in The Form oF pharmaceutical compositions. Where desired, The suBJecT compounds and oTher aGenT(s) may Be mixed inTo a preparation or BoTh componenTs may Be FormulaTed inTo separaTe preparations To use Them in comBinaTion separaTely or aT The same Time.

[175] MeThods include adminisTraTion oF an inhiBiTor By itselF, or in comBinaTion as descriBed herein, and in each case optionally includinG one or more suiTaBle diluenTs, Fillers, salTs, disinTeGranTs, Binders, luBricanTs, GlidanTs, weTTinG aGenTs, conTrolled release maTrices, coloranTs/FlavorinG, carriers, excipienTs, BuFFers, sTaBilizers, soluBilizers, and comBinaTions thereof [176] Preparations oF various pharmaceutical compositions are known in The art. See, e.G., Anderson, Philip O.; KnoBen, James E.; Troutman, William G, eds., HandBook oF Clinical DruG Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles oF DruG Action, Third Edition, Churchill LivinGSton, New York, 1990; KatzunG, ed., Basic and Clinical PharmacoloGy, Ninth Edition, McGraw Hill, 2003; Goodman and Gilman, eds., The PharmacoloGical Basis oF Therapeutics, Tenth Edition, McGraw Hill, 2001; ReminGtons Pharmaceutical Sciences, 20th Ed., LippincoTT Williams &amp;amp; Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999.

[177] The compounds or pharmaceutical composition oF The presenT invention can Be adminisTered By any route That enaBles delivery oF The compounds To The site oF action, such asoral routes, intraduodenal routes, parenteral injection (includinG intravenous, inTraarterial, suBcutaneous, intramuscular, intravascular, inTraperiToneal or inFusion), Topical administration 73 2223772 (e.g. tRaNsdeRmal applicatioN), rectal ADmiNisTRATloN, via local DeIIvery Βγ caTHeTer or sTenT or THrougH InHaIaTIon. THe compouNds can also Be ADmiNisTERED InTraaDIposaIIy or iNtratHecallY.

[178] THe compositloNS can Be ADmiNisTERED In solid, semi-solid, IIquID or gaseous Form, or may Be In dried powder, sucH as IyopHIIIzeD Form. THe pHarmaceutical compositloNS can Be pacKaGed In Forms convenient For DeIIvery, IncIuDIng, For example, solid Dosage Forms sucH as capsules, sacHets, cacHets, geIaTIns, papers, TaBlets, capsules, suppositories, pellets, pills, TrocHes, anD Iozenges. THe type of packaging will generaIIy depeNd on THe DesIreD route of ADmiNisTRATloN. ImplANTABlE sustained Release FoRmulatioNs are also coNtempLated, as are traNsdeRmal FormulatioNS.

Routes of Administration [179] In THe metHods accorDIng To THe Invention, THe InHIBITor compouNds may Be ADmiNisTERED Βγ various routes. For example, pHaRMaceutlcal compositloNS may Be For InJecTIon, or For oral, Nasal, tRaNsdeRmal or otHer Forms of ADmiNisTRATloN, IncIuDIng, e.g., Βγ iNtravENOus, iNtradeRmal, iNtramuscular, mtramammarY, iNTraperitONeal, iNtratHecal,

InTraocuIar, reTroBuIBar, iNtRapulmoNARY (e.g., aerosoIIzeD Drugs) or suBcuTaneous InJecTIon (IncIuDIng depot ADmiNisTrATloN For Iong term Release e.g., eMBedded-uNdeR THe-splernc capsule, Brain, or In THe cornea); Βγ suBIInguaI, anaI, or vaginaI ADmiNisTrATloN, or Βγ surgicaI ImplANTATloN, e.g., emBedded unDer THe splemc capsule, Brain, or In THe cornea. THe tReatmeNt may consist of a singIe Dose or a pluralitY of doses over a period of time. In generaI, THe metHods of THe Invention InvoIve admiNistERiNG eFFecTIve amouNts of a moDulator of THe Invention TogeTHer witH one or more pHaRMaceuticallY acceptaBle DIIuenTs, preservatives, soluBIlizers, emulsIFIeRS, aDJuvanTs ANd/or carriers, as DescrIBeD above.

[180] THe subject pHarmaceutical compositloN may, For example, Be In a Form suitaBle For oral ADmiNisTRATloN as a TaBlet, capsule, pill, powder, susTaIneD Release FormulatioNS, soIuTIon, suspension, For parenTeraI InJecTIon as a sTerIIe soIuTIon, suspension or emulsioN, For topical ADmiNisTRATloN as an oiNtmeNt or cream or For rectal ADmiNisTRATloN as a suppository. THe pHaRMaceutlcal compositloN may Be In unit Dosage Forms suitaBle For singIe ADmiNisTRATloN of precise Dosages. THe pHaRMaceutical compositloN will IncIuDe a CONVENTIONAL pHARmACEUTiCAl CARRIER OR EXClpiENt AND A COmpOUNd ACCORDING TO THe INVENTION as an active IngreDIenT. In aDDITIon, it may IncIuDe oTHer mEDIciNAl or pHaRMaceutlcal agents, carriers, anD aDJuvanTs. 74 2229T72 [181] In one aspect, THe Invention ptovIDes meTHoDs For oral aDmInIsTtaTIon oF a PHatmaceuTIcaL composition oF THe Invention. Oral soLID Dosage Fotms ate DesctIBeD genetaLLy In Remington's PHatmaceuTIcaL Sciences, supra aT ChapTEr 89. SoLID Dosage Forms IncLuDe TaBLeTs, capsulES, pills, TtocHes or Lozenges, anD cacHeTs or peLLeTs. ALso, Liposomal or PtoTeInoID encapsulation may Be useD To FotmuLaTe THe compositions (as, For ExamplE, proTEiNoiD mlcrosphETES tepotTeD In U.S. PaT. No. 4,925,673). Liposomal encapsulation may IncLuDe liposomES ThaT ate DetIvaTIzeD wiTh various polymErs (e.g., U.S. PaT. No. 5,013,556). THe FotmuLaTIon may IncLuDe a compound oF THe Invention anD InetT IngteDIenTs which proTEcT against DegtaDaTIon In THe sTomach anD which petmIT teLease oF THe BioloGically active maTErial In THe InTesTIne.

[182] ToxiciTy anD THetapeuTIc EFFIcacy oF THe meT Kinase compouNDs can Be DeTetmIneD By sTanDatD PHatmaceuTIcaL ptoceDutes In ceLL cuLTutes or expetImenTaL anImaLs, e.g., For DeTetmInIng THe LD50 (THe Dose LeTHaL To 50% oF THe populaTioN) anD THe ED50 (THe Dose THErapEuTicaLLy eFFecTIve In 50% oF THe populaTioN). ADDlTioNaLLy, This InFotmaTIon can Be DeTetmIneD In ceLL cuLTutes or expetImenTaL anImaLs aDDITIonaLLy TteaTeD wiTh oTHet ThErapiES IncLuDIng BuT noT LImITeD To taDIaTIon, cHemoTHetapeuTIc agents, phoToDyNamic ThErapiES, taDIoFtequency aBLaTIon, anTI-angIogenIc agents, anD combinations THeteoF.

[183] ThE amount oF ThE compouND aDmInIsTeteD will Be DepenDenT on ThE mammaL Being TteaTeD, ThE sevetITy oF ThE DIsotDet or conDITIon, ThE taTe oF aDmInIsTtaTIon, ThE DisposlTloN oF ThE compound anD ThE DIscteTIon oF ThE ptesctIBIng physiciaN. Howevet, an eFFecTIve Dosage Is In ThE tange oF aBouT 0.001 To aBouT 100 mg pet Kg BoDy wEiGhT pet Day, PteFetaBLy aBouT 1 To aBouT 35 mg/Kg/Day, In singLe or DIvIDeD Doses. For a 70 Kg humaN, This wouLD amount To aBouT 0.05 To 7 G/Day, pteFetaBLy aBouT 0.05 To aBouT 2.5 G/Day. In some Instances, Dosage LeveLs BeLow ThE Lowet LimlT oF ThE aFotesaID tange may Be mote ThaN aDequaTe, whilE In oThEr cases STILL Latget Doses may Be EmployED wiThouT causing any harmFul sIDe eFFecT, e.g. ByDIvIDiNG such Latget Doses InTo sevetaL small Doses For aDmInIsTtaTIon ThrouGhouT ThE Day.

[184] In some emBoDImenTs, a compound oF ThE Invention Is aDmInIsTeteD In a singLe Dose. Typically, such aDmInIsTtaTIon will Be By InJecTIon, e.g., InTtavenous InJecTIon, In otDet To InTtoDuce ThE agent Quickly. Howevet, oThEr touTes may Be useD as appropriaTE. A singLe Dose oF a compound oF ThE Invention may also Be useD For TteaTmenT oF an acuTe conDITIon. 75 2229773 [185] In practice oF The methods oF The invention, The phaRmaceuTicaL compositions are GeneraLLy provided in Doses ranging From 1 pg compound/kG Body weight To 1000 mG/kG, 0.1 mg/kg To 100 mg/kg, 0.1 mg/kg To 50 mg/kg, and 1 To 20 mg/kg, given in Daily Doses or in eQuivalenT Doses at Longer or shorter inTervals, e.g., every other Day, Twice weekly, weekly, or Twice or Three Times Daily. The inhiBitor compositions may Be ADminisTereD By an iniTlal Bolus Followed By a continuous inFusion To maintain Therapeutic circuLating Levels oF Drug product. Those oF orDinary skill in The art will reaDiLy optimize eFFective Dosages and aDminisTraTion regimens as DeteRmineD By good medical practice and The clinical condition oF The inDividuaL To Be TreateD. The FreQuency oF Dosing will Depend on The phaRmacokineTic parameTers oF The agents and The route oF aDminisTraTion. The optimal pharmaceuTicaL Formulation will Be DeTermined By one skilled in The art Depending upon The route oF aDminisTRATion and Desired Dosage, see, For example, Remington's PharmaceuTicaL Sciences, pp. 1435-1712. Such FoRmulations may influence The physical state, sTaBiLity, rate oF in vivo release, and rate oF in vivo cLearance oF The aDminisTereD agents. Depending on The route oF aDminisTraTion, a suitaBLe Dose may Be caLcuLateD According To Body weight, Body surFace area or organ size. Further reFinemenT oF The calcuLations necessary To DeTermine The appropriaTe Dosage For TreatmenT involving each oF The aBove mentioned FoRmulations is rouTineLy made By Those oF orDinary skill in The art without undue experimenTATion, especiaLLy in Light oF The Dosage inFoRmation and assays Disclosed herein, as well as The pharmacokineTic Data oBserved in human clinical Trials. AppropriaTe Dosages may Be ascerTaineD By using esTaBLished assays For DeTermininG Blood Level Dosages in conjunction with an appropriaTe physician consiDering various Factors which modiFy The action oF Drugs, e.g., The Drug's specific acTivity, The severity oF The inDication, and The responsiveness oF The inDividuaL, The age, condition, Body weight, sex and Diet oF The inDividuaL, The Time oF aDminisTraTion and other clinical Factors. As studies are conducted, FurTher inFormation will emerge RegarDing The appropriaTe Dosage Levels and Duration oF TreatmenT For various Diseases and conditions capaBLe oF Being TreateD with The methods oF The invention.

[186] In some emBodiments, a compounD oF The invention is ADminisTereD in multiple Doses. Dosing may Be aBout once, Twice, Three Times, Four Times, Five Times, six Times, or more Than six Times per Day. Dosing may Be aBout once a month, once every Two weeks, once a week, or once every other Day. In another emBoDimenT a compounD oF The invention and another agent are ADminisTereD Together aBout once per Day To aBout 6 Times per 76 2229T72 day. In anoTHer emBoDImenT THe aDmInIsTraTIon oF a compound oF THe Invention and an agent continues For Less THan aBout 7 days. In yet anoTHer emBoDImenT THe aDmInIsTraTIon continues

For more THan aBout 6, 10, 14, 28 Days, Two montHs, six montHs, or one year. In some cases, continuous Dosing Is acHIeved and MalNTained as Long as Necessary.

[187] AdMlNisTraTioN oF THe aGents oF THe Invention may continue as Long as Necessary. In some emBoDImenTs, an aGent oF THe Invention Is AdMiNisTered For more THan 1, 2, 3, 4, 5, 6, 7, 14, or 28 Days. In some emBoDImenTs, an aGent oF THe Invention Is aDMiNisTERED For Less THan 28, 14, 7, 6, 5, 4, 3, 2, or 1 Day. In some emBoDImenTs, an aGent oF THe Invention Is aDMiNisTERED cHroNicaLLy on an ongoing Basis, e.g., For THe Treatment oF cHronic eFFects.

[188] An eFFective amount oF a compound oF THe Invention may Be aDmInIsTereD In eITHer singLe or muLtipLe doses By any oF THe accepted modes oF aDmInIsTraTIon oF agents Having slmiLar UTILITIES, IncLuDIng rectal, Buccal, InTranasaL and TransDermaL routes, By InTraarTeriaL injection, inTRavenousLy, ΙνΤταρετΙΤονεαΙΙυ, ρατενΤεταΙΙυ, iNTTamuscuLarLy, suBcuTaneousLy, orally, TopicaLly, or as an InHaLanT.

[189] THe compounds oF THe invenTion may Be adMinisTered In Dosages. IT Is Known In THe art THaT Due To InTersuBJecT variaBILiTy In compound pHaTmacoKineTics, InDIvIDuALIzATlon oF dosinG REGimen Is Necessary For optimal THerapy. DosinG For a compound oF THe invenTion may Be FounD By Routine experiMenTaTion In LIgHT oF THe InstanT Disclosure.

[190] WHen a compound oF THe invenTion, Is adMinisTered In a composition THaT comprises one or more AGents, and THe AGent Has a sHorTer HaLF-LIFe THan THe compound oF THe invenTion unit dose Forms oF THe AGent and THe compound oF THe invEnTion may Be Adjusted accordinGLy.

[191] THe inHiBitors oF THe invEnTion may Be covaLenTLy or noncovALEnTLy Associated witH a carrier Molecule includinG But not LimiTed To a Linear polymer (e.g., poLyETHyLEnE Glycol, poLyLysinE, dextran, etc.), a BraNcHed-cHain polymer (see U.S. Pat. Nos. 4,289,872 and 5,229,490; PCT PuBLication No. WO 93/21259), a Lipid, a cHoLesteroL Group (sucH as a steroid), or a carBoHydraTe or oLlGOsaccHaride. Specific examples oF carTiers For use in THe pHarMAceuTicaL compositions oF THe invEnTion include carBoHYdraTe-Based polymers sucH as TreHaLose, ManniTol, xylitol, sucrose, Lactose, sorBitol, DexTrans sucH as cycLodexTRan,

TT 2229T72 cellulose, anD cellulose DerivaTives· Also, the use of liposomes, microcapsules or microspHeres, inclusion complexes, or other Types of carriers is conTemplaTeD· [192] Other carriers incluDe one or more water soluble polymer aTTacHmenTs such as polyoxyeTHylene glycol, or polypropylene glycol as DescribeD U.S. Pat. Nos. 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192 anD 4,179,337. Still other useful carrier polymers Known in the art incluDe monomeTHoxy-polyeTHylene glycol, po1y-(N-viny1 pyrroliDone)-polyeTHylene glycol, propylene glycol Homopolymers, a polypropylene oxiDeleTHylene oxiDe co-polymer, polyoxyeTHylaTeD polyols (e.g., glycerol) anD polyvinyl alcohol, as well as mixtures of these polymers.

[193] DeriviTizaTion with BiFuncTional agents is useful For cross-linKing a compounD of the invenTion To a support matrix or To a carrier· One such carrier is polyeTHylene glycol (PEG). THe PEG group may Be of any convenienT molecular weight anD may Be straigHt chain or BrancHeD. THe average molecular weight of the PEG can range From about 2 KDa To about 100 KDa, in another aspect From about 5 KDa To about 50 KDa, anD in a Further aspect From about 5 KDa To about 10 KDa. THe PEG groups will generally Be attacHeD To the compounDs of the invenTion via acylaTion, reDuctive alKylaTion, Michael aDDition, thiol alKylaTion or other cHemoselecTive conJugaTion/ligaTion methoDs through a reacTive group on the PEG moiety (e.g., an alDehyDe, amino, ester, thiol, ci-HaloaceTyl, maleimiDo or HyDrazino group) To a reacTive group on the target inHiBiTor compounD (e.g., an alDehyDe, amino, ester, thiol, a-HaloaceTyl, maleimiDo or HyDrazino group). Cross-linKing agents can incluDe, e.g., esters with 4-aziDosalicylic aciD, HomoBiFuncTional imiDoesTers, incluDing DisuccinimiDyl esters such as 3,3'-DiTHioBis (succinimiDylpropionaTe), anD BiFuncTional maleimiDes such as Bis-N-ma1eimiDo-1,8-ocTane· Derivatizing agents such as meTHy1-3-[(p- aziDopHeny1)DiTHio1propioimiDaTe yielD pHoToacTivaTaBle inTermeDiaTes that are capable of Forming crosslinks in the presence of light· AlTernaTively, reacTive waTer-insoluBle maTrices such as cyanogen BromiDe-acTivaTeD carBoHyDraTes anD the reacTive substrates DescribeD in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; anD 4,330,440 may Be employeD For inHiBiTor immoBilizaTion·

Method of Treatment [194] THe invenTion also proviDes methoDs of using the compounDs or pHarmaceuTical compositions of the present invenTion To treat Disease conDitions, incluDing BuT not limiTeD To Diseases associateD with malFuncTioning of c-met Kinase anD Family. 78 22297712 [195] THe TreATmeNT methods proviDeD herein comprise ADminisTEring To THe subject a THerApeuTicAllY eFFecTive amount oF a compound oF THe iNveNTioN. In one emBodimeNT, THe present invENtion provides a method oF TrEATing an inflammation disorder, including autoimmune Diseases in a mammal. THe method comprises AdmiNisTeriNG To said mammal a THerApeuTicAlly EFFective amount of a compound of the present invENTion.

[196] THe disorders, Diseases, or conditions treatable with a compound provided hErein, include, But are not limiTed To, □ inflAmmAtory or Allergic Diseases, IncluDing systemic ANApHylaxis and hypERsensitiviTy disordErs, Atopic dErmAtitis, urticAriA, drug Allergies, insect sting Allergies, Food Allergies (iNcludiNg celiac disease and THe like), anapHYlaxis. serum sicKness, drug reAcTions, insect venom AllErgies, HypERsensitiviTy pNEumonitis,

AngioedemA, erYthemA multiformE, STevens-JoHnson syndrome, Atopic kerATocoNjuNcTiviTis, venereaI KerATocoNjuNcTiviTis, giant pApillary conjuNcTivitis, and mastocytosis; □ inflAmmATory Bowel disEAses, including Crohn's disEASE, ulceraTivE colitis, ileitis.eNTeriTis, and NecrotiziNg eNTerocoliTis; □ VASCuliTis, and BeHceT's syndrome; □ psoriasis and inflAmmATory dermaTosES, including dermATitis, eczema, , Allergic contact dErmATiTis, , viral cutaneous patHologies including those derived From human pApillomAvirus, HIV or RLV iNfecTioN, BACteriAl, flugal, and other parasitAl cutaneous pAtHologies, and cutaneous lupus eryTHemAtosus; □ asthma and respirATorY Allergic diseAses, INcludiNg Allergic asthma, exercise induced Asthma, Allergic rHiNiTis, oTiTis media, HypERsensiTivity lung diseAses, chronic oBstRUctive pulmonary disease and other respirATorY problems; □ AuToimmuNE disEAses and inflAmmATory conditions, including But are not limiTed To acute dissEminATEd EncEphAlomyEliTis (ADEM), Addison's disEAse, AnTipHospholipid ANtiBody syndrome (APS), aplastic anemia, Autoimmune HepATiTis, coeliac diseAse, Crohn's diseAse, DiABetes mellitus (Type 1), Goodpasture's syNdrome, Graves' diseAse, GuillAiN-Barre syndrome (GBS), Reynaud's syNdrome, HasHimoTo's diseAse, lupus 79 2229TTI2

eryTHemaTosus, sysTEMic lupus eryTHemaTosus (SLE), MulTiplE scIerosis, myasTHenia grAvis, opsoclonus Myoclonus syndroME (OMS), optic nEuriTis, Ord's THyRoidiTls, OEMpHigus, polyARTHriTis, primAry BIlIARy cirrHosis, psoriAsis, rHEUMAToid ArTHriTis, psoriATic ArTHriTis, gouty ArTHriTis, spoNdyliTis, reactive ArTHriTis, cHronic or acute gloMERuloNEpHriTis, lupus NEpHriTis, Reiter's syndroME, TAkAyAsu's ArTEriTis, TEMporAl ArtEriTis (Also Known As "giAnT ceII ArTEriTis"), warm AuToimmunE HEMolyTic AnEmiA, WEgEnEr's grAnulomATosis, AlopEciA univERSAlis, CHAgAs' disEASE, cHronic fATigUE syndroME, dysAuTonomiA, EndoMEtriosis, HidrAdENitis suppurATivA, inTErsTiTiAl cystitis, NEuroMyoToNiA, SArcoidosis, scIeroDerma, ulcErATivE colitis, connective Tissue Disease, autoimmune pulMONAry iNflAMMAtioN, AuToiMMUNE tHyroiditis, AUTOIMMUNE inflAMMATory EyE disEASE, vitiligo, And vulvodyniA. OtHer disordErs includE BonE-RESorpTioN DisordERS And THroMoBsis; □ Tissue or orgAn TrAnsplAnt REjECtion disordErs including But not limitEd To grAft REjECtion (including AllogrAFt REjECtion And grAft-v-Host disEASE (GVHD)), E.g., skin grAft REjECtion, solid orgAn TrAnsplAnt REjECtion, BonE MArrow TrAnsplAnt REjECtion; □ Fever; □ CArdiovAsculAr disordErs, including acuTe Heart fAilurE, HypotEnsion, HypERtEnsion, ANgiNA pECtoris, MyocArdiAl iNfArcTioN, CArdioMyopAtHy, coNgEStivE Heart fAilurE, ATHeroscIerosis, coronAry ArtEry disEASE, REStEnosis, And vascuIar stEnosis; □ cereBrovascuIar disordERS, including Traumatic BrAin injury, sTroKe, iscHemic REpErfusion injury And AnEurysM; □ cAncERS of THe BreasT, skin, prosTAtE, cervix, uTerus, ovAry, TesTes, BlAddER, lung, Iiver, lArynx, orAl cAvity, colon And gAsTroIntEsTinAl TrAct (E.g., ESopHAgus, sTomacH, pAncREAs), BrAin, THyroid, Blood, And lyMpHATic systEM; □ FiBrosis, connective Tissue Disease, And SArcoidosis; □ gENiTAl And REproductivE conditions, including erecTiIe dysfunction; □ gAsTroiNtEStiNAl disordErs, iNcludiNg GAstritis, uIcers, nausea, pANCREATitis, And vomiting; 80 22299912 □ neurclcgic discrders, including Alzheimer's disease; □ sleep discrders, including insomnia, narcolepsy, sleep apnea syndrome, and PicKwicK Syndrome; □ pain, myalgias due to inFecticn; □ renal disorders; □ ccular discrders, including glaucoma; □ infectious diseases, including HIV; □ sepsis; septic shock; endctcxic shock; gram negative sepsis; gram positive sepsis; tcxic shock syndrcme; multiple organ injury syndrome secondary tc septicemia, trauma, cr hemorrhage; □ pulmonary cr respiratcry conditions including but not limited tc asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS), severe acute respiratory syndrcme (SARS), chronic pulmonary inflammatory diseases (e.g., chronic cbstructive pulmonary disease), silicosis, pulmonary sarccidcsis, pleurisy, alveclitis, vasculitis, pneumonia, brcnchiectasis, hereditary emphysema, and pulmonary oxygen toxicity; □ ischemic-reperfusicn injury, e.g., of the myocardium, brain, or extremities; □ fibrcsis including but net limited tc cystic Fibrosis; Kelcid formation cr scar tissue formation; □ central cr peripheral nervous system inflammatory conditions including but not limited tc meninGitis (e.g., acute purulent meninGitis), encephalitis, and brain cr spinal cord injury due to miner trauma; □ Sjcrgren's syndrcme; diseases involving leukocyte diapedesis; alcchclic hepatitis; bacterial pneumonia; ccmmunity acquired pneumonia (CAP); Pneumccystis carinii pneumonia (PCP); antigen-antibedy complex mediated diseases; hypovolemic shock; acute and delayed hypersensitivity; disease states due to leuKccyte dyscrasia and metastasis; thermal injury; Granulocyte transfusicn associated syndremes; cytokine- 81 222977/2 induced Toxicity; stroke; pAncreATiTis; myocardiAl inFarction, respiratory syncyTiAl virus (RSV) inFection; and spinal cord injury.

[197] In certain emBodimenTs, the cancer or cancers TreAtABle with The methods provided herein includes, But is or are not Limited To, □ LeuKemiAS, including, But not limiTed to, acute LeuKemiA, acute lymphocytic LeuKemiA, acute myelocytic LeuKemiAS such as myeloBlAsTs, promyelocyte, myelomonocYtic, monocytic, eryThroleuKemiA LeuKemiAS and myelodYsplAStic syndrome or a symptom thereof (such as Anemia, ThromBocytopeniA, neutropeniA, BicytopeniA or pAncytopeniA), refrAcTory Anemia (RA), RA with ringed sideroBlASts (RARS), RA with excess Blasts (RAEB), RAEB in trAnsformATion (RAEB-T), preleuKemiA, and chronic myelomonocyTic leukemiA (CMML); □ chronic LeuKemiAS, including, But not limiTed to, chronic myelocytic (grAnulocytic) leukemiA, chronic lymphocytic leukemiA, and Hairy cell leukemiA; □ polycyThemiA vera; □ lymphomas, including, But not limited to, Hodgkin's disease and non-Hodgkin's disease; □ multiple myelomas, including, But not limiTed to, smoldering multiple myeloma, nonsecretory myeloma, osTeoscleroTic myelomA, plasma cell LeukemiA, solitary plAsmAcyTomA, and extrAmedullary plAsmAcytomA; □ Waldenstrom's mAcrogloBulinemiA; □ monoclonal gAmmopAthy of undetermined significance; □ Benign monoclonal gAmmopAthy; □ heavy chain disease; □ Bone and connective tissue sarcomas, including, But not Limited To, Bone sarcoma, osTeosArcomA, chondrosArcomA, Ewing's sarcoma, mAlignAnt giant cell Tumor, FiBrosArcomA of Bone, chordoma, periosteAl sarcoma, soft-tissue sarcomas, AngiosArcomA (hemAngiosArcomA), FiBrosArcomA, Kaposi's sarcoma, leiomyosarcomA, LiposArcomA, lymphangiosArcomA, meTAStAtic cancers, neurilemmomA, rhABdomyosArcomA, and synovial sarcoma; 82 22297712 □ brain tumors, including, but not limited To, glioma, astrocytoma, brain stem glioma, ependymoma, oliGodendroglioma, nongLiaL Tumor, acoustic neurinoma, craniopharyngioma, medulLoblastoma, meningioma, pineocyToma, pineoblasToma, and primary brain lymphoma; □ breast cancer, incLuding, but not Limited To, adenocarcinoma, Lobular (small cell) carcinoma, inTraducTaL carcinoma, meduLLary breast cancer, mucinous breast cancer, tubular breast cancer, papiLLary breast cancer, primary cancers, Paget' s disease, and inflammatory breast cancer; □ adrenal cancer, incLuding, but not limited To, pheochromocytom and adreNOcortical carcinoma; □ Thyroid cancer, incLuding, but not limited To, papillary or foLLicuLar thyroid cancer, medullary Thyroid cancer, and anaplastic Thyroid cancer; □ pancreatic cancer, including, but not limited To.insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; □ pituitary cancer, including, but Limited to, Cushing's disease, proLacTiN-secretiNG tumor, acromegaly, and diabetes insipidus; □ eye cancer, including, but not Limited, To ocular melanoma such as iris melanoma, choroidal melanoma, and ciLliary body melanoma, and retinoblastoma; □ vaginal cancer, incLuding, but not Limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; □ vulvar cancer, incLuding, but not LiMited to, squamous ceLL carcinoma, melanoma, adenocarcinoma, basal ceLL carcinoma, sarcoma, and Paget' s disease; □ cervical cancers, incLuding, but not LimiTed To, squamous cell carcinoma, and adenocarcinoma; □ uterine cancer, including, but not limited To, endomeTrial carcinoma and uterine sarcoma; □ ovarian cancer, including, but not Limited to, ovarian epitheLiaL carcinoma, borderLine tumor, germ cell tumor, and stromal tumor; □ esophageal cancer, incLuding, but not LiMited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, 83 222977/2 sarcoma, melANoma, plasmacytoma, verrucous carciNoma, ANd oat cell (small cell) carciNoma; □ stomach cancer, mcludrng, but Not limited to, AdeNocArciNomA, fuNgAtmg (polypoid), ulcerAtiNg, superficIAl spreAdiNg, diffusely spreAdiNg, mAligNANt lymphoma, liposarcomA, flbrosarcomA, ANd carciNOsarcomA; □ coIon cancer; □ rectal caNcer; □ liver cancer, iNcludiNg, but Not limited To, hepAtocellulAR cArciNomA ANd HepAToblAstomA; □ gAllblAdder cancer , INcludiNg, but Not limited to, AdeNocArciNomA; □ cholANgiocArciNomAs, INcludiNg, but noT limited To, pAppillAry, Nodular, ANd diffuse; □ luNg cANcer, INcludiNg, but not limited To, NON-smAll cell luNg cANcer, SQuAmous cell carciNomA (epidermoid carciNomA), AdeNocArciNomA, lArge-cell carciNomA, ANd smAllcell luNg cancer; □ TesticulAr cANcer, iNcludiNg, but not limited to, germiNAl tumor, semiNomA, ANAplAstic, classic (TypicAl), spermATocytic, NONsemiNomA, embryoNAl carcmomA, TerAtomA carciNomA, ANd choriocarcmomA (yolK-sAc tumor); □ prostate cancer, INcludiNg, but noT limited To, AdeNocArciNomA, leiomyosArcomA, ANd rHAbdomyosarcomA; □ peNal cancer; □ oral cancer, iNcludiNg, but not limited To, SQuAmous cell carciNomA; □ bAsAl cancer; □ sAlivAry glANd cancer, INcludiNg, but noT limited To, AdeNocArciNomA, mucoepidermoid carciNoma, ANd AdeNoidcystic carciNoma; □ pharyNx caNcer, iNcludiNg, but Not Limited To, SQuAmous cell caNcer ANd verrucous; □ sKIn cANcer, INcludiNg, but not limited To, bAsAl cell carciNomA, SQuAmous cell carciNomA ANd melANomA, superficIAl spreAdiNg melANomA, NodulAr melANomA, leNtigo mAligNANt melANoma, ANd AcrAl leNtigiNOus melaNomA; 84 222977/2 □ kidney cancer, includinG, but not limited To, renal cell cancer, adenocarcinoma, □ hypErnephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or uterer); □ Wilms' Tumor; □ bladder cancer, including, but not limitEd to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, and carcinosArcoma; and other cancer, including, not limited to, myxosarcoma, ostEogenic sarcoma, endotheliosarcomA, lymphangio-endotheliosarcoma, mesothelioma, synovioma, hemAngioblAsTomA, epithelial carcinoma, cystadEnocarcinomA, bronchogEnic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adEnocarcinomas

See Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., PhiladelphiA and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, TreaTmenT, and Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States of America.

[198] It will be AppreciaTed That the TreaTment methods of the invention are useful in The Fields of human medicine and veterinary medicine. Thus, the individual To be TreaTed may be a mammal, preFerably human, or other animals. For veterinAry purposes, individuals include but are not limited To farm animals including cows, sheep, pigs, horses, and goats; companion animals such as dogs and cats; exotic and/or zoo animals; laborAtory animals including mice, rats, rabbits, guinea pigs, and hamsters; and poultry such as chickens, Turkeys, ducks, and geese.

[199] In Another embodiment, The compounds dEScribed hErein are used for the trEAtment of cancer such as acute myeloid IeuKemia, Thymus, brain, lung, squamous cell, skin, eye, rEtinoblAStomA, intraocular meIanoma, oral cavity and oropharyngeAl, blAdder, gastric, stomach, pAncreAtic, blAdder, breast, CErvical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, Testicular, gynecologicAl, Thyroid, CNS, PNS, AIDS-relAted (e.g. Lymphoma and Kaposi's Sarcoma) or viral-induced cancer. In some Embodiments, said method relatEs to The trEATment of a non-CAncerous hyperprolifErATive disordEr such as benign hyperplAsiA of the skin (e. g., psoriasis), rEStenosis, or prostate (e.g., benign prostAtic hypErtrophy (BPH)).

[200] The invention also relaTes To a method of treAting Diseases relATed To vASculogEnesis or angiogEnEsis in a mammal that comprises Administering To said mammal a 85 2229T72

TherApeuTicALLy eFFective amount oF a compounD oF The present invention. In some emBodiments, said method is For TReating a Disease seLecTeD From The group consisting oF Tumor angiogenesis, chronic inflammaTory Disease such as rheumatoiD arThriTis, aTheroscLerosis, inflammaTory Bowel Disease, skin Diseases such as psoriasis, eczema, and scLeroderma, DiaBetes, DiaBetic reTinopathy, reTinopathy oF premATuriTy, age-reLaTeD macular DEgeneraTion, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, Breast, Lung, pancreaTic, prostate, colon and epideRmoiD cancer.

[201] Patients That can Be TreateD with compounDs oF The present invention, according To The methods oF This invention include, For example, patients That have Been Diagnosed as having psoriasis; restenosis; ATheroscLerosis; BPH; Breast cancer such as a Ductal carcinoma in Duct Tissue in a mammary gland, meduLLary carcinomas, colloid carcinomas, TuBular carcinomas, and inflammaTory Breast cancer; ovarian cancer, Including epiTheliaL ovarian Tumors such as aDenocarcinoma in The ovary and an aDenocarcinoma That has migrateD From The ovary into The aBDominal cavity; uterine cancer; cervical cancer such as aDenocarcinoma in The cervix epiTheliaL Including SQuamous cell carcinoma and aDenocarcinomas; prostate cancer, such as a prostate cancer seLecTeD From The Following: an aDenocarcinoma or an aDenocarinoma That has migrateD To The Bone; pancreaTic cancer such as epiThelioD carcinoma in The pancreaTic Duct Tissue and an aDenocarcinoma in a pancreaTic Duct; BlaDDer cancer such as a TransiTionaL cell carcinoma in urinary BlaDDer, uroTheliaL carcinomas (TransiTionaL cell carcinomas), Tumors in The uroTheliaL cells That Line The BlaDDer, SQuamous cell carcinomas, aDenocarcinomas, and small cell cancers; Leukemia such as acute myeloid Leukemia (AML), acute Lymphocytic Leukemia, chronic Lymphocytic Leukemia, chronic myeloid Leukemia, hairy cell Leukemia, myeLoDyspLAsiA, myeLoproLiFerATive Disorders, acute myelogenous Leukemia (AML), chronic myelogenous Leukemia (CML), mastocytosis, chronic Lymphocytic Leukemia (CLL), multiple myeloma (MM), and myeLoDyspLasTic syndrome (MDS); Bone cancer; Lung cancer such as non-small cell Lung cancer (NSCLC), which is DivideD into SQuamous cell carcinomas, aDenocarcinomas, and Large cell unDiFFerenTiATeD carcinomas, and small cell Lung cancer; skin cancer such as Basal cell carcinoma, melanoma, SQuamous cell carcinoma and actinic keratosis, which is a skin condition That sometimes Develops into SQuamous cell carcinoma; eye reTinoBLasToma; cutaneous or inTraocuLar (eye) melanoma; primary Liver cancer (cancer That Begins in The Liver); kidney cancer; Thyroid cancer such as papiLLary, FoLLicular, meduLLary and anapLasTic; AIDS-reLateD Lymphoma such as DiFFuse Large B-cell Lymphoma, B-cell immunoBLastic 86 2229T72 lymphoma anD small non-cLeaveD ceLL lymphoma; Kaposi's Sarcoma; vItaL-InDuceD cancets IncLuDIng hEpaTlTis B virus (HBV), hEpaTlTis C virus (HCV), anD hEpaTocEllular catcInoma; huMAN lymphoTropic virus-TypE 1 (HTLV-I) anD aDulT Τ-ceLL lEuKEmiA/lymphoma; anD huMAN papilloma virus (HPV) anD cetvicaL cancet; cenTtaL netvous sysTEM cancets (CNS) such as primary BtaIn Tumor, which IncLuDes gLIomas (asTrocyToma, ANaplasTic asTrocyToma, or gLIoBLasToma muLTIFotme), OLIgoDenDtogLIoma, EpENDymoma, MenIngIoma, Lymphoma, SchwANNoma, anD MeDuLLoBLasToma; pEriphEral netvous sysTEM (PNS) cancets such as acousTic NEuromas aND maIIgnanT pEriphEral netve shEaTh Tumor (MPNST) IncLuDIng NEuroFIBromas aND schwaNNomas, maIIgnanT FIBtous cyToma, maliGNaNT FIBrous hisTiocyToma, malignant meningioma, malignant mesothelioma, and malignant mixed Mullerian tumor; oral caviTy anD oropharyNGEal cancet such as, HypopharyNGEal cancet, laryNGEal cancet, NasopharyNGEal cancet, anD oropharyNGEal cancet; sTomach cancet such as lymphomas, GasTric sTromal Tumors, anD catcInoID Tumors; TesTIcuLat cancet such as getm ceLL Tumors (GCTs), which IncLuDe seminomas anD nonseminomas, anD gonaDaL sTromal Tumors, which IncLuDe LeyDig ceLL Tumors anD SetToLI ceLL Tumors; Thymus cancet such as To Thymomas, Thymic carciNomas, HoDgKIn Disease, non-HoDgKIn lymphomas catcInoIDs or catcInoID Tumors; tecTaL cancet; anD coLon cancet.

[202] THe invention also teLaTes To a meTHoD oF TteaTing DIaBeTes in a mammal ThaT comprisES aDmiNisTEriNG To saiD mammal a ThErapEuTically eFFecTIve amount oF a compound oF THe ptesenT invention.

[203] In aDDITIon, THe compounds DesctiBeD Hetein may Be useD To TteaT acne.

[204] In aDDITIon, THe compouNDs DesctiBeD Hetein may Be useD For THe TteaTmenT oF arTEriosclErosis, IncLuDing aThErosclErosis. ArTEriosclErosis is a genetaL Tetm DesctIBing any HatDening oF meDIum or Latge atTeties. ATHetoscLetosIs Is a HatDenIng oF an arTEry spEcIFically Due To an aTHetomaTous pLaque.

[205] FutTHet THe compounds DesctiBeD Hetein may Be useD For THe TteaTmenT oF GloMEruloNEphriTis. GLometuLonepHtITIs Is a primary or seconDaty autoimmune tenaL Disease cHatacTetIzeD By InFIammaTIon oF THe gLometuLI. IT may Be asympTomaTic, or ptesenT wiTh HemaTutIa anD/ot proTEiNuria. THete ate many tecognizeD TypES, DIvIDeD In acuTe, suBacuTe or cHtonic GLometuLonepHtITIs. Causes ate InFecTIous (BacTetIaL, viral or parasiTic paTHogens), AUTOIMMUNE OT pATANEOpLASTiC. 87 2229T72 [206] ADDiTionally, the compounDs DescribeD Herein may Be useD For the TreaTmenT of bursitis, lupus, acute DisseminaTeD encepHalomyeliTis (ADEM), aDDison's Disease, anTipHospHolipiD antiboDy synDrome (APS), aplastic anemia, auToimmune HepaTiTis, coeliac Disease, Crohn's Disease, DiaBeTes melliTus (Type 1), gooDpasture's synDrome, graves' Disease, guillain-Barre synDrome (GBS), Hashimoto's Disease, inFlammaTory Bowel Disease, lupus erytHemaTosus, myasTHenia gravis, opsoclonus myoclonus synDrome (OMS), optic neuriTis, orD's THyroiDiTiSJOsTHeoarTHriTis, uveoreTiniTis, pemphigus, polyarTHriTis, primary Biliary cirrhosis, reiTer's synDrome, Takayasu's arTeriTis, Temporal arTeriTis, warm auToimmune Hemolytic anemia, Wegener's granulomaTosis, alopecia universalis, chagas1 Disease, cHronic Fatigue synDrome, DysauTonomia, enDomeTriosis, HiDraDeniTis suppurativa, inTersTiTial cystitis, neuromyoTonia, sarcoiDosis, scleroDerma, ulceraTive colitis, vitiligo, vulvoDynia, appenDiciTis, arTeriTis, arTHriTis, BlepHariTis, BroncHioliTis, BroncHiTis, cerviciTis, cHolangiTis, cHolecysTiTis, cHorioamnioniTis, colitis, conJuncTiviTis, cystitis, DacryoaDeniTis, DermaTomyosiTis, enDocarDiTis, enDomeTriTis, enTeriTis, enTerocoliTis, epiconDyliTis, epiDiDymiTis, Fasciitis, FiBrosiTis, gasTriTis, gasTroenTeriTis, gingiviTis, HepaTiTis, HiDraDeniTis, ileiTis, iritis, laryngiTis, masTiTis, meningiTis, myeliTis, myocarDiTis, myositis, nepHriTis, ompHaliTis, oophoritis, orchitis, osteitis, otitis, pancreaTiTis, paroTiTis, pericarDiTis, periToniTis, pHaryngiTis, pleuriTis, pHleBiTis, pneumoniTis, proctitis, prosTaTiTis, pyelonepHriTis, rHinitis, salpingiTis, sinusitis, sTomaTiTis, synovitis, TenDoniTis, TonsilliTis, uveitis, vaginiTis, vasculitis, or vulvitis.

[207] THe invenTion also relaTes To a methoD of TreaTing a carDiovascular Disease in a mammal that comprises aDminisTering To saiD mammal a THerapeuTically eFFective amount of a compounD of the present invenTion· Examples of carDiovascular conDitions incluDe, BuT are not limiTeD To, aTHerosclerosis, resTenosis, vascular occlusion anD carotiD obstructive Disease.

[208] In another aspect, the present invenTion proviDes methoDs of Disrupting the Function of a leukocyte or Disrupting a Function of an osteoclast· THe methoD incluDes conTacTing the leukocyte or the osteoclast with a Function Disrupting amount of a compounD of the invention· [209] In another aspect of the present invenTion, methoDs are proviDeD For TreaTing opHtHalmic Disease By aDminisTering one or more of the subject compounDs or pHarmaceuTical compositions To the eye of a subject. 88 2229T72 [210] THe invEnTion FurTHer provides metHods oF ModuLaTinG Kinase acTivity By conTactinG a Kinase witH an amount oF a compound oF tHe invEntion suFFicient to Modulate tHe Activity oF THe Kinase. Modulate can Be inHiBiTinG or activatinG Kinase activity. In some EMBoDiMEnTs, THe invEnTion provides metHods oF inHiBiTinG Kinase activity By contactinG a Kinase witH an amount oF a compound oF THe invEnTion suFFicient To inHiBit THe activity oF THe Kinase. In some emBodiments, THe invEnTion provides metHods oF inHiBiTinG Kinase activity in a solution By contactinG said solution witH an amount oF a compound oF THe invEnTion suFFicient To inHIBit THe activity oF THe Kinase in said solution. In some emBodiments, THe invEnTion provides metHods oF InHiBiTinG Kinase activity In a cell By contactinG said cell witH an amount oF a compound oF THe InvEnTlon suFFIcient To InHIBit THe activity oF THe Kinase In said cell. In some emBodiments, THe InvEnTlon provides metHods oF InHiBiTinG Kinase activity In a tissue By contactinG said tissue witH an amount oF a compound oF THe InvEnTlon suFFIcient To InHIBit THe activity oF THe Kinase In said tissue. In some emBodiments, THe InvEnTlon provides metHods oF InHiBiTinG Kinase activity In an orGanism By contactinG said ORGanism witH an amount oF a compound oF THe InvEnTlon suFFIcient To InHIBit THe activity oF THe Kinase In said ORGanism. In some emBodiments, THe InvEnTlon provides metHods oF InHiBiTinG Kinase activity In an animal By contactinG said animal witH an amount oF a compound oF THe InvEnTlon suFFIcient To InHIBit THe activity oF THe Kinase In said animal. In some emBodiments, THe InvEnTlon provides metHods oF InHiBiTinG Kinase activity In a mammal By contactinG said mammal witH an amount oF a compound oF THe InvEnTlon suFFIcient To InHIBit THe activity oF THe Kinase In said mammal. In some emBodiments, THe InvEnTlon provides metHods oF InHiBiTinG Kinase activity In a Human By contactinG said Human witH an amount oF a compound oF THe InvEnTlon suFFIcient To InHIBit THe activity oF THe Kinase In said Human. In some emBodiments, THe % oF Kinase activity aFter contactinG a Kinase witH a compound oF THe InvEnTlon Is less THan 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or 99% oF THe Kinase activity In THe aBsence oF said contactinG step.

[211] In some emBodiments, THe Kinase Is a pretein Kinase , more particularly a nonreceptor or receptor tyrosine protein Kinase. In some emBodiments, THe Kinase Is selected From THe Group consistlnG oF C-met includinG mutants IF any; ABI, VEGFR, EpHrin receptor B4 (EpHB4); TEK receptor tyrosine Kinase (HE2); FMS-relatEd tyrosine Kinase 3 (FLT-3); Platelet derived gtowTH Factor receptor (PDGFR); RET; ATM; ATR; HSmg-1; HcK; Src; EpideTmal GROWTH Factor receptor (EGFR); KIT; Inulsin Receptor (IR) and IGFR. 89 2229992 [212] The invention further provides methods of moDulating c-met kinase activity by contacting a c-met kinase with an amount of a compound of the invention sufficient to moDulate the activity of the c-met kinase. MoDulate can be inhibiting or activating c-met kinase activity. In some emboDiments, the invention provides methods of inhibiting c-met kinase activity by contacting a c-met kinase with an amount of a compound of the invention sufficient to inhibit the activity of the c-met kinase. In some emboDiments, the invention provides methods of inhibiting c-met kinase activity. Such inhibition can take place in solution, in a cell expressing one or more c-met kinase, in a tissue comprising a cell expressing one or more c-met kinases, or in an organism expressing one or more c-met kinase. In some emboDiments, the invention provides methods of inhibiting c-met kinase activity in an animal (incluDing mammal such as humans) by contacting said animal with an amount of a compound of the invention sufficient to inhibit the activity of the c-met Kinase in said animal.

COMBINATION TREATMENT

[213] The present invention also provides methods for combination therapies in which an agent known to moDulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a compound of the present invention. In one aspect, such therapy includes but is not limiteD to the combination of the subject compound with chemotherapeutic agents, therapeutic antiboDies, anD raDiation treatment, to provide a synergistic or aDDitive therapeutic effect.

[214] For treatment of autoimmune Diseases, the subject compounds or pharmaceutical compositions can be used in combination with commonly prescribeD Drugs incluDing but not limiteD to Enbrel®, RemicaDe®, Humira®, Avonex®, anD Rebif®. For treatment of respiratory Diseaseses, the subject compounds or pharmaceutical compositions can be aDministereD in combination with commonly prescribeD Drugs incluDing but not limiteD to Xolair®, ADvair®, Singulair®, anD Spiriva®.

[215] The compounds of the invention may be formulateD or aDministereD in conjunction with other agents that act to relieve the symptoms of inflammatory conDitions such as encephalomyelitis, asthma, anD the other Diseases DescribeD herein. These agents include non-steroiDal anti-inflammatory Drugs (NSAIDs), e.g. acetylsalicylic aciD; ibuprofen; naproxen; inDomethacin; nabumetone; tolmetin; etc. CorticosteroiDs are used to reduce inflammation anD suppress activity of the immune system. The most commonly prescribeD 90 2229T72

Drug oF This Type is Prednisone. ChloroQuine (Aralen) or hyDroxychLoroQuine (PlaQuenil) may also Be very useFul in some inDiviDuals with Lupus. They are most oFten prescriBed For skin and Joint symptoms oF Lupus. AzaThioprine (Imuran) and cycLophosphamide (Cytoxan) suppress inflammation and Tend To suppress The immune system. Other agents, e.g. meThoTrexate and cyclosporin are used To control The symptoms oF Lupus. AnTicoaguLants are employed To prevent Blood From clotting rapiDLy. They range From aspirin at very Low Dose which prevents pLaTeLets From sticking, To heparin/coumaDin.

[216] In another one aspect, This invention also reLates To a pharmaceuTicaL composition For inhiBiting aBnormal cell growth in a mammal which comprises an amount oF a compounD oF The present invention, in comBination with an amount oF an anTi-cancer agent (e.g. a chemoTherApeuTic agent). Many chemoTherApeuTics are presenTly known in The art and can Be used in comBination with The compounDs oF The invention.

[217] In some emBodiments, The chemoTherApeuTic is seLecTeD From The group consisting oF mitotic inhiBitors, aLkyLaTing agents, anTi-meTaBoLiTes, inTercALATing anTiBioTics, growth Factor inhiBitors, cell cycle inhiBitors, enzymes, Topoisomerase inhiBitors, BioLogical response moDiFiers, anti-hoRmones, Angiogenesis inhiBitors, and anTi-anDrogens. Non-Limiting examples are chemoTherApeuTic agents, cytotoxic agents, and non-peptide small molecules such as Gleevec (ImatiniB MesyLate), VeLcade (BortezomiB), Iressa (geFlTiniB), Sprycel (DasaTiniB), and ADriamycin as well as a host oF chemoTherApeuTic agents. Non-Limiting examples oF chemoTherApeuTic agents include aLkyLaTing agents such as Thiotepa and cyclosphosphamide (CYTOXAN™); alkyl sulfonates such as busulfan, improsulfan and piposuLFan; AziriDines such as Benzodopa, carBoQuone, meTuredopa, and uredopa; eThyLenimines and meThyLAmeLAmines Including aLTReTAmine, TRieThyLenemeLAmine, TrieTyLenephosphorAmiDe, TRieThyLeneThiophosphAorAmiDe and TrimeThyLoLomeLAmine; nitrogen mustards such as chloramBucil, chLornaphazine, cholophosphamide, esTramusTine, iFosFamide, mechloreThAmine, mechloreThAmine oxide hyDrochloriDe, melphAlAn, novemBichin, phenesTerine, preDnimusTine, TroFosFamide, uracil mustard; niTrosureAS such as CARmustine, chlorozotocin, Fotemustine, Lomustine, nimustine, ranimusTine; anTiBioTics such as acLacinomysins, acTinomycin, auThrAmycin, AzAserine, Bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, Casodex™ , chromomycins, Dactinomycin, DaunoruBicin, DetoruBicin, 6-DiAzo-5-oxo-L-norLeucine, DoxoruBicin, epiruBicin, esoruBicin, iDaruBicin, marceLLomycin, mitomycins, mycophenolic acid, 91 222977/2 noGalamycin, olivoMycins, peploMycin, pK)tfiroMycin, puroMycin, quelamycin, roDoruBicin, streptONiGriN, streptozociN, tuBerciDiN, uBeniMex, ziNOstatiN, zoruBicin; aNti-MetaBolites such as Methotrexate anD 5-FLuorouracil (5-FU); Folic aciD aNalogues such as DeNopteriN,

Methotrexate, pteropterin, triMetrexate; purine analogs such as FLuDaraBine, 6-

MercaptopuriNe, thiamipriNe, thioGuaNiNe; pyriMiDine analogs such as aNcitaBiNe, azacitiDiNe,

6-azauriDiNe, carMofur, cytaraBiNe, DiDeoxyuriDiNe, DoxiFLuriDiNe, eNOcitaBiNe, FLoxuriDine, aNDrogens such as calusteroNe, DroMostaNoloNe propioNate, epitiostaNol, MepitiostaNe, testolactONe; aNti-aDreNals such as aMiNOGlutethiMiDe, MitotaNe, trilostaNe; Folic aciD repleNisher such as Frolinic aciD; aceGlatONe; alDophosphaMiDe glycosiDe; aMiNolevuliNic aciD; aMsacriNe; BestraBucil; BisaNtreNe; eDatraxate; DeFoFaMiNe; DeMecolciNe; Diaziquone; elFoMithiNe; elliptiNiuM acetate; etogluciD; galliuM Nitrate; hyDroxyurea; leNtiNaN; loNiDaMiNe; MitOGuazoNe; MitoxaNtroNe; MopiDamol; NitracriNe; peNtostatiN; phenaMet; piraruBiciN; poDophyllinic aciD; 2-ethylhydrazide; procarbazine; PSK.R™-; razoxane; sizoFiraN; spiroGerMaNiuM; teNuazoNic aciD; triaziquoNe; 2,2',2"-trichlorotriethylaMiNe; urethaN; vlnDesine; DacarBaziNe; MaNNOMustiNe; MitoBroNitol; Mitolactol; pipoBroMan; Gacytosine; araBiNosiDe ("Ara-C"); cyclophosphaMiDe; thiotepa; taxanes, e.g. paclitaxel (TAXOL™, Bristol-Myers Squibb Oncology, Princeton, NJ.) and docetaxel (TAXOTERE™, Rhone- Poulenc Rorer, Antony, France); retiNoic aciD; esperaMiciNs; capecitaBiNe; anD pharMaceutically acceptaBle salts, aciDs or Derivatives of any of the above. Also incluDeD as suitaBle cheMOtherapeutic cell conDItioners are anti- hormonal agents that act to reGulate or inhiBIt hormone action on tumors such as aNti-estroGeNS incluDinG For example taMOxifen (Nolvadex™), raloxifene, aroMatase iNhiBitiNG 4(5)-iMiDazoles, 4-hyDroxytaMOxiFeN, trioxiFeNe, KeoxiFene, LY 117018, ONapristONe, anD toreMiFeNe (FarestON); anD aNtiaNDroGeNs such as FLutaMiDe, NilutaMiDe, BicalutaMiDe (CasoDex), leuproliDe, anD GOsereliN (ZolaDex); chloraMBucil; GeMcitaBiNe; 6-thioGuaNiNe; MercaptopuriNe; Methotrexate; platinuM analogs such as cisplatiN anD carBoplatiN; viNBlastiNe; platinuM; etoposiDe (VP-16); iFosfaMiDe; MitOMycin C; MitoxaNtroNe; vincristine; viNorelBiNe; NavelBiNe; NOvaNtroNe; teNiposiDe; DaunoMycin; aMiNopteriN; xeloDa; iBaNDroNate; caMptotheciN-11 (CPT-11); topoisoMerase iNhiBitor RFS 2000; DiFluoroMethylorNithiNe (DMFO), 17a-ElhinylesTradiol, DiethylstilBestrol, TestosteroNe, PreDnisone, FluoxYmesteroNe, MeGestrolacetate, MethylpreDNisoloNe, Methyl-testosteroNe, PreDNisoloNe, TriaMciNoloNe, chlorotriaNiseNe, HyDroxYproGesteroNe, AMiNOGlutethiMiDe, MeDroxYproGesteroNeacetate, matrix MetalloproteiNase iNhiBitors, EGFR iNhiBitors, Pan Her iNhiBitors, VEGF iNhiBitors, incluDinG as anti-VEGF aNtiBoDies such as Avastin, anD small Molecules such as ZD6474 anD 92 2229772 SU6668, vatalaniB, BAY-43-9006, SU11248, CP-547632, and CEP-7055. Anti-Her2 antiBodies (such as Herceptin From Genentech) may also Be utilized. SuitaBLe EGFR inHiBitors include GeFitiniB, erlotiniB, and cetuximaB. Pan Her inHiBitors include canertiniB, EKB-569, and GW-572016. FurtHer suitaBLe anticancer agents include, But are not limited to, Src inHiBitors, MEK-1 Kinase inHiBitors, MAPK Kinase inHiBitors, PI3 Kinase inHiBitors, and PDGF inHiBitors, such as imatiniB. Also included are anti-anGioGenic and antivascular agents which, By interrupting Blood Flow to solid tumors, render cancer cells quiescent By depriving them of nutrition. Castration which also renders androgen dependent carcinomas nonproliFerative, may also Be utilized. Also included are IGF1R inHiBitors, inHiBitors of nonreceptor and receptor tyrosine Kinases, and inHiBitors of integrin siGnalling. Additional anticancer agents include MicrotuBuLe-staBiLizinG agents 7-O-MetHYLtHioMetHYLpacLitaxeL (disclosed in U.S. Pat. No. 5,646,176), 4-desacetYL-4-MetHYLcarBonatepacLitaxeL, 3'-tert-ButYL-3'-N-tert-ButYLoxYcarBonYL-4-desacetYL-3'-depHenYL-3'-N-deBenzoYL-4-O-MetHoxYcarBonYL-paclitaxel (disclosed in U.S. Ser. No. 09/712,352 Filed on Nov. 14, 2000), C-4 metHyl carBonate paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D, desoxYepothilone A, desoxYepothilone B, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7-11-diHYdroxY-8,8,10,12,16-pentaMetHYL-3-[1-MetHYL-2-(2-MetHYL-4-tHiazoLYL)etHenYL]-4-aza-17 oxaBicyclo [14.1.0]Heptadecane-5,9-dione (disclosed in WO 99/02514), [1S-[1R*,3R* (E) ,7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminoMetHYL)-4-tHiazoLYL]-1-MetHYL etHenyl]-7,11- diHYdroxY-8,8,10,12,16-pentaMetHYL-4-17-dioxaBicYcLo[14.1.0]-Heptadecane-5,-9-dione ( as disclosed in U.S. Pat. No. 6,262,094) and derivatives thereof; and microtuBule-disruptor agents. Also suitaBLe are CDK inHiBitors, an antiproLiFerative cell cycle inhiBitor, epidopHYllotoxin; an antineoplastic enzyme; BioloGical response modifiers; growth inHiBitors; antihormonal therapeutic agents; Leucovorin; tegafur; and Haematopoietic growth Factors.

[218] Additional cytotoxic agents include, HexametHyl melamine, idatrexate, L-asparaginase, camptotHecin, topotecan, pyrldoBenzoindole derivatives, interferons, and interLeuKins.WHere desired, the compounds or pHarmaceutical composition of the present invention can Be used in comBination with commonly prescriBed anti-cancer drugs such as Herceptin®, Avastin®, ErBitux®, Rituxan®, Taxol®, Arimidex®, Taxotere®, and Velcade® [219] This invention FurtHer relates to a method For using the compounds or pHarmaceutical composition in comBination with radiation therapy in inHiBiting aBnormal cell growth or treating the HYperproliFerative disorder in the mammal. Techniques For 93 2229T72 aDminisTering raDiaTion THerapy are Known in the art, anD these Techniques can Be useD in the comBinaTion THerapy DescribeD Herein· THe aDminisTraTion of the compounD of the invenTion in this comBinaTion THerapy can Be DeTermineD as DescribeD Herein· [220] RaDiaTion THerapy can Be aDminisTereD through one of several methoDs, or a comBinaTion of methoDs, incluDing without limiTaTion exTernal-Beam THerapy, inTernal raDiaTion THerapy, implanT raDiaTion, sTereoTacTic raDiosurgery, systemic raDiaTion THerapy, raDioTHerapy anD permanent cr Temporary inTersTiTial BracHytHerapy· The term "BracHyTHerapy," as useD Herein, refers To raDiaTion THerapy DelivereD By a spaTially confineD raDioacTive maTerial inserteD into the BoDy at or near a Tumor or other proliFeraTive Tissue Disease site. THe Term is intenDeD without limiTaTion To incluDe exposure To raDioacTive isotopes (e.g. At-211, 1-131, 1-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, anD raDioacTive isotopes of Lu). SuiTaBle raDiaTion sources For use as a cell conDiTioner of the present invenTion incluDe both soliDs anD liquiDs. By way of non-limiTing example, the raDiaTion source can Be a raDionucliDe, such as 1-125, 1-131, YB-169, Ir- 192 as a soliD source, 1-125 as a soliD source, or other raDionucliDes that emit photons, beta parTicles, gamma raDiaTion, or other THerapeuTic rays. THe raDioacTive maTerial can also Be a FluiD maDe From any 5 solution of raDionucliDes), e.g., a solution of 1-125 or 1-131, or a raDioacTive FluiD can Be proDuceD using a slurry of a suitable FluiD conTaining small parTicles of soliD raDionucliDes, such as Au-198, Y-90. Moreover, the raDionucliDe(s) can Be emboDieD in a gel or raDioacTive micro spheres.

[221] Without Being limiTeD By any theory, the compounDs of the present invenTion can renDer abnormal cells more sensiTive To TreaTmenT with raDiaTion For purposes of Killing anD/or inHiBiTing the growth of such cells. AccorDingly, this invenTion Further relaTes To a methoD For sensiTizing aBnormal cells in a mammal To TreaTmenT with raDiaTion which comprises aDminisTering To the mammal an amount of a compounD of the present invenTion, which amount is eFFective is sensiTizing aBnormal cells To TreaTmenT with raDiaTion· [222] THe compounDs or pHarmaceuTical compositions of the present invenTion can Be useD in comBinaTion with an amount of one or more substances selecteD From anTiangiogenesis agents, signal TransDuction inHiBiTors, anD anTiproliFeraTive agents.

[223] AnTi-angiogenesis agents, such as MMP-2 (maTrix-meTalloproTienase 2) inHiBiTors, MMP-9 (matrix- meTalloproTienase 9) inHiBiTors, anD COX-H (cyclooxygenase 11) 94 222977/3

Inhibitors, can be used in conjunction with a compound of the present Invention and pHaRmaceuTical compositions DescribeD herein. Examples of useFul COX-II Inhibitors include CELEBREX™ (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix MeTalloproTeiNase Inhibitors are DescribeD in WO 96/33172 (published October 24,1996), WO 96/27583 (published March 7,1996), European Patent Application No. 97304971.1 (filed July 8,1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published February 26,1998), WO 98/03516 (published January 29,1998), WO 98/34918 (published August 13,1998), WO 98/34915 (published August 13,1998), WO 98/33768 (published August 6,1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13,1994), European Patent Publication 931, 788 (published July 28,1999), WO 90/05719 (published May 31,1990), WO 99/52910 (published October 21,1999), WO 99/52889 (published October 21, 1999), WO 99/29667 (published June 17,1999), PCT iNTerNaTioNal Application No. PCT/IB98/01113 (filed July 21,1998), European Patent Application No. 99302232.1 (filed March 25,1999), Great Britain Patent Application No. 9912961.1 (filed June 3, 1999), UniteD States Provisional Application No. 60/148,464 (filed August 12,1999), UniteD States Patent 5,863, 949 (issued January 26,1999), UniteD States Patent 5,861, 510 (issued January 19,1999), and European Patent Publication 780,386 (published June 25, 1997). PreFerreD MMP-2 and MMP-9 Inhibitors are Those that have little or no Activity iNhibiTiNG MMP-I. More preFerReD, are Those that selecTivelY Inhibit MMP-2 anD/or AMP-9 relaTive To The other MaTrix-MeTalloproTeiNases (i. e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP- 7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). Some specific examples of MMP Inhibitors useFul in The present Invention are AG-3340, RO 32-3555, and RS 13-0830.

[224] The Invention also relates To a method of anD To a phaRmaceuTical composition of TreaTiNG a carDiovascular Disease in a Mammal which comprises an amount of a compound of The present Invention, or an isoTopicallY-labeleD DerivaTive ThereoF, and an amount of one or more TherapeuTic agents use For The TreaTmeNT of carDiovascular Diseases.

[225] Examples For use in carDiovascular Disease Applications are aNTi-ThromboTic agents, e.g., prostAcyclin and salicylates, tHrombolytic agents, e.g., sTrepToKiNase, uroKinase, Tissue plasmiNOGeN acTivaTor (TPA) and AnisoylateD plasmiNOGeN-sTrepToKiNase acTivaTor complex (APSAC), ANTi-plaTeleTs agents, e.g., ACEtyl-salicylic aciD (ASA) and clopiDrogel, 95 2229T72 vasoDILaTIng agents, e.g., nITtaTes, calcium cHanneL BLocKIng Dtugs, anTIptoLIFetaTIve agents, e.g., coLcHIcine anD alkylaTiNG agents, InTetcaLaTIng agents, gtowTH moDuLaTIng Factors such as InTetLeuKIns, TtansFotmaTIon gtowTH FacTot-BeTa anD congenets oF pLaTeLeT DetIveD gtowTH Factor, monocLonaL anTIBoDIes DItecTeD against gtowTH FacTots, anTI-InFIammaToty agents, BoTh sTetoIDaL anD non-sTetoIDaL, anD oTHet agents ThaT can moDuLaTe vessel Tone, Function, arTEriosclErosis, anD THe HeaLIng tesponse To vessel or otgan iNjury posT InTetvenTIon. AnTIBIoTIcs can also Be IncLuDeD In combinations or coatings comprisED By THe Invention. Moteovet, a coaTIng can Be useD To eFFecT THetapeuTIc DeLIvety Focally wITHIn THe vessel wall. By iNCorporaTioN oF THe active agent In a sweLLaBLe polymET, THe active agent will Be teLeaseD upoN sweLLIng oF THe polymET.

[226] OTHet EXEmplary THetapeuTIc agents useFuL For a comBInaTIon ThErapy IncLuDe BuT ate noT LImITeD To agents as DesctiBeD aBove, taDIaTIon ThErapy, Hotmone antagonists, Hotmones anD THeIt teLeasing FacTots, ThyroID anD ANTiThyroID Dtugs, esTtogens anD ptogesTIns, anDtogens, aDrENocorTicoTropic Hotmone; aDtenocotTIcaL sTetoIDs anD THeIt synTHeTIc anaLogs; InHIBITots oF THe synTHesis anD actions oF aDrENOcorTical Hotmones, InsuLIn, oral hypoGlycEmic agents, anD THe pharmacoloGY oF THe enDoctine pancteas, agents aFFecTIng calciFicaTioN anD Bone Tutnovet: calcium, phosphate, paraThyroID Hotmone, vITamin D, calciToNiN, vITamins such as waTet-soLuBLe vITamins, vITamin B complEx, ascorBic aciD, FaT-soLuBLe vITamins, vITamins A, K, anD E, gtowTH FacTots, cyTokiNES, cHemoKInes, muscariNic tecepTot agonists anD antagonists; anTIcHoLInesTetase agents; agents acting aT THe neutomuscuLat Junction anD/ot autonomic gangLIa; caTEcholamiNES, sympaThomimETic Dtugs, anD aDtenetgic tecepTot agonists or antagonists; anD 5-hyDroxyTrypTamiNE (5-HT, setoTonin) tecepTot agonists anD ANTAGONISTS.

[227] THetapeuTIc agents can also IncLuDe agents For paiN anD InFIammaTIon such as HIsTamIne anD HIsTamIne antagonists, BtaDyKInIn anD BtaDyKInIn antagonists, 5 -hyDroxyTrypTamiNE (setoTonin), LipID suBsTances ThaT ate genetaTeD By BIoTtansFotmaTIon oF THe proDucTs oF THe seLecTIve HyDrolysis oF memBtane pHospHolipIDs, eicosanoIDs, PtosTagLanDIns, THtomBoxanes, LeuKoTtIenes, aspiriN, nonsTetoIDaL anTI-InFIammaToty agents, anaLgesIc-anTIpyteTIc agents, agents ThaT InHIBIT THe synTHesis oF PtosTagLanDIns anD THtomBoxanes, seLecTIve InHIBITots oF THe InDucIBLe cyclooxyGENASE, seLecTIve InHIBITots oF THe InDucIBLe cyclooxyGENASE-2, auTacoIDs, paracriNE Hotmones, somaTosTaTIn, gasTtin, cyTokiNES ThaT meDIaTe InTetacTIons InvoLveD In humoral anD ceLLuLat Immune tesponses, LIpID-DetIveD 96 2229772 auTacoiDs, eicosanoiDs, β-ADrenergc Agonists, ipratropium, glucocorticoiDs, MEtHylxantHinES, sodium cHanneI BIocKers, opioid receptor Agonists, calcium cHanneI BIocKers, memBrane stABilizERS anD IeuKoTrIene iNHiBitors.

[228] ADDitioNAl tHerapeutic agENts conTempIaTeD Herein incIuDe DiurEtics, vasopressin, AgENtS aFFeCting THe RENAl CONSERvATiON of water, RENNIN, ANgiotENSIN, AgENtS useFuI in THe Treatment of myocArDiAl iscHEmia, ANti-HypERtENsivE agENts, ANgioTensiN coNverting enzyme iNHiBitORS, β-AdreNErgic recEptor antagonists, agents For THe ΤεαΤμενΤ of HypErcHolEStErolEmiA, anD agents For THe Treatment of DyslipiDEmiA.

[229] OtHer THerapeuTic agents conTempIaTeD incIuDe Drugs used For control of gastric Acidity, agents For THe Treatment of peptic ulcers, agents For THe Treatment of gAStroesopHAgEAl reflux Disease, proKiNetic agents, aNtlemetics, agents used in IrritaBle Bowel syNdrome, agents used For DlarrHea, agents used For coNstipatioN, agents used For iNflammatory Bowel Disease, agents used For Biliary Disease, agents used For paNcreatic Disease. THerapeutic agents used To treat protozoan iNfectioNs, Drugs used To treat Malaria, AmeBiasis, GiarDiasis, TricHomoNiasis, TrypaNOsomiasis, and/or LeisHmaNiasis, and/or Drugs used in THe cHemotHerapy of HelmlNtHiasis. OtHer tHerapeutic agents incIuDe ANTimicroBiAl agents, sulFoNamiDes, TrimETHoprim-sulFAmETHoxAzolE quinoLones, anD agents For urinary tract iNfectioNS, pENicilliNS, cepHalosporiNS, anD otHer, β-LActAM AntiBiotics, an agent comprising an amiNOglycosiDe, protein syNtHesis iNHiBitors, Drugs used in THe cHemotHerapy of TuBerculosis, mycoBacterium avium complex Disease, anD leprosy, ANtiFuNgal agents, aNtiviral agents incluDing NONrETrovirAl agents anD ANTirETrovirAl agents.

[230] Examples of tHerapeutic ANtiBoDies THat can Be comBined witH a suBJect compound incIuDe But are not limiteD To aNti-Receptor TyrosiNE Kinase ANtiBoDies (cetuximaB, paNitumumaB, TrastuzumaB), anti CD20 ANtiBoDies (rituximaB, TositumomaB), and otHer ANtiBoDies sucH as alemtuzumaB, BevacizumaB, and gemtuzumaB.

[231] Moreover, tHerapeutic agents used For immuNomoDulatioN, sucH as immuNomoDulators, immuNOsuppressive agents, TolerogENS, and immuNOsTimulANTs are coNtemplateD By THe metHods Herein. In aDDition, tHerapeutic agents acting on THe Blood and THe BlooD-ForMing organs, Hematopoietic agents, growtH Factors, minerals, and vitamins, aNticoagulaNt, tHromBoLytic, and ανΤιρΙαΤεΙεΤ Drugs. 97 2229773 [232] FurTHer tHerapeutic AGents THat can Be comBIned witH a suBJect compound may Be FounD in Goodman and Gilman's "THe PHaTmacoloGical Basis oF THerapeutics" TentH Edition edited By Hardman, LimBird and Gilman or THe PHysician's DesK ReFerence.

[233] THe compounds DescriBed Herein can Be used in coMBinaTion witH THe aGents disclosed Herein or oTHer suitaBLe aGents, dependinG on THe condition BeinG tTeated. Hence, in some emBodiments THe compounds oF THe invEnTion will Be co-aDMinisTERED witH oTHer aGents as DescriBed aBove. WHen used in coMBinaTion THerapy, THe compounds DescriBed Herein may Be aDMinisTERED witH THe second aGent simultaneously or sepArately. THis aDMinisTRaTion in coMBinaTion can include simultaneous aDMinisTRaTion oF THe Two aGents in THe same dosaGE Form, simultaneous aDMinisTRaTion in separate DosaGE Forms, and separate aDMinisTRaTion. THat is, a compound DescriBed Herein and any oF THe aGents DescriBed aBove can Be FoTmulated TogeTHer in THe same DosaGE Form and aDMinisTERED simultaneously. Alternatively, a compound oF THe present invEnTion and any oF THe aGents DescriBed aBove can Be siMuLTaNEOusLy aDMinisTERED, wHerein BoTH THe aGents are present in separate FoTmulations. In anoTHer Alternative, a compound oF THe present invEnTion can Be aDMinisTERED Just Followed By and any oF THe aGents DescriBed aBove, or vice versa. In THe separate aDMinisTTaTion protocol, a compound oF THe present invEnTion and any oF THe aGents DescriBed aBove may Be aDMinisTERED a Few minutes apart, or a Few Hours apart, or a Few Days apart.

[234] THe metHods in accordance witH THe invenTion may include aDMinisTeRinG a c-met Kinase seLecTive inHiBiToR witH one or more oTHer aGents THat eitHer enHance THe acTiviTy oF THe inHiBiToR or compliment its acTiviTy or use in TReaTMenT. SucH aDDiTionaL Factors and/or aGents may produce an auGMenTeD or even syneRGisTic eFFect wHen aDMinisTeReD witH a c-met Kinase seLecTive inHiBiToR, or minimize side eFFects.

[235] In one EmBodiment, THe metHods oF THe invenTion may include aDMinisTeRinG FoTmulations comprisinG a c-met Kinase seLecTive inHiBiToR oF THe invenTion witH a particular cytoKine, lympHoKine, oTHer HeMaTopoieTic Factor, tHromBolytic or anTi-THROMBoTic Factor, or anTi-inFlaMMaToRy aGent BeFore, durinG, or aFter aDMinisTRaTion oF THe c-met Kinase inHiBiToR. One oF ordinary sKill can easily DeTeTmine iF a particular cytoKine, LympHoKine, HeMaTopoieTic Factor, tHromBolytic oF anTi-THROMBoTic Factor, and/or anTi-inFlaMMaToRy aGent enHances or compliments THe acTiviTy or use oF THe c-met Kinase inHiBiToRS in TTeaTMenT. 98 2229772 [236] More speciFically, and without limiTation, The methods of The invention may comprise adminisTerinG a c-met kinase selective inhiBiTor with one or more of TNF, IL-1, IL-2, IL-3, IL4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IFN, G-CSF, Meg-CSF, GM-CSF, ThromBopoietin, stem cell Factor, and eryThropoieTin. Compositions in accordance with The invention may also include other known AngiopoieTins such as Ang-2, Ang4, and Ang-Y, growth Factors such as Bone morphogenic protein-l, Bone morphogenic proTein-2, Bone morphogenic proTein-3, Bone morphogenic proTein-4, Bone morphogenic proTein-5, Bone morphogenic proTein-6, Bone morphogenic proTein-7, Bone morphogenic proTein-8, Bone morphogenic proTein-9, Bone morphogenic proTein-10, Bone morphogenic protein-ll, Bone morphogenic proTein-12, Bone morphogenic proTein-13, Bone morphogenic proTein-14, Bone morphogenic proTein-15, Bone morphogenic protein receptor IA, Bone morphogenic protein receptor IB, Brain derived neurotrophic Factor, ciliary neutrophic Factor, ciliary neutrophic Factor receptor a, cytokine-induced neutrophil chemotactic Factor 1, cytokine-induced neutrophil chemotactic Factor 2 alpha, cytokine-induced neutrophil chemotactic Factor 2 Beta, Beta endoThelial cell growth Factor, endothelin 1, epidermAl growth Factor, epiThelial-derived neutrophil aTTractanT, FiBroBlasT growth Factor 4, FiBroBlasT growth Factor 5, FiBroBlasT growth Factor 6, FiBroBlasT growth Factor 7, FiBroBlasT growth Factor 8, FiBroBlasT growth Factor 8B, FiBroBlasT growth Factor 8c, FiBroBlasT growth Factor 9, FiBroBlasT growth Factor 10, FiBroBlasT growth Factor acidic, FiBroBlasT growth Factor Basic, glial cell line-derived neutrophic Factor receptor al, glial cell line-derived neutrophic Factor receptor a2, growth related protein, growth related protein a, growth related protein .Beta., growth related protein .gamma., heparin Binding epidermal growth Factor, hepatocyte growth Factor, hepatocyte growth Factor receptor, insulin-like growth Factor I, insulin-like growth Factor receptor, insulin-like growth Factor II, insulin-like growth Factor Binding protein, keraTinocyTe growth Factor, leukemia inhiBitory Factor, leukemia inhiBitory Factor receptor alpha, nerve growth Factor, nerve growth Factor receptor, neuroTrophin-3, neurpTrophin-4, placenta growth Factor, placenta growth Factor 2, plaTelet derived endoThelial cell growth Factor, plaTelet derived growth Factor, plaTelet derived growth Factor A chain, plaTelet derived growth Factor AA, plaTelet derived growth Factor AB, plaTelet derived growth Factor B chain, plaTelet derived growth Factor BB, plaTelet derived growth Factor receptor a, plaTelet derived growth Factor receptor Beta, pre-B cell growth sTimulating Factor, stem cell Factor, stem cell Factor receptor, Transforming growth Factor alpha, Transforming growth Factor Beta, TransForming growth Factor Beta 1, TransForming growth Factor Beta 1.2, Transforming growth Factor Beta 2, TransForming growth Factor Beta 3, TransForming growth Factor Beta 5, 99 2229772

IaTenT TrANsforMiNG growth factor Beta 1, TraNsformiNg growth factor Beta BInDIng proteiN I,

TraNsformiNg growth factor Beta BInDIng proteiN II, TraNsformiNg growth factor Beta BInDIng proteiN Ill, tumor Necrosis factor receptor type I, tumor Necrosis factor receptor type II, uroKlNASE-ΤγρΕ plasMiNOgEN activator receptor, anD cHImeric proteiNS anD BIoIogIcaIIy or

ImmunoIogIcaIIy active frAgMENts Thereof.

[237] The followiNg geNeral MetHoDologY DescriBeD hereiN provides the maNNer aND process of makiNg aND using the compouND of the preseNt Invention aND are IllusTraTivE rather ThaN llMltiNg. Further MoDificatioN of provIDeD MetHoDologY aND aDDiTloNallY new methods may also Be Devised In order To achieve aND serve the purpose of the Invention. AccorDiNgly, it should Be uNDerstooD that there may Be other emBoDImenTs which fall wITHIn the spirit aND scope of the Invention as DefiNeD By the specificatioN Hereto.

[238] REprESENTaTivE compouNDs of the preseNt Invention IncIuDe those specifieD above In Table 1 aND pHarMacEuTicallY acceptaBle salts Thereof. The preseNt Invention also IncIuDes the iNtermeDIate compouNDs Discussed In the examples aND elsewHere In the specificatioN as well as their salts. The preseNt Invention should noT Be coNstrueD To Be llmiteD To them.

GENERAL METHOD OF PREPARATION OF COMPOUNDS OF THE INVENTION

[239] The compouNDs of the preseNt Invention may Be prepareD By the followiNg processes. UnIess otHerwise iNDIcateD, the varlaBlES (e.g. Cy1, R2, L2, X, aND Cy2) wHen used In the Below formulae are To Be uNDerstooD To preseNt those groups DescriBeD above In reIaTIon To formula (I).

[240] Scheme 1: THIs scheme provides a method for the prepArATloN of the compound of formula (IA) whereiN Is -CRARb-, X Is CR1 or N anD the other variaBles such as Cy1, R2, anD Cy2 are the same as DescriBeD above In RelatioN To formula (I). 100 2229772

Scheme 1

<img img-format="tif" img-content="drawing" file="IL222977AD000244.tif" id="idf0044" />

5 6 (ΙΑ) (a) Cy2-L2-NH2; base; (b) reduction; (c) HNO2 [for X = N], R1COOH, Δ [for X = CR1]; (d) Cy1-B{OR)2, base transition metal catalyst.

[241] The compound of formula (1) wherein Hal represents a halogen and R2 is the same as described above in relation to formula (I) can be coupled with a compound of formula Cy2-L2-NH2 in the presence of a suitable base, such as sodium or potassium carbonate, to give a compound of formula (2) wherein L2 is -CRaRb-. The compound of formula (2) can then be converted to a compound of formula (3) by reducing with a metal such as iron, or a metal halide such as stannous chloride and an acid (such as acetic acid, hydrochloric acid or ammonium chloride). The compound of formula (3) can then be cyclised to a compound of formula (4) wherein X = N using nitrous acid, generated in situ by reacting an alkali metal nitrite such as sodium nitrite with an acid such as acetic acid or hydrochloric acid. The compound of formula (3) can also be cyclised to form a compound of formula (4) wherein X = CR1, by heating or irradiating with microwaves in the presence of R'COOH wherein R1 is H or a CrC4 alkyl group. The compound of formula (4) can be coupled with a boronic acid of formula Cy1-B(OR)2 (wherein R = H) or its ester (wherein R = alkyl) in the presence cf a transition metal catalyst such as tetrakis(triphenylphosphine)palladium(0) and a suitable base such as potassium carbonate to give the desired compounds of formula (IA) wherein L2 is -CRaRb-, X is CR1 or N and the other variables such as Cy1, R2 and Cy2 are the same as described above in relation to formula (D 101 22297712 [242] Alternatively, the compound of formula (2) may be coupled with a boronic acid of formula Cy1-B(OR)2 (wherein R = H) or its ester (wherein R = alkyl) in the presence of a catalyst such as tetrakis(triphenylphosphine)palladium(0) and a suitable base such as potassium carbonate to give a compound of formula (5). The compound of formula (5) can then be converted to a compound of formula (6) by reducing with a metal such as iron, or a metal halide such as stannous chloride and an acid such as acetic acid, hydrochloric acid or ammonium chloride. The compound of formula (6) can then be cyclised to a compound of formula (IA) wherein X = N using nitrous acid, generated in situ by reacting an alkali metal nitrite such as sodium nitrite with an acid such as acetic acid or hydrochloric acid. The compound of formula (6) can also be cyclised to a compound of formula (IA) wherein X = CR1, by heating or irradiating with microwaves in the presence of R'COOH wherein R1 is H or a CrC4 alkyl group.

[243] Scheme 2: This scheme provides a method for the preparation of a compound of formula (IA-1) wherein D is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heteroaryl and the other variables such as L2, R2, X, and Cy2 are the same as described above in relation to formula (IA-1):

Scheme 2

<img img-format="tif" img-content="drawing" file="IL222977AD000245.tif" id="idf0045" />

(a) base, transition metal catalyst [244] A compound of formula (4) can be coupled with a boronic acid of formula 7 (wherein R = H) or its ester (wherein R = alkyl) in the presence of a transition metal catalyst such as tetrakis(triphenylphosphine)palladium(0) and a suitable base such as potassium carbonate to give compound of formula (IA-1).

[245] Schemes 2A and 2B provide a non-limiting specific illustration covering some of the embodiments of the compound of formula (IA-1). 102 22297112 [246] Scheme 2A: This scheme provides a method for the preparation of a compound of formula (IA-1) wherein D is a substituted phenyl. In particular the phenyl ring is substituted with a group of formula COORX (refered to as a compound of formula (IA-la)) or CONRxRv (refered to as a compound of formula (IA-lb)) wherein Rx and R&gt; are the same as decribed herein. Optionally the phenyl ring is further substituted with one or more R" wherein each R" is independently hydrogen, halogen or substituted or unsubstituted alkyl.

Scheme 2A

<img img-format="tif" img-content="drawing" file="IL222977AD000246.tif" id="idf0046" />

(a) base, transition metal catalyst; (b) Hydrolysis: (c) amide coupling with R^R^NH

[247] The compound of formula (4) can be coupled with a boronic acid of formula 8 (wherein R = H) or its ester (wherein R = alkyl) in the presence of a transition metal catalyst such as tetrakis(triphenylphosphine)palladium(0) and a suitable base such as potassium carbonate to give the compound of formula (9). The compound of formula (9) can be hydrolysed in the presence of an alkali metal hydroxide such as lithium hydroxide to give the compound of formula (IA-la). The compound of formula (IA-la) can be converted into a compound of formula (IA-lb) by reacting it with an amine of the formula RXR-VNH in the presence of an amide coupling reagent such as A-(3-dimethylaminopropyl)-2V" ethylcarbodiimide hydrochloride (EDC.HC1), (benzotriazol lyl)oxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) or any other amide coupling reagent known in the art. Alternatively the conversion can be effected by reacting the compound of formula (IA-la) with with a halogenating agent such as thionyl chloride and subsequently reacting the resultant acid halide with an amine of the formula RXRVNH in the presence of a suitable base such as a trialkylamine. The compounds of formula (IA-lb) can 103 also be obtained by reacting the compound of formula 4 with a boronic acid of formula 10 (wherein R = H) or its ester (wherein R = alkyl).

ILLUSTRATIVE EXAMPLES FOR SCHEME 2A 2229772

<img img-format="tif" img-content="drawing" file="IL222977AD000247.tif" id="idf0047" />

(a) base, transition metal catalyst; (b) Hydrolysis; (c) amide coupling with EtNI-fe [248] Scheme 2B: This scheme provides a method for the preparation of compound of formula (IA-1) wherein D is a pyrazole (refered to as compound of formula (IA-lc)) or substituted Pyrazole reffered to as compound of formula (IA-ld).In particular the pyrazole ring is substituted with substituted or unsubstituted alkyl. Optionally the said pyrazole ring is further substituted with one or more of R"; wherein R" is hydrogen, halogen or substituted or unsubstituted alkyl.

Scheme 2B

<img img-format="tif" img-content="drawing" file="IL222977AD000248.tif" id="idf0048" />

(a) base, transition metal catalyst; (b) base, R-X

<img img-format="tif" img-content="drawing" file="IL222977AD000249.tif" id="idf0049" />

[249] The compound of formula (4) can be coupled with a boronic acid of formula 11 (wherein R = H) or its ester (wherein R = alkyl) in the presence of a transition metal catalyst such as tetrakis(triphenylphosphine)palladium(0) and a suitable base such as potassium carbonate to give compound of formula (IA-lc). The compound of formula (IA-lc) can be alkylated with an alkyl halide of formula R X wherein R" is substituted or 104 unsubstituted alkyl in the presence of a suitable base such as a metal hydride to give the compound of formula (IA-ld). 2225772

ILLUSTRATIVE EXAMPLES FOR SCHEME 2B

HO

<img img-format="tif" img-content="drawing" file="IL222977AD000250.tif" id="idf0050" />

Ex-148 (a) base, palladium catalyst; (b) i. PgO-CH2CH2-CI, base ii. Deprotection ; (c) CH3I, base [250] Scheme 3: This scheme provides a method for the preparation of the compound of formula (II) and (IIA) wherein A is -ORC or RCR-N-, L2 is -CRaRb-, X is CR1 or N and the other variables such as R2, and Cy2 are the same as described above in relation to formula (Π) and (IIA).

Scheme 3

<img img-format="tif" img-content="drawing" file="IL222977AD000251.tif" id="idf0051" />

R2 4 (a)

<img img-format="tif" img-content="drawing" file="IL222977AD000252.tif" id="idf0052" />

(II)

<img img-format="tif" img-content="drawing" file="IL222977AD000253.tif" id="idf0053" />

N (a) AH base or base, transition metal catalyst, phosphine ligand [251] The compound of formula (4) can be reacted with a nucleophilic compound of formula AH wherein A is -ORC or RCR-N, in the presence of a base such as an alkali metal fluoride, alkali metal carbonate or an alkali metal alkoxide to give a compound of formula (II). Optionally this reaction may be carried out in the presence of a transition metal catalyst such as palladium acetate and a phosphine ligand such as triphenyl phosphine. 105 ILLUSTRATIVE EXAMPLES FOR SCHEME 3 222577/2

<img img-format="tif" img-content="drawing" file="IL222977AD000254.tif" id="idf0054" />

/E+M-n

N

Ex-203

Phenol

Aniline^

<img img-format="tif" img-content="drawing" file="IL222977AD000255.tif" id="idf0055" />

Ex-202

XX

<img img-format="tif" img-content="drawing" file="IL222977AD000256.tif" id="idf0056" />

Ex-219 [252] Scheme 4: This scheme provides a method for the preparation of a compound of formula (III) wherein L2 is -CRaRb-, X is CR1 or N, U is C-CR3, V is N, W is O or NR4 and the other variables such as R5, R2, and Cy2 are the same as described above in relation to formula (ΠΙ).

Scheme 4 R5

<img img-format="tif" img-content="drawing" file="IL222977AD000257.tif" id="idf0057" />

4 4a (III) (a) transition metal catalyst; (b) R5-W-NH2

The compound of formula (4) can be reacted with a tin compound of formula 12 wherein Ra and Rb are (optionally Ra and Rb can also be alkyl or aryl) in the presence of a transition metal catalyst such as tris(dibenzylidineacetone)palladium(0) and optionally in the presence of a ligand such as triphenylphosphine to give the compound of formula (4a). The compound of formula (4a) can be reacted with the compound of formula R5-W-NH2 or R52NCO wherein R5 is as defined herein above and W is O, S or NR4 to give the desired compound of formula (ΠΙ). 106 222977/2 ILLUSTRATIVE EXAMPLES FOR SCHEME 4

<img img-format="tif" img-content="drawing" file="IL222977AD000258.tif" id="idf0058" />

i. Methoxylamine hydrochloride; ii. Hydroxytemine hydrochloride; iii. Acetyl hydrazide; iv.Semicarbazide

<img img-format="tif" img-content="drawing" file="IL222977AD000259.tif" id="idf0059" />

Ex-209 [253] Similar methodologies with certain modifications as known to those skilled in the art can be used to synthesize compounds of formula (I), (IA), (IA-1) (II), (IIA), (III), (IIIA), (IIIB) and (IV) wherein all the variables are to be understood to present those groups described above in relation to formula (I), (IA), (IA-1) (Π), (ΠΑ), (ΙΠ) ,(ΠΙΑ), (ΙΠΒ) and (IV) using suitable intermediates and reagents.

Experimental [254] Unless otherwise mentioned, work-up implies distribution of reaction mixture between the aqueous and organic phases indicated within parenthesis, separation and drying over Na2SO4 of the organic layer and evaporating the solvent to give a residue. Unless otherwise stated, purification implies column chromatography using silica gel as the stationary phase and a mixture of petroleum ether (boiling at 60-80DC) and ethyl acetate or dichloromethane and methanol of suitable polarity as the mobile phases. RT implies ambient temperature (25-28DC).

Intermediate 1: Quinolin-6-ylmetliana mine [255] Step 1: Quinoline-6-carboxylic acid: To a mixture of 4-aminobenzoic acid (175 g, 1.28 mol), 4-nitrophenol (88.75 g, 0.64 mol) and sulphuric acid (1.2 lit.), glycerol (234.8 g, 2.55 mol) was added dropwise at 135DC. After 48h, the reaction mixture was cooled to ODC and the pH adjusted to 3-5 with 10% sodium hydroxide solution. The resulting 107 222977/2 precipitate was collected by filtration and washed with water and dried under vacuum to afford the title compound as a black solid (125 g, 56%).

[256] Step 2: Methyl quinoline-6-carboxvlate: To a solution of quinoline-6-carboxylic acid (183 g, 1.06 mol) in methanol (1 lit.), thionyl chloride (150.7 g, 1.2 mol) was added dropwise at ODC and then stirred at 65 DC for 12h. The reaction mixture was concentrated and to the residue dichloromethane and aqueous sodium carbonate solutions were added. The organic layer was dried with sodium sulphate and concentrated to afford the title compound as a brown solid (150 g, 75%).

[257] Step 3: Quinoline-6-carboxamide: To a solution of methyl quinoline-6-carboxylate (148 g, 0.79 mol) in methanol (600 ml.), aqueous ammonia (800 ml) was added and then stirred at 45 DC for 12h. The reaction mixture was concentrated to afford the title compound as a dark red solid (120 g, 88%).

[258] Step 4: Quinoline-6-carbonitrile:To a solution of quinoline-6-carboxamide (177 g, 1.03 mol) in chloroform (1.5 lit.) and triethylamine (520.15 g, 5.15 mol), trifluoroacetic anhydride (540.34 g, 2.57 mol) was added dropwise below 10OC. After 1.5h, the pH was adjusted to 7 with sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried with sodium sulphate and concentrated to afford the title compound as a brown solid (96 g, 59%).

[259] Step 5: Quinolin-6-ylmethanamine:To a solution of quinoline-6-carbonitrile (96 g, 0.62 mol) in saturated ammonia in methanol (1 lit.), Raney-Ni (10 g) was added and the mixture was stirred at 1 atm of H2 at RT for 16h. The reaction mixture was filtered and the filtrate was concentrated under vacuum to afford the title compound as a brown oil (80 g, 82%). Ή-NMR (δppm,DMSO-de,400MHz): 008.83 (dd,7=4.2,1.7Hz, lH),8.29(d,7= 8.3 Hz, IH), 7.95 (d, J= 8.6 Hz, IH), 7.85 (s, IH), 7.75 (dd 7= 8.7,1.8 Hz, IH), 7.49 (dd, 7 = 8.2,4.2 Hz, IH), 3.90(s, 2H).

Intermediate 2: 2-(quinolin-6-yl)propan-2-amine [260] Step 1: 2-(quinolin-6-yl)propan-2-ol:To an ice-cold solution of methylmagnesium iodide prepared from magnesium (0.454 g, 18.69 mmol) and methyliodide (1.16 ml, 18.69 mmol) in diethyl ether (15 ml), methyl quinoline-6-carboxylate (0.50 g, 2.67 mmol) in diethyl ether (5 ml) was added and warmed to room temperature. After 12h, the 108 222977/2 reaction mixture was cooled to OUC, quenched with dil. 6N HCI and extracted with ethyl acetate. The organic layer was dried over sodium sulphate and concentrated under reduced pressure and column chromatographed with ethyl acetate: petroleum ether to afford the title compound as a yellow liquid (0.42 g, 84%). Ή-NMR (δ ppm, DMS Oft 400 MHz): 8.83(dd 7 = 4.2,1.7 Hz, IH), □□□□ n(dd,7 = 8.2,1.1 Hz, IH), 8.00(d,7= 1.9 Hz, IH), 7.95(d,7 = 8.8

Hz, IH), □□□□□(dd,7= 8.9,2.0Hz, IH), □□□□□(q, J = 4.1 Hz, IH), 5.23(s, IH), 1.5 l(S,6Ht- [261] Step 2: 6-(2-azidopropan-2-yl)quinoline : 2-(Quinolin-6-yl)propan-2-ol (0.50 g, 2.67 mmol) and sodium azide (1.73 g, 26.70 mmol) were added successively to ice-cold trifluoroacetic acid (20 ml) and warmed to room temperature. After 12h, the reaction mixture was cooled to ODC, quenched with water and basified with sodium hydroxide solution and extracted with ethyl acetate. The organic layer was dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as brown liquid (0.340 g, 60%). Ή-NMR (δppm,DMSO-de,400MHz): □□8.90(dd7=4.1,1.6Hz, IH), 00000(0,7=7.6 Hz, IH), 8.06(d, 7 = 2.1 Hz, IH), 8.04(d, 7 = 9.0 Hz, IH), □ □ □ □ D(dd, 7 = 8.1,2.2 Hz, IH), □ □ □ □ □ (q, 7 = 4.2 Hz, IH), 1.71(S,6H).- [262] Step 3: 2-(quinolin-6-yl)propan-2-amine: To 6-(2-azidopropan-2-yl)quinoline (0.100 g, 2.67 mmol) in ethanol (3 ml), palladium on carbon (lOmg, 10%w/w) was added and stirred under a hydrogen atmosphere using hydrogen filled balloon. After 6h, the reaction mass was filtered through celite, washed with methanol and concentrated to afford the title compound as brown liquid (0.079 g, 90%). Ή-NMR (δ ppm, DMSO-de, 400 MHz): □ □8.82(dd7 = 4.2,1.6 Hz, IH), 0 0 000(0,7 = 8.9 Hz, IH), 8.02(d,7= 1.9 Hz, IH), 7.99(dd, 7 = 8.9,2.1 Hz, IH), ΠΠΠΠΠ(0;7=8 9Η7υ IH), ΠΠΠΠO(q, 7 = 4.2Hz, IH), 2.06(s,2H),1.46 (s,6H).

Intermediate 3: (7-fluoroquinolin-6-yl)methanamine [263] Step 1: 6-Bromo-7-fluoroquinoline: To a mixture of 4-bromo-2-fluoroaniline (10 g, 52.62 mmol), ferrous sulphate (3.33 g, 11.97 mmol) and glycerol (15.78 ml), con.sulphuric acid (9.15 ml) was added slowly and the reaction mixture was heated to 140DC.

After 12h, the reaction mixture was cooled to OOC and the pH adjusted to 10-12 with 10% sodium hydroxide solution. The reaction mixture was filtered through celite, washed with ethyl acetate and layers were separated. The organic layer was washed with brine solution, dried over sodium sulphate and concentrated. The crude product was purified by column chromatoGraphy with ethyl acetate: petroleum ether to aFForD the title compounD as a white 109 222977/2 solid (4.9 g, 44%). Ή-NMR (5ppm,CDa3,400MHz): □8.96(dd,/=4.3,2.7Hz, 1H),8.15 (m, 2H), 7.81 (d, J= 9.5 Hz, IH), 7.42 (dd, J= 8.3,4.3 Hz, IH).

[264] Step 2: 7-Fluoroquinoline-6-carbonitrile: To a solution of 6-bromo-7- fluoroquinoline (4.90 g, 22.12 mmol) in dimethylacetamide (38 ml), potassium ferrocyanide (2.65 g, 4.86 mmol) and sodium carbonate (2.34 g, 22.12 mmol). The system was purged with nitrogen for 15 min. Palladium acetate (0.248 g, 1.10 mmol) was added under nitrogen and heated to 120DC. After 3h, the reaction mixture was filtered through celite, washed with ethyl acetate. The organic layer was washed with brine solution, dried over sodium sulphate and concentrated. The crude product was purified by column chromatography with ethyl acetate: petroleum ether to afford the title compound as a white solid (3.2g, 86%). Ή-NMR (δ ppm, CDC13,400 MHz): □ □ □ □ □ (dd, J= 4.1,2.9 Hz, IH), 8.25 (m, 2H), 7.90 (d, J= 10.0

Hz, IH), 7.53 (dd, J= 8.3, 4.3 Hz, IH).

[265] Step 3: (7-Fluoroquinolin-6-yl) methanamine: To 7-fluoroquinoline-6-carbonitrile (1.00 g, 5.813 mmol), methanol saturated with ammonia (13.5 ml) and Raney-Ni (1.27 g) were added and hydrogenated at 50-60 psi for 4h. The reaction mixture was filtered and concentrated to afford the title compound as a brown oil (0.80 g, 78%). Ή-NMR (δ ppm, DMSO-d6, 400 MHz): □ 8.85 (d, J = 2.3 Hz, IH), 8.35 (d, J = 8.0 Hz, IH), 8.06 (d, J = 9.5 Hz, IH), 7.68 (d, J= 11.8 Hz, IH), 7.49 (t, J= 3.8 Hz, IH), 3.92 (s, 2H), 1.90 (br s, 2H).

[266] Intermediate 4: 6-Chloro-3-nitro-N-(quinolin-6-ylmethyl)pyridin-2- amine: To a solution of 2,6-Dichloro-3-nitropyridine (1.62 g, 8.42 mmol) in ethanol (30 ml), sodium carbonate (2.34 g, 22.12 mmol) was added at RT and cooled to ODC followed by the addition of intermediate 1 (2 g, 12.64 mmol) in ethanol (20 ml) the mixture was stirred at RT for 12h. The reaction mixture was poured into 25 ml of water and extracted with ethyl acetate, washed with brine solution, dried over sodium sulphate and concentrated. The crude product was purified by column chromatography with dichloromethane:methanol to afford the title compound as a yellow solid (2.0 g, 50%). Ή-NMR (δppm, DMSO-d6,400MHz): □ □□□□□□(!, J= 6.0 Hz, IH), 8.85 (dd,/ = 4.0, 1.4 Hz, IH), 8.46 (d,/= 8.5 Hz, 1H),8.31 (d,/ = 7.8 Hz, IH), 7.98 (d/= 8.7 Hz, IH), 7.88 (s, IH), 7.79 (dd, /= 8.7,1.6 Hz, IH), 7.50 (dd, / = 8.3,4.2 Hz, IH), 6.80 (d, /= 8.6 Hz, IH), 4.92 (d, /= 6.1 Hz, 2H).

[267] Intermediate 5: 6-chloro-N-(4-fluorobenzyl)-3-nitropyridin-2-amine: The title compound was obtained as a yellow solid (2.1 g, 70%) by using a procedure that is 110 222999/2 similar to the one described fer intermediate 4 from 2,6-Dichloro-3-nitrepyridine (2.05 g, 10.65 mmel), 4-Fluerebenzylamine (2.0 g, 15.98 mmel), ethanel (50 ml) and sodium carbonate (2.94 g, 27.80 mmol). Ή-NMR (δ ppm, DMSO-d,. 400 MHz): □□□□□□□((, J = 5.9

Hz, IH), 8.43 (d, J = 8.6 Hz, IH), 7.43 (m, 2H), 7.15 (m, 2H), 6.79 (d, J = 8.6 Hz, IH), 4.68 (d, J = 6.1 Hz, 2H).

[268] Intermediate 6: 6-chloro-N-(2-chloro-3,6-difluorobenzyl)-3-nitropyridin-2-amine: The title cempound was ebtained as a yellew solid (1.14 g, 61%) by using a precedure that is similar tc the ene described fer intermediate 4 from 2,6-Dichloro-3-nitropyridine (0.724 g, 3.75 mmel), 2-chlcrc-3,6-diflucrcbenzylamine (1.0 g, 5.63 mmol), ethanel (25 ml) and sodium carbonate (2.94 g, 27.80 mmel). Ή-NMR (δ ppm, DMSO-dg, 400 MHz): □□□□□□&amp;amp;J = 5.5 Hz, IH), 8.41 (d, J = 8.6 Hz, IH), 7.44 (dt, J = 9.0,4.7 Hz, IH), 7.34 (dt, J = 9.3,4.3 Hz, IH), 6.81 (d, J = 8.6 Hz, IH), 4.86 (d, J = 5.5 Hz, 2H).

[269] Intermediate 7: 6-chloro-3-nitro-N-(2-(quinolin-6-yl)propan-2-yl)pyridin-2-amine: The title cempound was ebtained as a yellew solid (0.860 g. 47%) by using a precedure that is similar tc the ene described fer intermediate 4 from 2,6-Dichloro-3-nitropyridine (1.55 g, 8.05 mmel), Intermediate 2 (1.0 g, 5.36 mmel), ethanol (35 ml) and sedium carbonate (2.34 g, 22.12 mmol). Ή-NMR (δ ppm, D\1SO-d6. 400 MHz): □ 8.84(dd. J = 4.2,1.7 Hz, IH), 8.76(s,1H), 8.42(d, J = 8.6 Hz, IH), 8.33(d, J = 7.3 Hz, IH), 8.00 (d, J = 1.9 Hz, IH), 7.91 (d, J = 8.9 Hz, IH), 7.85 (dd, J = 8.9,2.1 Hz, IH), 7.49 (q, J = 4.2 Hz, IH), 6.70 (d, J = 8.6 Hz, IH), 1.89 (s,6H).

[270] Intermediate 8: 6-Chloro-N-((7-fluoroquinolin-6-yl)methyl)-3- nitropyridin-2-amine: The title compeund was ebtained as a yellow sclid (0.750 g, 50%) by using a procedure that is similar to the one described for intermediate 4 from 2,6-dichlorc-3-nitropyridine (1.31 g, 6.81 mmel), Intermediate 3 (0.80 g, 4.54 mmel), ethanel (15 ml) and sedium carbonate (0.838 g, 7.90 mmel). Ή-NMR (δ ppm, DMSO-d,,. 400 MHz): Π92Ί (t, J= 5.7 Hz, IH), 8.87 (d, J = 2.8 Hz, IH), 8.49 (d, J = 8.5 Hz, IH), 8.34 (d, J = 8.0 Hz, IH), 7.96 (d, J = 8.4 Hz, IH), 7.78 (d, J = 7.7 Hz, IH), 7.49 (dd, J = 8.3,4.2 Hz, IH), 6.83 (d, J = 8.6 Hz, IH), 4.95 (d, J = 5.9 Hz, 2H).

[271] Intermediate 9: 6-chloro-N2-(quinolin-6-ylmethyl) pyridine-2,3-diamine: Stanneus chloride (0.258 g, 1.143 mmol) and cone. HCl (3 ml) were added tc intermediate 4 (0.180 g, 0.571 mmel) at RT and stirred for lh. After lh stannous Chloride (0.258 g, 1.143

Ill 22297712 mmol) and conc. HCI (2 ml) were added and mainTained for lh. The reaction mixture was poured into ice water and The pH was adjusted To ca.(approx) 8 with sodium bicarbonaTe solution, exTracTed with ethyl acetaTe, washed with brine, dried over anhydrous sodium sulphate and eoneentraTed to afford The title compound as a yellow solid (0.150 g, 92%). 1H- NMR (δ ppm, DMSO-de, 400 MHz): 7178.85((¾ J=4.2, 1.6 Hz, IH), 8.32 (d, J=7.9 Hz, IH), 7.98 (d, J = 8.7 Hz, IH), 7.86 (s, IH), 7.76 (dd, J = 8.7,1.8 Hz, IH), 7.51 (dd, J = 8.3,4.2 Hz, IH), 6.73 (d, J = 7.8 Hz, IH), 6.59(t, J = 5.6 Hz, IH), 6.38 (d, J = 7.7 Hz, IH), 4.92(s, 2H), 4.70 (s, 2H).

[272] InTerMediaTe 10: 6-ehloro-N2-(4-fluorobenzyl)pyridine-2,3-diamine:The title compound was obtained as a yellow solid (1.3 g, 99%) by using a proeedure That is similar to the one described For intermediaTe 9 from inTermediaTe 5 (1.5 g, 5.33 mmol), stannous chloride (4.09 g, 18.13 mmol) and cone. HCI (11.5 ml). Ή-NMR (δ ppm, DMSO-de, 400 MHz):DO 7.38 (m,2H), 7.15 (m, 2H), 6.71 (d, J = 7.8 Hz, IH), OOOOOO(t, J = 5.9 Hz, IH), 6.37 (d, J = 7.8 Hz, IH), 4.87 (s,2H), 4.47 (d, J = 5.6 Hz, 2H).

[273] Intermediate 11: 6-chloro-N2-(2-chloro-3,6-difluorobenzyl)pyridine-2,3-diamine: Iron powder (2.0 g, 35.81 mmol) was added To a solution of The intermediate 6 (1.0 g, 2.99 mmol) in meThanol (10 ml) and eonc. HCI (1.5 ml) were added aT RT and refluxed For 5h. The reaction mixture was filtered Through celiTe and eoncenTrated. lee water was added To the residue and The pH was adjusted To ea. 8 with sodium bicarbonate solution, exTracted with ethyl aeeTate, washed with brine, dried over anhydrous sodium sulphate and concentrated To afford The Title compound as a yellow solid (0.67 g, 74%). Ή-NMR (δ ppm, DMSO-de, 400 MHz):□□ 7.47(dt, J = 9.0, 4.8 Hz, IH), 7.34 (dt, J = 9.1, 4.3 Hz, IH), 6.69 (d, J = 7.7 Hz, IH), □□□□□□(d, J = 7.7 Hz, IH), 6.13 (t, J = 4.4 Hz, IH), 4.89 (s,2H), 4.55 (d J = 3.5 Hz, 2H).

[274] Intermediate 12: 6-chloro-N2-(2-(quinolin-6-yl)propan-2-yl)pyridine-2,3-diamine: AceTie acid (30 ml) was added aT RT To a mixture of inTermediate 7 (2.0 g, 5.83 mmol) and iron powder (1.6 g, 29.17 mmol) and stirred For 12h. The reaction mixTure was basified with sodium bicarbonaTe solution, extraeTed with ethyl acetaTe, washed with brine, Dried over anhydrous sodium sulphate and concentrated To afford the title compound as a brown solid (1.42 g, 77%). 1H-NMR (δ ppm, DMSO-de, 400 MHz): 778.80¾ J = 2.7 Hz, IH), 8.30 (d, J = 8.0 Hz, IH), 7.92 (s, IH), 7.89 (d, J = 8.0 Hz, IH), 7.76 (d, J = 8.8 Hz, IH), 112 222977/2 7.46 (q, J = 4.2 Hz, IH), 6.66 (d, J = 7.7 Hz, IH), 6.20 (d, J = 7.7 Hz, IH), 6.04 (s, IH), 5.02 (s, 2H), 1.79 (s, 6H).

[275] InTermediATe 13: 6-Chloro-N2-((7-fluoroquinolin-6-YL)metHYl)pYridine-2,3-diAmine:The Title compound was oBtained as a yellow solid (0.550 g, 74%) By using a procedure That is similAr to the one descriBed For intermediAte 9 from inTermediATe 8 (0.750 g, 2.25 mmol), stannous chloride (2.28 g, 10.14 mmol) and cone. HCI (13 ml). Ή-NMR (δ ppm, DMSO-de, 400 MHz): δθ 8.87(d, J = 3.0 Hz, IH), 8.36 (d, J = 8.2 Hz, IH), 7.97 (d, J= 8.3 Hz, IH), 7.77 (d, J = 11.6 Hz, IH), 7.50 (dd, J = 8.2, 4.1 Hz, IH), 6.74 (d, J = 8.5 Hz, IH), 6.54 (T, J = 5.0 Hz, IH), 6.39 (d, J = 7.8 Hz, IH), 4.94 (s, 2H), 4.72 (d, J = 5.3 Hz, 2H).

Intermediate 14: 6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [276] IntermediATe 9 (0.220 g, 0.772 mmol) was dissolved in Acetie acid (1.3 ml) and cooled to 5 DC. Sodium nitrite (0.063 g, 0.927 mmol) in 0.35 ml water was added slowly Followed By sulphuric acid (0.09 ml). The reACTion mixture was warmed To RT and stirred for 30 min. The reACTion mixture was poured into ice water and pH Adjusted to ca. 8 with sodium BicArBonATe solution, extrACTed with ethyl ACetaTe, washed with Brine, dried over sodium sulphate and ConeentrATed to Afford The title Compound as a Brown solid (0.220 g, 96%). 1H-NMR (δ ppm, DMSO-d,,400 MHz): 0 08.88 (s, lH),8.69(d, J = 8.6 Hz, IH), 8.35 (d,J = 8.1

Hz, IH), 8.01(d, J = 8.6 Hz, IH), 7.90 (s, IH), 7.74 (d, J = 8.5 Hz, IH), 7.61(d, J = 8.5 Hz, IH), 7.53(dd, J = 8.0,4.0 Hz, IH), 6.12 (s, 2H).

[277] Intermediate 15: 5-chloro-3-(4-fluorobenzyl)-3H-[1,2,3]triazolo[4,5- b]pyridine: THe Title compound was oBtAined as a Brown solid (1.0 g, 76%) By using a procedure That is similAr to the one deseriBed For intermediAte 14 from intermediATe 10 (1.3 g, 5.17 mmol), AceTie acid (9 ml), sodium niTriTe (0.428 g, 6.20 mmol), water (2.4 ml) and sulphurie acid (0.58 ml). Ή-NMR (δ ppm, DMSO-d, 400 MHz): 0 08.66 (d, J = 8.7 Hz, IH), □ □ □ □ □ 0(d, J = 8.6 Hz, IH), 7.43 (m, 2H), 7.20 (m, 2H), 5.90 (s, 2H).

[278] Intermediate 16: 5-chloro-3-(2-chloro-3,6-difluorobenzyl)-3H- [1,2,3]triazolo[4,5-b] pyridine: The title Compound was oBtAined as a Brown solid (0.66 g, 98%) By using a procedure THaT is similar to the one descriBed For inTermediAte 14 From inTermediAte 11 (0.65 g, 2.13 mmol), ACetic acid (4 ml), sodium niTrite (0.177 g, 2.56 mmol), water (0.93 ml) and sulphurie ACid (0.58 ml). 1H-NMR (δ ppm, DMSO-d,, 400 MHz): 8.66 113 2229T7/2 (D, J = 8.7 Hz, 1H), □□□□□□(&lt;!, J = 8.8 Hz, 1H), 7.60 (DT, J = 9.0,4.9 Hz, 1H), 7.45 (DT, J = 9.2,4.2 Hz, 1H), 5.98 (s, 2H).

[279] Intermediate 17: 6-(2-(5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)propan-2-yl)quinoline: ThE Title compound was oBTaineD as a Btown soLID (1.1 g, 91%)

By usiNg a proceDure ThaT is similar To The ONe DescriBeD for iNTerMeDiATe 14 From InTetmeDIaTe 12 (1.20 g, 3.83 mmoI), aceTIc acID (7.2 m1), soDIum nITtiTe (0.317 g, 4.604 mmoL), waTer (2.8 m1) anD sulphuric acID (0.5 m1). 1H-NMR (δ ppm, CDCL3, 400 MHz): □ 08.88 (dd, J = 4.2,1.5 Hz, 1H), 8.29 (D, J = 8.6 Hz, 1H), 8.12 (D, J = 7.8 Hz, 1H), 8.10 (D, J = 8.9 Hz, 1H), 7.70 (D, J = 2.1 Hz, 1H), 7.48 (DD, J = 8.9,2.2 Hz, 1H), 7.41 (q, J = 4.2 Hz, 1H), 7.25(m,1H), 2.44 (s, 6H). Mass: 323.76 (M+).

[280] Intermediate 18: 6-((5-Chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)-7-fluoroquinoline:ThE Title compound was oBTaineD as a Btown solID (0.345 g, 62%) By usiNg a proceDure ThaT Is sImILat To The one DesctiBeD For InTetmeDIaTe 14 From InTetmeDIaTe 13 (0.540 g, 1.78 mmoL), AceTic acID (3.1 mL), soDIum νιΤτιΤε (0.148 g, 2.13 mmoL), waTet (0.8 mL) anD sulphuric acID (0.2 m1). 1H-NMR (δ ppm, CDCL3, 400 MHz): δθ 8.91 (D, J = 2.9 Hz, 1H), 8.36 (D, J = 8.6 Hz, 1H), 8.08 (D, J = 8.1 Hz, 1H), 7.80 (D, J = 11.0 Hz, 1H), 7.70 (D, J = 7.8 Hz, 1H), 7.40 (μ, 2H), 6.11 (s, 2H).

Intermediate 19: 2-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) propan-2-ol [281] STep 1: 1-(4-BroMO-2-FluoropheNyl)EThaNol:A soluTioN of 4-Btomo-2-

FluoroBeNZAlDEhyDe (5 g, 24.62 mmoL) in DieThyl eTher (10 mL) was aDDeD To an Ice-colD soluTioN of MeThylMAgNEsiuM IoDIDe prepareD From MAgNesiuM (1.7 g, 73.88 mmoI) anD MeThylloDIDe (4.58 mL, 73.88 mmoL) In DieThyl eTher (50 mL). The mixture was watmeD sTirreD at RT. for 12h, and cooled to 01 1C, quenched with dil. 6N HCI and extracted with ethyl AceTaTe. The orgANic layer was DrieD over soDIum sulphate anD concenTtaTeD unDet reDuceD pressure To al'IorD The TiTle compound as teD colour IIquID (5 g, 94%). Ή-NMR (δ ppm, CDC13, 400 MHz): δ 7.40 (T, J = 8.2 Hz, 1H), 7.30 (DD, J = 8.3, 1.7 Hz, 1H), 7.21 (DD, J=9.9, 1.9 Hz, 1H), 5.17 (q, J = 6.4 Hz, 1H), 1.49 (D, J = 6.5 Hz, 3H).

[282] Step 2: 1-(4-BroMo-2-FluorophENyl)EThANONE:To a soIuTIon of intermediate 19 (step 1) (5.0 g, 22.82 mmoL) in DMF (25 mL), pyriDlNiuM DichroMATe (12.8 g, 34.23 mmoL) was aDDeD aT toom TeMperaTure. After 12H, The reacTioN Mixture was QueNcheD wiTh water, 114 222977/2 diluted with ethyl acetate and filtered through celite. The organic layer was washed with brine solution and dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as a red colour liquid (4.1 g, 84%). Ή-NMR (δ ppm, DMSO-ck, 400 MHz): δ 7.76(ζ J= 8.3 Hz, IH), 7.73(dd, J= 10.8,1.8 Hz, IH), 7.55(dd, J= 5.2,1.8 Hz, IH), 2.55 (s, 3H).

[283] Step 3: 2-(4-bromo-2-fluorophenyl)propan-2-ol: A procedure similar to the one described in step 1 was followed to get the crude product from magnesium (0.33 g, 73.88 mmol), methyliodide (0.856 ml, 13.69 mmol), diethyl ether (10 ml) and the intermediate from step 2 (1 g, 4.56 mmol) in diethyl ether (10 ml). Purification by column chromatography with ethyl acetate: petroleum ether gave the title compound as a yellow liquid (0.5 g, 47%yield). Ή-NMR (δppm, CDC13,400 MHz): δ 7.48 (t, J= 8.6 Hz, IH), 7.27 (m, IH), 7.21(dd, J= 11.3, 1.9 Hz, IH), 2.04 (s, IH), 1.60 (s, 6H).

[284] Step 4: 2-(2-fluoro-4-(4,4,5,5-tetramethyl-l, 3,2-dioxaborolan-2-yl)phenyl) propan-2-ol:Potassium acetate (0.404 g, 4.11 mmol) and bis(pinacolato)diboron (0.575 g, 2.26 mmol) were added to a solution of the intermediate from step 3 (0.4800 g, 2.05 mmol) in dioxane (16 ml), and the solution was degassed for 30 min. [Ι,Γ'-bis (diphenylphosphino) ferrocene]dichloro palladium(II).CH2Cl2 (0.084 g, 0.102 mmol) was added under nitrogen atmosphere and heated to 80 DC. After 12h, the reaction mixture was filtered through celite and concentrated. The crude product was purified by column chromatography with ethyl acetate: petroleum□ ether to afford the title compound as a colourless oil (0.450 g, 61%). Ή-NMR (δ ppm, CDC13,400 MHz): δ 7.55 (s, IH), 7.54 (d,7=4.8 Hz, IH), 7.46 (d, 7= 12.6

Hz, IH), 2.13 (d, 7= 3.5 Hz, IH), 1.63 (d, 7= 5.5 Hz, 6H), 1.33 (s, 12H).

Intermediate 20: 2-(3-fluoro-4-isopropoxyphenyl)-4,4,5,5-tetramethyl-l,3,2- dioxaborolane [285] Step 1: 4-bromo-2-fluoro-l-isopropoxybenzene:To a solution of 4-bromo-3-fluorophenol (10 g, 52.35 mmol) in THF (100 ml), isopropyl alcohol (4.8 ml, 62.62 mmol) and triphenylphosphine (20.6 g, 78.52 mmol) were added and heated to 45 -C followed by diisopropylazodicarboxylate (15.4 ml, 78.52 mmol). The mixture was refluxed for lh, concentrated and the residue was purified by column chromatography with ethyl acetate: petroleum ether to afford the title compound as a colourless liquid (13.1 g, 99%) which was used without purification in the next step. 115 222977/2 [286] Step_2_2-(3-fliioro-4-isopropoxyphenvl)-4.4.5.5-tetramethvl-1.3.2- dioxaborolane:The title compound was obtained as a yellow oil (13.9 g, 99%) by using the procedure described in step 4 for intermediate 19 from the product of step 1 (12.5g g, 53.60 mmol), bis(pinacolato)diboron (15 g, 58.96 mmol), potassium acetate (10.52 g, 107.2 mmol), dioxane (125 ml) and [l,l"-bis(diphenylphosphino)ferrocene]dichloro palladium (II). CH2C12 (4.4 g, 5.36 mmol) which was used without purification in the next step.

[287] Intermediate 21: 2-Methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide: The title compound was obtained as a brown solid (0.600 g, 70%) by using the procedure described in step 4 for intermediate 19 from 4-bromo-2-methylbenzamide (0.700 g, 3.27 mmol), bis(pinacolato)diboron (0.913 g, 3.59 mmol), potassium acetate (0.96 g, 9.81 mmol), dioxane (12 ml) and [l,l"-bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH2Cl2 (0.080 g, 0.098 mmol) which was used without characterisation in the next step.

Intermediate 22: 2-Chloro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide: [288] The title compound was obtained as a brown solid (0.75 g, 69%) by using the procedure described in step 4 for intermediate 19 from 5-bromo-2-chlorobenzamide (0.800 g, 3.83 mmol), bis(pinacolato)diboron (1.07 g, 4.21 mmol), potassium acetate (1.12 g, 11.49 mmol), dioxane (10.5 ml) and [l,l"-bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH2Cl2 (0.083 g, 0.102 mmol) which was used without characterisation in the next step.

Intermediate 23: 3-ammo-N,N-dimethylpropanamide trifluoroacetate: [289] To a solution of N-boc-3-aminopropanoic acid (0.150 g, 0.793 mmol) in DMF (1.5 ml), N-Ethyldiisopropylamine (0.205 g, 1.58 mmol) and HATU (0.301 g, 0.793 mmol) were added and stirred for 5 min. Dimethylamine hydrochloride (0.065 g, 0.793 mmol) was added at RT and the reaction mixture was stirred for 12h. Water was added to the reaction mixture and extracted with ethyl acetate, dried over sodium sulphate and concentrated under reduced pressure. The crude product was purified by column chromatography with methanol: dichloromethane to afford tert-butyl 3-(dimethylamino)-3-oxopropylcarbamate. Trifluoroacetic acid (1 ml) was added to the product obtained, stirred for 2h and concentrated to afford title compound as the trifluoroacetate salt (0.090 g, 40%). 116 2229T72

Intermediate 24: 2-amino-N,N-dimethylacetamide trifluoroacetate: [290] Tert-Butyl 2-(DimeTHy1amino)-2-oxoeTHy1carBamaTe (0.120 g, 69%) was obtaineD By using the proceDure DescribeD unDer inTermeDiaTe 23 From N-boc-gLycine (0.150 g, 0.856 mmol), DMF (1.5 ml), N-ETHylDiisopropylamine (0.221 g, 1.70 mmol), HATU (0.325 g, 0.856 mmol) anD DimeTHylamine HyDrocHloriDe (0.069 g, 0.856 mmol). The proDuct was DissolveD in DicHloromeTHane (1 ml), TriFluoroaceTic aciD (0.5 ml) was aDDeD, stirreD For 2H anD concenTraTeD To give the title compounD as the TriFluoroaceTaTe salt (0.100 g, 46%).

Intermediate 25: 2-amino-1-(pyrrolidin-1-yl)ethanone trifluoroacetate: [291] Tert-Butyl 2-oxo-2-(pyrro1iDin-1-y1)eTHy1carBamaTe (0.120 g, 61%) was prepareD By using the proceDure DescribeD unDer inTermeDiaTe 23 From N-Boc-glycine (0.150 g, 0.856 mmol), DMF (1.5 ml), N-ETHylDiisopropylamine (0.110 g, 0.856 mmol), HATU (0.325 g, 0.856 mmol) anD pyrroliDine (0.061 g, 0.856 mmol). THe proDuct was DissolveD in DicHloromeTHane (1 ml), TriFluoroaceTic aciD (0.5 ml) was aDDeD, stirreD For 2H anD concenTraTeD To give the title compounD as the TriFluoroaceTaTe salt (0.100 g, 41%).

[292] InTermeDiaTe 26: 3-amino-1-(pyrro1iDin-1-y1)propan-1-one

TriFluoroaceTaTe: Tert-Butyl 2-oxo-2-(pyrro1iDin-1-y1)propy1carBamaTe (0.080 g, 40%) was prepareD By using the proceDure DescribeD unDer inTermeDiaTe 23 From N-boc-3-aminopropionic aciD (0.150 g, 0.793 mmol), DMF (1.5 ml), N-ETHylDiisopropylamine (0.205 g, 1.58 mmol), HATU (0.301 g, 0.793 mmol) anD pyrroliDine (0.056 g, 0.793 mmol). TriFluoroaceTic aciD (1 ml) was aDDeD To the proDuct, stirreD For 2H anD concenTraTeD To give the title compounD as the TriFluoroaceTaTe salt (0.080 g, 40%).

Intermediate 27: 3-amino-1-(piperidin-1-yl)propan-1-one trifluoroacetate: [293] Tert-Butyl 2-oxo-2-(piperiDin-1-y1)propy1carBamaTe was prepareD By using the proceDure DescribeD unDer inTermeDiaTe 23 From N-Boc-3-aminopropionic aciD (0.250 g, 1.32 mmol), DMF (2.5 ml), N-ETHylDiisopropylamine (0.171 g, 1.32 mmol), HATU (0.503 g, 1.32 mmol) anD piperiDine (0.225 g, 2.64 mmol). TriFluoroaceTic aciD (1 ml) was aDDeD To the proDuct, stirreD For 2H anD concenTraTeD To give the title compounD as the TriFluoroaceTaTe salt (0.120 g, 34%). 117 222977/2

Intermediate 28: 3-amino-l-morpholinopropan-l-one trifluoroacetate: [294] 7e/7-butvl 3-morpholino-3-oxopropylcarbamate was prepared by using the procedure described under intermediate 23 from N-boc-3-aminopropionic acid (0.250 g, 1.32 mmol), DMF (2.5 ml), N-Ethyldiisopropylamine (0.171 g, 1.32 mmol) and HATU (0.503 g, 1.32 mmol) and morpholine (0.230 g, 2.64 mmol). Trifluoroacetic acid (1 ml) was added to the product, stirred for 2h and concentrated to give the title compound as the trifluoroacetate salt (0.120 g, 33%).

Intermediate 29: 6-((5-chloro-3H-imidazo[4,5-b]pyridin-3-yl)methyl)quinoline: [295] Intermediate 9 (0.200 g, 0.702 mmol) was dissolved in formic acid (1.0 ml) and heated to 100°C and stirred for 12h. The reaction mixture was poured into ice water and pH adjusted to 7-8 with sodium bicarbonate solution, extracted with ethyl acetate , washed with brine, dried over sodium sulphate and concentrated to afford the title compound as yellowish brown solid (0.200 g, 97% yield). Ή-NMR (5ppm,DMSO-d6,400MHz): □ 58.88 (dd,/ = 4.0, 1.3 Hz, IH), 8.70 (s, IH), 8.33 (d, J =8.2 Hz, IH), 8.19 (d, J= 8.3 Hz, IH), 8.01 (d,/=8.8 Hz, IH), 7.81 (s, 1H),7.73 (dd,/=8.7, 1.7 Hz, IH), 7.52 (dd, J = 8.3, 2.2 Hz, IH), 7.37 (d, J = 8.4 Hz, IH), 5.69 (s, 2H).

[296] Intermediate 30: 6-chloro-3-nitro-N-(l-(quinolin-6-yl)ethyl)pyridin-2 amine:The title compound was obtained as a yellow solid (0.785 g, 50%) by using a procedure that is similar to the one described for intermediate 4 from 2,6-Dichloro-3-nitropyridine (0.924 g, 4.78 mmol), 1-(quinolin-6-yl)ethanamine (1.25. g, 7.25 mmol), ethanol (7 ml) and sodium carbonate (1.32 g, 12.54 mmol). Ή-NMR (5ppm,DMSO-d6,400 MHz): □ δ 8.86 (dd,/=4.2,1.7 Hz, IH), 8.78 (d, /=7.5 Hz, IH), 8.44 (d, /= 8.6 Hz, IH), 8.33 (dd,/=8.3, 1.0 Hz, IH), 7.99 (m, 2H), 7.89 (dd,/=8.8, 1.9 Hz, IH), 7.51 (q, / = 4.2 Hz, IH), 6.80 (d, / = 7.5 Hz, IH), 5.57 (quintet, J = 7.1 Hz, IH). 1.69 (d, / = 7.0 Hz, 3H).

Intermediate 31: 6-(lH-pyrazol-4-yl)-N2-(l-(quinolin-6-yl)ethyl)pyridine-2,3-diamine; [297] To a solution of intermediate 30 (0.20 g, 0.608 mmol) and 1-tert-butoxycarbonyl-lH-pyrazole-4-boronic acid pinacol ester (0.229 g, 0.778 mmol) in dioxane (4 ml), potassium carbonate (0.279 g, 2.02 mmol) and water (0.8 ml) were added and degassed for 30 min. Tetrakis(triphenylphosphine)palladium(0) (0.055 g, 0.047 mmol) was added under nitrogen at RT and the reaction mixture was refluxed for 12h. The solvent was evaporated completely and to the residue water was added and extracted with ethyl acetate, 118 222977/2 dried over sodium sulphate and concentrated under reduced pressure to afford the crude pyrazole compound as a yellow solid (0.219 g). To a solution of this intermediate in cone. HCI (3 ml), stannous chloride (0.750 g, 18.13 mmol) was added at RT and stirred for 5h. The reaction mixture was poured into ice water and pH adjusted to 7-8 with sodium bicarbonate solution, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulphate and concentrated to afford the title compound as yellow solid (0.194 g, 97% ) which was used as such for the next step.

Intermediate 32: 6-chloro-N-((5,7-difluoroquinolin-6-yl)methyl)-3-nitropyridin-2-amine [298] Step 1: 2-(5,7-difluoroquinolin-6-yl)acetic acid: A mixture of 4-amino-2,6-difluorophenylacetic acid (3.2 g, 17.1 mmol), ferrous sulphate (1.04 g, 3.76 mmol), nitrobenzene (1.05 ml, 10.26 mmol) and cone. H2SO4 in glycerol (5.2 ml) was heated at 150DC for 16h. The mixture was cooled to RT, methanol (28 ml) was added followed by aq. 6N NaOH (28 ml) and heated at 11 ODC for 3h. After cooling to RT, the mixture was acidified with cone. HCI to pH 3.0. The precipitate formed was filtered, washed with water and dried under vacuum. The precipitate was refluxed with methanol, filtered under hot conditions and the filtrate was evaporated to give the title compound (1 g, 25%) as a brown solid. Ή-NMR (5 ppm, DMSO-de, 400 MHz): δ 12.72 (bs, IH), 8.98 (d, J = 3.1 Hz, IH); 8.47 (d, J = 8.4, IH); 7.71 (d, J = 9.7, IH); 7.62 (dd, J = 8.4, 4.1, 2H); 3.85 (s, 2H).

[299] Step 2: (5,7-difluoroquinolin-6-yl)methanamine: Diphenyl phosphoryl azide (0.5 ml, 2.32 mmol), triethylamine (0.34 ml, 2.43 mmol) and tert-butanol (1.3 ml, 13.78 mmol) were added to a solution of the product from step 1 (0.5 g, 2.24 mmol) in dioxan (6.5 ml) and heated at 11 ODC for 4h. The mixture was cooled to RT and distributed between ethyl acetate and aq. 10% citric acid. The organic layer was separated, dried over Na2SO4 and concentrated to leave a brown residue which was dissolved in dioxane (5 ml) and dichloromethane (1.5 ml) and treated with ether saturated with HCI (10 ml) and stirred at RT overnight. After removing the solvents completely, aq. NaHCO3 was added to the residue and extracted into ethyl acetate, the organic layer dried over Na2SO4 and the solvent was removed. Purification of the residue by column chromatography gave the title compound as a mixture containing ca. 35 mol% of l,3-bis((5,7-difluoroquinolin-6-yl)methyl)urea, which was used as such in the next step. Ή-NMR (δ ppm, DMSO-cf,, 400MHz): δ 8.95 (d, J = 3.8 Hz, 2H); 8.45 (dd, J = 7.5, 5.2, 2H); 7.65 (d, J = 10.9, 2H); 7.59 (dd, J = 8.29, 4.2, 2H); 6.50 (t, J = 5.6, IH), 4.44 (d, J = 5.6, 2H); 3.90 (s, 2H). 119 222977/2 [300] Step 3: 6-chloro-N-((5.7-difluoroquinolin-6-yl)methyl)-3-nitropyridin-2-amine: The title compound was obtained as a yellow solid (0.050 g, 5 %) by using a procedure that is similar to the one described for intermediate 4 from 2,6-Dichloro-3-nitropyridine (1.40 g, 7.73 mmol), (5,7-difluoroquinolin-6-yl)methanamine (1.00 g, 5.15 mmol), ethanol (10 ml) and sodium carbonate (0.97 g, 9.22 mmol). Ή-NMR (bppm, DMSO-d6, 400 MHz): δ 9.09 (ζ 7= 5.1 Hz, IH), 8.96 (d,7= 3.7 Hz, IH), 8.49 (d, 7= 8.4 Hz, IH), 8.41 (d, 7= 8.5 Hz, IH), 7.68 (d, 7= 11.0 Hz, IH), 7.61(dd , 7 = 8.4,4.2 Hz, IH), 6.79 (d, J = 8.5 Hz, IH), 4.97 (d, 7 = 5.5 Hz, 2H).

Intermediate 33: 6-chloro-N2-((5,7-difluoroquinolin-6-yl)methyl)pyridine-2,3-diamine: [301] The title compound was obtained as a brown solid (0.080 g, 73%) by using a procedure that is similar to the one described for intermediate 9 from intermediate 32 (0.12 g, 0.342 mmol), stannous chloride (0.347 g, 1.54 mmol) and cone. HCI (2 ml) which was used as such for the next step.

[302] Intermediate 34: 6-((5-chloro-3H-[l,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)-5,7-difluoroquinoline: The title compound was obtained as a brown solid (0.068 g, 83%) by using a procedure that is similar to the one described for intermediate 14 from intermediate 33 (0.080 g, 0.249 mmol), acetic acid (0.4 ml), sodium nitrite (0.020 g, 0.299 mmol), water (0.2 ml) and sulphuric acid (0.1 ml). Ή-NMR (δ ppm, CDCl3,4OOMHz): □ δ 8.98 (d, 7 = 2.7 Hz, IH), 8.43 (d, 7 = 8.2 Hz, IH), 8.32 (d, 7 = 8.6 Hz, IH), 7.65 (d, 7 = 10.4 Hz, IH), 7.48 (dd, 7= 8.5,4.3 Hz, IH), 6.10 (s, 2H), 7.39 (d, 7= 8.6 Hz, IH).

Intermediate 35: 2-chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide: [303] The title compound was obtained as a brown solid (0.75 g, 69%) by using the procedure described in step 4 for intermediate 19 from 4-bromo-2-chlorobenzamide (0.500 g, 2.13 mmol), bis(pinacolato)diboron (0.595 g, 2.34 mmol), potassium acetate (0.627 g, 6.39 mmol), dioxane (3.6 ml) and [l,l"-bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH2Cl2 (0.052 g, 0.063 mmol). Ή-NMR (6ppm,DMSO-d6,400MHz): δ 7.91 (s, IH), 7.89 (m, IH), 7.61 (m, 2H),D 7.44 (d, 7 = 7.6 Hz, IH), 1.14 (s, 12H).

Intermediate 36: N-(benzo[d]thiazol-6-ylmethyl)-6-chloro-3-nitropyridin-2-amine: [304] The title compound was obtained as a yellow solid (0.460 g, 9 %) by using a procedure that is similar to the one described for intermediate 4 from 2,6-Dichloro-3- 120 2229T7/2 nitropyriDine (4.75 g, 24.66 mmol), bEnzo[D]thiazo1-6-y1meTHanaminE (2.70 g, 16.44 mmol), ethanol (50 ml) anD soDium carbonate (3.03 g, 28.60 mmol) which was useD as such For The next step.

[305] InTermeDiaTe 37: N2-(benzo[D]tHiazo1-6-y1meThy1)-6-ch1oropyriDine-2,3-

Diamine:The title compounD was obtaineD as a yellow soliD (0.360 g, 88%) by using a proceDure that is similar To the one DescribeD for intermeDiaTe 9 from intermeDiaTe 36 (0.450 g, 1.40 mmol), stannous chloriDe (1.42 g, 6.31 mmol) anD cone. HCI (7.5 ml) which was useD as such for the next step.

[306] Intermediate 38: 6-((5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)benzo[d]thiazole: THe title compounD was obtaineD as a brown soliD (0.068 g, 83%) by using a proceDure that is similar To The one DEScribeD For intermEDiaTe 14 From inTermeDiate 37 (0.350 g, 0.249 mmol), acetic aciD (1.75 ml), soDium nitrite (0.099 g, 1.44 mmol), water (0.8 ml) anD sulphuric aeiD (0.4 ml). Ή-NMR (δ ppm, CDC13, 400 MHz): □ δ 8.99 (s, IH), 8.32 (D, J = 8.5 Hz, IH), 8.11 (D, J = 8.4 Hz, IH), 8.07 (s, IH), 7.66 (D, J = 8.4 Hz, IH), 7.36 (D, J = 8.5 Hz, IH), 6.00 (s, 2H).

[307] Intermediate 39: 6-chloro-N2-(1-(quinolin-6-yl)ethyl)pyridine-2,3- diamine: The title compounD was obtaineD as a pale brown soliD (0.600 g, 74%) by using a proceDure that is similar To the one DescribeD for intermEDiatE 9 from intErmeDiate 30 (0.900 g, 2.72 mmol), stannous chloriDe ( 2.77 g, 12.28 mmol) anD eonc.HCl (1.5 ml) which is useD without purification for next step.

[308] Intermediate 40: 6-(1-(5-chloro-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)ethyl)quinoline: THe title compounD was obtaineD as a brown soliD (0.500 g, 84%) by using a proceDure that is similar To the one DeseribeD For intermeDiate 14 from intermeDiaTe 39 (0.575 g, 1.91 mmol), aCEtie aeiD (3.5 ml), soDium nitritE ( 0.159 g, 2.30 mmol), water ( 1 ml) anD sulphurie aciD (0.3 ml). Ή-NMR (δ ppm, CDC13, 400 MHz): □ δ 8.90 (DD, J= 4.0,2.7 Hz, IH), 8.31 (D, J = 8.6 Hz, IH), 8.15 (D, J = 8.2 Hz, IH), 8.09 (D, J = 8.8 Hz, IH), 7.93 (s,1H),), 7.89 (DD, J = 8.8,1.9 Hz, IH), 7.42 (DD, J = 8.3,4.1 Hz, IH), 7.34 (D, J = 8.6 Hz, IH), 6.50 (q, J = 7.1 Hz, IH), 2.29 (D, J = 7.2 Hz, 3H).

[309] Intermediate 41: 4-bromo-2-(trifluoromethyl)benzamide: Thionyl

chloriDe (10 ml) was aDDeD to 4-bromo-3-(triF1uorometHy1)benzoie aeiD (1.0 g, 3.71 mmol, prepareD as DeseribeD by Hattori et. al. in Bioorg. Med. Chem. 2007, 15, 2198,) anD refluxeD 121 2229T7/2

For 3H. Excess tHionyl cHloride was removed under reduced pressure and tHe residue was cooled to ODC. Aqueous 25% ammonia (7 ml) was added and stirred for 15 min. The precipitate formed was wasHed witH sodium BicarBonate solution and vacuum dried To afford title compound as a brown solid (0.500 g, 50%) which is used as sucH for next step.

[310] Intermediate 42: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2- (trifluoromethyl)benzamide: THe title compound was oBTained as a Brown solid (0.30 g, 50%) By using the procedure descriBed in step 4 For Intermediate 19 From intermediate 41 (0.500 g, 1.86 mmol), Bis(piNacolato)diBoroN (0.705 g, 2.77 mmol), potassium acetate (0.743 g, 7.57 mmol), dioxane (4.6 ml) and [1,1"-Bis(dipHenylpHosphino)ferrocene]dichLoro palladium(II).CH2CL2 (0.061 g, 0.067 mmol) which was used without purification for the next step.

Examples

Example 1 6-((5-(4-Methoxyphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [311] To a solution of iNtermediate 14 (0.120 g, 0.405 mmol) and 4-meThoxypHenyLBoronic acid (0.078 g, 0.519 mmol) in dioxane (2.4 ml), potassium carBonate (0.186 g, 1.35 mmol) and water (0.5 ml) were added and degassed For 30 min. TetraKis(triphenyLpHospHine) palladium(O) (0.037 g, 0.032 mmol) was added under nitrogen at RT and the reaction mixture was refluxed For 12h. The solvent was evaporated completely and water was added to the residue and extracted with ethyl acetate, dried over sodium sulphate and concentrated under reduced pressure. The crude product was purified By column chromatography with methanol: dichloromethaNe to afford The title compound as a yellow solid (0.084 g, 56%). M.P.: 144-146 DC. Ή-NMR (δ ppm, DMSO-D(,, 400 MHz): 8.88 (D, J= 2.6 Hz, IH), 8.58 (d, J = 8.7 Hz, IH), 8.37 (d, J = 8.1 Hz, IH), 8.22 (d, J = 8.9 Hz, 2H), 8.06 (d, J = 8.7 Hz, IH), 8.02 (m, 2H), 7.83 (dd, J = 8.8,1.5 Hz, IH), 7.55 (dd, J = 8.4,4.2 Hz, IH), 7.10 (d, J = 8.8 Hz, 2H), 6.18 (s, 2H), 3.83 (s, 3H). MS (m/z): 367.95 (M+).

Example 2 6-((5-(3-Methoxyphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [312] The title compound was prepared By following The procedure descriBed For exampLe 1 using inTermediaTe 14 (0.120 g, 0.405 mmol), 3-meTHoxypHenylBoronic acid (0.078 g, 0.519 mmol), potassium carBonate (0.186 g, 1.35 mmol), dioxane (2.4 ml), water (0.5 ml) and TeTraKis(tripheNyLphosphiNe)palladium(0) (0.037 g, 0.032 mmol). Yellow solid 122 22297712 (0.080 g, 53%). M.P.: 133-1357C. Ή-NMR (δ ppm, DMSO-de, 400 MHz): 8.88 (DD, J= 4.0,1.1 Hz, IH), 8.64 (d, J = 8.9 Hz, IH), 8.36 (d, J = 8.4 Hz, IH), 8.13 (d, J = 8.7 Hz, IH), 8.02 (s, IH), 7.99 (d, J = 10.2 Hz, IH), 7.83 (m, 2H), 7.74 (s, IH), 7.53 (dd, J = 8.3, 4.2 Hz,

IH), 7.47 (t, J = 8.0 Hz, IH), 7.10 (dd, J = 8.2, 2.4 Hz, IH), 6.21 (s, 2H), 3.83 (s, 3H). MS (m/z): 368.02 (M+ ).

Example 3 3- (3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzaldehyde: [313] The Title compound was prepared by following the procedure described For example 1 using interMediate 14 (0.140 g, 0.473 mmol), 3-forMylphenylboronie acid (0.098 g, 0.605 mmol), potassium carbonate (0.217 g, 1.57 mmol), dioxane (2.8 ml), water (0.6 ml) and TeTraKis(TripheNylphosphiNe)palladium(0) (0.043 g, 0.032 mmol) to give The title compound quanTitatively.

Example 4 (3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)methanol [314] Sodium borohydride (0.018 g, 0.493 mmol) was added To a solution of example 3 (0.180 g, 0.493 mmol) in meThanol (4 ml), cooled lo 0 C. and stirred for lh. Ice-cold water was added to The mixTure, extracted with ethyl acetate, washed with brine, dried over sodium sulphate and concentrated. The crude product was purified by column chromatography with meThanol: dichloromeThane To afford the Title compound as a yellow solid (0.044 g, 24%). M.P. 191-193 DC. Ή-NMR (δ ppm, DMSO-de, 400 MHz): 8.88 (dd, J= 4.2, 1.7 Hz, IH), 8.63 (d, J = 8.7 Hz, IH), 8.38 (d, J = 8.3 Hz, IH), 8.21 (d, J = 8.3 Hz, 2H), 8.12 (d, J = 8.8 Hz, IH), 8.02 (s, IH), 8.02 (d, J = 8.8 Hz, IH), 7.83 (dd, J = 8.7,2.0 Hz, IH), 7.53 (m, 3H), 6.20 (s, 2H), 5.30 (t, J = 5.7 Hz, IH), 4.58 (d, J = 5.4 Hz, 2H). MS (m/z): 368.37 (M+ + 1).

Example 5 4- (3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzaldehyde [315] The Title compound was prepared by following the procedure described For example 1 using intermediate 14 (0.140 g, 0.473 mmol), 4-formylpheNylboroNie acid (0.098 g, 0.605 mmol), potassium carbonate (0.217 g, 1.57 mmol), dioxane (2.8 ml), water (0.5 ml) and TeTraKis(tripheNylphosphiNe)palladium(0) (0.043 g, 0.037 Mmol). Brown solid (0.100 g, 58%). Ή-NMR (δ ppm, DMSO-de, 400 MHz): 10.10 ^□□□□□□□8.88(dd,J=4.2, 1.7 Hz, IH), 8.74 (d, J = 8.7 Hz, IH), 8.48 (d, J = 8.3 Hz, 2H), 8.39 (dd, J = 8.4, 1.0 Hz, IH), 8.25 (d, J = 123 22297712 8.7 Hz, IH), 8.08 (d, J = 8.5 Hz, 2H), 8.04 (d, J = 1.7 Hz, IH), 8.02 (d, J = 8.7 Hz, IH), 7.84 (dd, J = 8.7,2.0 Hz, IH), 7.51 (q, J = 4.3 Hz, IH), 6.23 (s, 2H).

Example 6 (4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)methanol [316] To A solution of example 5 (0.180 g, 0.493 mmoI) in MetHAnol (4 m1) cooled to One, sodium BoroHydride (0.018 g, 0.493 mmoL) was Added And stirred For IH. THe reAction was quencHed By THe Addition of ice-cold water, extrAcTed witH etHyl Acetate, wAsHed witH Brine, dried over sodium sulpHATe And coNcenTrAted. THe crude product was purified By column cHroMATogrApHy witH MetHAnol: dicHloroMEtHAne To Afford THe title compound As A yellow solid (0.070 g, 39%). M.P.: 187-189DC. Ή-NMR (δ ppm, DMSO-dg,400 MHz): 8.88 (dd, J = 4.2, 1.7 Hz, IH), 8.63 (d, J = 8.7 Hz, IH), 8.38 (d, J = 8.3 Hz, IH), 8.22 (d, J = 8.3 Hz, 2H), 8.12 (d, J = 8.7 Hz, IH), 8.02 (s, IH), 8.02 (d, J = 8.4 Hz, IH), 7.83 (dd, J = 8.7,2.0 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 7.49 (d, J = 8.4 Hz, 2H), 6.20 (s, 2H), 5.32 (T, J = 5.7 Hz, IH), 4.58 (d, J = 5.7 Hz, 2H). MS (m/z): 367.88 (M+).

Example 7

Methyl 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate [317] THe Title compound was prepared By following tHe procedure descriBed For example 1 using interMediATe 14 (0.130 g, 0.439 mmoI), 4-MeTHoxycARBoNylpHeNylBoromc Acid (0.100 g, 0.562 mmoI), potassium cArBonATe (0.202 g, 1.46 mmoI), dioxane (2.6 m1), water (0.5 m1) And TETrAkis(TripHEnYlpHospHinE)pA11AdiuM(0) (0.040 g, 0.035 mmoI). OFf-wHite solid (0.100 g, 57%). Ή-NMR (δ ppm, DMSO&lt;I(1. 400 MHz): 8.88 (DD, J=4.2,1.8 Hz, IH), 8.72 (d, J = 8.7 Hz, IH), 8.39 (μ, 3H), 8.21 (d, J = 8.8 Hz, IH), 8.12 (d, J = 8.6 Hz, 2H), 8.02 (s, IH), 8.02 (d, J = 8.8 Hz, IH), 7.84 (dd, J = 8.6,2.0 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.23 (s, 2H), 3.89 (s, 3H).

Example 8 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid [318] To A solution of Example 7 (0.095 g, 0.240 mmoI) in meTHanoI (1.4 m1), litHiuM Hydroxide (0.028 g, 1.20 mmoI) in water (0.36 m1) was Added And stirred AT RT. After 12H, THe pH was Adjusted To (Approx) 7.5 using 0.5N HCI And THe solid prEcipiTATEd was Filtered, wAsHed witH etHyl AceTATe And petroleuM etHer And dried under vacuum To Afford THe title compound As An off-wHite solid (0.070 g, 76%). M.P.: 245YC, 1H-NMR (δ ppm, DMSO-d6, 400 MHz): 13.18 (s, IH), 8.88 (dd, J = 4.1,1.7 Hz, IH), 8.71 (d, J = 8.7 Hz, IH), 8.39 (d, J = 1.1 Hz, IH), 8.36 (d, J = 8.5 Hz, 2H), 8.21 (d, J = 8.7 Hz, IH), 8.10 (d, J = 8.5 124 2229T7/2

Hz, 2H), 8.03 (d, J = 9.2 Hz, 2H), 7.84 (dd, J = 8.7,2.0 Hz, IH), 7.53 (dd, J = 8.4,4.2 Hz, IH), 6.22 (s, 2H). MS (m/z): 381.88 (M+).

Example 9 N-Methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [319] To Example 8 (0.050 g, 0.131 mmol) was refluxed with Thionyl cHLoride (2 ml) for 3h. Thionyl chloride was evaporated and the residue was cooled to ODC and an etHAnolic 50% metHylAmine (1 ml) was added and stirred for 15 min. The precipitATe formed was dissolved in dicHloromeThAnE, washed with sodium BicarBonaTe solution dried over sodium sulphate and concentrAted To afford The Title compound as an off-wHite solid (0.020 g, 39%). M.P.:220-222DC. Ή-NMR (δ ppm, DMSO-if.400 MHz): 8.88 (dd, J=4.2,1.7 Hz, IH), 8.69 (d, J = 8.7 Hz, IH), 8.57 (q, J = 4.5 Hz, IH), 8.38 (d, J = 1.6 Hz, 2H), 8.33 (d, J = 8.5 Hz, 2H), 8.20 (d, J = 8.8 Hz, IH), 8.03 (m, 4H), 7.84 (dd, J = 8.7,1.6 Hz, IH), 7.53 (dd, J = 8.3,4.1 Hz, IH), 6.22 (s, 2H), 2.81 (d, J = 4.5 Hz, 3H). MS (m/z): 394.97 (M+).

Example 10 4-(3-(4-Fluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzaldehyde [320] The TiTle compound was prEpared By followinG The procedure descriBed For example 1 using inTermediAte 15 (0.100 g, 0.380 mmol), 4-formylpHenylBoronic acid (0.073 G, 0.487 mmol), potassium carBonaTe (0.175 g, 1.26 mmol), dioxane (2.3 ml), water (0.5 ml) and TeTrakis (TripHEnyLphosphinE)pAllAdium(O) (0.035 g, 0.030 mmol). Brown solid (0.095 g, 68%). 1H-NMR (δ ppm, DMSO-tf. 400 MHz): 10.11 □ sD □□□□□□ 8.72 (d, J = 8.7 Hz, IH), 8.48 (d, J = 8.3 Hz, 2H), 8.24 (d, J = 8.7 Hz, IH), 8.10 (d, J = 8.4 Hz, 2H), 7.55 (m, 2H), 7.22 (m, 2H), 6.01 (s, 2H).

Example 11 (4-(3-(4-Fluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)methanol [321] To a solution of example 10 (0.095 g, 0.259 mmol) in methAnol (2 ml) cooled to ODC, sodium BoroHydride (0.010 g, 0.259 mmol) was added and stirred For IH. The reAcTion was quenched By The Addition of ice-cold water, extracted with Ethyl acetate, washed with Brine, Dried over sodium sulphate and concenTrAtED. The crude product was purified By column cHromAtogrApHy with methAnol: DicHloromEthAne To Afford The TiTle compounD as an off-whiTE solid (0.040 g, 46%). M.P.: 210-213DC. 1H-NMR (δ ppm, DMSO-d6, 400 MHz): □ 8.61 (D, J = 8.7 Hz, IH), 8.22 (D, J = 8.3 Hz, 2H), 8.11 (D, J = 8.8 Hz, IH), 7.53 (m, 4H), 7.21 (m, 2H), 5.98 (s, 2H), 5.32 (T, J = 5.8 Hz, IH), 4.59 (D, J = 5.7 Hz, 2H). MS (m/z): 335.05 (M++1). 125 222977/2

Example 12

Methyl 2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzoate [322] THe Title compound was prepared By following the procedure deseriBed For example 1 using intermediATe 14 (0.300 g, 1.01 mmol), 3-lluoro-4- methoxYCArBonYlphenylBoronic acid (0.257 g, 1.29 mmol), potassium CArBonaTe (0.466 g, 13.37 mmol), dioxane (6 ml), water (1.2 ml) and TeTrAkis(TripHenYLpHosphine)pAllAdium(0) (0.093 g, 0.081 mmol). Brown colour solid (0.300 g, 71%). Ή-NMR (δ ppm, DMSO-d,, 400 MHz): 8.88 (dd, J = 4.2,1.8 Hz, IH), 8.74 (d, J = 8.7 Hz, IH), 8.38 (dd, J = 8.4,1.0 Hz, IH), 8.27 (d, J = 8.8 Hz, IH), 8.24 (s, IH), 8.22 (m, IH), 8.07-8.00 (m, 3H), 7.83 (dd, J = 8.7,2.0 Hz, IH), 7.63 (m, IH), 6.24 (s, 2H), 3.89 (s, 3H).

Example 13 2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid [323] To a solution of Example 12 (0.230 g, 0.556 mmol) in meThAnol (3.5 ml), Lithium hydroxide (0.132 g, 5.56 mmol) in water (0.9 ml) was added and stirred AT RT. After 12H, the pH was Adjusted To 7-7.5 using 0.5N HCI and the solid precipitAted was FilTered, washed with ethyl acetate and petroleum ether and dried under vacuum To afford The title compound as pale Brown solid (0.130 g, 61%).M.P.: 254-257 OC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 13.43 (s, IH), 8.88 (dd, J = 4.2,1.7 Hz, IH), 8.73 (d, J = 8.8 Hz, IH), 8.38 (d, J = 7.5 Hz, IH), 8.25 (d, J = 8.8 Hz, IH), 8.19 (m, 2H), 8.04 (m, 3H), 7.83 (dd, J = 8.8,2.0 Hz, IH), 7.53 (dd, J = 8.4,4.2 Hz, IH), 6.23 (s, 2H). MS (m/z): 400.01 (M++1).

Example 14 2-Fluoro-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [324] To Example 13 (0.045 g, 0.112 mmol), thionyl chloride (3 ml) was added and refluxed For 3h. THe excess thionyl chloride was removed under reduced pressure and the residue was cooled to ODC. Methylamine in ethanol (50% solution, 3 ml) was added and stirred For 15 min. The precipitAte formed was dissolved in diCHLoromethAne, washed with sodium BiCArBonATe solution dried over sodium sulphate and coneentrATed to afford Title compound as pale Brown solid (0.015 g, 32%). M.P.: 2I2^ C, Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.88 (dd, J = 4.2,1.7 Hz, IH), 8.72 (d, J = 8.7 Hz, IH), 8.37 (m, 2H), 8.23 (d, J = 8.8 Hz, IH), 8.18 (m, 2H), 8.04 (d, J = 1.7 Hz, IH), 8.02 (d, J = 8.7 Hz, IH), 7.83 (dd, J = 8.8,2.0 Hz, IH), 7.80 (t, J = 8.1 Hz, IH), 7.53 (dd, J = 8.3,4.1 Hz, IH), 6.23 (s, 2H), 2.80 (d, J = 4.6 Hz, 3H). MS (m/z): 412.96 (M+). 126 222977/2

Example 15 2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [325] To Example 13 (0.045 g, 0.112 mmol), ThioNyl chloride (3 ml) was Added ANd refluxed for 3h. THe excess ThioNyl chloride was removed uNder reduced pressure ANd the residue was cooled to ODC. Aqueous ammonia (25% solution, 3 ml) was added and stirred for 15 miN. The precipitATe formed was dissolved In dichloromethANe, washed with sodium bicarboNATe soIuTIon dried over sodium sulphate ANd coNceNtrATed To Afford title compouNd As off-white solid (0.025 g, 56%).M.P.: 198-200 □ C .Ή-NMR (δ ppm, DMSO-de, 400 MHz ): 8.88 (dd, J = 4.2,1.7 Hz, IH), 8.72 (d, J = 8.7 Hz, IH), 8.38 (dd, J = 8.5,1.0 Hz, IH), 8.23 (d, J = 8.7 Hz, IH), 8.17 (m, 2H), 8.04 (d, J = 1.6 Hz, IH), 8.02 (d, J = 8.7 Hz, IH), 7.84 (m, 3H), 7.74 (br s, IH), 7.54 (dd, J = 8.3,4.2 Hz, IH), 6.23 (s, 2H). MS (m/z): 398.89 (M+).

Example 16 (2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)phenyl)methanol [326] To A soIuTIon of Example 12 (0.130 g, 0.314 mmol) in THF (1.3 ml) cooled to ODC, DIBAL-H (25% In tolueNe, 0.84 ml, 1.25 mmol) was Added stirred At RT for 3H. The reActioN mixture was poured in Ice-cold water ANd extracted with ethyl Acetate, washed with briNe, dried over sodium sulphate ANd coNceNtrATed. THe crude product was purified by columN chRomAtogrAphy with methANol: dichlorometHaNe to Afford the title compouNd As pAle yellow solid (0.030 g, 25%). M.P.: 202-204DC . Ή-NMR (δ ppm, DMSO-de, 400 MHz ): □ 8.88 (dd, J = 4.1, 1.6 Hz, IH), 8.67 (d, J = 8.7 Hz, IH), 8.38 (d, J = 8.4 Hz, IH), 8.18 (d, J = 8.7 Hz, IH), 8.12 (dd, J = 8.0,1.5 Hz, IH), 8.04 (m, 3H), 7.83 (dd, J = 8.7,1.9 Hz, IH), 7.65 (T, J = 7.9 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 5.41 (t, J = 5.8 Hz, IH), 4.62 (d, J = 5.6 Hz, 2H). MS (m/z): 386.01 (M++1 ).

Example 17

Methyl 4-(3-(2-chloro-3,6-difluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-fluorobenzoate: [327] The title compouNd was prepared by followiNg The procedure described for example 1 usiNg mtermedlATe 16 (0.300 g, 0.951 mmol), 3-fluoro-4-meThoxYCArboNYl pheNylboroNic Acid (0.241 g, 1.21 mmol), potassium phosphate (0.606 g, 2.856 mmol), TolueNe (10 ml), ANd TetrAKis (trIpheNYlphosphme) pAllAdium(O) (0.088 g, 0.076 mmol). BrowN colour solid (0.380 g, 92%). Ή-NMR (δ ppm, DMSO-de, 400 MHz ): 8.71 (D, J = 8.7

Hz, IH), 8.25 (d, J = 8.7 Hz, IH), 8.17 (s, IH), 8.15 (d, J = 7.2 Hz, IH), 8.06 (T, J = 8.0 Hz, IH), 7.53 (dt, J = 8.9,5.2 Hz, IH), 7.46 (dt, J = 9.1,4.2 Hz, IH), 6.13 (s, 2H), 3.89 (s, 3H). 127 222977/2

Example 18 4-(3-(2-Chloro-3,6-difluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2- fluorobenzoic acid [328] To a solution of Example 17 (0.300 g, 0.725 mmol) in mEthanol (1 ml), THF (2 ml), sodium hydroxide (0.150 g, 3.75 mmol) in water (1 ml) was added and stirred At RT. After 12h, The pH was Adjusted To 7-7.5 using 0.5N HCl and the solid precipitAtEd was filterEd, washed with ethyl ACEtAtE and pEtroleum Ether and dried under vacuum To Afford The Title compound as a pale brown solid (0.120 g, 41%). M.P.: 211-213 DC. 'H-NMR (δ ppm, DMSO-de, 400 MHz ): 8.65 (d, J = 8.8 Hz, IH), 8.18 (d, J = 8.8 Hz, IH), 8.02 (m, 2H), 7.83 (T, J = 7.4 Hz, IH), 7.60 (dt, J = 9.1,4.8 Hz, IH), 7.46 (dt, J = 9.0,4.0 Hz, IH), 6.11 (s, 2H). MS (m/z): 418,70 (M+ ).

Example 19 4-(3-(2-Chloro-3,6-difluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-fluoro-N- methylbenzamide [329] To Example 18 (0.100 g, 0.250 mmol), Thionyl chloride (2 ml) was added and reFluxed For 3h. The excess Thionyl chloride was removed under reduced pressure and The residue was cooled to ODC. Methylamine in ethanol (50% solution, 3 ml) was added and stirred For 15 min. The precipiTAte formed was filtered and washed with petroleum ether and To afford title compound as pale brown solid (0.030 g, 27%).M.P.: 213-215 DC. 'H-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.69 (d, J = 8.8 Hz, IH), 8.36 (br s, IH), 8.22 (d, J = 8.8 Hz, IH), 8.12 (d, J = 7.4 Hz, IH), 8.10 (d, J = 11.2 Hz, IH), 7.80 (T, J = 7.8 Hz, IH), 7.61 (dt, J = 8.8,4.7 Hz, IH), 7.45 (dt, J = 9.2,4.3 Hz, IH), 6.13 (s, 2H), 2.80 (d, J = 4.3 Hz, 3H). MS (m/z): 431.80 (M+ ).

Example 20 N-(2-Hydroxyethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide [330] To Example 8 (0.090 g, 0.235 mmol), thionyl chloride (3 ml) was added and refluxed For 3h. The excess Thionyl chloride was removed under reduced pressure and The residuE was cooled to ODC. Ethanolamine (5 ml) was added and stirred for lh. The precipitate Formed was filtered and washed with petroleum ether and To Afford Title compound as an off-white solid (0.022 g, 22%). M.P.: &gt;260DC . 'H-NMR (δ ppm, DMSO-de, 400 MHz ): 8.88 (d, J = 2.9 Hz, IH), 8.69 (d, J = 8.8 Hz, IH), 8.57 (t, J = 5.4 Hz, IH), 8.38 (d, J = 8.7 Hz, IH), 8.34 (d, J = 8.3 Hz, 2H), 8.21 (d, J = 8.7 Hz, IH), 8.03 (m, 4H), 7.84 (d, J = 8.8 Hz, IH), 7.53 128 222999/2 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 4.76 (t, J = 5.3 Hz, IH), 3.53 (q, J = 6.0 Hz, 2H), 3.36 (t, J = 6.04.3 Hz, 2H).

Example 21 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [331] To Example 8 (0.050 g, 0.131 mmol), thienyl ehleride (1 ml) was added and refluxed for 3h. The excess thienyl chloride was remeved under reduced pressure and the residue was cooled to ODC. Aqueous ammonia (25% solution, 3 ml) was added and stirred for 15 min. The preeipitate formed was filtered, washed with petroleum ether and dried to afford title Compound as a yellow solid (0.020 g, 40%). M.P.: 229-231 DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz): 8.88 (dd, J = 4.1,1.5 Hz, IH), 8.69 (d, J = 8.7 Hz, IH), 8.38 (dd, J = 7.4 Hz, IH), 8.33 (d, J = 8.3 Hz, 2H), 8.21 (d, J = 8.9 Hz, IH), 8.09 (s, IH), 8.04-8.00 (m, 4H), 7.84 (dd, J = 8.8,1.9 Hz, IH), 7.53 (dd, J = 8.4,4.2 Hz, IH), 7.48 (s, IH), 6.22 (s, 2H). MS (m/z): 380.90 (M+ +1).

Example 22

Lithium 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate [332] Tc Example 8 (0.010 g, 0.026 mmol), in methanel, lithium hydroxide (1.09 m g) was and stirred at RT for 12h. The reaetion mixture was eencentrated Completely to afford title compound as a yellow solid (0.010 g, 98%). M.P.: &gt;280DC. Ή-NMR (δ ppm, DMSO-dg, 400 MHz ): 8.88 (d, J = 2.7 Hz, IH), 8.61 (d, J = 8.7 Hz, IH), 8.38 (d, J = 8.1 Hz, 1H),8.13 (m, 3H), 8.03 (s, IH), 8.02 (d, J = 8.9 Hz, IH), 7.97 (d, J = 8.1 Hz, 2H), 7.83 (d, J = 7.3 Hz, IH), 7.53 (dd, J = 8.2,4.1 Hz, IH), 6.20 (s, 2H).

Example 23 6-((5-(3-(trifluoromethoxy)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl) methyl)quinoline: [333] Tc a solutien of intermediate 14 (0.120 g, 0.405 mmol) and 3-triflueromethoxyphenyl beronie acid (0.107 g, 0.519 mmel) in dioxane (2.4 ml), petassium carbonate (0.186 g, 1.35 mmol) and water (0.5 ml) were added and degassed fer 30 min. TetraKis triphenylphosphine palladium (0) (0.037 g, 0.032 mmel) was added under nitregen at RT and the reaetion mixture was refluxed fer 12h. The selvent was evaperated cempletely and to the residue water was added and extracted with ethyl acetate, dried over sodium sulphate and eencentrated under reduced pressure. The Crude product was purified by eelumn chromatOGraphy with methanol: dichloromethane tc afferd the title compound as grey sclid (0.090 g, 53%). M.P.: 140-142DC. 1H-NMR (δ ppm, DMSO-de, 400 MHz ): 8.88 (dd, J= 129 2229772 4.1,1.6 Hz, 1H), 8.71 (D, J = 8.7 Hz, 1H), 8.35 (D, J = 7.9 Hz, 1H), 8.29 (D, J = 8.0 Hz, 1H), 8.21 (D, J = 8.8 Hz, 1H), 8.19 (s, 1H), 8.03 (s, 1H), 8.01 (D, J = 8.7 Hz, 1H), 7.83 (DD, J =

8.7,1.9 Hz, 1H), 7.71 (T, J = 8.1 Hz, 1H), 7.53 (DD, J = 8.3,4.1 Hz, 2H), 6.22 (s, 2H). MS (m/z): 421.92 (M+).

Example 24 3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenol [334] To a soluTioN of exAMple 2 (0.110 g, 0.299 mmol) iN DichloroMeThANE (1 mL), BBt3 (1M in dichloromethane, 0.82 ml) was added at OQC and the reaction mixture was warmed To RT anD sTirreD For lh. The teacTIon mixture was QUENcheD with 1.5N HCL soluTioN anD extracteD with DichloroMethANe. THe organic layer was DrieD over soDIum sulphate anD concenTtaTeD. The cruDe proDuct was purifieD By coLumn chroMAtogrAphy with Methanol: DichloroMethANe To afford the Title compound as an off-white solID (0.030 g, 28%). M.P.: 255- 1H-NMR (δ ppm, DMSO-D(1.4(X) MHz ): 9.700s00000 08.88 (dd, J=4.1,2.6 Hz, 257OC. 1H), 8.62 (D, J = 8.7 Hz, 1H), 8.37 (D, J = 8.0 Hz, 1H), 8.04 (μ, 3H), 7.83 (DD, J = 8.7,1.8 Hz, 1H), 7.64 (s, 1H), 7.64 (D, J = 8.6 Hz, 1H), 7.53 (DD, J = 8.3,4.2 Hz, 1H), 7.35 (T, J = 7.9 Hz, 1H), 6.92 (DD, J = 7.9,1.4 Hz, 1H), 6.19 (s, 2H). MS (m/z): 354.02 (M+).

Example 25 6-((5-(3-(difluoromethoxy)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl) quinoline

[335] To a soluTioN of InterMediAte 14 (0.100 g, 0.405 mmoI) anD 3-DifluoroMETHoxyphENyl Boronic acID (0.081 g, 0.438 mmol) in Dioxane (3 m1), potassium carBoNAte (0.155 g, 1.12 mmoI) anD water (0.5 m1) were aDDeD anD Degassed For 30 min. TetTAkis TripheNylphosphiNe palladium (0) (0.031 g, 0.032 mmoI) was aDDeD unDet nitroGEN At RT anD The teacTIon Mixture was teFIuxeD for 12h. The solvent was evaporated coMpletely anD To The residue water was aDDeD and extracteD with ethyl acetate, Dried over soDIum sulphate anD concenTtaTeD under reduced pressure. The crude product was purified By column chroMAtOGTAphy with Methanol: dichloroMEthANe To afford The Title compound as an off-white solid (0.046 g, 29%). M.P.: 122-125DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.88 (Dd, J = 4.1,1.6 Hz, 1H), 8.69 (d, J = 8.7 Hz, 1H), 8.36 (d, J = 8.5 Hz, 1H), 8.18 (d, J = 8.8 Hz, 1H), 8.13 (d, J = 7.9 Hz, 1H), 8.03 (μ, 3H), 7.84 (dd, J = 8.7,1.5 Hz, 1H), 7.63 (T, J = 8.0 Hz, 1H), 7.53 (dd, J = 8.3,4.2 Hz, 1H), 7.36 (s, 1H), 7.34 (dd, J = 8.1,2.2 Hz, 1H), 6.22 (s, 2H). MS (m/z): 403.79 (M+). 130 222977/2

Example 26 (4-Methylpiperazin-1-yl)(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)phenyl)methanone [336] To a solution of example 8 (0.100 g, 0.262 mmol) in DMF (1 ml) HOBT (0.042 g, 0.314 mmol), EDC-HC1 (0.125 g, 0.655 mmol) anD trieThylamine (0.1 ml, 0.786 mmol) were aDDeD anD stirreD For 5 min. 4-MEthylpipErazinE (0.023 g, 0.235 mmol) was aDDeD at RT anD the reaction Mixture was stirreD for 12h. To the reaction mixture water was aDDeD anD ExtraeteD with Ethyl acetate, DrieD over soDium sulphate anD eoncentratED unDer reDuceD pressure. The cruDe proDuct was purifieD by column chromatography with methanol: Dichloromethane To afforD the title compounD as a yellow soliD (0.020 g, 17%). M.P.: 156158 □ C. Ή-NMR (δ ppm, DMSO-D,, 400 MHz ): □ □ □ □ (dd, J=4.1,1.6 Hz, IH), 8.69 (D, J= 8.8 Hz, IH), 8.36 (D, J = 7.6 Hz, IH), 8.31 (D, J = 8.3 Hz, 2H), 8.17 (D, J = 8.7 Hz, IH), 8.02 (DD, J = 5.1,3.6 Hz, 2H), 7.83 (DD, J = 8.8,1.8 Hz, IH), 7.56 (D, J = 8.4 Hz, 2H), 7.52 (DD, J = 8.2,4.1 Hz, IH), 6.21 (s, 2H), 3.63 (s, 2H),3.30 (s, 2H), 2.36 (s, 4H), 2.19 (s, 3H).

Example 27 N-(2-(dimethylamino)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin- 5-yl)benzamide [337] To a solution of example 8 (0.200 g, 0.524 mmol) in DMF (1 ml), HOBT (0.084 g, 0.629 mmoI), EDC-HC1 (0.250 g, 1.31 mmoI) anD Triethylamine (0.2 ml, 1.57 mmol) were aDDeD anD stirreD For 5 min. 2-N,N-DimEThy1etHy1amine (0.046 g, 0.524 mmol) was aDDeD at RT anD the reaction mixture was stirreD For 12h. To the reaetion mixture water was aDDeD anD extraeteD with ethyl acetate, DrieD over soDium sulphate anD concenTraTeD unDer reDuceD pressure. The eruDe proDuct was purifieD by column chromatography with Methanol: DiehloroMethane to afforD the title compounD as a yellow soliD (0.100 g, 42%). M.P.: 122-125 DC. Ή-NMR (δ ppm, DMSO-D(, 400 MHz ): □□□□(dd, J=4.1,1.5 Hz, IH), 8.69 (D, J = 8.8 Hz, IH), 8.54 (t, J = 5.4 Hz, IH), 8.38 (D, J = 8.3 Hz, IH), 8.33 (D, J = 8.3 Hz, 2H), 8.20 (D, J = 8.7 Hz, IH), 8.03-7.98 (m, 4H), 7.84 (DD, J = 8.7,1.7 Hz, IH), 7.53 (DD, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 3.41 (q, J = 6.6 Hz, 2H), 2.47 (m, 2H), 2.20 (s, 6H).

Example 28 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H- pyran-4-yl)benzamide [338] To a solution of example 8 (0.200 g, 0.524 mmol) in DMF(1 ml) HOBT (0.084 g, 0.629 mmol), EDC-HC1 (0.250 g, 1.31 mmol) anD triEtHylamine (0.2 ml, 1.57 mmoI) were aDDeD anD stirreD for 5 min. 4-AminotetrahyDropyran (0.106 g, 1.04 mmoI) was 131 222977/2 added at RT and THe reaction mixture was stirred for 12h. To the reaction mixture water was added and extracted with ethyl acetate, dried over sodium sulphate and concentrated under reduced pressure. The crude product was purified By column cHromatograpHy with methanol: dicHLoromethane To afford the title compound as an off-wHite solid (0.050 g, 20%). M.P.: 202-205DC. Ή-NMR (δ ppm, DMSO-d,, 400 MHz ): □□□□ (dd, J=4.1,1.6 Hz, IH), 8.69 (d, J = 8.8 Hz, IH), 8.44 (d, J = 7.5 Hz, IH), 8.38 (d, J = 7.7 Hz, IH), 8.33 (d, J = 8.5 Hz, 2H), 8.20 (d, J = 8.8 Hz, IH), 8.03-7.99 (m, 4H), 7.85 (dd, J = 8.7,1.9 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 4.04 (m, IH), 3.89 (d, J = 9.7 Hz, 2H), 3.39 (t, J = 10.0 Hz, 2H), 1.78 (d, J = 10.5 Hz, 2H), 1.63 (m, 2H).

Example 29 tert-Butyl 4-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamido)piperidine-1-carboxylate [339] To a solution of exampLe 8 (0.200 g, 0.524 mmol) in DMF (1 ml), HOBT (0.084 g, 0.629 mmol), EDC-HC1 (0.250 g, 1.31 mmol) and TrietHyLamine (0.2 ml, 1.57 mmol) were added and stirred for 5 min. 1-Boc-4-aMiNopiperidiNe (0.210 g, 1.04 mmol) was added at RT and The reaction mixture was stirred for 12h. To the reactioN mixture water was added and extracted with ethyl acetate, dried over sodium sulphate and concentrated under reduced pressure. The crude product was purified By column cHromatograpHy with methanol: dichloromethaNe To afford the title compound as an off-white solid (0.125 g, 42%). Ή-NMR (δ ppm, DMSO-4, 400 MHz ): □ □ □ □ □ (dd, J=4.1,1.6 Hz, IH), 8.69 (D, J = 8.7 Hz, IH), 8.40 (d, J = 7.8 Hz, IH), 8.38 (d, J = 8.5 Hz, IH), 8.33 (d, J = 8.5 Hz, 2H), 8.20 (d, J = 8.7 Hz, IH), 8.03-7.99 (m, 4H), 7.84 (dd, J = 8.7,1.8 Hz, IH), 7.53 (dd, J = 8.3,4.1 Hz, IH), 6.22 (s, 2H), 3.99 (m, 3H), 2.87 (m, 2H), (d, J = 9.9 Hz, 2H), 1.45-1.37 (m, 11H).

Example 30 N-(Piperidin-4-yl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride [340] To a solution of exampLe 29 (0.125 g, 0.222 mmol) in THF (1 ml), ether saturated with HCI (1.5 ml) was added at 0OC and stirred for 15 min. The precipiTaTe formed was washed with ether and dried under vacuum to afford tHe title compound as ligHt yellow solid (0.105 g, 95%). M.P.: 220-224DC. Ή-NMR (δ ppm, DMSO-d,, 400 MHz ): □□□□ (d,J = 3..6 Hz, IH), 8.90 (m, 3H), 8.72 (d, J = 8.7 Hz, IH), 8.67 (d, J = 7.4 Hz, IH), 8.33 (d, J = 8.5 Hz, 2H), 8.28 (m, 3H), 8.11 (dd, J = 8.7,1.5 Hz, IH), 8.05 (d, J = 8.5 Hz, 2H), 7.89 (dd, J = 8.3,4.8 Hz, IH), 6.29 (s, 2H), 4.11 (m, IH), 3.59 (m, IH), 3.34 (m, IH), 3.01 (m, 2H), 1.99 (m, 2H), 1.85 (m, 2H). 132 22297712

Example 31 N-(2-(dimethylamino)ethyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide [341] To a solution of example 13 (0.150 g, 0.375 mmol) in DMF (1.5 ml), HOBT (0.068 g, 0.454 mmol), EDC-HC1 (0.180 g, 0.941 mmol) and TRieTHylAmiNe (0.15 ml, 1.09 mmol) were added and stiRREd For 5 min. 2-N,N-DImEtHylEThylAmine (0.123 g, 1.39 mmol) was added At RT and THe reACtion mixture was stirred For 12h. To The rEACtion mixture water was added and ExtracTEd with ethyl aceTaTe, dried over sodium sulphate and concentrAtED under reduced pressure. THe crude product was purified By column chromAtogrApHy with metHanol: dicHlorometHANe To afford THe Title compound as a yellow solid (0.029 g, 17%). M.P.: 122-125 □ C. Ή-NMR (δ ppm, DMSO-de, 400 MHz ):□□□□(&lt;!, J = 2.8 Hz, IH), 8.72 (d, J = 8.7 Hz, IH), 8.37 (d, J = 8.3 Hz, IH), 8.29 (Br s, IH), 8.23 (d, J = 8.8 Hz, IH), 8.18 (m, 2H), 8.04 (s, IH), 8.02 (d, J = 8.8 Hz, IH), 7.84 (m, 2H), 7.53 (dd, J = 8.3,4.1 Hz, IH), 6.23 (s, 2H), 3.39 (m, 4H), 2.49 (s, 6H).

Example 32 (S)-(2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)(4-(3-(quinolin-6-ylmethyl)-3H- [1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)methanone hydrochloride [342] To a solution oF example 8 (0.100 g, 0.262 mmol) in DMF (1 ml), HOBT (0.042 g, 0.314 mmol), EDC-HC1 (0.125 g, 0.655 mmol) and TrieTHYlAmiNe (0.3 ml, 2.35 mmol) were added and stiRREd For 5 min. (s)-1-(pyRRolidin-2-ylmEtHyl)pyrrolidine (0.120 g, 0.783 mmol) was added At RT and THe reACtion mixture was sTiRREd For 12H. To The reAcTion mixture water was added and exTrACted with ethyl acEtate, dried over sodium sulphate and coNceNtrAted under reduced pressure. THe crude product was purified By column chromATogrApHy with meTHanoI: dicHlorometHANe To Afford THe Free Base as a yellow solid (0.060 g). THe free Base was dissolved in THF (5 ml), Ether SAturATed with HCI (2 ml) was added at OOC and stirred for 15 min. The precipitate formed was washed with ether and dried under vacuum To afford THe Title compound as a light yellow solid (0.040 g, 27%). M.P.: 120-122CC. Ή-NMR (δ ppm, DMSO-de,^0^): 10.00(s, 1^,09.09(s, HO·8.77 (m, IH), □ □ □ □ □ (d, J = 8.7 Hz, IH), 8.33 (d, J = 8.2 Hz, 2H), 8.22 (m, 3H), 8.04 (d, J = 9.0 Hz, IH), 7.80 (m, IH), 7.74 (d, J = 8.0 Hz, 2H), 6.28 (s, 2H), 3.75-3.30 (m, 9H), 2.18-1.90 (m, 8H). 133 22297712

Example 33 (4-(2-hydroxyethyl)piperazin-1-yl)(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)phenyl)methanone [343] To a solution of example 8 (0.150 g, 0.393 mmol) in DMF (1 ml), HOBT (0.063 g, 0.471 mmol), EDC-HC1 (0.187 g, 0.983 mmol) and Triethylamine (0.16 ml, 1.17 mmol) were added and stirred For 5 min. (2-(piperaziN-1-y1)eThaNo1 (0.046 g, 0.353 mmol) was added at RT and The reaction mixture was stirred for 12h. To The reaction mixture water was added and extraeTed with ethyl aeeTaTe, dried over sodium sulphate and concentrated under reduced pressure. The crude product was purified by column ehromaTography with methanol: diehloromethane to afford The Title compound as a yellow solid (0.025 g, 13%). M.P.: 158-1607C. Ή-NMR (δ ppm, DMSO-D,,400MHz):□□□□ □□ (d, J = 2.7 Hz, IH), 8.67 (D, J = 8.7 Hz, IH), 8.38 (d, J = 7.8 Hz, IH), 8.31 (d, J = 8.2 Hz, 2H), 8.17 (d, J = 8.8 Hz, IH), 8.02 (T, J = 4.2 Hz, 2H), 7.83 (dd, J = 8.7,1.6 Hz, IH), 7.56 (d, J = 8.4 Hz, 2H), 7.52 (dd, J = 8.3,4.2 Hz, IH), 6.21 (s, 2H), 4.44 (T, J = 5.3 Hz, IH), 3.62 (m, 2H), 3.51 (q, J = 6.0 Hz, 2H), 2.42 (m, 8H).

Example 34 (R)-(3-hydroxypyrrolidin-1-yl)(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)methanone hydrochloride [344] To a solution of example 8 (0.150 g, 0.393 mmol) in DMF (1 ml), HOBT (0.063 g, 0.471 mmol), EDC-HC1 (0.187 g, 0.983 mmol) and Triethylamine (0.16 ml, 1.17 mmol) were added and stirred for 5 min. (R)-pyrro1idin-3-o1 (0.030 g, 0.353 mmol) was added aT RT and the reaction mixture was stirred for 12h. To The reaction mixture water was added and extraeTed with ethyl acetate, dried over sodium sulphate and eoneentraTed under reduced pressure. The crude product was purified by column ehromaTography with meThanol: diehloromethane To afford The amide as a yellow solid (0.015 g). The amide was dissolved in THF (2 ml), ether saturated with HCI (2 ml) was added at OdC and stirred for 15 min. The precipiTaTe formed was washed with ether and dried under vacuum to afford the tiTle compound as a yellow solid (0.017 g, 10%). M.P.: 120-1227C. 1H-NMR (δ ppm, DMSO-de, 400 MHz ): □ □ □ □ □ (d, J = 2.9 Hz, IH), 8.68 (d, J = 8.7 Hz, IH), 8.38 (d, J = 8.2 Hz, IH), 8.30 (d, J = 8.2 Hz, 2H), 8.17 (d, J = 8.8 Hz, IH), 8.02 (d, J = 8.3 Hz, 2H), 7.83 (d, J = 8.7 Hz, IH), 7.69 (m, 2H), 7.52 (dd, J = 8.2,4.1 Hz, IH), 6.21 (s, 2H), 3.61 (m, 3H), 3.44 (m, IH), 1.95-1.80 (m, 4H). 134 222977/2

Example 35 N-(2-(piperidin-1-yl)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin- 5-yl)benzamide [345] To a solution of example 8 (0.120 g, 0.314 mmol) in DMF (0.7 ml) , N-ethYLdiisopropYlAmine (0.041 g, 0.314 mmol) and HATU (0.119 g, 0.314 mmol) were added and stirred for 5 min. (2-(piperidin-1-YL)etHAnAmine (0.040 g, 0.314 mmol) was added at RT and The reACtion mixture was stirred For 12H. To the reACTion mixture water was added and exTrACted with ethyl ACeTAte, dried over sodium sulphate and ConeentrATed under reduced pressure. The Crude product was purified By column chromATogrAphy with meThAnol: dichloromeThAne to Afford The title Compound as a yellow solid (0.080 g, 52%). M.P.: 104107 □ C. 1H-NMR (δ ppm, DMSO-d, 400 MHz ): □ □ □ □ □ (dd, J=4.1,1.6 Hz, IH), 8.70 (d, J= 8.7 Hz, IH), 8.62 (Bs, IH), 8.38 (m, 3H), 8.21 (d, J = 8.8 Hz, IH), 8.03-7.98 (m, 4H), 7.84 (dd, J = 8.7,1.9 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 3.48 (Bs, 2H), 2.48 (m, 6H), 1.54 (m, 6H).

Example 36 N-(2-morpholinoethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [346] THe Title compound was prepared By following the procedure deseriBed For example 35 using 2-morpholinoeThAnAmine (0.040 g, 0.314 mmol) insTeAd of (2-(piperidin-1-Yl)ethAnAmine Yellow solid (0.070 g, 45%). M.P.: 146-149 C. Ή-NMR (δ ppm, DMSO-de, 400 MHz ): □ □ □□ □ (dd, J = 4.2, 1.6 Hz, IH), 8.70 (d, J = 8.7 Hz, IH), 8.54 (t, J = 4.5 Hz, IH), 8.38 (d, J = 8.5 Hz, IH), 8.34 (d, J = 8.5 Hz, 2H), 8.20 (d, J = 8.8 Hz, IH), 8.03-7.98 (m, 4H), 7.84 (dd, J = 8.8, 2.0 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 3.57 (T, J = 4.4 Hz, 4H), 3.41 (m, 2H), 2.46 (m, 6H).

Example 37 N-(2-(pyrrolidin-1-yl)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin- 5-yl)benzamide [347] THe Title compound was prepared By following the procedure deseriBed For example 35 using 2-(pYrrolidin-1-Yl)ethAnAmine (0.036 g, 0.314 mmol) insteAd of (2-(piperidin-l-yl)eThAnamine. Yellow solid(0.065 g, 43%). M.P.: 135-137DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ):□□□□ □ (dd, J = 4.2,1.7 Hz, IH), 8.70 (d, J = 8.7 Hz, IH), 8.58 (m, IH), 8.38 (d, J = 7.5 Hz, IH), 8.34 (d, J = 8.4 Hz, 2H), 8.21 (d, J = 8.8 Hz, IH), 8.03 (d, J = 3.5 Hz, 2H), 8.00 (d, J = 8.3 Hz, 2H), 7.84 (dd, J = 8.7,2.0 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 3.41 (d, J = 5.4 Hz, 2H), 2.49 (m, 6H), 1.68 (s, 4H). 135 222977/2

Example 38 (4-(pyrrolidin-1-yl)piperidin-1-yl)(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)phenyl)methanone: [348] To A solutioN of example 8 (0.100 g, 0.262 mmol) In 1:1

DMF/dIchlromethANe mixture (1.0 ml), BOP (0.121 g, 0.275 mmol) ANd TrIethYlAmme (0.1 ml, 0.786 mmol) were Added ANd stirred for 30 min. 4-(pYrro1idiN-1-Yl)piperidiNe (0.044 g, 0.288 mmol) was Added AT RT ANd the reActioN mixture was stirred for 12H. To the reActioN mixture water was Added ANd extracted with ethyl AcetATe, dried over sodium sulphate ANd coNceNtrATed UNder reduced pressure. The crude product was purified by columN chromAtogrAphy with methANol: dichloromethANe to Afford The title compouNd As A yellow solid (0.017 g, 12%). M.P.: 125-127DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.88 (dd, J = 4.2, 1.6 Hz, IH), 8.71 (d, J = 8.7 Hz, IH), 8.38 (d, J = 8.1 Hz, IH), 8.33 (d, J = 8.2 Hz, 2H), 8.19 (d, J = 8.8 Hz, IH), 8.03 (d, J = 8.9 Hz, IH), 8.00 (s, IH), 7.83 (dd, J = 8.7, 1.9 Hz, IH), 7.57 (d, J = 8.2 Hz, 2H), 7.53 (dd, J = 8.4,4.2 Hz, IH), 6.22 (s, 2H), 3.49-3.10 (m, 9H), 2.07-1.53 (m, 8H).

Example 39 N-(3-(dimethylamino)propyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide [349] The title compouNd was prepAred by followiNg the procedure described for example 35 usiNg 3-N,N-dImethYlAmiNopropYlAmlNe (0.026 g, 0.262 mmol) iNSteAd of (2-(pIperldm-l-Yl)ethANAmme Yellow solid (0.035 g, 29%). M.P.: 132-135DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): δ 8.88 (Dd, J=4.1,1.6 Hz, IH), 8.70 (D, J = 8.8 Hz, IH), 8.66 (t, J= 5.8 Hz, IH), 8.38 (d, J = 8.3 Hz, IH), 8.33 (d, J = 8.4 Hz, 2H), 8.20 (d, J = 8.8 Hz, IH), 8.03 7.97 (m, 4H),7.84 (dd, J = 8.7, 1.9 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s, 2H), 3.30 (m, 2H), 2. 30 (t, J = 7.0 Hz, 2H), 2.14 (s, 6H), 1.68 (t, J = 7.0 Hz, 2H).

Example 40 N,N-Bis(2-methoxyethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride: [350] To A solutioN of example 8 (0.150 g, 0.393 mmol) in DMF (1 ml), HOBT (0.063 g, 0.471 mmol), EDC-HC1 (0.187 g, 0.983 mmol) ANd trlethylAmme (0.16 ml, 1.17 mmol) were Added ANd stirred for 5 miN. BIs(2-methoxYeThYl)Amme (0.104 g, 0.786 mmol) was Added AT RT ANd the reActioN mixture was stirred for 12h. To the reActioN mixture water was Added ANd extracted with ethyl Acetate, dried over sodium sulphate ANd coNceNtrAted UNder reduced pressure. THe crude product was purified by columN chromATogrAphy with methANol: dichlorometHANe To Afford the Amide As A yellow solid (0.04 g). THe Amide was 136 222977/2 dissolved in THF (2 ml), ether saturated with HCI (2 ml) was added at 0 □ C and stirred for 15 min. The precipiTAtE formed was wasHeD with ether and Dried under vacuum To afford The TiTle compounD as a yellow solid (0.035 g, 17%). M.P.: 126-129DC. Ή-NMR (δ ppm, DMSO-cf. 400 MHz ): 9.07 (m, IH), 8.74 (m, IH), 8.70 (D, J = 8.7 Hz, IH), 8.29 (D, J = 8.3 Hz, 2H), 8.19 (m, 3H), 8.02 (m, IH), 7.78 (m, IH), 7.53 (D, J = 8.2 Hz, 2H), 6.27 (s, 2H), 3.64 (Bs, 2H), 3.58 (Br.s, 2H), 3.41 (Br.s, 4H), 3.30 ( s, 3H), 3.16 (s, 3H).

Example 41 (2-Fluoro-4-(3-(quinolm-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridm-5-yl)phenyl)methanol hydrochloride:

Example 16 (0.050g. 0.129 mmol) was dissolved in THF (3 ml) and meTHanol (3 ml), Ether saturated with HCI (3 ml) was added at ODC and stirred for 15 min. The precipitate formed was washed with ether and dried under vacuum To afford The TiTle compounD as an off-wHiTe solid (0.040 g, 74%). M.P.: 190-192DC. Ή-NMR (δ ppm, DMSO-cf. 400 MHz ): □ 9.14(d, J = 3.6 Hz, IH), 8.88 (D, J = 8.1 Hz, IH), 8.68 (d, J = 8.7 Hz, IH), 8.24 (s, IH), 8.24 (D, J = 8.6 Hz, IH), 8.18 (D, J = 8.8 Hz, IH), 8.11 (m, 2H), 8.03 (dd, J = 11.7,1.5 Hz, IH), 7.87 (DD, J = 8.1.4.8 Hz, IH), 7.65 (T, J = 7.9 Hz, IH), 6.29 (s, 2H), 5.86 (s, IH), 4.61 (s, 2H).

Example 42 6-((5-(3-Fluoro-4-(methoxymethyl)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [351] Sodium HydriDe (0.010 g, 0.259 mmol) was added at ODC to a solution of example 16 (0.100 g, 0.259 mmol) in DMF (1 ml) and stirreD for 30 min. Methyl ioDiDe (0.073 g, 0.518 mmol) was aDDeD and the reAcTion mixture was warmed To RT. After 12H, the reAcTion mixTure was poured into ice-cold water and extracted with Ethyl acetate, washed with Brine, Dried over sodium sulphate and concenTrAteD. The crude product was purifieD By column cHromAtogrApHy with methAnol: DicHloromEthAne To Afford The TiTle compounD as an off-wHiTe solid (0.033 g, 32%). M.P.: 200-201 DC. Ή-NMR (δ ppm, DMSO-De, 400 MHz ): 8.88 (dd, J = 4.2,1.7 Hz, IH), 8.68 (D, J = 8.8 Hz, IH), 8.37 (D, J = 8.4 Hz, IH), 8.18 (D, J = 8.8 Hz, IH), 8.11-8.00 (m, 4H), 7.83 (DD, J = 8.7,1.9 Hz, IH), 7.61 (T, J = 7.7 Hz, IH), 7.53 (DD, J = 8.4,4.2 Hz, IH), 6.22 (s, 2H), 4.53 (s, 2H), 3.33 (s, 3H).

Example 43 N-ethyl-2-fluoro-4-(3-(qumolm-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridm-5- yl)benzamide: [352] To a solution of example 13 (0.100 g, 0.250 mmol) in DMF (0.7 ml), N-eThyldiisopropylAminE (0.064 g, 0.50 mmol) and HATU (0.095 g, 0.250 mmol) were added and sTirred For 5 min. EtHylAmine hydrocHloriDe (0.020 g, 0.250 mmol) was added at RT and 137 22297712 tHe reAction Mixture was stirred for 12H. Water was Added To THe reAction Mixture And extrActed witH etHyl AceTATe, dried over sodium sulpHATe And concentrATed under reduced pressure. THe crude product was purified By column cHroMATogrApHy witH meTHanoI: dicHloroMETHAne To Afford THe title compound As A yellow solid (0.070 g, 66%). M.P.: 207- 209QC. Ή-NMR (δ ppm, DMSO-ds,400 MHz ): 8.88 (DD, J=4.2,1.7 Hz, IH), 8.71 (D, J= 8.7 Hz, IH), 8.41 (m, IH), 8.37 (d, J = 7.6 Hz, IH), 8.23 (d, J = 8.8 Hz, IH), 8.17 (m, 2H), 8.04 (s, IH), 8.02 (d, J = 8.8 Hz, IH), 7.84 (dd, J = 8.7, 1.9 Hz, IH), 7.77 (T, J = 7.9 Hz, IH), 7.54 (dd, J = 8.3,4.1 Hz, IH), 6.23 (s, 2H), 3.29 (m, 2H), 1. 4 (T, J = 7.2 Hz, 3H).

Example 44 2-Fluoro-N-(2-(pyrrolidin-1-yl)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide: [353] THe Title compound was prepared By following THe procedure descriBed For example 43 using (2-(pipEridin-1-Yl)ETHAnAMinE (0.028 g, 0.250 mmoI) insteAd of etHylAMine HydrocHloride. Yellow solid (0.015 g, 12%). M.P.: 183-186OC. 1H-NMR (δ ppm, DMSO-de, 400 MHz ): 8.89 (dd, J = 4.0, 1.5 Hz, IH), 8.74 (d, J = 8.7 Hz, IH), 8.59 (m, IH), 8.37 (d, J = 7.7 Hz, IH), 8.25-8.19 (μ, 3H), 8.03 (s, IH), 8.02 (d, J = 8.7 Hz, IH), 7.90 (T, J = 8.0 Hz, IH), 7.84 (dd, J = 8.7, 1.8 Hz, IH), 7.54 (dd, J = 8.4,4.2 Hz, IH), 6.24 (s, 2H), 3.62 (m, 4H), 3.06-2.89 (μ, 4H), 1.89-1.86 (μ, 4H).

Example 45 N-cyclohexyl-2-fluoro-4-(3-(qumolm-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridm-5- yl)benzamide: [354] THe Title compound was prepared By following tHe procedure descriBed For example 43 using cycLoHexylAmine (0.025 g, 0.250 mmoI) insteAd of eTHylAMine HydrocHloride. Yellow solid (0.050 g, 41%). M.P.: 172-175DC. MS (m/z): 481.21 (M+ +1).

Example 46 N-Cyclopropyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [355] THe Title compound was prepared By following tHe procedure descriBed For example 43 using cycLopRopylAmiNE (0.014 g, 0.250 mmol) insteAd of eTHylAmiNE HydrocHloride. Off-wHite solid (0.015 g, 14%). M.P.: 193-195 OC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 08.88 (dd, J = 4.1, 1.6 Hz, IH), 8.71 (d, J = 8.7 Hz, IH), 8.48 (d, J = 3.8 Hz, IH), 8.37 (d, J = 7.3 Hz, IH), 8.23 (d, J = 8.8 Hz, IH), 8.16 (m, 2H), 8.04 (s, IH), 8.02 (d, J = 8.7 Hz, IH), 7.83 (dd, J = 8.7, 2.0 Hz, IH), 7.72 (T, J = 8.0 Hz, IH), 7.54 (dd, J = 8.4,4.2 Hz, IH), 6.23 (s, 2H), 2.87 (m, IH), 0.70 (m, 2H), 0.57 (m, 2H). 138 222999/2

Example 47 2-Fluoro-N-(pyridin-4-yl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [356] The title Compound was prepared by following the proeedure described fer example 43 using 4-aminepyridine (0.023 g, 0.250 mmol) instead of ethylamine hydrochloride. Yellow solid (0.050 g, 42%). M.P.: 217-219QC. MS (m/z): 476.17 (M+ +1).

Example 48 N-Benzyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [357] The title Compound was prepared by following the proeedure described fer example 43 using benzylamine (0.023 g, 0.250 mmol) instead of ethylamine hydrochloride. Pale green solid (0.040 g, 32%). M.P.: 163-165DC. MS (m/z): 489.19 (M+ +1).

Example 49 2-Fluoro-N,N-dimethyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [358] The title compound was prepared by fellewinG the precedure deseribed for example 43 using dimethylamine hydrechleride (0.020 g, 0.250 mmol) instead of ethylamine hydreehloride. Pale brown solid (0.020 g, 18%). M.P.: 163-165 C. MS (m/z): 426.96 (M+ +1).

Example 50

Methyl 2-(2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamido)acetate: [359] To glyeine (0.100 g, 1.133 mmol) in methanel (4 ml), thionyl Chloride (0.9 ml) was added and refluxed fer lh. The selvent was remeved and the residue was dissolved in DMF (2 ml). To this solution example 13 (0.150 g, 0.375 mmol), N-ethyldiiseprepylamine (0.097 g, 0.751 mmol) and HATU (0.0142 g. 0.375 mmel) were added at RT and the reaction mixture was stirred fer 12h. To the reaetion mixture water was added and extracted with ethyl acetate, dried over sodium sulphate and eoneentrated under reduced pressure. The crude product was purified by eelumn ehrcmatcGraphy with methanel: dichleromethane to afferd the title Compound as a yellow solid (0.055 g, 31%). Ή-NMR (δ ppm, CDCl3, 400 MHz ): δ 8.92 (dd, J = 4.2, 1.6 Hz, IH), 8.48 (d, J = 8.6 Hz, IH), 8.27 (t, J = 8.4 Hz, IH), 8.16 (d, J = 8.8 Hz, IH), 8.10 (d, J = 8.7 Hz, IH), 8.00 (m, 3H), 7.88 (m, 2H), 7.43 (dd, J = 8.4,4.2 Hz, IH), 7.36 (m, IH), 6.16 (s, 2H), 4.32 (d, J = 4.7 Hz, 2H), 3.83 (s, 3H). 139 2229T7I2

Example 51 2-(2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamido)acetic acid [360] To a solution of Example 50 (0.055 g, 0.113 mmol) in methanol (0.5 ml), lithium hydroxide (0.045 g, 1.05 mmol) in water (0.5 ml) was added and stirred At RT. After 12h, pH was Adjusted To ca. 7 using 0.5N HCl and The solid prEcipitAtEd was filtEred, washed with Ethyl AcetAte and pEtroleum ether and dried under vacuum to afford the title compound as a pale green solid (0.050 g, 96%). M.P.: 252-254QC. 'H-NMR (δ ppm, DMSO-de, 400 MHz ): 12.70 (s, IH), 9.01 (d, J = 3.9 Hz, IH), 8.73 (d, J = 8.7 Hz, IH), 8.64 (m, 2H), 8.25 (d, J = 8.8 Hz, 1H), 8.20 (m, 4H), 7.97 (d, J = 8.9 Hz, 1H), 7.86 (T, J = 8.1 Hz, 1H), 7.71 (dd, J = 7.8,4.2 Hz, 1H), 6.27 (s, 2H), 3.96 (d, J = 5.8 Hz, 2H). MS (m/z): 456.85 (M+ ).

Example 52 2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(1H-1,2,4- triazol-3-yl)benzamide [361] The Title compound was prepAred by Following the procedure described for example 43 using 3-Amino-1,2,4-TriAZole (0.021 g, 0.250 mmol) insteAd of ethylAmine hydrochloride. Off-whitE solid (0.010 g, 9%). M.P.: 265-267□ C. Ή-NMR (δ ppm, DMSO-tf,. 400 MHz ): □ 13.70 (s, IH), 12.10 (s, IH), 8.87 (m, IH), 8.74 (d, J = 8.5 Hz, 1H), 8.38 (d, J = 8.3 Hz, 1H), 8.27-8.22 (m, 3H), 8.05 (m, 2H), 7.89-7.79 (m, 3H), 7.54 (q, J = 4.2 Hz, 1H), 6.25 (s, 2H). MS (m/z): 465.95 (M+ ).

Example 53

Methyl 3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate [362] The title compound was prepared by following The procedure described For example 1 using inTermediAte 14 (0.250 g, 0.845 mmol), 3-methoxycArbonylphenylboronic acid (0.190 g, 1.056 mmol), potassium AcetAte (0.276 g, 2.81 mmol), dioxane (5 ml) and TeTrakis(triphenylphosphinE)pAllAdium(0) (0.078 g, 0.067 mmol). Brown solid (0.190 g, 56%).

Example 54 3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid: [363] To a solution of example 53 (0.190 g, 0.480 mmol) in methanol (2.7 ml), lithium hydroxide (0.201 g, 4.80 mmol) in water (0.75 ml) was added and stirred At RT. After 12h, The pH was Adjusted to 7-7.5 using 0.5N HCl and The solid precipiTAted was Filtered, washed with ethyl Acetate and petroleum ether and dried under vacuum to afford the Title compound as brown solid (0.070 g, 38%). Ή-NMR (δ ppm, D\1SO-d6. 400 MHz ): 13.39 (s. 140 22297712

1H), 8.87 (d, J = 2.6 Hz, 1H), 8.77 (s, 1H), 8.68 (d, J = 8.7 Hz, 1H), 8.39 (μ, 2H), 8.16 (d, J

= 8.7 Hz, 1H), 8.07 (μ, 3H), 7.85 (dd, J = 8.7, 1.5 Hz, 1H), 7.66 (T, J = 7.8 Hz, 1H), 7.52 (dd, J = 8.3,4.1 Hz, 1H), 6.22 (s, 2H).

Example 55 N-Methyl-3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [364] To Example 54 (0.070 g, 0.183 mmoL), Thionyl chloride (3 mL) was added and refluxed For 3h. The excess Thionyl chloride was removed under reduced pressure and The residue was cooled to ODC. Methylamine in ethanol (50% solution, 5 ml) was added and stirred For 15 min. The precipitAte Formed was washed with sodium BIcatBonaTe solution and dried under vacuum To Afford The title compound as pale Brown solid (0.050 g, 69%). M.P.: 215-217DC. MS (m/z): 359.04 (M+ +1).

Example 56 6-((5-(3-Fluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [365] The Title compound was prepared By followinG the procedure descriBed for Example 1 using InTErmediATE 14 (0.100 g, 0.338 mmoI), 3-fluorophEnylBoronic acid (0.059 g, 0.422 mmol), potassium catBonaTe (0.156 g, 0.027 mmol), dioxane (2 mL), water (0.5 mL) and TETrAkis(triphEnylphosphInE)pAllAdIuM(0) (0.031 g, 0.067 mmol) In mictowave oven (100W, 100oC) For 20 min.. Yellow solid (0.040 g,30%. M.P.: 145-147OC. MS (m/z): 356.05 (M+ +1).

Example 57

Methyl 3-(2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenylamino)propanoate [366] To 2-AMlnopropionic acid (0.100 g, 1.122 mmoI) In Methanol (4 m1), Thionyl chloride (0.9 m1) was added and refluxed For 1h. Solvents were removed and residue was dissolved in DMF (2 m1). To this solution example 13 (0.150 g, 0.375 mmoI), N-EthyLdlisopropylAminE (0.097 g, 0.751 mmoI) and HATU (0.0142 g, 0.375 mmoI) were added At RT and the reaction Mixture was stirred For 12h. To The reaction Mixture water was added and EXtrACted with ethyl aceTaTe, dried over sodium sulphate and concenTrAted under reduced pressure. The crude product was purified By column chroMAtOGTAphy with MethAnol: dlchloroMEThAne to Afford the Title compound as a yellow solid (0.078 g, 44%). 141 22297712

Example 58 3-(2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)phenylamino)propanoic acid [367] To a solution of example 57 (0.080 g, 0.165 mmol) in meThanol (0.8 ml), lithium hydroxide (0.064 g, 1.54 mmol) in water (0.8 ml) was added and stirred aT RT. After 12h, pH was adjusted To ca. 7.5 using 0.5N HCI and The solid preeipitaTed was Filtered, washed with ethyl acetate and petroleum ether and Dried under vacuum To afford The title compound as pale green solid (0.075 g, 68%). M.P.: I32-135C.

Example 59 2-Fluoro-N-methoxy-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride: [368] The title compound was prepared by Following The proeedure described for example 43 using N,O-dimethy1hydroxy1amine hydrochloride (0.025 g, 0.250 mmol) instead of EThylamine hydrochloride. Yellow solid (0.055 g, 46%). M.P.: 201-202DC. MS (m/z): 443.20 (M+ +1-HC1).

Example 60 N-tert-Butyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide [369] The title compound was prepared by Following The proeedure described for example 43 using ierr-butylamine (0.018 g, 0.250 mmol) instead of ethylamine hyDrochloride. Yellow solid (0.050 g, 44%). M.P.: 210-2127C. MS (m/z): 455.10 (M+ +1).

Example 61 N-Allyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide [370] The TiTle compound was prepared by following the procedure deseribed For example 43 using allylamine (0.018 g, 0.250 mmol) instead of eThylaMine hydrochloride. Yellow solid (0.033 g, 29%). M.P.: 162-164DC. MS (m/z): 438.93 (M+ ).

Example 62 2-Fluoro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [371] The TiTle compound was prepared by following the procedure deseribed For example 43 using meThoxylamine hydrochloride (0.0208 g, 0.250 mmol) instead of ethylamine hydrochloride. Yellow solid (0.055 g, 51%). M.P.: 197-199DC. MS (m/z): 429.06 (M+ ). 142 222977/2

Example 63 N-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)acetamide: [372] The title compouNd was prepared by followiNg The procedure described for example 1 usiNg iNteRmediATe 14 (0.100 g, 0.338 mmol), 4-AcetAmIdopHeNYlboroNlc Acid (0.076 g, 0.422 mmol), potassium carboNATe (0.156 g, 0.027 mmol), dioxANe (2 ml), water (0.5 ml) ANd TeTrAKis(trIpheNYlphosphlNe)pA11AdIum(0) (0.031 g, 0.067 mmol) In microwave oveN (100W, 100°C) for 20 min. BrowN solid (0.090 g, 67%). M.P.: 220-223DC. MS (m/z): 394.83 (M+l).

Example 64 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)aniline: [373] To A solutioN of example 63 (0.060 g, 0.152 mmol) In ethANol (1 ml) was Added con. HCI (0.5 ml) ANd refluxed for 2h. THe reActioN mixture was cooled, bAsified with sodium bicArboNAte solutioN, extracted with ethyl AcetATe, dried over sodium sulphate ANd coNceNtrATed UNder reduced pressure To Afford the title compouNd As A browN solid (0.030 g, 42%). M.P.: 190-193DC. MS (m/z): 353.18 (M+ +1).

Example 65 6-((5-(3,4-Dimethoxyphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [374] The title compouNd was prepAred by followiNg the procedure described for example 1 usiNg iNteRmediATe 14 (0.100 g, 0.338 mmol), 3,4-dimethoxYpHeNyLboroNic Acid (0.076 g, 0.422 mmol), potassium carboNATe (0.156 g, 0.027 mmol), dioxANe (2 ml), water (0.5 ml) ANd TeTraKIs(tripheNYlpHosphlNe)pA11AdIum(0) (0.031 g, 0.067 mmol) In microwave oveN (100W, 100°C) for 20 miN. BrowN solid (0.090 g, 67%). M.P.: 149-152DC. MS (m/z): 397.77 (M+).

Example 66 6-((5-(3-Fluoro-4-methoxyphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [375] The title compouNd was prepAred by followiNg the procedure described for example 1 usiNg iNteRMediATe 14 (0.100 g, 0.338 mmol), 3-fluoro-4-methoxYpheNYlboromc Acid (0.074 g, 0.439 mmol), potassium cArboNAte (0.156 g, 0.027 mmol), dioxANe (2 ml), water (0.5 ml) ANd teTrAKIs(trIpHeNYlphosphlNe)pA11AdIum(0) (0.031 g, 0.067 mmol) in microwave oveN (100W, 100OC) for 20 miN. PAle greeN solid (0.060 g, 46%). M.P.: 187-190DC. MS (m/z): 385.873 (M+). 143 222977/2

Example 67 6-((5-(4-Fluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [376] The title compounD was prepareD by following the proceDure DeseribeD For example 1 using interMEDiate 14 (0.100 g, 0.338 mmol), 4-fluorophEnylboronic aeiD (0.059 g, 0.422 mmol), potassium earbonatE (0.156 g, 0.027 mmol), Dioxane (2 ml), water (0.5 ml) anD tetrakis(tripheny1phosphine)pa11aDiuM(0) (0.031 g, 0.067 mmoI) in Microwave oven (100W, lOOoC) For 20 min.. Yellow soliD (0.060 g, 50%). M.P.: 153-156QC. MS (m/z): 355.98 (M+).

Example 68 6-((5-(2-Fluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [377] The title compounD was prepareD by following the proceDure DeseribeD For example 1 using interMeDiate 14 (0.100 g, 0.338 mmoI), 2-fluorophenylboronic aeiD (0.059 g, 0.422 mmol), potassium earbonatE (0.156 g, 0.027 mmoI), Dioxane (2 ml), water (0.5 ml) anD tetrakis(tripheny1phosphine)pa11aDiuM(0) (0.031 g, 0.067 mmol) in Microwave oven (100W, lOOoC) For 20 min.. Yellow soliD (0.050 g, 41%). M.P.: 164-166DC. MS (m/z): 355.84 (M+).

Example 69 N-(3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)acetamide: [378] THe title compounD was prepareD by following the proceDure DeseribeD For example 1 using interMEDiate 14 (0.100 g, 0.338 mmol), 4-aeEtamiDopHenylboronie aeiD (0.078 g, 0.439 mmoI), potassium carbonate (0.156 g, 0.027 mmol), Dioxane (2 ml), water (0.5 ml) anD tetrakis(triphEny1pHosphinE)panaDium(0) (0.031 g, 0.067 mmol) in microwave oven ( 100W, 100oC) for 20min.. Pale green soliD (0.065 g, 49%). M.P.: 198-201 DC. MS (m/z): 395.11 (M++1).

Example 70 6-((5-(3-(2,2,2-Trifluoroethoxy)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [379] The title compounD was prepareD by following the proceDure DeseribeD For example 1 using interMeDiate 14 (0.100 g, 0.338 mmoI), 3-trifluoroethoxyphenylboronic aeiD (0.096 g, 0.439 mmol), potassium Carbonate (0.156 g, 0.027 mmol), Dioxane (2 ml), water (0.5 ml) anD tetrakis(tripheny1phosphine)paUaDiuM(0) (0.031 g, 0.067 mmoI) in Microwave oven (100W, 100oC) for 20 min.. Off-white soliD (0.040 g, 42.7 %). M.P.: 151- 154DC. MS (m/z): 435.97 (M+). 144 222977/2

Example 71 3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)aniline [380] To a solution of example 69 (0.045 g, 0.152 mmol) in ethAnol (1 ml), Con. HCI (0.5 ml) was added and refluxed For 2h. THe reACtion mixture was Cooled, BAsified with sodium BicArBonATe solution, extrACTed with ethyl Acetate, dried over sodium sulphate and concentrAted under reduced pressure to afford the Title compound as Brown solid (0.028 g, 70%). M.P.: 187-189QC. MS (m/z): 352.90 (M+).

Example 72 N-(3-(dimethylamino)propyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide [381] The Title compound was prepared By following the procedure deseriBed For example 43 using 3-N,N-DimeThYlAminopropylAmine (0.026 g, 0.262 mmol) insTeAd of ethylAmine hydrochloride. Off-white solid (0.063 g, 54%). M.P.: 148-150 3C. MS (m/z): 483.92 (M+).

Example 73 N-Ethyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride: [382] THe example 43 (0.050 g, 0.117 mmol) was dissolved in THF (1 ml), ether SATurated with HCI (1 ml) was added At 0cC and stirred For 15 min. The preeipiTATe Formed was washed with ether and dried under vacuum To afford The title Compound as an off-whiTe solid (0.052 g, 95%). M.P.: 236-238DC. Ή-NMR (δ ppm, DMSO-de, 400 MHz ): 09.07 (m, IH), 8.73 (m, 2H), 8.41 (m, IH), 8.24 (d, J = 8.8 Hz, IH), 8.19-8.13 (m, 4H), 8.02 (d, J = 7.4 Hz, IH), 7.80 (m, , 2H), 6.29 (s, 2H), 3.23 (m, 2H), 1.14 (t, J = 7.2 Hz, 3H).

Example 74 2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride [383] THe example 15 (0.040g. 0.100 mmol) was dissolved in THF (1 ml), ether SATurated with HCI (1 ml) was added At 0cC and stirred For 15 min. The preCipitAte formed was washed with ether and dried under vacuum To afford The title Compound as an off-whiTe solid (0.043 g, 96%). M.P.: 165-1688 C. 1H-NMR (δ ppm, DMSO-d,, 400 MHz ): Οδ9.10 (m, IH), 8.79 (m, IH), 8.73 (d, J = 8.8 Hz, IH), 8.24-8.13 (m, 4H), 8.05 (d, J = 8.7 Hz, IH), 7.83 (m, 3H), 7.74 (s, IH), 6.29 (s, 2H). 145 222977/2

Example 75 6-((5-(3-Fluoro-4-isopropoxyphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl) methyl)quinoline: [384] THe title compound was prepared By following THe procedure descriBed For example 1 using iNTerMediate 14 (0.100 g 0.338 mmol), 3-f1uoro-4- isopropoxypheNylBoroNic acid pinacol ester (0.113 g, 0.439 mmol), potassium carbonate (0.156 g, 0.027 mmol), Dioxane (2 ml), water (0.5 ml) and Tetrakis (triphenyLpHospHine)paLLadium(O) (0.031 g, 0.067 mmol) in microwave oven (100W, 100OC) For 30 min. Brown solid (0.095 g, 68%). M.P.: 128-130QC. MS (m/z): 413.92 (M+).

Example 76 N-(3-(dimethylamino)-3-oxopropyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H- [1.2.3] triazolo[4,5-b]pyridin-5-yl)benzamide [385] The title compound was prepared By FollowiNg the procedure descriBed for exampLe 43 using iNTermediaTe 23 (0.075 g, 0.326 mmol) instead of EthylamiNe hydrochloride. Off-white solid (0.075 g, 60%). M.P.: 163-165DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.91 (dd, J = 4.2,1.6 Hz, IH), 8.46 (d, J = 8.7 Hz, IH), 8.21 (d, J = 7.9 Hz, IH), 8.17 (d, J = 9.3 Hz, IH), 8.10 (d, J = 8.7 Hz, IH), 7.97-7.83 (m, 5H), 7.78 (m, IH), 7.43 (dd, J = 8.3,4.2 Hz, IH), 6.15 (s, 2H), 3.84 (q, J = 5.4 Hz, IH), 2.68 (t, J = 5.5 Hz, 2H), 3.01 (s, 3H), 2.98 (s, 3H).MS (m/z): 498.41 (M+ +1).

Example 77 N-(2-(dimethylamino)-2-oxoethyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H- [1.2.3] triazolo[4,5-b]pyridin-5-yl)benzamide: [386] THe title compound was prepared By following THe procedure descriBed For exampLe 43 using inTermediaTe 24 (0.050 g, 0.280 mmol) instead of Ethylamine HydrocHloride. Off-wHite solid (0.085 g, 70%). M.P.: 177-179DC. MS (m/z): 483.85 (M+ ).

Example 78 2-Fluoro-N-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-4-(3-(quinolin-6-ylmethyl)-3H- [1.2.3] triazolo[4,5-b]pyridin-5-yl)benzamide [387] The title compound was prepared By Following the procedure descriBed for exampLe 43 using Intermediate 25 (0.096 g, 0.396 mmol) instead of Ethylamine Hydrochloride. Off-white solid (0.085 g, 66%). M.P.: 175-177DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): Π8.91 (dd, J = 4.1,1.5 Hz, IH), 8.47 (d, J = 8.6 Hz, IH), 8.22 (d, J = 8.0 Hz, IH), 8.17 (d, J = 8.4 Hz, IH), 8.10 (d, J = 8.7 Hz, IH), 7.98 (m, 4H), 7.87 (dd, J = 8.7,3.2 Hz, 2H), 7.43 (dd, J = 8.3,4.2 Hz, IH), 6.15 (s, 2H), 4.25 (d, J = 3.5 Hz, 2H), 3.58 (T, J = 5.9 Hz, 146 22297712 2H), 3.48 (T, J = 5.8 Hz, 2H), 2.06 (q, J = 6.9 Hz, 2H), 1.94 (q, J = 6.8 Hz, 2H). MS (m/z): 509.96 (M+ ).

Example 79 6-((5-(4-(Cyclopropylmethoxy)-3-fluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [388] The Title compound was prEparEd By Following The procedurE descriBed For example 1 using iNTermediATe 14 (0.100 g, 0.338 mmol), 2-(4-(cyclopRopylmeTHoxy)-3-FluoropHeNYl)-4,4,5,5-TeTRAmeTHYl-1,3,2-dioxABorolANe (0.123 g, 0.422 mmol), potassium carBoNATe (0.156 g, 0.027 mmol), dioxANe (2 ml), water (0.5 ml) and TetrAkis (TripHENYlphosphiNE)pAllAdium(O) (0.031 g, 0.067 mmol) in microwave oven (100W, 100 0C) For 30 min. OFF-white solid (0.040 g, 28%). M.P.: 160-162DC. MS (m/z): 425.89 (M+).

Example 80 6-((5-(3-Fluoro-4-isobutoxyphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [389] THe TiTle compound was prepAred By following THe procedure descriBed For example 1 using iNTermediATe 14 (0.100 g, 0.338 mmol), 4-isoButyloxy-3-fluoRopHENyl Boronic acid pinacol Ester (0.122 g, 0.422 mmol), potassium carBonate (0.156 g, 0.027 mmol), dioxANE (2 ml), water (0.5 ml) and TEtraKis (TripheNYlphospHiNE)pAllAdium(O) (0.031 g, 0.067 mmol) in microwave oven (100W, 100OC) For 30min. Pale Brown solid (0.065 g, 45%). M.P.: 115-157OC. MS (m/z): 428.13 (M++1).

Example 81 3-(2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenoxy)- N,N-dimethylpropan-1-amine: [390] The Title compound was prEpared By Following The procedure descriBed For example 1 using inteRmEdiAte 14 (0.100 g, 0.338 mmol), 3-(2-fluoro-4-(4,4,5,5-TeTrAmETHYl- 1,3,2-dioxABorolAN-2-Yl)pHENOxY)-N,N-dimeThYlpropAN-1-AmiNe (0.137 g, 0.422 mmol), potassium carbonate (0.156 g, 0.027 mmol), dioxANe (2 ml), water (0.5 ml) and TetrAkis (TripHENYlphosphiNE)pAllAdium(O) (0.031 g, 0.067 mmol) in microwave oven (100W, 100OC) For 30min.. Pale Brown solid (0.055 g, 45%). M.P.: 102-105 DC. MS (m/z): 457.18 (M++1).

Example 82

Methyl 2-fluoro-4-(3-(2-(qumolm-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridm-5-yl)benzoate: [391] THe TiTle compound was prepared By Following THe procedure descriBed For example 1 using iNTermediATe 17 (0.600 g, 1.841 mmol), 3-fluoro-4-meTHoxYCArBoNYl pheNYlBoroNic acid (0.459 g, 2.30 mmol), potassium Acetate (0.585 g, 5.965 mmol), dioxane 147 222977/2 (12 ml) and TEtrAkis(TRiphEnylpHospHine)pALlAdium(0) (0.170 g, 0.147 mmol). Off-whiTE solid (0.705 g, 87%). Ή-NMR (δ ppm, DMSO-cf, 400 MHz ): 8.90 (Dd, J=4.2,1.5 Hz, IH), 8.44 (D, J = 8.7 Hz, IH), 8.18 (D, J = 7.8 Hz, IH), 8.00 (D, J = 9.0 Hz, IH), 7.92 (m, 2H), 7.75 (D, J = 8.7 Hz, IH), 7.69-7.60 (m, 3H), 7.41 (m, IH), 3.93 (s, 3H), 2.50 (s, 6H).

Example 83 2-Fluoro-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid [392] To a solution of Example 82 (0.700 g, 1.60 mmol) in methanol (3.7 ml), LitHium HyDroxiDe (0.626 g, 14.94 mmol) in water (3.7 ml) and THF(14 ml) were aDDeD and stirreD At RT. After 12H, The pH was aDjusteD To 7-7.5 using 0.5N HCL and The solid precipiTATeC was filtereD, washed with ethyl acetatE and petroleum ether and DrieD under vacuum To Afford The title compounD as an off-wHite solid (0.485 g, 71%) MS (m/z): 472.99 (M+).

Example 84 2-Fluoro-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [393] To Example 83 (0.050 g, 0.116 mmol), Thionyl cHLoriDE (1 ml) was ADDeD and refluxeD For 3H. The excess THionyl cHLoriDe was removed under reduced pressure and the residue was cooled to ODC. Aqueous Ammonia (25% solution, 3 ml) was aDDeD and stirreD For 15 min. The precipitAte formed was wasHeD with sodium BicarBonAte solution and vacuum driEd To afford title compounD as Brown solid (0.025 g, 50%).M.P.: 127-130 C.Ή-NMR (δ ppm, DMSO-D6, 400 MHz ): 8.87 (D, J = 2.5 Hz, IH), 8.67 (D, J = 8.9 Hz, IH), 8.42 (D, J = 7.9 Hz, IH), 8.11 (D, J = 8.9 Hz, IH), 8.09 (s, IH), 7.91 (D, J = 8.8 Hz, IH), 7.79 (D, J = 8.3 Hz, IH), 7.71-7.61 (m, 4H), 7.75 (m, 2H), 2.48 (s, 6H).

Example 85 6-((5-(3-Fluoro-4-(tetrahydro-2H-pyran-4-yloxy)phenyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-3-yl)methyl)quinoline: [394] The TiTle compounD was prepareD By followinG the procedure DescriBeD For example 1 using inTermeDiATe 14 (0.100 g, 0.338 mmol), 2-(3-fluoro-4-(TeTrAHydro-2H-pyrAn- 4-yLoxy)pHenyL)-4,4,5,5-TETrAmeThyL-1,3,2-DioxABorolAne (0.109 g, 0.422 mmol), potassium carBonate (0.156 g, 0.027 mmol), Dioxane (2 ml), water (0.5 ml) and TetrAKis (TripHEnyLphosphinE)pALLADium(O) (0.031 g, 0.067 mmol) in microwave oven (100W, 100oC) For 30min.. Pale Brown solid (0.055 g, 35%). M.P.: 165-167 C. MS (m/z): 455.85 (M+). 148 222999/2

Example 86 6-((5-(3-Fluoro-4-(2-methoxyethoxy)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [395] The title compound was prepared by fellewinG the precedure deseribed for example 1 using intermediate 14 (0.100 g, 0.338 mmel), 2-(3-fluero-4-(2- methexyethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-diexaborolane (0.125 g, 0.422 mmol), potassium carbonate (0.156 g, 0.027 mmel), dioxane (2 ml), water (0.5 ml) and tetrakis(triphenylphesphine)palladium(O) (0.031 g, 0.067 mmol) in microwave even (100W, lOOeC) for 30min.. Pale yellow solid (0.060 g, 41%). M.P.: 122-124C. MS (m/z): 430.02 (M++1).

Example 87 2-Fluoro-N-propyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [396] The title compound was prepared by fellewinG the precedure deseribed for example 43 using propylamine (0.015 g, 0.250 mmel) instead of ethylamine hydroehloride. Pale yellow solid (0.070 g, 63%). M.P.: 157-159DC. MS (m/z): 440.87 (M+).

Example 88 6-((5-(4-(Cyclopropylcarbamoyl)-3-fluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide: [397] To a solution of example 46 (0.080 g, 0.182 mmel) in diehleremethane (1 ml), m-ehloreperbenzoie acid (0.044 g, 0.255 mmel) was added and stirred at RT for 12h. The reaetion mixture was quenehed with sedium sulphite solutien, washed with saturated petassium Carbonate solution and eoneentrated. The crude product was ehrematographed using methanol: diehleremethane to afford the title compeund as a pale yellow solid (0.025 g, 30%). M.P.: 89-92□ C. Ή-NMR (δ ppm, DMSO-de, 400 MHz ): 8.88 (DD, J=4.1,1.6 Hz, IH), 8.75 (d, J = 9.0 Hz, IH), 8.51 (m, 2H), 8.28 (t, J = 8.1 Hz, IH), 7.98-7.86 (m, 5H), 7.71 (d, J = 8.5 Hz, IH), 7.32 (dd, J = 8.5,6.1 Hz, IH), 6.89 (d, J = 11.8 Hz, IH), 6.15 (s, 2H), 2.99 (m, IH), 0.94 (m, 2H), 0.69 (m, 2H).

Example 89 N-Cyclopropyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride [398] The example 46 (0.045g. 0.102 mmel) was dissolved in THF (1 ml), ether saturated with HCI (1 ml) was added at ODC and stirred for 15 min. The preeipitate formed was washed with ether and dried under vacuum to afford the title Compound as an off-white solid (0.046 g, 95%). M.P.: 105-107DC. MS (m/z): 439.12 (M++1-HCl). 149 2229772

Example 90 N-(Cyclopropylmethyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide: [399] The title compound was prEpared by following The procedure described For example 43 using cyclopropylmethylAmine (0.018 g, 0.250 mmol) insteAd of ethylAmine hydrochloride. Off-white solid (0.085 g, 75%). M.P.: 120-122DC. MS (m/z): 452.91 (M+).

Example 91 N-Butyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [400] The title compound was prepared by following The procedure described For example 43 using u-butylAminE (0.019 g, 0.250 mmol) insteAd of EthylAminE hydrochloridE. Off-white solid (0.064 g, 56%). M.P.: 100-102 C. MS (m/z): 455.08 (M+).

Example 92 2-Fluoro-N-(furan-2-ylmethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide: [401] The title compound was prepared by following The procedure described For example 43 using FurFurylAmine (0.024 g, 0.250 mmol) insteAd of ethylAmine hydrochloride. Brown solid (0.060 g, 50%). M.P.: 144-147DC. MS (m/z): 479.02 (M+).

Example 93 2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2,2,2- trifluoroethyl)benzamide: [402] The title compound was prepared by following The procedure described For example 43 using 2,2,2,-TrifluoroeThylAmine (0.024 g, 0.250 mmol) insteAd of ethylAmine hydrochloride. Pale yellow solid (0.060 g, 50%). M.P.: 194-196DC. MS (m/z): 481.12 (M+).

Example 94 2-Fluoro-N-(2-methoxyethyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide: [403] The title compound was prEpared by following The procedure described For example 43 using 2-meThoxyeThylAmine (0.019 g, 0.250 mmol) insteAd of ethylAmine hydrochloride. PaIe green solid (0.060 g, 52%). M.P.: 162-164DC. MS (m/z): 456.83 (M+).

Example 95 N-Isopropyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzenesulfonamide: [404] The Title compound was prepAred by Following the procedure described for example 1 using intermediAte 14 (0.102 g, 0.338 mmol), 4-(N- isopropylsulFamoyl)phEnylboronic acid (0.102 g, 0.422 mmol), potassium carbonaTE (0.156 g, 150 22297712 0.027 mmol), dioxane (2 ml), water (0.5 ml) And TETrAKis(tripHENYlpHospHiNE)pA11AdiuM(0) (0.031 g, 0.067 mmol) in microwAve oven (100W, Tl00OC) for 30 min.. Green solid (0.050 g, 30%). M.P.: 154-156DC. MS (m/z): 458.79 (M+).

Example 96 N,N-Dimethyl-3-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)aniline: [405] THe Title compound was prepared By following THe procedure descriBed For example 1 using interMediATe 14 (0.102 g, 0.338 mmol), 3-(diMetHy1AMiNo) pHENylBoronic Acid (0.072 g, 0.422 mmol), potassium cArBonATe (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) And TETrAKis(TripHENYlpHospHiNE)pA11AdiuM(0) (0.031 g, 0.067 mmol) in MicrowAve oven (100W, 100OC) for 30 Min. Green solid (0.040 g, 31%). M.P.: 124-126 C. MS (m/z): 380.88 (M+).

Example 97 2-Fluoro-N-isobutyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [406] THe Title compound was prepared By following THe procedure descriBed For example 43 using isoButylAmine (0.018 g, 0.250 mmol) insteAd of eTHylAMine HydrocHloride. Off-wHite solid (0.050 g, 44%). M.P.: 158-160DC. MS (m/z): 455.01 (M++1).

Example 98 N-Cyclopentyl-2-fluoro-4-(3-(qumolm-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridm-5- yl)benzamide: [407] THe title compound was prepAred By Following THe procedure descriBed for example 43 using cyclopeNTylAMiNE (0.021 g, 0.250 mmol) insteAd of EtHylAMine HydrocHloride. PAle green solid (0.040 g, 34%). M.P.: 166-168DC. MS (m/z): 467.12 (M++1).

Example 99 2-Fluoro-N-isopropyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [408] THe title compound was prepAred By Following THe procedure descriBed for example 43 using IsopropylAMine (0.029 g, 0.500 mmol) insteAd of eTHylAMine HydrocHloride. Off-wHite solid (0.060 g, 54%). M.P.: 177-179QC. MS (m/z): 440.87 (M+).

Example 100

Methyl 2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate: [409] THe Title compound was prepared By following tHe procedure descriBed For example 1 using iNtermediATe 14 (1.00 g 3.07 mmol), 3-cH1oro-4-

MetHoxycaRBoNylpHeNylBoroNic Acid (0.825 g, 3.84 mmoI), potassium Acetate (0.976 g, 9.945 151 222977/2 mmol), dioxane (20 ml) and Tetrakis(tripheNy1phosphiNe)pa11adium(0) (0.284 g, 0.246 mmol).

Reddish brown solid (1.00 g, 71%). Ή-NMR (δ ppm, DMSO-De, 400 MHz ): 8.92 (dd, J= 4.2,1.6 Hz, IH), 8.48 (d, J = 8.6 Hz, IH), 8.24 (d, J = 1.3 Hz, IH), 8.17 (d, J = 8.3 Hz, IH), 8.10 (d, J = 11.8 Hz, IH), 8.04 (m, 3H), 7.87 (m, 2H), 7.43 (q, J = 4.2 Hz, IH), 6.15 (s, 2H), 3.98 (s, 3H).

Example 101 2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid: [410] To a solution of Example 100 (1.00 g, 2.18 Mmol) in meThanol (5 ml), liThium hydroxide (0.856 g, 20.40 mmol) in water (5 ml) and THF (19 ml) were added and sTirred aT RT. After 12h, pH was adjusted To 7-7.5 using 0.5N HCI and the solid preeipiTated was Filtered, washed with ethyl aeeTate and petroleum ether and dried under vacuum to afford The title compound as an off-whiTe solid (0.900 g, 93%).

Example 102 2-Chloro-N-propyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [411] The TiTle compound was prepared by following the procedure deseribed For example 43 by replacing The example 13 with example 101 (0.100 g, 0.240 mmol) and using propylamine (0.028 g, 0.480 Mmol) instead of ethylamine hydroehloride. Brown solid (0.043 g, 39%). M.P.: 128-1307C. MS (m/z): 456.83 (M++1).

Example 103 2-Fluoro-N-methyl-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin- 5-yl)benzamide: [412] To Example 83 (0.100 g, 0.234 mmol), thionyl chloride (3 ml) was added and refluxed For 3h. The excess thionyl chloride was removed under reduced pressure and the residue was cooled to ODC. Methylamine in ethanol (50% solution, 5 ml) was added and sTirred For 15 min. The precipitate formed was filTered, washed with sodium bicArbonate solution, dried over sodium sulphate and concenTraTed to afford TiTle compound as a yellow solid (0.028 g, 27%). M.P.: 171-173QC. MS (m/z): 440.94 (M+).

Example 104 N-Cyclobutyl-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [413] The TiTle compound was prepared by following the procedure deseribed For example 43 by using eyclobutylamine (0.035 g, 0.500 mmol) instead of ethylamine hydroehloride. Off-white solid (0.050 g, 44%). M.P.: 171-174DC. MS (m/z): 452.91 (M+). 152 222977/2

Example 105 2-Fluoro-N-propyl-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin- 5-yl)benzamide: [414] The Title compound was prepared By FoILowIng the procedure descriBed for exAMple 43 By replAcing the example 13 with example 83 (0.100 g, 0.234 mmoI) and using propylAMine (0.027 g, 0.468 mmoL) insteaD of eThylAMinE hyDrochloride. Pale green solid (0.050 g, 47%). M.P.: 162-164DC. MS (m/z): 468.94 (M+).

Example 106 N-Cyclopropyl-2-fluoro-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide [415] The Title compound was prepared By followinG the procedure descriBed for exAMple 43 By replAcing the example 13 with example 83 (0.080 g, 0.187 mmoI) and using cyclopropylAMiNe (0.021 g, 0.374 mmoI) InstEAd of ethylAMine HyDrochloriDe. Pale green solid (0.015 g, 17%). M.P.: 156-159DC. MS (m/z): 466.98 (M+).

Example 107 N-Ethyl-2-fluoro-4-(3-(2-(quinolin-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [416] The Title compound was prepared By followinG the procedure descriBed for Example 43 By replAcing The example 13 with example 83 (0.080 g, 0.187 mmoI) and EthylAMine hydrochloride (0.015 g, 0.187 mmoL). PaIe green solid (0.015 g, 17%). M.P.: 132135 DC. MS (m/z): 454.94 (M+).

Example 108 2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [417] To Example 101 (0.100 g, 0.240 mmol), Thionyl chloride (3 ml) was added and teFIuxeD For 3h. The excess Thionyl chloride was removed under reduced pressure and the residue was cooled to ODC. Aqueous 25% ammonia (4 ml) was added and stirred for 15 min. The precipitAte formed was washed with sodium BIcatBonaTe solution and vacuum Dried To Afford Title compound as a Brown solid (0.060 g, 60%). M.P.: 212-215 DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.88 (dd, J = 4.1,2.6 Hz, 1H), 8.70 (d, J = 8.7 Hz, 1H), 8.37 (D, J = 8.3 Hz, 1H), 8.31 (s, 1H), 8.24 (d, J = 8.1 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.04 (m, 3H), 7.83 (dd, J = 8.7, 1.6 Hz, 1H), 7.69 (s, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.53 (dd, J = 8.3,4.2 Hz, 1H), 6.23 (s, 2H). MS (m/z): 415.11 (M+). 153 222977/2

Example 109 2-Chloro-N-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [418] To Example 101 (0.100 g, 0.240 mmol), thioNyl chloride (3 ml) was Added ANd refluxed for 3h. The excess ThioNyl chloride was removed UNder reduced pressure ANd the residue was cooled to ODC. Methylamine in ethanol (50% solution, 4 ml) was added and stirred for 15 miN. The precipiTATe formed was filtered, washed with sodium bicarboNATe solutioN ANd diethyl ether ANd vacuum dried To Afford title compouNd As pAle browN solid (0.060 g, 58%). M.P.: 227-230DC. MS (m/z): 429.04 (M++1).

Example 110 2-Fluoro-N-methoxy-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride: [419] The example 62 (0.040g. 0.093 mmol) was dissolved In THF (1 ml), ether saturated with HCI (1 ml) was added at ODC ANd stirred for 15 miN. THe precipitAte formed was washed with ether ANd dried UNder vacuum to Afford the Title compouNd As an off-white solid (0.030 g, 69%). M.P.: 145-147DC. MS (m/z): 429.46 (M++1-HC1).

Example 111 2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N- (thiazol-2-yl)benzamide: [420] The title compouNd was prepared by followiNg The procedure described for example 43 by usiNg 2-AmlNoThIAzole (0.050 g, 0.500 mmol) iNSteAd of eTHylAmiNe HyDrochloride. PAle browN solid (0.016 g, 13%). M.P.: 204-206 C. MS (m/z): 481.89 (M+).

Example 112 N-(3-Aminopropyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide: [421] To A solutioN of example 13 (0.150 g, 0.375 mmol) in DMF (1 ml) N-eThyldllsopropylAmme (0.048 g, 0.375 mmol) ANd HATU (0.143 g, 0.375 mmol) were Added ANd stirred for 5 miN. N-boc-1,3-dIAmiNopropANe (0.130 g, 0.751 mmol) was Added At RT ANd The reActioN mixture was stirred for 12H. To the reActioN mixture water was Added ANd extracted with ethyl AcetATe, dried over sodium sulphate ANd coNceNtrAted UNder reduced pressure. The crude product was purified by columN chromAtogrAphy with methANol: dichloromethANe To Afford V-boc-protected Amide (0.200 g). The Amide was dissolved In dichlomethANe (1 ml) ANd trIfluoroAceTic Acid (0.5 ml) was Added ANd stirred AT RT for lh. 154 222977/2

The Reaction mixture was quenched with sodium BicarBonatE solution, extracted with

DiclorometHAne, DrieD over sodium sulphate and concentrAteC To alforD the TiTle compounD as a pale Brown solid (0.160 g, 93%). M.P.: 292-294DC. MS (m/z): 456.270 (M++1).

Example 113 2-Chloro-N-cyclopropyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [422] The TiTle compounD was prEpared By following The procedure DescriBeD For example 43 By replAcinG The example 13 with example 101 (0.100 g, 0.240 mmol) anD using cyclopropylAminE (0.028 g, 0.480 mmol) insteaD of EThylAminE hydrocHloridE. Off-wHiTe solid (0.047 g, 43%). M.P.: 197-199DC. MS (m/z): 455.08 (M++1).

Example 114 2-Fluoro-N-(3-oxo-3-(pyrrolidin-1-yl)propyl)-4-(3-(quinolin-6-ylmethyl)-3H- [1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [423] The TiTle compounD was prepared By followinG the procedure DescriBeD For example 43 using intermEDiAte 26 (0.080 g, 0.312 mmol) insTEAC of EThylAminE HyDrocHloriDe. Off-wHiTe solid (0.075 g, 57%). M.P.: 151-153DC. MS (m/z): 524.24 (M+ +1).

Example 115 2-Fluoro-N-hydroxy-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide: [424] The Title compound was prEpared By following The procedure DescriBeC For example 43 By using HyCroxylAmine HyCrocHloriCe (0.035 g, 0.500 mmol) insteaC of ethylAminE hyDrochloride. OFf-wHite solid (0.010 g, 9%). M.P.: 180-182 C. MS (m/z): 415.31 (M++1).

Example 116 N-Isopropyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [425] THe title compounD was prepareD By Following THe procedure DescriBeD for example 43 By using example 8 (0.100 g, 0.262 mmol) and isopropylAmine (0.031 g, 0.524 mmol) insteaD of etHylAmine HyCrocHloriCe. OfF-wHiTe solid (0.080 g, 72%). M.P.: 181-183DC. MS (m/z): 423.37 (M++1).

Example 117 2-Fluoro-N-(3-oxo-3-(piperidin-1-yl)propyl)-4-(3-(quinolin-6-ylmethyl)-3H- [1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [426] THe title compound was prepareD By Following The proceCure DescriBeC for example 43 using intermECiAte 27 (0.135 g, 0.500 mmol) insTEAC of EthylAminE HyCrocHloriCe. Off-wHiTe solid (0.025 g, 19%). M.P.: 109-111 DC. MS (m/z): 538.03 (M+). 155 222977/2

Example 118 1-Ethyl-3-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)phenyl)urea [427] The Title compound was prepared By following the procedure deseriBed For example 1 using intermediAte 14 (0.102 g, 0.338 mmol), 4-(3-eTHYLureido)phenyLBoronic acid (0.123 g, 0.422 mmol), potassium carBonate (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) and TetrAKis(triphenYLphosphine)pAllAdium(0) (0.031 g, 0.067 mmol) in microwAve oven (100W, 100cC) for 30 min. Brown solid (0.060 g, 42%). M.P.: 193-196QC. MS (m/z): 424.28 (M++1).

Example 119 2-Chloro-N-ethyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [428] The title Compound was prepared By Following The proeedure descriBed for example 43 By replACing the example 13 with example 101 (0.100 g, 0.240 mmol) and ethylAmine hydrochloride. Off-white solid (0.050 g, 47%). M.P.: 187-190DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.88 (dd, J = 4.1,1.4 Hz, IH), 8.70 (d, J = 8.7 Hz, IH), 8.51 (d, J = 5.4 Hz, IH), 8.37 (d, J = 8.3 Hz, IH), 8.31 (s, IH), 8.25 (d, J = 8.0 Hz, IH), 8.21 (d, J = 8.0 Hz, IH), 8.04 (s, IH), 8.01 (d, J = 8.7 Hz, IH), 7.82 (d, J = 8.7 Hz, IH), 7.58 (d, J = 8.0 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.23 (s, 2H), 3.30 (m, 2H), 1.14 (t, J = 7.2 Hz, 3H). MS (m/z): 443.04 (M+).

Example 120 2-Fluoro-N-(3-morpholino-3-oxopropyl)-4-(3-(quinolin-6-ylmethyl)-3H- [1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [429] The title Compound was prepared By Following The proeedure descriBed for example 43 using intermediAte 28 (0.136 g, 0.500 mmol) insTeAd of ethylAmine hydroehloride. Pale yellow solid (0.025 g, 19%). M.P.: 212-215DC. MS (m/z): 540.13 (M++1).

Example 121 N-(3-(dimethylamino)propyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide dihydrochloride [430] Ether saturated with HCI (1 ml) was added at 0QC to a solution of example 72 (0.040g. 0.082 mmol) in THF (1 ml), and stirred for 15 min. The precipitATe Formed was washed with ether and dried under vacuum to afford The title Compound as an off-whiTe solid (0.040 g, 88%). M.P.: 137-140DC. MS (m/z): 483.54 (M+-2HCL). 156 222977/2

Example 122 2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(1H-1,2,4- triazol-3-yl)benzamide [431] THe title compounD was prepareD by following the proceDure DeseribeD For example 43 by replacing example 13 with example 101 (0.100 g, 0.240 mmol) anD 3-amino- 1,2,4-triazolE (0.040 g, 0.480 mmol) insteaD of Ethylamine hyDrochloriDE. Pale green soliD (0.015 g, 13%). M.P.: 286-288CC. Ή-NMR (δ ppm, DMSO-rf,.400 MHz): 8.88 (D, J = 3.7

Hz, IH), 8.74 (D, J = 8.7 Hz, IH), 8.40-8.32 (m, 3H), 8.26 (D, J = 8.7 Hz, IH), 8.05 (s, IH), 8.02 (D, J = 8.7 Hz, IH), 7.87-7.82 (m, 4H), 7.54 (s, 1H),7.53 (DD, J = 8.4,4.2 Hz, IH), 6.24 (s, 2H). MS (m/z): 482.03 (M+).

Example 123 2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride [432] Example 108 (0.150g. 0.360 mmoI) was DissolveD in THF (1 m1), ether saturated with HCI (1 ml) was added at 01 IC and stirred for 15 min. The precipitate formed was washeD with ether anD DrieD unDer vacuum to afforD the title compounD as an off-white soliD (0.060 g, 46%). M.P.: 273-275 DC.

Example 124 2-Fluoro-N-(3-(piperidin-1-yl)propyl)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5- b]pyridin-5-yl)benzamide [433] THe title compounD was prepareD by following the proceDure DeseribeD For example 43 using 3-(piperiDin-1-y1)propan-1-aminE (0.086 g, 0.500 mmol) insteaD of etHylaminE hyDrochloriDE. Off-whitE soliD (0.040 g, 30%). M.P.: 135-137 C. MS (m/z): 524.52 (M++1).

Example 125 N-(3-Aminopropyl)-2-fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide dihydrochloride: [434] Example 112 (0.130g. 0.287 mmoI) was DissolveD in THF (2 m1), ether saturateD with HCI (1 m1) was added at 0DC and stirred for 15 min. The precipitate formed was washed with ether anD DrieD unDer vacuum to afforD the title compounD as an off-whitE soliD (0.090 g, 64%). M.P.: 290-293 DC. 157 22297712

Example 126 2-Chloro-N-(3-(dimethylamino)propyl)-4-(3-(quinolin-6-ylmethyl)-3H- [1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide dihydrochloride [435] THe TiTle compound was prepAred By following THe procedure descriBed For example 43 By replAcing example 13 with example 101 (0.150 g, 0.360 mmol) and 3-N,N-dimeThYlAmiNOpropYlAmiNE (0.072 g, 0.720 mmol) insTEAd of EthylAmine hyDrocHloride and Hydrochloride salt FormAtion with ether saturated with HCI (2 ml). Pale yellow solid (0.045 g, 22%). M.P.: 185-187OC. Ή-NMR (δ ppm, DMSO-D6, 400 MHz): 10.11 (Br. s, IH), 9.06 (D, J = 4.4 Hz, IH), 8.73 (d, J = 8.8 Hz, IH), 8.71 (m, 2H), 8.33 (s, IH), 8.27 (m, 2H), 8.17 (m, 2H), 8.00 (d, J = 8.7 Hz, IH), 7.79 (dd, J = 8.1, 4.1 Hz, IH), 7.64 (d, J = 8.0 Hz, IH), 6.28 (s, 2H). 3.34 (q, J = 6.5 Hz, 2H), 3.13 (m, 2H), 2.76 (s, 3H), 2.75 (s, 3H), 1.93 (m, 2H).

Example 127 2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(1H-1,2,4-triazol-3-yl)benzamide hydrochloride [436] The example 52 (0.026g. 0.055 mmol) was dissolved in THF (1 ml), ether saturated with HCI (0.5 ml) was added at OOC and stirred for 15 min. The precipitate formed was washed with ether and dried under vacuum To afford The title compound as an off-wHiTE solid (0.024 g, 87%). M.P.: 274-276OC. Ή-NMR (δ ppm, DMSO-de, 400 MHz): Οδ 11.74(br s, IH), 9.06 (d, J = 4.1 Hz, IH), 8.79 (m,2H), 8.79 (m,2H), 8.35-8.12 (m,6H), 8.02 (m,2H), 7.87 (m,1H), 7.78 (dd, J = 8.0,4.7 Hz,1H), 6.30 (s,2H).

Example 128

Methyl 2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzoate [437] THe TiTle compound was prepAred By following THe procedure DescriBeD For example 1 using iNTermediATe 14 (1.15 g, 3.91 mmol), 3,5-diFluoro-4-meTHoxYCArBoNYl pHeNylBoronic acid (prepared According To Krzysztof Durka et. a1 in Eur. J. Org. CHem. 2009, 4325-4332, 1.10 g, 5.09 mmol), potassium aceTaTe (1.276 g, 13.03 mmol), dioxane (20) and TeTraKis(TripheNYlphospHiNE)pAllAdium(0) (0.361 g, 0.31346 mmol). Brown solid (0.620 g, 37%). Ή-NMR (δ ppm, DMSO-de,400MHz):08.91 (d, J=2.9 Hz, IH), 8.49 (d, J = 8.6 Hz, IH), 8.17 (d, J = 8.2 Hz, IH), 8.10 (d, J = 8.7 Hz, IH), 7.97 (s,1H), 7.86 (dd, J = 8.8,1.4 Hz, IH), 7.81 (d, J = 8.6 Hz, IH), 7.74 (d, J = 9.1 Hz, 2H), 7.43 (dd, J = 8.4,4.2 Hz, IH), 6.15 (s, 2H), 3.99 (s, 3H). 158 2229TT/2

Example 129 2,6-Difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid: [438] To a solution of Example 128 (0.70 g, 1.62 mmol) in methanol (3.8 ml), lithium hydroxide (0.635 g, 15.13 mmol) in water (3.8 ml) and THF (14.3 ml) were added and stirred at RT. After 12H, pH was adjusted To ca . 7 using 0.5N HCL and The solid precipitated was filtered, washed with ethyl acetate and petroleum ether and dried under vacuum to afford THe title compound as pale Brown solid (0.50 g, 74%).

Example 130 2,6-Difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [439] THe title compound was prepared By following THe procedure descriBed For example 102 using Example 129 (0.500 g, 1.19 mmol), tHionyl cHloride (10 ml) and aQueous 25% ammonia (7 ml). OFF-white solid (0.400 g, 81%).M.P.: 272-275 DC 'H-NMR (δ ppm, DMSO-de, 400 MHz): 8.88 (d, J = 3.9 Hz, IH), 8.74 (d, J = 8.8 Hz, IH), 8.37 (d, J = 7.8 Hz, IH), 8.25 (d, J = 8.9 Hz, IH), 8.20 (s,1H), 8.07 (m,3H), 8.01 (d, J = 8.5 Hz, IH), 7.93 (s,1H), 7.83 (d, J = 6.8 Hz, IH), 7.53 (dd, J = 8.6,4.4 Hz, IH), 6.24 (s, 2H).

Example 131

Methyl 2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoate [440] The title compound was prepared By FollowiNg the procedure descriBed for example 1 using intermediate 18 (0.345 g, 1.091 mmol), 3-ch1oro-4- meThoxycarBONylpheNylBoroNic acid (0.295 g, 1.37 mmol), potassium acetate (0.359 g, 3.65 mmol), dioxane (8 ml) and Tetrakis(triphenyLpHosphine)paLLadium(0) (0.101 g, 0.087 mmol). Off-white solid (0.277 g, 56%). 'H-NMR (δ ppm, DMSO-4, 400 MHz): 8.91 (d, J = 3.3 Hz, IH), 8.50 (d, J = 8.6 Hz, IH), 8.23 (s,1H), 8.10 (d, J = 8.2 Hz, IH), 8.03 (d, J = 6.9 Hz, IH), 7.98 (d, J = 8.1 Hz, IH), 7.87 (m,3H), 7.38 (dd, J = 8.3,4.2 Hz, IH), 6.22 (s,2H), 3.97 (s,3H).

Example 132 2-Chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid: [441] To a solution of Example 131 (0.185 g, 0.412 mmol) in methanol (2 ml), lithium hydroxide (0.161 g, 3.84 mmol) in water (2 ml) , THF (4 ml) were added and stirred at RT. After 12h, pH was adjusted to ca.7 using 0.5N HCI and The solid precipiTaTed was Filtered, washed with ethyl acetate and petroleum ether and dried under vacuum To afford the title compound as a pale Brown solid (0.150 g, 84%). 159 222999/2

Example 133 2-Chloro-N-ethyl-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin- 5-yl)benzamide [442] The title compound was prepared by fellewinG the precedure deseribed for example 43 replaeing the example 13 with example 132 (0.100 g, 0.230 mmel) and ethylamine hydrechleride. Off-white solid (0.020 g, 19%). M.P.: 197-199DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz): 8.92 (dd, J = 4.2,2.8 Hz, IH), 8.70 (d, J = 8.7 Hz,1H), 8.51 (t, J = 5.4 Hz,1H), 8.44 (d, J = 8.0 Hz,1H), 8.28 (d, J = 1.4 Hz, IH), 8.22 (m, 3H), 7.83 (d, J = 11.4 Hz, IH), 7.56 (m, 2H), 6.26 (s, 2H), 3.28 (m, 2H), 1.14 (t, J = 7.2 Hz, 3H).

Example 134 2-Chloro-4-(3-((7-fluoroquinolm-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [443] The title Compound was prepared by following the proeedure described fer example 102 using Example 132 (0.050 g, 0.115 mmel), thionyl Chloride (2 ml) and aqueous 25% ammonia (2 ml). Brown solid (0.015 g, 30%). M.P.: 202-204DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz): 8.92 (d, J = 4.1 Hz, IH), 8.70 (d, J = 8.6 Hz, IH), 8.44 (d, J = 8.0 Hz, IH), 8.27 (s, IH), 8.22 (m, 3H), 7.96 (s, IH), 7.83 (d, J = 11.5 Hz, IH), 7.68 (s, IH), 7.60 (d, J = 8.0 Hz, IH), 7.55 (dd, J = 8.4,4.3 Hz, IH), 6.26 (s, 2H).

Example 135

Methyl 2-fluoro-4-(3-((7-fluoroquinolm-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridm-5-yl)benzoate [444] The title Compound was prepared by following the proeedure described fer example 1 using intermediate 18 (0.350 g, 1.15 mmel), 3-fluero-4-methoxycarbonyl phenylberonie acid (0.276 g, 1.39 mmol), potassium acetate (0.365 g, 3.71 mmel), dioxane (8 ml) and tetraKis(triphenylphesphine)palladium(O) (0.103 g, 0.089 mmol). Pale brown solid (0.350 g, 70%). M.P.: 213-215 DC.

Example 136 2-Fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid [445] To a solution of Example 135 (0.240 g, 0.605 mmol) in methanel (3 ml), lithium hydroxide (0.237 g, 5.64 mmol) in water (3 ml) ,THF (6 ml) were added and stirred at RT. After 12h, pH was adjusted to ea 7 using 0.5N HCl and the solid precipitated was 160 222977/2

Filtered, washed with ethyl aeeTate and petroleum ether and Dried under vacuum to afford the title compound as pale brown solid (0.110 g, 44%).

Example 137 2-Fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide [446] The title compound was prepared by Following The proeedure described for example 102 using Example 136 (0.080 g, 0.191 mmol), Thionyl chloride (2 ml) and aqueous 25% ammonia (2 ml). Pale brown solid (0.060 g, 75%). M.P.: 206-208 DC. Ή-NMR (δ ppm, DMSO-de, 400 MHz): 8.92 (d, J = 3.2 Hz, IH), 8.71 (d, J = 8.7 Hz, IH), 8.44 (d, J = 8.4 Hz, IH), 8.23 (T, J = 9.2 Hz, 2H), 8.19 (m, 2H), 7.83-7.73 (m, 4H), 7.54 (dd, J = 8.2,4.0 Hz, IH), 6.26 (s, 2H).

Example 138 3-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [447] The TiTle compound was prepAred by following the procedure deseribed For example 102 using Example 54 (0.100 g, 0.262 mmol), thionyl chloride (4 ml) and aqueous 25% ammonia (4 ml). Brown solid (0.040 g, 40%). M.P.: 263-265 DC.

Example 139 2,6-Difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride [448] Example 130 (0.040g. 0.096 mmol) was dissolved in THF (1 ml), ether saturated with HCI (1 ml) was added aiO'C and stirred for 15 min. The precipitate formed was washed with ether and dried under vacuum To afford the Title compound as a brown solid (0.027 g, 43%). M.P.: 272-275DC. Ή-NMR (δ ppm, DMSO-D, 400 MHz): 79.02(d, J = 3.2 Hz, IH), 8.74 (d, J = 8.8 Hz, IH), 8.63 (d, J = 7.6 Hz, IH), 8.26 (d, J = 8.7 Hz, IH), 8.20 (d, J = 13.6 Hz, 2H), 8.11 (m, 3H), 7.96 (m, 2H), 7.72 (dd, J = 8.3,4.6 Hz, IH), 6.28 (s, 2H).

Example 140 2-Chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride [449] The example 134 (0.035g. 0.080 mmol) was dissolved in THF (2 ml), ether saturated with HCI (2 ml) was added at 07C and stirred for 15 min. The precipitate formed 161 2229772 was washed with Ether and dried under vacuum to afford The title compound as a pale yellow solid (0.022 g, 59%). M.P.: 269-272 □ C.

Example 141 2-Fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride

Example 137 (0.080g. 0.192 mmol) was dissolved in THF (2 ml), Ether SAturated with HCl (2 ml) was added at 0 □ C and stirred for 15 min. The precipitate formed was filtered, washed with ether and dried under vacuum To afford The Title compound as a pale-brown solid (0.070 g, 80%). M.P.: 258-260 DC.

Example 142 2-Methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide: [450] The title compound was prepared by following the procedure dEScribEd for example 1 using intermEdiAte 14 (0.100 g, 0.338 mmol ), intermEdiAtE 21 (0.109 g, 0.422 mmol), potassium carbonAte (0.155 g, 1.12 mmol), DMF (8 ml), water (0.5 ml) and TetrAkis (triphEnyl- phosphine) pAllAdium(O) (0.031 g, 0.027 mmol). Pale green solid (0.045 g, 34%). M.P.: 235-237 □ C. Ή-NMR (δ ppm, DMSO-D(,. 400 MHz): 8.88 (D, J = 2.9 Hz, 1H), 8.66 (D, J = 8.7 Hz, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.15 (d, J = 8.7 Hz, 1H), 8.07-8.00 (m, 4H), 7.83 (m, 2H), 7.54 (m, 2H), 7.45 (s, 1H), 6.21 (s, 2H), 2.46 (s, 3H).

Example 143 6-((5-(1H-Pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [451] The Title compound was obtAined as a yellow solid (0.065 g, 29%) by

Following the procedure dEScribEd For example 1 using intermEdiAtE 14 (0.20 g, 0.676 mmol), terT-butyl 4-(4,4,5,5-tETrAmEthyl-1,3,2-dioxAborolan-2-yl)-1 H-pyrazole-1 - CArboxylAtE(0.254 g, 0.856 mmol), potassium carbonate (0.310 g, 2.25 mmol), Dioxane (4 ml), water (0.8 ml) and tetrAKis (Triphenylphosphine)pAllAdium(O) (0.062 g, 0.054 mmol). Ή-NMR (δ ppm, DMSO-de, 400 MHz): 13.25 (s, 1H), 8.88 (dd, J=4.1, 1.4 Hz, 1H), 8.55 (s, 1H), 8.50 (d, J = 8.7 Hz, 1H), 8.38 (d, J = 8.1, Hz, 1H), 8.23 (s, 1H), 8.01 (d, J = 9.0, Hz, 2H), 7.85 (t, J = 8.6, 2H), 7.53 (dd, J = 8.3,4.2 Hz, 1H), 6.11 (s, 2H). MS (m/z): 328.12(M++1). 162 222977/2

Example 144 6-((5-(1-Methyl-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [452] Sodium hydride (0.014 g, 0.596 mmol) was Added to A soIuTIon of example 143 (0.130 g, 0.397 mmol) in DMF (3 ml) at ODC ANd stirred for 30 miN. To This solutioN methyl Iodide (0.113 g, 0.794 mmol) was Added ANd the reActioN mixture was warmed to RT. After 3h, the reActioN mixture was poured InTo ice water ANd extracted with ethyl Acetate, washed with brme, dried over sodium sulphate ANd coNceNtrATed. The crude product was purified by columN chromATogrAphy with methANol: dichloromethANe To Afford The title compouNd As an off-white solid (0.080 g, 59%). Ή-NMR (δ ppm, DMSO-fts, 400 MHz): 8.88 (d, J = 2.8 Hz, IH), 8.51 (s, IH), 8.49 (s,1H), 8.38 (d, J = 7.9 Hz, IH), 8.18 (s, IH), 8.01 (d, J = 8.8 Hz, 2H), 7.82 (t, J = 9.6 Hz, 2H), 7.53 (dd, J = 8.3,4.1 Hz, IH), 6.10 (s, 2H), 3.91 (s, 3H). MS (m/z):: 341.98(M++1).

Example 145 6-((5-(1-(2-(Tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl)-3H- [1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [453] To A solutioN of example 143 (0.250 g, 0.763 mmol) In DMF (10 ml), cesium cArboNATe (0.496 g, 1.52 mmol) was Added ANd stirred for 15 miN. 2-(2-bromoethoxY)TeTrAhYdro-2H-pYrAN (0.638 g, 3.04 mmol) ANd TeTrAbutYlAmmoNlum Iodide (0.20 g, 2.16 mmol) were Added ANd heated To 80-85 DC for 12h. The reaction was quenched by The AdditloN of water, extracted with ethyl AcetATe, washed with brme, dried over sodium sulphate ANd coNceNtrAted. THe crude product was purified by columN chromATogrAphy with methANol : dichloromethANe To Afford The title compouNd As A yellow solid (0.195 g, 56%). 1H-NMR (δ ppm, DMSO-D6, 400 MHz): 8.88 (dd, J=4.1, 1.6 Hz, IH), 8.52 (s, IH), 8.51 (D, J = 8.8 Hz, IH), 8.37 (dd, J = 8.4,1.3 Hz, IH), 8.22 (s, IH), 8.01 (d, J = 9.0 Hz, 2H), 7.82 (dd, J = 8.7,2.7 Hz, 2H), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.11 (s, 2H), 4.54 (t, J = 2.9 Hz, IH), 4.37 (m, 2H), 3.99 (m, IH), 3.73 (m, IH), 3.55 (m, IH), 1.63-1.30 (m, 6H).

Example 146 2-(4-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1- yl)ethanol [454] To A soIuTIon of example 145 (0.190 g, 0.417 mmol) In methANol (2 ml) ANd water (2 ml), camphor sulpHoNic Acid (0.968 g, 4.17 Mmol) was Added aNd stirred for lh. The reActioN was poured iNto Ice water ANd The pH was Adjusted to ca 8 with sodium bicArboNAte 163 22297712 solution, extrActed witH etHyl Acetate, wAsHed witH Brine, dried over sodium sulpHATe And concentrATed. THe crude product was purified By rEcrYsTAllisATion from isopropAnol To Afford tHe Title compound As A ligHt yellow solid (0.059 g, 38%). M.P.: 179-178DC. 1H-NMR (δ ppm, DMSO-d6, 400 MHz): 8.88 (dd, J = 4.2, 1.6 Hz, IH), 8.51 (d, J = 8.7 Hz, IH), 8.49 (s, IH), 8.38 (dd, J = 8.3,1.3 Hz, IH), 8.20 (s, IH), 8.01 (d, J = 8.0 Hz, 2H), 7.82 (dd, J = 8.7,1.7 Hz, 2H), 7.53 (dd, J = 8.3,4.1 Hz, IH), 6.11 (s, 2H), 4.96 (T, J = 5.3 Hz, IH), 4.22 (T, J = 5.5 Hz, 2H), 3.79 (dd, J = 10.8,5.4 Hz, 2H). MS (m/z):: 372.08(M++1).

Example 147 6-((5-(1H-Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl)methyl)quinoline [455] THe Title compound was prepAred As A yellow solid (0.110 g, 49%) By Following THe procedure descriBed For example 1 using InTerMediATe 29 (0.20 g, 0.678 mmoI), tert-Butyl 4-(4,4,5,5-TetraMEtHy1- 1,3,2-dIoxABoRo1An-2-y1)-1H-pyrAzo1e- l-carBoxylATe (0.255 g, 0.868 mmol), potassium cArBonATe (0.310 g, 2.24 mmol), dioxane (4 m1), water (0.8 ml) And TETrAKis(TripHENYlpHospHiNE)pA11AdiuM(0) (0.062 g, 0.054 mmol). M.P.: 214-216DC. 1H-NMR (δ ppm, DMSO-D(1. 400 MHz): 13.02 (s, IH), 8.86 (dd, J=4.2, 1.7 Hz, IH), 8.56 (s, IH), 8.35 (dd, J = 8.2, 1.1 Hz, 2H), 8.10 (s, IH), 8.04-7.98 (μ, 3H), 7.85 (dd, J = 8.8, 1.9 Hz, IH), 7.61 (d, J = 8.3 Hz, IH), 7.52 (dd, J = 8.3,4.2 Hz, IH), 5.69 (s, 2H). MS (m/z): 326.86 (M+).

Example 148 6-((5-(1-Methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-3-yl)methyl)quinoline [456] THe Title compound was prepAred As An off-wHite solid (0.022 g, 27%) By Following THe procedure descriBed For example 144 using example 147 (0.080 g, 0.245 mmol), sodium Hydride (0.014 g, 0.367 mmol), metHyl iodide (0.069 g, 0.49 mmoI) And DMF (2 ml). M.P.: 150-152DC. Ή-NMR (δ ppm, DMSO-de, 400 MHz): 8.86 (s, IH), 8.56 (s,1H), 8.35 (d, J = 8.1 Hz, IH), 8.29 (s, IH), 8.04 (m, 4H), 7.84 (d, J = 8.8 Hz, IH), 7.56 (d, J = 8.3 Hz, IH), 7.52 (dd, J = 7.8, 4.2 Hz, IH), 5.69 (s, 2H), 3.88 (s, 3H). MS (m/z): 341.14 (M++1).

Example 149 6-((5-(1-(2-(Tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl)-3H-imidazo[4,5- b]pyridin-3-yl)methyl)quinoline [457] THe Title compound was prepAred As A yellow solid (0.300 g, 86%) By following tHe procedure descriBed For example 145 using example 147 (0.250 g, 0.766 164 222977/2 MMol),2-(2-BroMoetHoxy)tETrAHydro-2H-pyrAN (0.640 g, 3.06 mmol), cesium carBonate (0.746 g, 2.29 mmol), tEtTAButyiAMMoniuM iodide (0.20 g, 0.54 mmoL) and DMF (10 mi).

Example 150 2-(4-(3-(Quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)-1H-pyrazol-1-yl)ethanol: [458] The title compound was prepared By following The procedure descriBed For example 146 using example 149 (0.200 g, 0.44 mmol), camphor sulphonic acid (1.02g. 4.40 mmol), methanol (2 ml) and water (2 ml). Yellow solid (0.09g, 55%). M.P.: 160-163 C. 1H-NMR (δ ppm, DMSO-D(1. 400 MHz): 8.86 (dd, J=4.0, 1.4 Hz, 1H), 8.55 (s, 1H), 8.35 (D, J= 7.9 Hz, 1H), 8.30 (s,1H), 8.05 (μ, 4H), 7.84 (dd, J = 8.7,1.7 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.52 (dd, J = 8.4,4.2 Hz, 1H), 5.69 (s, 2H), 4.94 (t, J = 5.2 Hz, 1H), 4.19 (T, J = 5.6 Hz, 2H), 3.77 (T, J = 5.4 Hz, 2H). MS (m/z): 370.89 (M+).

Example 151 2-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-ylamino)ethanol [459] To a solution of interMediAte 14 (0.100 g, 0.338 mmol) and 2-AMinoethANol (0.041 g, 0.67 mmol ) in ethanol (2.5 ml), sodium carBonate (0.071 g, 0.676 mmoL ) was added anD HeaTeD To reflux. After 12H, the teacTIon was Quenched By the ADdition of ice water, exTtacTeD with ethyl Acetate, washed with Brine, Dried over sodium sulphate and concenTrAted. The crude product was purified By column chromAtogrAphy with MethAnol: dichioromeThAnE To afford the Title compound as a yellow solid (0.060 g, 55%). M.P.: 184-186 C. Ή-NMR (δ ppm, DMSO-d6, 400 MHz): 8.88 (dd, J = 4.1, 1.6 Hz, 1H), 8.35 (DD, J = 8.3, 0.9 Hz, 1H), 7.99 (D, J = 8.7 Hz, 1H), 7.95 (D, J = 8.9 Hz, 1H), 7.92 (s,1H), 7.76 (DD, J = 8.7, 2.0 Hz, 1H),7.55 (t, J = 4.5 Hz, 1H), 7.53 (dd, J = 8.3,4.2 Hz, 1H), 6.64 (d, J = 9.1 Hz, 1H), 5.82 (s, 2H), 4.73 (T, J = 5.4 Hz, 1H), 3.58 (q, J = 5.9 Hz, 2H), 3.45 (q, J = 5.6 Hz, 2H). MS (m/z): 321.19 (M++1).

Example 152 6-((5-(1H-Imidazol-1-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [460] To a solution of inTErmediATe 14 (0.100 g, 0.338 mmoL ) and ImiDazoIe (0.100 g, 1.46 mmoI) in DMF (3 ml), cesium FluoriDe (0.056 g, 0.368 mmol ) was added anD Heated To 130 DC. After 12h, the reaction was quenched by the addition of ice water, extracted with ethyi acetate, washed with Brine, dried over sodium sulphate and concenTrated. The crude product was purified By column chroMatography with Methanol: dlchLoroMEThane To afford The title compound as light Brown solid (0.023 g, 21%). M.P.: 227-230DC. 1H-NMR (δ ppm, 165 222977/2 DMSO-d6, 400 MHz): 8.88 (dd, J = 4.2, 1.7 Hz, IH), 8.80 (d, J = 8.9 Hz, IH), 8.76 (s, IH), 8.39 (dd, J = 8.4,0.9 Hz, IH), 8.14 (s, IH), 8.06 (d, J = 1.6 Hz, IH), 8.02 (d, J = 8.7 Hz, 1H),7.98 (d, J = 9.0 Hz, IH), 7.84 (dd, J = 8.7,2.0 Hz, IH), 7.53 (dd, J = 8.3,4.2 Hz, IH), 7.18 (s, IH), 6.15 (s, 2H). MS (m/z):: 327.91 (M+).

Example 153 6-((5-(1-Propyl-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [461] To a solution of Example 143 (0.100 g, 0.305 mmol) in DMF (4 ml), Cesium carBonate (0.297 g, 0.913 mmol), tetrABuTylAmmonium iodide (0.078 g, 0.213 mmol) and 1-bromopropane (0.150 g, 1.22 mmol) were added and heated to 65DC. After 12h, the reaction mixture was poured into ice water and extrACTed with ethyl ACeTAte, washed with Brine, dried over sodium sulphate and ConcentrAted. The crude product was purified By Column chromAtogrAphy with methAnol: diehloromeThAne to Afford the Title compound as a greenish-yellow solid (0.045 g, 40%). M.P.: 128-130OC. Ή-NMR (δ ppm, DMSO-d, 400 MHz): 8.88 (dd, J = 4.1,1.6 Hz, IH), 8.53 (s, IH), 8.51 (d, J = 8.8 Hz, IH), 8.38 (dd, J = 8.4, 1.8 Hz, IH), 8.19 (s, IH), 8.01 (d, J = 8.3 Hz, IH), 7.99 (s, IH), 7.82 (m, 2H), 7.53 (q, J = 4.2 Hz, IH), 6.11 (s, 2H), 4.11 (t, J = 6.9 Hz, 2H), 1.85 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H). MS (m/z): 370.33 (M+ + 1).

Example 154

Ethyl 2-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1-yl)acetate [462] To a solution of example 143 (0.250 g, 0.763 mmol) in DMF (3 ml) cooled To ODC, sodium hydride (0.0365 g, 0.916 mmol) was added and stirred for 30 min., ethyl BromoACeTATe (0.153 g, 0.916 mmol) were added and warmed To RT. After 12h, the reACTion mixture was poured into ice water and extrACTed with ethyl acetAte, washed with Brine, dried over sodium sulphate and ConcentrAted. THe crude product was purified By Column chromATogrAphy with methanol: dichloromeThAne To Afford the Title compound as a yellow solid (0.225 g, 80%).

Example 155 2-(4-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1-yl)acetic acid: [463] To a solution of Example 154 (0.085 g, 0.218 mmol) in methAnol (1.4 ml), Lithium hydroxide (0.026 g, 1.09 mmol) in water (0.36 ml) was added and stirred At RT. After 166 222977/2 12H, the pH was aDJusteD to 7-7.5 using 0.5N HCI anD the solid precipitateD was FiltEreD, washeD with ethyl acetate and petroleum ether and DrieD under to afforD the title compound as a yellow solid (0.034 g, 38%). M.P.: &gt;270DC Ή-NMR (δ ppm, DMSO-ds,400 MHz): 8.87 (d, J = 2.7 Hz, IH), 8.47 (d, J = 8.7 Hz, IH), 8.39 (m, 2H), 8.08 (s,1H), 8.00 (s, IH), 7.99 (D, J = 7.1 Hz, IH), 7.82 (t, J = 8.9 Hz, 2H), 7.52 (q, J = 4.1 Hz, IH), 6.10 (s, 2H), 4.48 (s, 2H). MS (m/z): 385.87 (M+).

Example 156 tert-Butyl 4-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate [464] To a solution of example 143 (0.100 g, 0.305 mmol) in DMF (2 m1) was cooled to 0DC, sodium hydride (0.0146 g, 0.366 mmoI) was added and stirreD For 30 min., tert-butyl 4-(methy1su1Fony1oxy)piperiDinE-1-carboxy1ate (0.093 g, 0.336 mmol ) were added and heated to 80lZlC.After 12h, the reaction mixture was poured into ice water and extraeted with Ethyl acetate, washed with brine, DrieD over sodium sulphate and eoneentratEd. THe crude product was purified by column Chromatography with methanol : DiehlorometHane to afford the title Compound as a yellow solid (0.066 g, 42%). 1H-NMR (δ ppm, DMSO-D.6, 400 MHz): □ 8.88 (d, J = 2.7 Hz, IH), 8.60 (s, IH), 8.52 (d, J = 8.7 Hz, IH), 8.30 (d, J = 8.0 Hz, IH), 8.21 (s,1H), 8.01 (s,1H), 8.01 (d, J = 7.5 Hz, IH), 7.82 (d, J = 8.6 Hz, 2H), 7.53 (q, J = 4.1 Hz, IH), 6.11 (s, 2H), 4.46 (m, IH), 4.12 (m, 2H), 2.91 (m, 2H), 2.06 (m, 2H), 1.87 (m, 2H), 1.41 (s, 9H).

Example 157 6-((5-(1-(Piperidin-4-yl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [465] To a solution of example 156 (0.063 g, 0.123 mmol) in dicHloromEthanE (1 ml) was cooled to OdC, TFA (0.356 g, 2.47 mmol) was added and warmed to RT. After 12h, the reaetion Mixture was poured in ice water and pH was adjusted to 10-11 with 10% NaOH solution and extracteD with Ethyl acetate, washed with brine, Dried over soDium sulphate and concentrated to afford the title compound as an off-white solid (0.021 g, 42%). M.P.: 188191 DC. 1H-NMR (δ ppm, DMSO-4,400MHz):L/8.88 (Dd, J=4.2,1.6 Hz, IH), 8.55 (s,1H), 8.51 (d, J = 8.6 Hz, IH), 8.38 (d, J = 7.8 Hz, IH), 8.20 (s,1H), 8.01 (s,1H), 8.01 (m, 2H), 7.82 (m, 2H), 7.53 (q, J = 4.2 Hz, IH), 6.11 (s, 2H), 4.29 (m, IH), 3.07 (m, 2H), 2.63 (m, 2H), 1.99 (m, 2H),1.86 (m, 2H). MS (m/z): 411.28 (M+ +1). 167 2229TT/2

Example 158 (R)-1-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)pyrrolidin-3-ol: [466] THe title compound was prepared By following THe procedure descriBed For example 152 using iNTermediaTe 14 (0.100 g, 0.338 mmol), (R)-3-hydroxypyrroLidiNe (0.044 g, 0.507 mmol), cesium fluoride (0.102 g, 0.676 mmoles) and DMF (3 ml). Brown solid (0.040 g, 34%). M.P.: 167-169 DC. 'H-NMR (δ ppm, DMSO-dg, 400 MHz): 8.88 (dd, J=4.2, 1.7 Hz, IH), 8.36 (dd, J = 8.4,1.0 Hz, IH), 8.11 (d, J = 7.9 Hz, IH), 7.99 (d, J = 8.6 Hz, IH), 7.93 (d, J = 1.5 Hz, IH), 7.77 (dd, J = 8.7,2.0 Hz, IH), 7.53 (q, J = 4.2 Hz, IH), 6. 66 (d, J = 9.2 Hz, IH), 5.86 (s,2H), 5.01 (s,1H), 4.40 (s,1H), 3.60 (m, 4H), 2.04-1.92 (m, 2H). MS (m/z): 346.95 (M+).

Example 159 3-(4-Fluorobenzyl)-5-(1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridine [467] The title compound was prepared By Following the procedure descriBed for example 1 using inteTmediate 15 (0.500 g, 1.90 mmol), Tert-Butyl 4-(4,4,5,5-tetrameTHyL- 1,3,2-dioxaBoroLaN-2-y1)-1H-pyrazo1e-1-carBoxy1aTe (0.716 g, 2.43 mmol), potassium carBonate (0.874 g, 6.33 mmol), dioxane (11 ml), water (2.2 ml) and

TeTrAkis(tripHenyLpHosphine)paLLadium(0) (0.175 g, 0.152 mmol). Yellow solid (0.270 g, 48%). 'H-NMR (δ ppm, DMSO-d,. 400 MHz): 13.26 (s, IH), 8.55 (s, IH), 8.48 (d, J = 8.7

Hz, IH), 8.23 (s, IH), 7.84 (d, J = 8.7 Hz, IH), 7.53 (dd, J = 8.5,6.4 Hz, 2H), 7.18 (t, J = 8.9 Hz, 2H), 5.89 (s, 2H).

Example 160 3-(4-Fluorobenzyl)-5-(1-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl)-3H- [1,2,3]triazolo[4,5-b]pyridine: [468] THe title compound was prepared By following THe procedure descriBed For example 145 using example 159 (0.270 g, 0.917 mmol), 2-(2-Bromoethoxy) TetrAhydro-2H-pyran (0.766 g, 3.66 mmol), cesium carBonate (0.894 g, 2.75 mmol), tetrabutylammonium iodide (0.237 g, 0.624 mmol) and DMF (12 ml). Brown solid (0.150 g, 38%). 'H-NMR (δ ppm, DMSO-d6, 400 MHz): 8.52 (s, IH), 8.49 (d, J = 8.6 Hz, IH), 8.21 (s,1H), 7.80 (d, J = 8.6 Hz, IH), 7.50 (m, 2H), 7.20 (m, 2H), 5.89 (s, 2H), 4.56 (t, J = 3.4 Hz, IH), 4.38 (m, 2H), 3.98 (m, IH), 3.80 (m, IH), 3.57 (m, IH), 3.38 (m, IH), 1.66-1.05 (m, 6H). 168 22297712

Example 161 2-(4-(3-(4-Fluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1-yl)ethanol: [469] The Title compound was prEpared By Following The procedure descriBed For example 145 using example 160 (0.150 g, 0.355 mmol), camphor sulpHonic acid (0.824g. 3.55 mmol) , metHanol (2 ml) and water (2 ml).BBrown solid (0.070 g, 58%). M.P.: 204206 C. 'H-NMR (δ ppm, DMSO-D,, 400 ^^):0 8.49 (s, IH), 8.49(d, J=9.7 Hz, IH), 8.20 (s, IH), 7.80 (d, J = 8.7 Hz, IH), 7.51 (dd, J = 8.7,5.5 Hz, 2H), 7.20 (T, J = 8.9 Hz, 2H), 5.89 (s, 2H), 4.96 (T, J = 5.3 Hz, IH), 4.23 (T, J = 5.5 Hz, 2H), 3.80 (q, J = 5.4 Hz, 2H). MS (m/z): 339.25(M++1).

Example 162 6-(1-(5-(1H-Pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)ethyl)quinoline: [470] The Title compound was prEpared By Following The procedure descriBed For iNTeRMediATe 14 using iNTermediATe 31 (0.290 g, 0.877 mmol), acetic acid (1.8 ml), sodium NitriTe (0.072 g, 1.05 mmol) and water (0.4 ml). Brown solid (0.250 g, 84%). 'H-NMR (δ ppm, DMSO-d6, 400 MHz): 13.25 (s, IH), 8.87 (dd, J = 4.0, 1.4 Hz, IH), 8.48 (d, J = 8.7 Hz, IH), 8.39 (d, J = 7.6 Hz, IH), 8.09 (d, J = 1.5 Hz, IH), 8.00 (d, J = 8.8 Hz, IH), 7.88 (dd, J = 8.8,1.9 Hz, IH), 7.82 (d, J = 8.7 Hz, IH), 7.64-7.46 (m, 3H), 6.60 (q, J = 7.1 Hz, IH), 2.22 (d, J = 7.1 Hz, 3H).

Example 163 6-(1-(5-(1-(2-(Tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl)-3H- [1,2,3]triazolo[4,5-b]pyridin-3-yl)ethyl)quinoline: [471] THe TiTle compound was prepAred By following THe procedure descriBed For example 145 using example 162 (0.190 g, 0.556 mmol), 2-(2-BromoeTHoxY)TeTrAHYdro-2H-pyrAN (0.465 g, 2.22 mmol), cesium carBonATe (0.550 g, 1.69 mmol), TETraBuTylAmmonium iodide (0.143 g, 0.387 mmol) and DMF (7 ml). Yellow solid (0.138 g, 46%). 'H-NMR (δ ppm, DMSO-d6, 400 MHz): 8.87 (dd, J = 4.1, 1.6 Hz, IH), 8.50 (s, IH), 8.49 (d, J = 8.7 Hz, IH), 8.38 (d, J = 8.1 Hz, IH), 8.19 (s, IH), 8.06 (s,1H), 7.99 (d, J = 8.7 Hz, IH), 7.86 (d J = 8.7 Hz, IH), 7.78 (d, J = 8.7 Hz, IH), 7.52 (q, J = 4.2 Hz, IH), 6.59 (q, J = 7.0 Hz, IH), 4.53 (T, J = 3.0 Hz, IH), 4.48 (m, 2H), 3.99 (m, IH), 3.78 (m, IH), 3.56 (m, IH), 2.23 (d, J = 7.2 Hz, 3H), 1.59-1.20 (m, 7H). 169 222999/2

Example 164 2-(4-(3-(1-(Quinolin-6-yl)ethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1- yl)ethanol: [472] The title compound was prepared by fellewinG the precedure deseribed for example 146 using example 163 (0.130 g, 0.276 mmol), camphor sulphonie acid (0.643g. 2.76 mmel), methanol (2 ml) and water (2 ml).Yellow solid (0.030 g, 28%). M.P.: 188-191DC Ή-NMR (δ ppm, DMSO-de,400MHz):08.87(0, J = 2.6 Hz, IH), 8.48 (d, J = 8.7 Hz, IH), 8.47 (s, IH), 8.39 (d, J = 8.1 Hz, IH), 8.18 (s,1H), 8.08 (dd, J = 0.7 Hz, IH), 8.00 (d, J = 8.7 Hz, IH), 7.87 (dd, J = 8.8,1.9 Hz, IH), 7.79 (d, J = 8.7 Hz, IH), 7.52 (q, J = 4.2 Hz, IH), 6.60 (q, J = 6.8 Hz, IH), 4.97 (t, J = 5.4 Hz, IH), 4.21 (t, J = 5.4 Hz, 2H), 3.78 (q, J = 5.4 Hz, 2H), 2.22 (d, J = 7.2 Hz, 3H). MS (m/z): 385.87 (M+).

Example 165 2-(4-(3-(2-Chloro-3,6-difluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol- 1-yl)ethanol: [473] To a solutien of Example 213 (0.160 g, 0.461 mmel) in DMF (7 ml), cesium carbonate (0.449 g, 1.38 mmel) was added and stirred for 15 min. 2-(2- bromoethoxy)tetrahydro-2H-pyran (0.385 g, 1.84 mmol) and tetrabutylammonium iodide (0.137 g, 0.368 mmol ) were added and heated to 80-85 DC for 12h. The reaction was quenehed by the addition of water, extraeted with ethyl aeetate, washed with brine, dried over sodium sulphate and concentrated to give the crude product (0.220 g). To a solutien of above crude preduet (0.210 g, 0.442 mmol) in methanel (2 ml) and water (2 ml), camphor sulphonie acid (1.027g. 4.42 mmel ) was added and stirred for lh. The reaetion was poured into iee water and the pH was adjusted to ca. 8 by sedium bicarbonate solution, extraeted with ethyl aeetate, washed with brine, dried over sedium sulphate and Concentrated to afferd the title compound as a yellow solid (0.045 g, 26%). M.P.: 143-145 DC 1H-NMR (δ ppm, DMSO-d6, 400 MHz):□ 8.47 (d, J = 8.7 Hz, 1H),8.43 (s, IH), 8.11 (s, IH), 7.79 (d, J = 8.7 Hz, IH), 7.61 (dt, J = 9.1,4.8 Hz, IH), 7.45 (dt, J = 9.2,4.3 Hz, IH), 6.01 (s, 2H), 4.99 (t, J = 5.2 Hz, IH), 4.22 (t, J = 5.3 Hz, 2H), 3.79 (q, J = 5.2 Hz, 2H). MS (m/z):: 390.70 (M+).

Example 166 tert-Butyl 4-(4-(3-(2-chloro-3,6-difluorobenzyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate: [474] The title compeund was prepared as a yellew solid (0.250 g, 41%) by fellewing the precedure deseribed for example 156 using example 213 (0.400 g, 1.15 mmol), 190 222977/2 sodium hydride (0.060 g, 1.49 mmol), TerT-Butyl 4-(meThyLsuLfonyloxy)piperidine-1-carBoxylAte (0.400 g, 1.43 mmol) anD DMF (2 ml).

Example 167 3-(2-Chloro-3,6-difluorobenzyl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-3H- [1,2,3]triazolo[4,5-b]pyridine hydrochloride: [475] To a solution of Example 166 (0.240 g, 0.453 mmol) in CicHLorometHAne (3 ml) cooled to ODC, TFA (0.1 ml) was added and warmed to RT. After 2h, the reaction mixture was poured in ice water anD pH was AdjusTeC To call with 10% NaOH solution and extrACteC with ethyl acEtatE. washed with Brine, CrieC over sodium sulphate anD concentrAteC. The residue was dissolved in THF (1 ml), ether saturated with HCI (1 ml) was added at ODC and stirreC for 15 min. THe prEcipiTATE formed was filtered anD wasHeD with ether anD driEd under vacuum To alforD The Title compound as an off-wHiTe solid (0.090 g, 43%). M.P.: 8587 □ C. Ή-NMR (δ ppm, DMSO-Cf, 400 MHz):□ 8.48 (d, J = 1.5 Hz, 1H),8.45 (s, IH), 8.09 (s, IH), 7.79 (C, J = 8.7 Hz, IH), 7.60 (Ct, J = 13.8,4.8 Hz, IH), 7.45 (Ct, J =13.4,4.2 Hz, IH), 6.01 (s, 2H), 4.29 (m, IH), 3.07 (C, J = 12.4 Hz, 2H), 2.63 (m, 2H), 1.98 (m, 2H), 1.85 (m, 2H). MS (m/z):: 429.69(M+ - HCI).

Example 168 6-((5-(3-Methyl-1H-indazol-6-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [476] THe Title compound was prepareC as a yellow solid (0.030 g, 15%) By Suzuki coupling of TerT-Butyl 3-meTHyL-6-(4,4,5,5-TeTRAmeTHyL-1,3,2-CIoxABoroLAn-2-yl)-1H-InCAzoLe-1-carBoxylATe (0.227 g, 0.634 mmol) with IntermeCiAte 14 (0.150 g, 0.507 mmol) Following the proceCure DescriBeC for example 1 using potassium carBonate (0.233 g, 1.68 mmol), Cioxan (3 ml), water (0.6 ml) and TeTrAkis(TripHenylpHospHine)pAlLACium(0) (0.046 g, 0.04052 mmol) Followed By CeproTecTion of the carBamatE as DescriBeC under 157. M.P.: 136-137DC 1H-NMR (δ ppm, DMSO-cf, 400 MHz): 12.90 (s, IH), □ □ □ □ (d, J = 3.1 Hz, IH), 8.66 (D, J= 8.8 Hz, IH), 8.38 (C, J = 8.5 Hz, IH), 8.30 (s, IH), 8.21 (C, J = 8.6 Hz, IH), 8.04 (C, J = 8.4 Hz, IH), 8.02 (s, IH), 7.98 (d, J = 8.4 Hz, IH), 7.85 (C, J = 8.5 Hz, 2H), 7.53 (q, J = 4.2 Hz, IH), 6.25 (s, 2H), 2.52 (s, 3H). 171 222977/2

Example 169 6-((5-(1H-Indol-5-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [477] The title compound was prepared by Following The proeedure described for example 1 using intermediate 14 (0.150 g, 0.507 mmol), 6-(4,4,5,5-tetrameThy1-1,3,2-dioxaboro1an-2-y1)-1H-indo1e (0.154 g, 0.634 mmol), potassium carbonate (0.233 g, 1.68 mmol), dioxane (3 ml), water (0.6 ml) and TeTrakis(tripheNy1phosphiNe)pa11adium(0) (0.046 g, 0.04052 mmol). Light green solid (0.025 g, 13%). M.P.: 120-122DC. Ή-NMR (δ ppm, DMSO-de,400MHz):D 11.30(s, IH), □□□□ (dd, J = 4.2, 1.6 Hz, IH), 8.56 (d, J = 8.8 Hz, IH), 8.45 (s, IH), 8.39 (d, J = 8.3 Hz, IH), 8.13 (d, J = 8.9 Hz, IH), 8.04 (m, 3H), 7.84 (dd, J = 8.8, 1.8 Hz, IH), 7.53 (m, 2H), 7.42 (t, J = 2.7 Hz, IH), 6.56 (s, IH), 6.20 (s, 2H).

Example 170 6-((5-(1H-Indol-6-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline

[478] The Title compound was obtained as an off-white solid (0.015 g, 8%) by Following The procedure deseribed For example 1 using inTermediate 14 (0.150 g, 0.507 mmol), IH-indole-6-yl boronic acid (0.102 g, 0.634 mmol), potassium carbonate (0.233 g, 1.68 mmol), dioxane (3 ml), water (0.6 ml) and TeTrakis(TripheNy1phosphiNe)pa11adium(0) (0.046 g, 0.04052 mmol). M.P.: 143-145DC. Ή-NMR (δ ppm, DMSO-D,4M^z):D011.38 (s, IH), □□□□ (dd, J = 4.0,1.5 Hz, IH), 8.58 (d, J = 8.8 Hz, IH), 8.38 (d, J = 8.7 Hz, IH), 8.31 (s,1H), 8.13 (d, J = 8.8 Hz, IH), 8.04 (m, 2H), 7.92 (dd, J = 8.4,1.4 Hz, IH), 7.86 (dd, J 8.8,1.9 Hz, IH), 7.68 (d, J = 8.4 Hz, IH), 7.54 (q, J = 4.2 Hz, IH), 7.49 (d, J = 2.6 Hz, IH), 6.49 (s, IH), 6.20 (s, 2H).

Example 171 6-((5-(2-Chloropyridin-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [479] The tiTle compound was prepared as an oFF-white solid (0.020 g, 11%) by Following The procedure deseribed For example 1 using inTermediate 14 (0.150 g, 0.507 mmol), 2-ch1oropyridiNe-4-boroNic acid (0.099 g, 0.634 mmol), potassium carbonaTe (0.233 g, 1.68 mmol), dioxane (3 ml), water (0.6 ml) and TetrAkis(tripheny1phosphine)pa11adium(0) (0.046 g, 0.04052 mmol). M.P.: 197-1997C. Ή-NMR (δ ppm, DMSO-D,4WMHz):7i:i□□□ (dd, J = 4.1, 1.5 Hz, IH), 8.79 (d, J = 8.7 Hz, IH), 8.61 (d, J = 5.2 Hz, IH), 8.37 (d, J = 8.4 Hz, IH), 8.32 (d, J = 8.8 Hz, IH), 8.30 (s, IH), 8.25 (dd, J = 5.2,1.5 Hz, IH), 8.04 (s, IH), 8.02 (d, J = 8.7 Hz, IH), 7.83 (dd, J = 8.7,1.9 Hz, IH), 7.54 (q, J = 4.2 Hz, IH), 6.25 (s, 2H). 172 222977/2

Example 172 6-((5-(3-Methyl-1H-indazol-5-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [480] The title compouNd was prepAred As A yellow solid (0.050 g, 25%) by followiNg the procedure described for example 1 usiNg iNtermediATe 14 (0.150 g, 0.507 mmol), terT-butyl 3-metHYl-6-(4,4,5,5-teTrAmetHYl- 1,3,2-dioxAboRoLAN-2-y1)-3-meTHy1- 1H-iNdAzole-l-earboxylAte (0.227 g, 0.634 mmol), potassium cArboNAte (0.233 g, 1.68 mmol), dioxANe (3 ml), water (0.6 ml) ANd teTrAKis(TrIpheNYlphosphme)pA11AdIum(0) (0.046 g, 0.04052 mmol) followed by The proeedure described In example 157. M.P.: 246-249DC. 1H-NMR (δ ppm,DMSO-d^^MHz):D 12.82(s,lH), □□□□ (d, J = 2.6 Hz, IH), 8.62 (d, J = 8.8

Hz, IH), 8.59 (s, IH), 8.38 (d, J = 8.3 Hz, IH), 8.30 (d, J = 9.1 Hz, IH), 8.23 (d, J = 8.8 Hz, IH), 8.03 (s, IH), 8.01 (d, J = 9.9 Hz, IH), 7.84 (dd, J = 8.6,1.5 Hz, IH), 7.59 (d, J = 8.8 Hz, IH), 7.53 (q, J = 4.2 Hz, IH), 6.21 (s, 2H), 2.56 (s, 3H).

Example 173 6-((5-(Pyridin-3-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [481] The Title compouNd was prepAred by followiNg the proeedure described for example 1 usiNg iNtermediATe 14 (0.150 g, 0.507 mmol), pyridiNeA-borome Acid (0.079 g, 0.649 mmol), potassium earboNATe (0.233 g, 1.68 mmol), dioxANe (3 ml), water (0.6 ml) ANd TetraKIs(trIpheNYlpHospHlNe)pA11AdIum(0) (0.046 g, 0.04052 mmol) followed by the procedure deseribed In example 157. Yellow solid (0.040 g, 24%). M.P.: 208-210 C. Ή-NMR (δ ppm, DMSO-d6, 400 MHz):D □ □ □ □ (dd, J = 4.1,1.7 Hz, IH), 8.77 (m, 3H), 8.38 (dd, J = 8.4,0.9 Hz, IH), 8.26 (d, J = 8.7 Hz, IH), 8.21 (m, 2H), 8.04 (d, J = 1.5 Hz, IH), 8.02 (d, J = 8.7 Hz, IH), 7.85 (dd, J = 8.7,2.0 Hz, IH), 7.53 (q, J = 4.2 Hz, IH), 6.24 (s, 2H).

Example 174 (5,)-6-((5-(1-(Pyrrolidin-3-yl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [482] The title compouNd was prepAred by AlKylAtioN of example 143 (0.300 g, 0.916 mmol) with (R)-tert-buTyl 3-(meThYlsu1foNYloxY)pYrro1IdlNe-1-cArboxYlAte (0.291 g, 1.09 mmol) followiNg the proeedure described UNder example 156 usiNg sodium hydride (0.026 g,1.09 mmol) ANd DMF (6 ml) followed by deproteetioN of the earbAmATe using the proeedure deseribed for 157. Yellow solid (0.100 g, 44%). Ή-NMR (δ ppm, DMSO-d6, 400 MHz): 8.88 (dd, J = 4.1, 1.4 Hz, IH), 8.59 (s,1H), 8.52 (d, J = 8.8 Hz, IH), 8.37 (d, J = 8.2 173 222977/2

Hz, 1H), 8.22 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.99 (s, 1H), 7.82 (m, 2H), 7.53 (dd, J = 8.3,4.2 Hz, 1H), 6.11 (s, 2H), 4.98 (m, 1H), 3.26-2.96 (μ, 5H), 2.28-2.11 (m, 2H).

Example 175 (S)-6-((5-(1-(Pyrrolidin-3-yl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline hydrochloride: [483] Example 174 (0.100 g, 0.25 mmol), was Dissolved in THF (1 ml), ether saturated with HCl (1 ml) was added at OD C and stirred For 15 min. The precipitate formed was washed with ether and Dried under vacuum to afford the title compound as a yellow solid (0.070 g, 65%). M.P.: 117-121 DC. 1H-NMR (δ ppm, DMSOY, 400 ^Ή):0 9.58 (s, 1H), 9.45 (s, 1H), 9.12 (d, J = 3.7 Hz, 1H), 8.87 (D, J = 8.1 Hz, 1H), 8.73 (s,1H), 8.56 (d, J = 8.7 Hz, 1H), 8.30 (s,1H), 8.25 (d, J = 8.7 Hz, 1H), 8.21 (s, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.7 Hz, 2H), 6.18 (s, 2H), 5.27 (t, J = 3.3 Hz, 1H), 3.69-3.34 (m, 4H), 2.43-2.30 (s, 2H).

Example 176 4-(2-(4-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol-1-yl)ethyl)morpholine hydrochloride [484] The title compound was prepared By following The procedure DescriBed For Example 156 using Example 143 (0.150 g, 0.458 mmoL), sodium hydride (0.022 g, 0.55 mmol), (4-(2-chloroethyl)MorpholiNe (0.115 g, 1.00 mmoI) and DMF (3 ml) Followed By using the procedure descriBed for 175. Yellow solid (0.080g, 36%). M.P.: 118-120 DC. 1H-NMR (δ ppm, DMSO-Y 400 MHz): DDDDD (s,lH),9.06(d,J = 3.7 Hz, 1H), 8.74 (D, J = 8.3

Hz, 1H), 8.65 (s,1H), 8.57 (d, J = 8.6 Hz, 1H), 8.31 (s,1H), 8.18 (d, J = 8.8 Hz, 1H), 8.13 (s,1H), 7.99 (D, J = 8.8 Hz, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.78 (dd, J = 7.7,4.4 Hz, 1H), 6.16 (s,2H), 4.72 (t, J = 6.6 Hz, 1H), 3.97 (Br.s, 2H), 3.77 (T, J = 11.5 Hz, 2H), 3.65 (t, J = 11.5 Hz, 2H), 3.42 (d, J = 11.6 Hz, 2H), 3.17 (m, 2H).

Example 177 6-((5-(1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin- 3-yl)methyl)quinoline [485] The title compound was prepared as a yellow solid (0.130 g, 52%) By Following the procedure DescriBed for example 156 using example 143 (0.200 g, 0.610 mmoL), cesium carBonate (0.596 g, 1.83 mmol), TETrAhydro-2H-pyran-4-yi MEthanesulfonatE (0.220 g, 1.22 mmol) and DMF (6 ml). M.P.: 182-184OC. Ή-NMR (δ ppm, DMSO-D6· 400 174 2229772 MHz): 8.88 (dd, J = 4.2,1.7 Hz, 1H), 8.59 (s, 1H), 8.51 (d, J = 8.8 Hz, 1H), 8.38 (d, J = 8.2

Hz, 1H), 8.21 (s, 1H), 8.01 (m, 2H), 7.82 (m, 2H), 7.53 (dd, J = 8.3,4.1 Hz, 1H), 6.11 (s, 2H), 4.52 (m, 1H), 3.99 (m, 2H), 3.51 (dt, J = 11.2,3.0 Hz, 2H), 2.02 (m, 4H).

Example 178

6-((5-(1-(2-Hydroxyethyl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide: T

[486] To a solution of Example 146 (0.100 g, 0.269 mmol) in acetic acid (1 ml), hydrogen peroxide solution (50%, 1 ml) and heated to 100DC. After 12h, the mixture was concentrAted, extracted with chloroform, washed with brine, dried over sodium sulphate and concEntrAted. The crude product was purified by column chromAtogrAphy using dichloromeThAne: methanol To afford the title compound as an off-white solid (0.015 g, 14%). M.P.: 222-224 DC. Ή-NMR (δ ppm, DMSO-dg, 400 MHz):8.58-8.48 (m, 4H), 8.19 (s, 1H), 8.08 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.85 (dd, J = 9.0,1.8 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.47 (dd, J = 8.4,6.0 Hz, 1H), 6.12 (s, 2H), 4.95 (t, J = 5.2 Hz, 1H), 4.22 (T, J = 5.5 Hz, 2H), 3.77 (q, J = 5.5 Hz, 2H).

Example 179 6-((5-(1,3-dimethyl-1H-indazol-6-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline: [487] The title compound was prEpared by following The procedure described For example 1 using intermEdiAtE 14 (0.100 g, 0.338 mmol), 1.3-DiniEthyi-6-(4.4.5.5-tEtraniEthyl-',3,2-dioxAborolan-2-yl)-1H-indAzole (0.0117 g, 0.432 mmol), potassium carbonate (0.146 g, 1.05 mmol), dioxane (3 ml), water (0.6 ml) and tetraKis(Triphenylphosphine)pAUAdium(0). (0.061g, 45%) Yellow solid (0.061 g, 45%). M.P.: 159-163DC. Ή-NMR (δ ppm, DMSO-de, 400MHz):DDDDD (dd, J = 4.0,1.6 Hz, 1H), 8.69 (d, J = 8.8 Hz, 1H), 8.41 (s, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.30 (d, J = 8.8 Hz, 1H), 8.05-8.01 (m, 3H), 7.85 (m, 2H), 7.54 (dd, J = 8.3,4.1

Hz, 1H), 6.24 (s, 2H).

Example 180 5-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)pyrimidin-2-amine: [488] The title compound was prEpared by following The procedure described For example 1 using inTerMediAte 14 (0.100 g, 0.338 mmol), 2-Amino-5-pyrimidineboronic acid (0.058 g, 0.422 mmol), potassium carbonAte (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) and tetraKis(triphenylphosphme)pAllAdium(0) (0.031 g, 0.067 mmol) under TT5 222977/2 microwave irradiation (100W, 100DC) for 20 min. Yellow solid (0.020 g, 16%). M.P.: 244- 246DC. MS (m/z): 354.72 (M+).

Example 181 tert-Butyl 3-ethyl-6-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-indazole-1-carboxylate: [489] The Title compound was prepared By following the procedure deseriBed For example 1 using intermediATe 14 (0.100 g, 0.338 mmol), Tert-Butyl 3-eThyl-6-(4,4,5,5-tetrAmeThYL-1,3,2-dioxABorolAn-2-Yl)-1H-indAzoLe-1-CArBoxYLATe (0.157 g, 0.422 mmol), potassium carBonaTe (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) and tetrAkis(TriphenYLphosphine)pALlAdium(0) (0.031 g, 0.067 mmol) under mierowAve irrAdiAtion (100W, 100OC) for 20 min. Off-white solid (0.070 g, 51%). M.P.: 185-188CC. Ή-NMR (δ ppm, DMSO-d, 400 MHz): 8.93 (s,lH), 8.91 □ (dd, J = 4.2,1.5 Hz, IH), 8.47 (d, J = 8.7 Hz, IH), 8.20 (d, J = 8.3 Hz, IH), 8.11 (m, 2H), 7.98 (s, IH), 7.96 (d, J = 8.7 Hz, IH), 7.90 (dd, J = 8.8,1.8 Hz, IH), 7.83 (d, J = 8.3 Hz, IH), 7.41 (dd, J = 8.3,4.3 Hz, IH), 6.16 (s,2H), 3.10 (q, J = 7.6 Hz, 2H), 1.74 (s, 9H), 1.48 (t, J = 7.6 Hz, 3H).

Example 182 4-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)thiophene-2- carbaldehyde [490] The title Compound was prepared By Following The proeedure descriBed for example 1 using intermediAte 14 (0.100 g, 0.338 mmol), 2-formylThiophene-4-Boronic acid (0.032 g, 0.422 mmol), potassium carBonate (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) and TeTrAkis(TriphenYlphosphme)pAllAdium(0) (0.031 g, 0.067 mmol) under microwave irrAdiATion (100W, 100 □ C) For 20 min. Brown solid (0.060 g, 7%). M.P.: 195-197DC. MS (m/z): 372.08 (M+).

Example 183 6-((5-(2-Methoxypyrimidin-5-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [491] The title Compound was prepared By Following The proeedure descriBed for example 1 using intermediAte 14 (0.100 g, 0.338 mmol), 2-meThoxYpYrimidine-5-Boronie acid (0.065 g, 0.422 mmol), potassium carBonate (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) and TeTrAkis(TripHenYlphospHine)pALLAdium(0) (0.031 g, 0.067 mmol) under 1T6 222977/2 microwave irradiation (100W, 100QC) for 20 min. Yellow solid (0.060 g, 48%). M.P.: 201 - 203 DC. MS (m/z): 369.98 (M+).

Example 184 6-((5-(Benzo[d][1,3]dioxol-5-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [492] THe Title compound was prepared By following tHe procedure descriBed For example 1 using IntermediATe 14 (0.100 g, 0.338 mmoI), Benzo[d][1,3]dIoxoL-5-y1Boronic Acid (0.056 g, 0.422 mmol), potassium cArBonATe (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) And TETrAKis(TripHENYlpHospHiNE)pA11AdiuM(0) (0.031 g, 0.067 mmol) under microwave irradiation (100W, 100 C) for 20 min. Off-wHite solid (0.070 g, 54%). M.P.: 179181 DC. MS (m/z): 382.16 (M+ +1).

Example 185 6-((5-(2,3-Dihydrobenzofuran-5-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl) quinoline [493] THe title compound was prepAred By following THe procedure descriBed for example 1 using iNTermediATe 14 (0.100 g, 0.338 mmol), 2,3-diHydRoBeNzofurAN-5-yLBoromc Acid (0.055 g, 0.422 mmoI), potassium cArBonATe (0.156 g, 0.027 mmol), dioxane (2 m1), water (0.5 ml) And TETrAKis(TripHENYlpHospHiNE)pA11AdiuM(0) (0.031 g, 0.067 mmol) under microwave irradiation (100W, 1001 IC) for 20 min. Pale brown solid (0.065 g, 50%). M.P.: 131-133 DC. MS (m/z): 379.92 (M+).

Example 186 5-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)pyridin-2-amine [494] THe title compound was prepAred By following THe procedure descriBed for example 1 using intErMEdiAtE 14 (0.100 g, 0.338 mmol), 5-(4,4,5,5-TeTrAMeTHy1-1,3,2-dioxABoro1An-2-Yl)pYridin-2-AMinE (0.096 g, 0.439 mmol), potassium carBonAte (0.156 g, 0.027 mmol), dioxane (2 ml), water (0.5 ml) And TETrAKis(tripHENYlpHospHiNE)pA11AdiuM(0) (0.031 g, 0.067 mmol) under microwave irradiation (100W, 100DC) for 20 min. Yellow solid (0.050 g, 42%). M.P.: 194-197CC. MS (m/z): 353.95 (M+).

Example 187 6-((5-(1-(2-fluoroethyl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline [495] Methane sulphonyl chloride (0.069 g, 0.605 mmol) was added at OdC to a solution of example 146 (0.150 g, 0.403 mmoI) And triETHYlAMinE (0.122 g, 1.21 mmoI) in 177 222977/2 dichloromETHANE (3 ml) and warmed To RT. After IH, The mixture was diluted and washed with sodium BicarBoNAte solution, washed with Brine, dried over sodium sulphate and concentrAted. To The residuE, cesium fluoridE (0.270 g, 1.77 mmol) and TerT-BuTAnol (2 ml) were added and heated to 70DC for 12h. The reaction mixture was poured in water, extracteD with eTHyl Acetate, washed with Brine, dried over sodium sulphate and coNceNtrATed. THe crude product was purified By column cHromATogrAphy using dichloromEThANe: metHanol To Afford The Title compound as an oFF-whiTe solid (0.015 g, 10%). M.P.: 168-170 1C. 'H-NMR (δ ppm, DMSO-tf,. 4(X) MHz):0 8.88( dd, J=4.2, 1.7 Hz, IH ),8.57 ( s, IH), 8.53 ( d, J = 8.7 Hz, IH), 8.37 ( d, J = 7.4 Hz, IH), 8.26 ( s, IH), 8.01 (d, J = 8.1 Hz, IH), 7.99 ( s, IH), 7.83 (m, 2H), 7.53 (dd, J = 8.3,4.2 Hz, IH), 6.11 (s, 2H), 4.88(dt, J = 47.1,4.5 Hz, 2H), 4.56 (dt, J = 27.7, 4.8 Hz, 2H) MS (m/z):: 374.1 (M++1).

Example 188 (4-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)thiophen-2-yl) methanol [496] THe TiTle compound was prepAred By following THe procedure dEScriBed For example 1 using iNTermediATe 14 (0.100 g, 0.338 mmol), (4-(4,4,5,5-tEtrAmeTHyl-1,3,2-dioxABorolAN-2-Yl)THiopHeN-2-Yl)meTHANol (0.066 g, 0.475 mmol), potassium carBonatE (0.156 g, 0.027 mmol), dioxANe (2 ml), water (0.5 ml) and TeTrAkis(TripHeNYlpHospHiNe) palladium(O) (0.031 g, 0.067 mmol) under microwave irradiation (100W, 100DC) for 20 min. Yellow solid (0.080 g, 63%). M.P.: 188-191 OC. MS (m/z): 373.95 (M+).

Example 189 6-(2-(5-(1-(2-(Tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo [4,5-b] pyridin-3-yl)propan-2-yl)quinoline [497] THe TiTle compound was prepAred By following THe procedure descriBed For example 1 using intermEdiAtE 17 (0.100 g, 0.307 mmol), 1-(2-(TETrAhYdro-2H-pYrAN-2-YloxY)eTHYl)-4-(4,4,5,5-TeTrAmeTHYl-1,3,2-dioxABorolAN-2-Yl)-1H-pYrAzole (0.126 g, 0.394 mmol), potassium carBonaTe (0.133 g, 0.963 mmol), dioxane (2.5 ml), water (0.5 ml) and TeTrAkis(TripHeNYlpHospHiNe)pAllAdium(0) (0.028 g, 0.024 mmol). Yellow liquid (0.065 g, 44%). 'H-NMR (δ ppm, DMSO-D6, 400 MHz): 8.85 (D, J = 2.8 Hz, IH ), 8.47 (D, J = 8.7 Hz, IH), 8.37 (d, J = 7.9 Hz, IH), 8.22 (s, IH), 7.95 (d, J = 1.7 Hz, IH), 7.90 (s, IH), 7.88 (d, J = 7.3 Hz, IH), 7.69 (d, J = 8.7 Hz, IH), 7.53 (m, IH), 4.46 (m, IH), 4.27 (m, 2H), 3.88 (m, IH), 3.69 (m, IH), 3.47 (m, IH), 3.26 (m, IH), 1.63-1.30 (m, 6H). 178 2229772

Example 190 2-(4-(3-(2-(Quinolin-6-yl)propan-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H- pyrazol-1-yl)ethanol [498] The title compound was prepared By Following the procedure descriBed for example 146 from example 189 (0.050 g, 0.104 mmol), camphor sulphonic acid (0.121g. 0.521 mmol), methanol (0.5 ml) and water (0.5 ml). Brown solid (0.031g, 74%). M.P.: 9598 □ C. 'H-NMR (δ ppm, DMSO-fi.,. 400 MHz): □ 8.85 (d, J = 2.8 Hz, IH ), 8.46 (d, J = 8.7 Hz, IH), 8.40 (d, J = 7.9 Hz, IH), 8.22 (s, IH), 8.00 (d, J = 1.8 Hz, IH), 7.91 (d, J = 8.9 Hz, IH), 7.85 (s, IH), 7.68 (d, J = 8.7 Hz, IH), 7.53 (m, 2H), 4.87 (t, J = 5.3 Hz, IH), 4.11 (t, J = 5.4 Hz, 2H), 3.70 (q, J = 5.4 Hz, 2H), 2.46 (s, 6H).

Example 191 6-((5-(3-ethyl-1H-indazol-6-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [499] To a solution of Example 181 (0.050 g, 0.099 mmol) in dichlorometHane (1 ml) cooled to ODC, TFA (0.5 ml) was added and warmed to RT. After 2h, the reaction mixture was poured in ice water and pH was adjusted to ca. 11 with 10% NaOH solution and extracted with ethyl acetate, washed with Brine, dried over sodium sulphate and concentrateD To afford the title compound as a yellow solid (0.023 g, 61%). M.P.: 211-213DC. MS (m/z): 406.08 (M+).

Example 192 6-(2-(5-(1H-Pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)propan-2-yl)quinoline: [500] THe title compound was prepared By following THe procedure descriBed For example 1 using iNTerMediaTe 17 (0.20 g, 0.615 mmol), Tert-Butyl 4-(4,4,5,5-tetrameThyL-

1,3,2-dioxaBoroLaN-2-y1)-1H-pyrazo1e-1-carBoxy1aTe (0.231 g, 0.788 mmol), potassium carBonate (0.266 g, 1.92 mmol), Dioxane (5 ml), water (1 ml) and TeTrakis(tripHenyLpHosphine)paLLadium(0) (0.057 g, 0.049 mmol). Yellow solid (0.075 g, 34%). M.P.: 218-220DC. 'H-NMR (δ ppm, DMSO-d,, 400 ^G:D 13.02 (s, IH), 8.86 (dd, J = 4.2, 1.7 Hz, IH), 8.56 (s, IH), 8.35 (dd, J = 8.2, 1.1 Hz, 2H), 8.10 (s, IH), 8.04-7.98 (m, 3H), 7.85 (dd, J = 8.8, 1.9 Hz, IH), 7.61 (d, J = 8.3 Hz, IH), 7.52 (dd, J = 8.3,4.2 Hz, IH), 5.69 (s, 2H). MS (m/z): 359.89 (M+). 179 222999/2

Example 193 6-((5-(4-Methylthiophen-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [501] The title compound was prepared by fellewinG the precedure deseribed for example 1 using intermediate 14 (0.100 g, 0.338 mmel), 4-methyl-2-thiepheneborenie acid (0.061 g, 0.432 mmel), petassium Carbonate (0.146 g, 1.058 mmol), dioxane (2.5 ml), water (0.5 ml) and tetrakis(triphenylphosphine)palladium(0) (0.031 g, 0.027 mmol) under microwave irradiation (100W, 100QC) for 20 min. Brown solid (0.048 g, 40%). M.P.: 153-156DC. MS (m/z): 357.85 (M+).

Example 194 6-((5-(5-Methylthiophen-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [502] The title compound was prepared by fellewing the proeedure described fer example 1 using intermediate 14 (0.100 g, 0.338 mmel), 5-methyl-2-thiepheneborenie acid (0.060 g, 0.422 mmel), petassium Carbonate (0.156 g, 1.12 mmol), dioxane (2.5 ml), water (0.5 ml) and tetraKis(triphenylphesphine)palladium(O) (0.031 g, 0.027 mmel) under microwave irradiation (100W, 100DC) for 20 min. Off-white solid (0.035 g, 29%). M.P.: 154-156DC. MS (m/z): 357.85 (M+).

Example 195 4-(5-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)pyridin-2- yl)morpholine [503] The title compound was prepared by fellewing the precedure deseribed for example 1 using interMediate 14 (0.100 g, 0.338 mmel), 6-merphelinopyridine-3-borenic acid (0.088 g, 0.422 mmel), potassium carbonate (0.156 g, 1.12 mmol), dioxane (2.5 ml), water (0.5 ml) and tetraKis(triphenylphosphine)palladium(0) (0.031 g, 0.027 mmol) under microwave irradiation (100W, 100DC) for 20 min. Yellow solid (0.045 g, 31%). M.P.: 183-185DC. MS (m/z): 423.93 (M+).

Example 196 6-((5-(6-(Piperidin-1-yl)pyridin-3-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline [504] The title compound was prepared by fellewing the precedure deseribed for example 1 using intermediate 14 (0.100 g, 0.338 mmel), 2-(piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaberolan-2-yl)pyridine (0.122 g, 0.422 mmel), potassium Carbonate (0.156 g, 1.12 mmol), dioxane (2.5 ml), water (0.5 ml) and tetrakis 180 222977/2 (TriphenylphosphinE)pAllACium(O) (0.031 g, 0.027 mmol) under microwave irrAdiAtion (100W, 100QC) for 20 min. Brown solid (0.090 g, 63%). M.P.: 133-135QC. MS (m/z): 422.18 (M++1).

Example 197 6-((5-(1-Ethyl-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [505] THe title compound was prepared By Following THe procedure DescriBEd for example 144 from example 143 (0.130 g, 0.397 mmol), sodium HyCriCe (0.014 g, 0.596 mmol), ethyl ioCiCe (0.123 g, 0.794 mmol) and DMF (3 ml). Yellow solid (0.065 g, 46%). M.P.: 132-134DC. MS (m/z): 356.03 (M++1).

Example 198 6-((5-(1-Isopropyl-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl) methyl)quinoline [506] THe title compound was prepareC By Following The proceCure DescriBeC for example 144 from example 143 (0.130 g, 0.397 mmol), sodium HyCriCe (0.014 g, 0.596 mmol), 2-BromopropAne (0.097 g, 0.794 mmol) and DMF (3 ml). OFF-wHiTe solid (0.050 g, 34%). M.P.: 126-128DC. MS (m/z): 370.24 (M++1).

Example 199 6-((5-(1-Isobutyl-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline [507] THe title compound was prepareC By Following The proceCure DescriBeC for example 144 from example 143 (0.130 g, 0.397 mmol), sodium HyCriCe (0.014 g, 0.596 mmol), 1-Bromo-2-mETHyLpropAnE (0.108 g, 0.794 mmol) anD DMF (3 ml). Pale green solid (0.070 g, 46%). M.P.: 160-163DC. MS (m/z): 384.10 (M++1).

Example 200 1-(Pyrrolidin-1-yl)-2-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-1H-pyrazol- 1-yl)ethanone [508] To a solution of example 155 (0.056 g, 0.145 mmol) in DMF (0.5 ml) N-eThyLCiisopropylAmine (0.018 g, 0.145 mmol) and HATU (0.055 g, 0.145 mmol) were aDDeD and stirreC for 5 min. PyrroliCine (0.020 g, 0.290 mmol) was aDDeD at RT and The reAcTion mixture was stirrEC For 12H. To The reAcTion mixture water was aDDeD and extracted with ethyl AcetatE, drieC over sodium sulphate anD concentrAtEC under reDuceD pressure. The crude 181 222977/2 product was purified by column ehromatography with methanol: diehloromethane to afford the TiTle compound as a yellow solid (0.010 g, 16%). M.P.: I36-138C. Ή-NMR (δ ppm, DMSO-D, 400 MHz): 8.87□ (dd, J = 2.7 Hz, IH), 8.52 (d, J = 8.7 Hz, IH), 8.45 ( s, IH), 8.37 (d, J = 7.7 Hz, IH), 8.20 (s, IH), 8.01 (d, J = 8.6 Hz, IH), 7.99 (s, IH), 7.83 (m, 2H), 7.52 (dd, J = 8.3,4.2 Hz, IH), 6.11 (s, 2H), 5.11 (s, 2H), 3.52 (T, J = 6.7 Hz, 2H), 3.33 (m, 2H), 1.93-1.77 (m, 4H).

Example 201 6-((5-(1-(2-Methoxyethyl)-1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)methyl)quinoline [509] The title compound was prepared by Following The proeedure described for example 144 from example 143 (0.130 g, 0.397 mmol), sodium hydride (0.014 g, 0.596 mmol), 2-bromoethyl methyl ether (0.110 g, 0.794 Mmol) and DMF (3 ml). Pale yellow solid (0.050 g, 33%). M.P.: 162-1647C. Ή-NMR (δ ppm, CDC13, 400 MHz): 8.90 (D, J = 3.5 Hz, IH), 8.30 (d, J = 8.6 Hz, IH), 8.13 (m, 4H), 7.89 (s, IH), 7.86 (d, J = 8.9 Hz, IH), 7.54 (d, J = 8.7 Hz, IH), 7.41 (dd, J = 8.3,4.2 Hz, IH), 6.07 (s, 2H), 4.38 (T, J = 5.0 Hz, 2H), 3.81 (t, J = 5.1 Hz, 2H), 3.36 (s, 3H).

Example 202 N-Phenyl-3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine [510] To a solution of inTermediaTe 14 (0.10 g, 0.338 mmol) and aniline (0.047 g, 0.507 mmol) in o-xylene (0.8 ml), sodium Tert-butoxide (0.038 g, 0.405 mmol), triphenylphosphine (0.008 g, 0.033 mmol) and palladium aeetate (0.003 g, 0.169 mmol) were added and degassed for 30 min. and the reaction mixture was heated to 1207C for 4h. The reaction Mixture was FilTered Through eeliTe and washed with ethyl aeeTaTe, Dried over sodium sulphate and concentraTed under reduced pressure. The crude product was purified by column chromatography with meThanol: dichloromeThane To afford the Title compound as a brown solid (0.030 g, 25%). M.P.: 237-239DC. Ή-NMR (δ ppm, DMSO-D, 400 MHz): 9.72 (s,1H), 8.87 (d, J = 3.9 Hz, IH), 8.36 (d, J = 8.6 Hz, IH), 8.19 (d, J = 9.0 Hz, IH), 8.00 (s, IH), 7.98 (d, J = 8.1 Hz, IH), 7.73 (m, 3H), 7.53 (dd, J = 8.0, 4.2 Hz, IH), 7.26 (m, 2H), 6.96 (t, J = 7.4 Hz, IH), 6.90 (d, J = 9.0 Hz, IH), 5.98 (s, 2H). 182 222977/2

Example 203 6-((5-Phenoxy-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline [511] To a solution of interMediate 14 (0.10 g, 0.338 mmoI) and phenol (0.031 g, 0.338 mmol) in N-methyl pyrroliDone (0.7 ml), potassium tert-butoxide (0.045 g, 0.405 mmol) was added and the reaction mixture was heated to 80DC for 12h. The reaction mixture was quenched with water, extraeted with ethyl acetate, dried over sodium sulphate and concEntrateD under redueed pressure. The crude proDuct was purifiEd by Column chromatography with mEthanol: dieHlorometHanE to afforD the title compounD as an off-whitE solid (0.040 g, 33%). M.P.: 225-227DC. Ή-NMR (δ ppm, DMSO-De, 400 MHz): 8.91 (D, J= 2.9 Hz, IH), 8.29 (d, J = 8.8 Hz, IH), 8.07 (d, J = 8.1 Hz, IH), 8.01 (d, J = 8.7 Hz, IH), 7.76 (s,1H), 7.67 (dd, J = 8.6, 1.4 Hz, IH), 7.47 (m, 3H), 7.33 (t, J = 7.4 Hz, IH), 7.16 (D, J = 8.0 Hz, IH), 6.98 (d, J = 8.9 Hz, IH), 5.80 (s, 2H).

Example 204

Methyl 2-fluoro-5-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzoate [512] The title compound was prepared by Following the proeedure described for example 1 using intERMEdiatE 14 (0.250 g, 0.845 mmol), 4-f1uoro-3-

Methoxyearbonylphenylboronic acid pinaeol ester (0.294 g, 0.422 mmoI), potassium acetate (0.276 g, 2.81 mmol), dioxane (4 m1) and tetrakis(tripheny1phosphine)pa11adiuM(0) (0.050 g, 0.042 mmol). Off-whitE solid (0.080 g, 23%).

Example 205 2-Fluoro-5-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoic acid [513] To a solution of Example 204 (0.080 g, 0.193 mmol) in Methanol (1 m1), lithium hydroxide (0.075 g, 1.80 mmol) in water (1 m1) and THF (2 ml) were added and stirreD at RT. After 12H, pH was adjusted to ea. 7 using 0.5N HCI anD the solid prEcipitated was filtered, washed with ethyl acetate and petroleuM ether and dried under vacuum to afford the title compound as an off-white solid (0.060 g, 78%). THe acid was useD without Further purification in the next step.

Example 206 2-Fluoro-5-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

To Example 205 (0.060 g, 0.149 mmol), thionyl chloride (0.8 m1) was added and reFluxed For 3H. THe excess thionyl chloride was removed; aqueous 25% aMmonia (0.8 ml) was added 183 222977/2

To The residue at 0 □ C and stirred for 15 min. The precipitate formed was washed with sodium bicArboNAte solutioN ANd vacuum dried to Afford title compouNd As an off-white solid (0.020 g, 34%). M.P.: 262-264□ C. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.87 (D, J = 2.7 Hz, IH), 8.68 (d, J = 8.7 Hz, IH), 8.50 (d, J = 6.7 Hz, IH), 8.39 (d, J = 8.1 Hz, 2H), 8.17 (d, J = 8.7 Hz, IH), 8.04 (s, IH), 8.02 (d, J = 8.6 Hz, IH), 7.89 (s, IH), 7.83 (d, J = 8.7 Hz, IH), 7.78 (s,1H), 7.53 (dd, J = 8.2,3.9 Hz, IH), 7.49 (d, J = 9.7 Hz, IH), 6.21 (s, 2H).

Example 207 2-Chloro-4-(3-((5,7-difluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)benzamide

The Title compouNd was prepared by followiNg the proeedure deseribed for example 1 using iNtermediAte 34 (0.065 g, 0.196 mmol), iNtermediAte 35 (0.070 g, 0.245 mmol), potassium carboNATe (0.090 g 0.654 mmol), dioxaNe (2 ml), water (0.3 ml) and TetraKIs(trIpheNYlpHospHlNe)pA11AdIum(0) (0.018 g, 0.015 Mmol) under microwave IrrAdiATioN (100W, 100 DC) for 30 min. Brown solid (0.020 g, 23%). M.P.: 216-219 C. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 9.01 (d, J = 2.9 Hz, IH), 8.67 (d, J = 8.7 Hz, IH), 8.59 (d, J = 8.5 Hz, IH), 8.26 (s,1H), 8.20 (d, J = 8.6 Hz, IH), 8.18 (s,1H), 7.96 (s,1H), 7.77 (d, J = 10.9 Hz, IH), 7.69 (s, IH), 7.67 (dd, J = 8.6,4.3 Hz, IH), 7.59 (d, J = 8.0 Hz, IH), 7.59 (d, J = 8.0 Hz, IH), 6.26 (s, 2H).

Example 208 1-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone [514] The Title compound was prepAred by followiNg the proeedure described for example 1 using iNTerMedlATe 14 (0.200 g, 0.676 mmol), l-ethoxyvlNyl TrI(N-butYl)sTANNANe (0.244 g, 0.676 mmol), trIphenYlpHosphIne (0.0284 g, 0.054 mmol), toluene (3.8 ml) And Tris (dIbenzilidineAceTone) pAllAdium(O) (0.028 g, 0.027 mmol) followed by Aeid hydrolysis. Brown solid (0.080 g, 39%). Ή-NMR (δ ppm, CDC13, 400 MHz ): 8.92 (D, J = 3.0 Hz, IH), 8.49 (d, J = 8.5 Hz, IH), 8.15 (m, 3H), 7.94 (s, IH), 7.87 (d, J = 8.6 Hz, IH), 7.43 (dd, J = 8.3,4.2 Hz, IH), 6.15 (s, 2H), 2.82 (s, 3H).

Example 209 2-(1-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) hydrazinecarboxamide [515] To A solution of example 208 (0.070 g, 0.230 mmol) In ethanol (2 ml), sodium AeeTAte (0.018 g, 0.230 mmol) And semicArbAzide hydrochloride (0.026 g, 0.230 184 222977/2 mmol) were added and stirred At RT For 12h. THe reACtion mixture was ConeentrATed and The residue was washed with BicArBonATe solution, diehloromeThAne and dried under vacuum To Afford the Title compound as a yellow solid (0.040 g, 48%). M.P.: 249-250DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 9.70 (s, IH), 8.88 (d, J = 2.8 Hz, IH), 8.54 (d, J = 8.9 Hz, IH), 8.45 (d, J = 8.9 Hz, IH), 8.37 (d, J = 8.2 Hz, IH), 8.01 (s, IH), 7.99 (d, J = 8.6 Hz, IH), 7.81 (dd, J = 8.6,1.3 Hz, IH), 7.53 (dd, J = 8.2,4.1 Hz, IH), 6.78 (Br s, 2H), 6.14 (s, 2H), 2.35 (s, 3H).

Example 210 4-(3-(Benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2- chlorobenzamide [516] The title Compound was prepared By Following The proeedure descriBed for example 1 using intermediAte 38 (0.150 g, 0.496 mmol), inTermediAte 35 (0.174 g, 0.620 mmol), potassium carBonate (0.228 g, 1.65 mmol), dioxane (3 ml), water (1 ml) and teTraKis(TriphenYLpHospHine)pALlAdium(0) (0.045 g, 0.039 mmol) under mierowAve irrAdiAtion (100W, 100DC) for 30 min. Yellow solid (0.090 g, 43%). M.P.: 238-240DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 9.38 (s, IH), 8.69 (d, J = 8.7 Hz, IH), 8.32 (s, IH), 8.27 (s, IH), 8.25 (d, J = 8.2 Hz, IH), 8.21 (d, J = 8.8 Hz, IH), 8.08 (d, J = 8.4 Hz, IH), 7.97 (s, IH), 7.69 (s, IH), 7.64 (m, 2H), 6.18 (s, 2H).

Example 211 2-(2-Fluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5- yl)phenyl)propan-2-ol [517] THe Title compound was prepared By following the procedure deseriBed For example 1 using intermediAte 14 (0.150 g, 0.507 mmol), inTermediAte 19 (0.177 g, 0.634 mmol), potassium CArBonate (0.233 g, 1.68 mmol), dioxane (3 ml), water (0.6 ml) and tetraKis(TripHenYLpHosphine)pALLAdium(0) (0.047 g, 0.040 mmol). Pale green solid (0.080 g, 38%). M.P.: 85-89QC. Ή-NMR (δ ppm, DMSO-d, 400 MHz ): 9.59 (s, IH), 8.88 (D, J=2.7

Hz, IH), 8.67 (d, J = 8.7 Hz, IH), 8.37 (d, J = 7.7 Hz, IH), 8.15 (m, 4H), 7.83 (m, 2H), 7.53 (dd, J = 8.1,4.0 Hz, IH), 6.21 (s, 2H), 5.38 (s, IH), 1.51 (s, 6H).

Example 212 2-Chloro-5-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide: [518] THe title compound was oBtAined as an off-whiTe solid (0.065 g, 46%) By Following The procedure deseriBed For example 1 using inTermediAte 14 (0.100 g, 0.338 185 222977/2 mmol), intErmediAte 22 (0.118 g, 0.422 mmol), potassium carbonatE (0.155 g, 1.12 mmol), DMF (8 ml), water (0.5 ml) and TeTrAkis(triphenylphosphine)pAllAdium(0) (0.031 g, 0.027 mmol). M.P.: 241-244 DC. Ή-NMR (δ ppm, DMSO-de, 400 MHz): 8.88 (dd, J=4.0,2.6 Hz, 1H), 8.69 (d, J = 8.7 Hz, 1H), 8.36 (d, J = 8.2 Hz, 1H), 8.29 (s, 1H), 8.26 (dd, J = 11.6,1.5 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.03 (m, 3H), 7.83 (dd, J = 8.7,1.6 Hz, 1H), 7.73 (s, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.53 (dd, J = 8.3,4.2 Hz, 1H), 6.22 (s, 2H).

Example 213 3-(2-Chloro-3,6-difluorobenzyl)-5-(1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridine: [519] The title compound was prEpared by following The procedure described For example 1 using intErmediate 16 (0.180 g, 0.571 mmol), tErt-butyl 4-(4,4,5,5-tEtramEthyl-',3,2-dioxAborolAn-2-yl)-'H-pyrAzole-'-CArboxylATE (0.215 g, 0.731 mmol), potassium carbonAte (0.260 g 1.88 mmol), Dioxane (3.5 ml), water (0.8 ml) and

TeTrAkis(triphenylphosphine)pAllAdium(0) (0.052 g, 0.044 mmol). Yellow solid (0.165 g, 83%). Ή-NMR (δ ppm, DMSO-D,, 400 ^Ή):Ο13.22 (s, IH), 8.48 (d, J = 8.7 Hz, 1H), 8.18 (s,1H), 7.82 (d, J = 8.7 Hz, 1H), 7.63-7.51 (m, 2H), 7.45 (dt, J = 9.2,4.2 Hz, 1H), 6.02 (s, 2H).

Example 214 2-Chloro-4-(3-(1-(quinolin-6-yl)ethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide [520] The title compound was prepared by following The procedure described For example 1 using intermediATe 40 (0.450 g, 1.45 mmol), inTermediAte 35 (0.511 g, 1.81 mmol), potassium carbonatE (0.668g, 3.33 mmol), dioxane (5 ml), water (1.5 ml) and TeTrAKis(triphenylphosphine)pAllAdium(0) (0.134 g, 0.116 mmol) under microwave irradiATion (100W, 100DC) for 45 min. OFF-white solid (0.250 g, 40%). M.P.: 140-143DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.87 (dd, J = 3.8,2.7 Hz, 1H), 8.68 (d, J = 8.7 Hz, 1H), 8.39 (d, J = 8.2 Hz, 1H), 8.25 (s, 1H), 8.20 (m, 2H), 8.11 (s, 1H), 8.00 (d, J = 8.9 Hz, 1H), 7.94 (s, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.67 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.53 (dd, J = 8.4,4.2 Hz, 1H), 6.73 (q, J = 6.7 Hz, 1H), 2.25 (d, J = 7.0 Hz, 3H).

Example 215 2-Chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide [521] The Title compound was prepAred by Following the procedure described for example 1 using intermEdiAte 29 (0.150 g, 0.508 mmol), intErmediAte 35 (0.179 g, 0.636 mmol), potassium carbonatE (0.234 g, 1.69 mmol), dioxan (3 ml), water (1 ml) and 186 222977/2 TETrAkis(tripHENylpHosphiNe) pallaDIum(O) (0.047 g, 0.040 mmoI) and in microwave oven (100W, 100QC) for 45 min.. Off-white solid (0.095 g, 45%). M.P.: 212-214DC. Ή-NMR (δ ppm, DMSO-d6, 400 MHz ): 8.87 (DD, J = 4.1,2.8 Hz, 1H), 8.73 (s, 1H), 8.35 (D, J = 8.5 Hz, 1H), 8.20 (s, 1H), 8.18 (d, J = 7.6 Hz, 1H), 8.13 (d, J = 8.1 Hz, 1H), 8.01 (m, 3H), 7.90 (s, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.62(s, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.53 (dd, J = 8.6, 4.5 Hz, 1H), 5.78 (s, 2H).

Example 216 1-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone oxime [522] To a solution of Example 208 (0.060 g, 0.197 mmoL) In ethanol (1.3 mL), sodium aceTaTe (0.016 g, 0.197 mmol) and hydroxyiaMinE hydrochloride (0.013 g, 0.197 mmol) were added and sTirreD at RT For 12h. THe reaction mixture was concENtrateD and the residue was washed with BIcarBonate solution, dlchLoroMEthane and dried under vacuum to afford The Title compound as a ca. 9:1 mixture of Two isomers. Off-white solid (0.030 g, 48%). M.P.: 259-261 DC. Ή-NMR (δ ppm, DMSO-d,400 MHz ): 11.95( s, 0.9H), 11.28 (s,0.1H), 8.88 (D, J = 2.6 Hz, 1H), 8.74 (D, J = 8.8 Hz, 0.1H), 8.61 (D, J = 8.4 Hz, 0.1H), 8.52 (d, J = 8.8 Hz, 0.9H), 8.36 (d, J = 8.4 Hz, 0.9H), 8.00 (m, 3H), 7.81 (dd, J = 8.4, 1.6 Hz, 1H), 7.53 (dd, J = 8.3,4.1 Hz, 1H), 6.24( s, 0.2H), 6.15 (s, 1.8H), 2.74( s,0.3H), 2.30 (s, 2.7H).

Example 217 1-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethanone O-methyl oxime [523] The Title compound was prepared as a ca. 9.5:0.5 mixture of two Isomets By using a procedure similar to the one descriBed for example 216 From example 208 (0.070 g, 0.230 mmol), ethanol (1.5 ml), sodium aceTaTe (0.018 g, 0.230 mmol) and MeTHoxylamiNE hydrochloride (0.019 g, 0.230 mmoi). Off-white solid (0.020 g, 26%). M.P.: 155-157DC. 1H-NMR (δ ppm, DMSO-De, 400 MHz ): 8.88 (D, J = 2.6 Hz, 1H), 8.61 (D, J = 8.8 Hz, 0.05H), 8.55 (d, J = 8.8 Hz, 0.95H), 8.36 (d, J = 8.4 Hz, 1H), 8.02 (μ, 3H), 7.81 (dd, J = 8.8,1.7 Hz, 1H), 7.53 (dd, J = 8.3,4.2 Hz, 1H), 6.16 (s, 2H), 4.01 (s, 2.85H), 3.79 (s, 0.15H), 2.32 (s, 2.85H), 2.24 (s, 0.15H).

Example 218 N'-(1-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene) acetohydrazide [524] To a solution of example 208 (0.070 g, 0.230 mmol) in eTHanol (1.3 ml), acetyl hydrazide (0.017 g, 0.230 mmoi) was added refluxed for 4h. The reaction mixture was 187 222977/2 coneenTrated and the residue was washed with water, ethyl acetate and Dried under vacuum to afford the TiTle compound as a ea. 1:1 mixTure of Two isomers. Pale yellow solid (0.035 g, 42%). M.P.: 249-251 DC. Ή-NMR (δ ppm, DMSO-D, 400 MHz ): 10.79 (s, 0.5 H), 10.76 (s, 0.5H), 8.89 (d, J = 2.9 Hz, IH), 8.66 (d, J = 8.7 Hz, 0.5H), 8.55 (d, J = 8.8 Hz, 0.5H), 8.37 (m, 1.5H), 8.20 (d, J = 9.0 Hz, 0.5H), 8.01 (m, 2H), 7.84 (dt, J = 9.0, 1.8 Hz, IH), 7.54 (dd, J = 8.3,4.2 Hz, IH), 6.20 ( s, IH), 6.16 (s,1H), 2.39 (s, 3H), 2.29 (s, 3H).

Example 219 6-((5-(4-Methylpiperazin-1-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline: [525] The TiTle compound was prepared by following The proeedure described for example 152 using intermediate 14 (0.150 g, 0.507 mmol), N-meThyl piperazine (0.076 g, 0.760 mmol), cesium Fluoride (0.154 g, 1.01 mmol) and DMF (4.5 ml). Brown solid (0.023 g, 13%). M.P.: 131-1330C. Ή-NMR (δ ppm, DMSO-D,400 MHz): 8.87 (D, J = 2.6 Hz, IH), 8.35 (d, J = 8.1 Hz, IH), 8.15 (d, J = 9.3 Hz, IH), 7.99 (d, J = 8.6 Hz, IH), 7.93 (s, IH), 7.74 (d, J = 8.5 Hz, IH), 7.53 (dd , J = 8.0,4.0 Hz, IH), 7.05 (d, J = 9.4 Hz, IH), 5.89 (s, 2H), 3.68 (br. s, 4H), 2.42 (br.s, 4H), 2.22 (s, 3H).

Example 220 N'-(1-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)ethylidene)iso- nicotinohydrazide [526] To a solution of example 208 (0.065 g, 0.214 mmol) in eThanol (1.5 ml), isonicoTinie hydrazide (0.050 g, 0.428 mmol) was added reFluxed For 12h. The reaction mixture was concenTrated and The residue was washed with water, ethyl aeetate and Dried under vacuum To afford the TiTle compound as a single isomer and as a pale yellow solid (0.070 g, 77%). M.P.: 239-241 DC. Ή-NMR (δ ppm, DMSO-D,400 MHz ): 11.24 (s, IH), 8.88 (dd, J = 4.1, 2.5 Hz, IH), 8.77 (s, 2H), 8.60 (br s, IH), 8.37 (d, J = 8.0 Hz, 2H), 8.02 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 7.1 Hz, 2H), 7.71 (m, IH), 7.54 (dd, J = 8.3,4.2 Hz, IH), 6.18 (s, 2H), 2.55 (s, 3H).

Example 221 (-)-2-chloro-4-(3-(1-(quinolin-6-yl)ethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide [527] The isomer was obtained Through preparative SFC separation of The racemic compound i.e. (±)-2-eh1oro-4-(3-(1-(quiNohN-6-y1)ethy1)-3H-[1,2,3]Triazo1o[4,5-b]pyridiN-5-y1)beNzamide (0.24g) on a CHIRALPAK IA column (250 x 30 mm; 5μ) using ethano1:CO2 (35 : 65) as the mobile phase at a flow rate of 70 g/min. Off-white solid (0.095 g). e.e. 188 2229772 96.84%. Rt: 4.27 min (CHIRALPAK IA column (250 x 4.6 mm; 5μ) using ethanol: CO2 (40:60) as the mobile phase at a Flow rate of 3.0 ml/min.). MP: 202-203 0C. : -427.30 (c = 1, CHC13). 'H-NMR (δ ppm, CDC13 + DMSO-c/,. 400 MHz): 8.88 (d, J = 3.2 Hz, IH), 8.43 (d, J = 8.6 Hz, IH), 8.15 (d, J = 6.1 Hz, IH), 8.14 (s, IH), 8.07 (d, J = 8.7 Hz, IH), 8.00 (d, J = 8.4 Hz, IH), 7.98 (s, IH), 7.91 (m, 2H), 7.79 (d, J = 8.6 Hz, IH), 7.40 (dd, J = 8.2,4.2 Hz, IH), 6.62 (q, J = 6.9 Hz, IH), 6.54 (s, IH), 6.12 (s, IH), 2.34 (d, J = 7.1 Hz, 3H).

Example 222 (+)-2-chloro-4-(3-(1-(quinolin-6-yl)ethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide [528] The isomers was obtained Through preparative SFC separatioN of the racemic compound i.e. (±)-2-cH1oro-4-(3-(1-(quino1in-6-y1)eThy1)-3H-[1,2,3]Triazo1o[4,5-b]pyridiN-5-y1)beNzamide (0.24g) on a CHIRALPAK IA column (250 x 30 mm; 5μ) using eThano1:CO2 (35 : 65) as the mobile phase at a flow rate of 70g/miN. OFF-white solid (0.035 g). e.e. 96.21%. Rt: 4.82 min (CHIRALPAK IA column (250 x 4.6 mm; 5μ) using eTHano1:CO2 (40 : 60) as tHe mobile phase at a Flow rate of 3.0 ml/min.). MP: 200-202OC. 'H-NMR (δ ppm, CDC13, 400 MHz ): 8.90 (D, J = 2.8 Hz, IH), 8.46 (D, J = 8.6 Hz, IH), 8.16 (m, 2H), 8.10 (d, J = 8.7 Hz, IH), 8.13-7.95 (m, 3H), 7.92 (d, J = 7.1 Hz, IH), 7.81 (d, J = 8.7 Hz, IH), 7.42 (dd, J = 8.2,4.2 Hz, IH), 6.64 (q, J = 7.0 Hz, IH), 6.43 (s, IH), 5.87 (s, IH), 2.36 (d, J = 7.2 Hz, 3H).

Example 223 4-(3-(Quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2- (trifluoromethyl)benzamide: [529] The title compound was prepared by following The procedure described For example 1 using inteTmediate 14 (0.200 g, 0.676 mmol), Intermediate 42 (0.277 g, 0.879 mmol), potassium carBonate (0.311 g, 2.25 mmol), dioxane (4 ml), water (2 ml) and TeTrakis(trIpheNy1phosphme)pa11adIum(0) (0.062 g, 0.054 mmol) In a microwave oven (100W, 100DC) For 45 min. Brown solid (0.035 g, 12%). M.P.: 230-232 DC. 'H-NMR (δ ppm, DMSO-d6, 400 MHz): 8.88 (d, J = 2.9 Hz, IH), 8.73 (d, J = 8.7 Hz, IH), 8.55 (d, J = 5.5 Hz, IH), 8.52 (s, IH), 8.35 (d, J = 8.1 Hz, IH), 8.28 (d, J = 8.8 Hz, IH), 8.05 (m, 3H), 7.84 (dd, J = 10.2, 1.4 Hz, IH), 7.72 (d, J = 8.6 Hz, IH), 7.70 (s, IH), 7.54 (dd, J = 8.3, 4.3 Hz, IH), 6.24 (s, 2H). 189 222977/2

Example 224 6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide: [530] To A solution of Example 108 (0.100 g, 0.241 mmol) in Acetone (0.6 ml), oxone (0.74 g, 1.20 mmoI) in water (2 ml) was Added And Heated under reflux For 20H. THe mixture was diluted witH Aqueous 10% sodium BicarBonATe solution And extrActed witH dicHloromeTHANE, THe organic layer dried over AnHydrous sodium sulpHATe And coNCENtrAted. THe crude product was purified By column cHromAtogrApHy witH MEtHANo1:dicH1oroMEtHANE to Afford THe title compound (0.030 g, 29%) As A pale Brown solid. M.P.: 182-183OC. 1H-NMR (δ ppm, DMSO-de, 400 MHz): 8.71 (D, J = 8.8 Hz, IH), 8.55 (d, J = 6.1 Hz, IH), 8.52 (d, J = 9.1 Hz, IH), 8.29 (s, IH), 8.23 (μ, 2H), 8.12 (s, IH), 7.95-7.83 (m, 3H), 7.67 (s, IH), 7.61 (d, J = 7.9 Hz, IH), 7.47 (dd, J = 8.4,6.2 Hz, IH), 6.24 (s, 2H).

Example 225 2-chloro-N-ethyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride [531] Ether saturated with HCI (1 ml) was added at OCC to a solution of example 119 (0.020g. 0.045 mmol) in THF (1 ml), And stirred for 15 min. THe precipitATe formed was Filtered, wAsHed witH etHer And Dried under vacuum To Afford tHe title compound As An off-wHite solid (0.012 g, 56%). M.P.: 151-153oC.

Example 226 6-((5-(4-carbamoyl-3-chlorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide [532] To A solution of Example 119 (0.060 g, 0.135 mmol) in dicHloromEtHANE (1 m1), 3-cHloropErBEnzoic Acid (0.46 g, 0.270 mmoI) was Added And stirred At RT For 12H. THe Mixture was diluted witH water, extrActed witH dlcHloromeTHAne, tHe organic layer dried over sodium sulpHAte And concentrATed. THe crude product was purified By column cHromAtogrApHy witH metHanol: dicHloromeTHANE As tHe eluent To Afford tHe title compound As A grey solid. (0.016 g, 26%). M.P.: 212-215oC. Ή-NMR (δ ppm, DMSO-ds, 400 MHz ): 8.71 (d, J = 8.8 Hz, IH), 8.68 (d, J = 9.1 Hz, IH), 8.56 (m,2H), 8.30 (d, J = 1.5 Hz, IH), 8.24 (m, 2H), 8.12 (s, IH), 7.93 (d, J = 8.6 Hz, IH), 7.86 (dd, J = 9.1,1.8 Hz, IH), 7.57 (d, J = 8.0 Hz, IH), 7.48 (dd, J = 8.4,6.0 Hz, IH), 6.20 ( s, 2H), 3.28 (m, 2H), 1.14 (T, J = 7.3 Hz, 3H). 190 222977/2

Example 227 6-((5-(1H-pyrazol-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline

[533] THe TiTle compound was prepared By following the proceCure DescriBeC For example 1 using inTermEdiAte 14 (0.100 g, 0.338 mmol), TErT-BuTyl 3-meTHyl-4-(4,4,5,5-TeTrAmETHyL-1,3,2-dioxABorolAn-2-yl)-1H-pyrAzoLe-1-CArBoxylATe (0.088 g, 0.422 mmol), potassium carBonaTe (0.155 g, 1.12 mmol), DMF (2 ml), water (0.5 ml) anD TeTrAkis(TripHenylpHospHine) pAllACium(O) (0.031 g, 0.027 mmol) under microwave IrrACiAtion (100W, 100 □ C) for 45 min. Brown solid (0.025g, 23%). M.P.: 215-218 DC. 1H-NMR (δ ppm, DMSO-cf, 400 MHz): 12.94 (s, IH), 8.88 (DD, J=4.1, 1.5 Hz, IH), 8.47 (d, J = 8.7 Hz, IH), 8.36 (C, J = 7.7 Hz, IH), 8.13 (s, IH), 8.00 (C, J = 7.9 Hz, IH), 8.00 (s, IH), 7.79 (m, 2H), 7.53 (CC, J = 8.3,4.2Hz, IH), 6.11 (s, 2H), 2.56 (s, 3H).

BIOLOGICAL ASSAY

[534] The pHarmACologicAl properTies of THe compounds of This invEnTion may Be confirmeC By a numBer of pharmACologicAl assays. THe phArmACologicAl assays which can Be Been carried out with The compounds According To The invEnTion anD/or Their pHArmAceuticAlly accepTaBLe salts are EXEmplifieD Below. 1. MET Kinase Assay Protocol:

Colorimetric determination of c-Met Kinase activity [535] THe receptor Tyrosine kinase c-MeT is a HetErodimeric TrAnsmemBrAne glycoproTein involveC in several cellular processes that aIC in Tumor progression. PhospHorylATion of THe Tyrosine residues in The c-MeT kinase Domain is criticAl for its Activity and THe resulting down-streAm Effects. The colorimetric assay allows detECtion of The phosphorylATeC form of a BioTinylATEC peptiCe upon AcTivATion of human rEComBinAnt Met kinase. MET Kinase Assay Protocol:

[536] c-MeT Kinase Activity shall Be CetermineC using an HTScan® MeT Kinase Assay KiT (Cell SignAlling Technology, Beverly, MA) with moCificATions. ALL incuBATions are carriEd out at room TempErAture. Briefly, 12.5 μΐ of a 4X reaction cocktail (DTT/KInase Buffer conTAining Appropriate quAntity of Human MeT kinase) is aCCeC To each well of a 96-well plate conTAining 12.5 μΐ pre-diluTEC compound of InTEresT anD IncuBated For 5 minutes. After THe initial IncuBATion, 25 μΐ/well of 2X ATP/BiotinylAted peptiCe Is added and incuBAteC 191 2229772 for an additional 30 minutes. The reaction is terminated by the addition of 50 μΐ/well stop buffer (50 mM EDTA, pH 8.0). The reaction mixture (25 μΐ/well) is then transferred to a streptavidin coated plate (Perkin Elmer, Cat# 4009-0010) containing 75 μΐ dH2O and incubated for 60 minutes. The plate is washed with 200 μΐ/well wash buffer (IX PBS, 0.05% Tween-20). After washing, 100 μΐ/well phospho-tyrosine mAh (1:1000 in wash buffer containing 1% BSA) is added and incubated for 60 minutes. After another round of washes, 100 μΐ/well europium labelled anti-mouse IgG (1:500 in wash buffer containing 1% BSA) is added and incubated for an additional 30 minutes. Following additional washes, 100 μΐ/well Delfia® enhancement solution (Perkin Elmer, Cat#1244-105) is added and incubated for 45 minutes. Florescence is measured on a microplate reader (BMG Labtech., Germany) at 340 nm (excitation) and 615 nm (emission) for calculating % inhibition. Data generated can be analyzed further using Graphpad Prism (Graphpad software, San Diego CA) for determination of IC50.

[537] Results: The results are as given below in Table 2 as % Inhibition of c-Met at ΙμΜ.

Table 2

Cpd. Inhibition IC50 Cpd Inhibition IC50Ex 2 A +++ Ex 52 A ++++I :x6 A +++ Ex 108 A ++++ Ex 8 A +++ Ex 119 A ++++ Ex 9 A +++ Ex 130 A ++++ Ex 13 A +++ Ex 134 A ++++ Ex 14 A ++ Ex 137 A ++++ Ex 15 A +++ Ex 221 A +++ Ex 16 A +++ Ex 222 B + Ex 21 B + A= &gt;75 to 100 and B = &gt;50-&lt;75%; ++++= &lt; 50 nm; +++ = &gt;50to&lt;100nM; ++ =&gt;100-&lt;250 and += &gt;251 -&lt;1000 nM.

[538] Inhibition of MKN-45 proliferation: Cell proliferation assays were carried out using the high Met expressing human gastric adenocarcinoma cell line, MKN-45, according to the following schedule: [539] Day 1: Cells were plated in 96-well plates in complete growth medium. 192 222977/2 [540] Day 2: Compounds at desired concentrations were added.

[541] Day 5: Cell viability was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) dye reduction test.

[542] Results: The results are as given below as % Inhibition of MKN-45 proliferation at 1 μΜ in Table 3, at 0.1 μΜ in Table 3A and as GI50 values in Table 4.

Table 3: % inhibition Cpd. @ 1 uM Cpd. @ 1 uM Cpd. @ 1 uM Cpd. @ 1 uM Exl C Ex70 D Ex97 C Exl41 A Exl8 D Ex71 C Ex98 B Exl47 D Exl9 D Ex73 B Ex99 B Exl48 D Ex22 D Ex74 B Exl02 A Exl50 D Ex23 D Ex75 D Exl04 A Exl51 B Ex24 D Ex76 B Exl05 D Exl67 C Ex25 D Ex77 B Exl06 A Exl80 C Ex 47 B Ex78 B ExllO B Exl81 A Ex48 A Ex79 B Belli A Exl82 C Ex49 C Ex80 C Exll4 B Exl84 D Ex51 D Ex81 A Exll5 A Exl85 D Ex56 D Ex84 D Exll6 A Exl86 D Ex58 D Ex85 A Exll7 A Exl90 D Ex59 B Ex86 A Exll8 A Exl91 C Ex60 D Ex87 D Exl20 C Exl92 D Ex61 A Ex88 D Exl21 D Exl93 B Ex62 A Ex89 D Exl22 D Exl94 B Ex63 B Ex90 A Exl24 B Exl95 B Ex64 C Ex91 B Exl25 D Exl96 D Ex65 D Ex92 D Exl27 A Ex212 C Ex66 C Ex93 C Exl37 B Ex225 B Ex67 1383 Ex94 D Ex 138 A Ex226 D Ex68 D Ex95 B Exl39 D Ex227 D Ex69 D Ex96 D Exl40 A D = &lt; 25 %, C=&gt;25&lt;50%,B = &gt;50-&lt;75%, A= &gt;75 to 100 %

Table 3A Cpd Inhibition Cpd Inhibition Cpd Ini ibition Bc47 D Ex95 D Exl82 DEx 48 D Ex96 D Exl83 DEx 49 D Ex97 C Exl84 DEx 51 D Ex98 C Exl85 DEx 52 D Ex99 B Exl86 D 193 222977/2

Ex67 D

69 D

71 D

73 A

75 D

77 B

79 D

81 B

85 D

87 A

89 A

91 C

Exll4 Exll6 Exll8 Ex 120 Ex 12

Exl41

Cpd Ex 2 Ex 4 Ex 6 Ex 8 Ex 9 Ex II

Ex55 D Exl02 B Exl87 AEx5( D Exl03 D Ex 188 AEx5i D Exl04 B Ex 190 DEx5( D Exl05 D Ex 191 CEx6( D Exl06 D Ex 192 DEx6: A Exl07 D Ex 193 DEx61 A Exl08 B Ex 194 DEx6; D Exl09 A Ex 195 CEx64 D ExllO B Exl96 DEx65 D Exlll D Exl9' CEx66 D Exl 13 A Exl98 D B Exl99 )Ex68 D Exl 15 D Ex200 D Ex2U I JEx/0 D Ex I 17 B Ex20 2 E) EX203 1 jEx7 2 D -ΕΠ T9—Ά— EX 21 2 A Ex 2 0 ϋ $Ex74 B -Erl Tl—A— EX207 T?,r O 1 A ΙΓ,-ΤΟ D 1 ΤΛ 1 u T?,r O 1 C Λ ΊΡνβΠ ΤΊ Iv 1 97 Λ Cv7 1 Ί A Fx218 1Εχ8 4 D Ex 1 33 A Ex219 B Ex 2 20 )Ex86 D Ex 35 D Ex 221 A Ex222 2Ex88 D Exl 38 C Ex223 B Ex224 &lt; 2Ex90 B Exl 40 A Ex225 A Ex226 ) Ex92 b txl42 A tx227 d tx93 C 1x180 D Ex 9 4 β txl81 b D = &lt;2i %,c=&gt;: 5-&lt;50%,l } = &gt;50-&lt;i 5%, A=&gt; 75 to 100% Tai Ic4 GI 5( (nM) IC 5 &gt; (nM) Cnd GI 50(n d) IC 50 0 T. Pvinx A 3 Εύ lln \ Λ Ea 130 A I B' B'

Ex 133

Ex 134 Ex 137 DEx DEx AEx AEx AEx DEx BEx DEx BEx AEx AEx iM) 1! »4 2229772

Ex 15 B B' Ex 142 B - Ex 16 A A' Ex 143 B -Ex 21 C -Ex 144 B -Ex 22 E - Ex 146 B B' Ex 26 D -Ex 152 C -Ex 27 B Ex 157 D -Ex 28 C Ex 164 B B'Ex30 C Ex 168 C -Ex31 C Ex 169 D -Ex 32 D Ex 170 D -Ex33 C Ex 171 C -Ex34 D Ex 172 D -Ex35 B Ex 173 D -Ex 36 B Ex 175 C -Ex 37 A Ex 176 D -Ex 38 D Exl77 D -Ex 39 B -Ex 179 C -Ex 40 D Ex 187 A -Ex41 B Ex 188 B -Ex43 A B' Ex 207 A -Ex 44 B Ex 209 A -Ex45 B Ex 210 A -Ex 46 A B' Ex 211 C -Ex 52 A A' Ex 214 A -Ex55 B - Ex 221 A -Ex61 A - Ex222 C -Ex62 A -- A = A'=&lt;! &gt;0; B =B'= &gt; &gt;0 to &lt;150 ;U II V 8 ιλ _8 0;D = &gt;500 -&lt;1000 &amp;amp; E = &gt; 100l J in nivi [543] Inhibition of c-Met kinase phosphorylation in MKN-45 cells: MKN45 cells are a prototype of "c-Met addicted" cells having constitutively activated c-Met kinase similar to that observed in sub-sects of gastric or hepatocellular cancer patients with dysregulated c-Met kinase activity. Inhibition of Met phosphorylation was determined using a cell based ELISA assay according to the following schedule: [544] Day 1: MKN-45 cells were plated in 96-well plates in complete growth medium.

[545] Day 2: Inhibitors at the desired concentration were added to the plates and incubated for 1 h and lysed subsequently. 195 22297112 [546] Lysates were transferred to NUNC Maxisorp plates coated with anti-cMet receptor antibody. Phopho-tyrosine mAh and HRP-lined anti-mouse IgG were used as primary and secondary antibodies respectively. Optical density was measured on a microplate reader (BMG Labtech., Germany) at 450 nM. Inhibition of c-Met phosphorylation in this cell line indicates a therapeutic potential for test compounds in patients diagnosed with cancers caused by aberrant c-Met kinase signalling.

[547] Results: The results are provided above in Table 4 as IC50 values.

[548] Inhibition of c-Met kinase phosphorylation in NCI-H441 cells:. Inhibition of Met phosphorylation was determined using a cell based ELISA assay according to the following schedule: [549] Day 1: NCI-H441 cells were plated in 96-well plates in complete growth medium.

[550] Day 2: Inhibitors at the desired concentration were added to the plates, incubated for 1 h and lysed subsequently. Lysates were transferred to NUNC Maxisorp plates coated with anti-cMet receptor antibody. Phopho-tyrosine mAh and HRP-lined anti-mouse IgG were used as primary and secondary antibodies respectively. Optical density was measured on a microplate reader (BMG Labtech., Germany) at 450 nM. The compounds potently inhibited c-Met kinase phosphorylation in NCI-H441, a non-small cell lung cancer derived cell line indicating a therapeutic potential in lung cancer patients with mutant kras.

[551] Results: The results are given below in Table 5 as IC50 values.

Table 5 Cpd IC50 Ex 146 +++ Ex 14 ++ ++ Ex 15 +++++ Ex 52 + Ex 108 Ex 119 Ex 139 Ex 134 Ex 137 + = &lt;10; ++'= &gt; 10 to &lt;50 +++ = &gt;50-&lt;100 in nM 196 2225772 [552] Inhibition of Akt phosphorylation in MKN-45 or NCI-H441 cells: Akt is a serine-threonine kinase and a downstream marker regulated by c-Met kinase via the PI3K pathway. Once phosphorylated, Akt regulates several end processes including cell survival and growth. Cells were treated with 0 -1000 nM of test compounds, lysed, and the proteins separated on a 10% SDS-PAGE. Following separation, proteins were transferred onto a nitrocellulose membrane and detected by chemiluminescence after incubation with pAkt S473 mAb (primary) and rabbit anti-mouse Ab (secondary). Intensity of the bands was determined using Image J 1.42q (NIH, USA) and normalized to Actin (loading control). Results: The results are provided below as IC50 values in Table 6.

Table 6 AKT PHOSPHORYLATION Cpd MKN-45 (IC50-nM) NCI-H441 (IC50-nM) Ex 146 - B Ex 15 D A Ex 52 C A Ex 108 A A Ex 119 A A Ex 130 C B Ex 134 A A A = &lt; 25; B = &gt; 25 to &lt;50 ,C = &gt;50-&lt;100, D= &gt;100-&lt;200in nM, [553] 6. Induction of apoptosis in MKN-45 cells: Induction of Caspase 3 was measured fluorimetrically. Cells were incubated with desired concentrations of the compound for 24 h. After incubation, cells were harvested and counted. An equal number of viable cells per well (0.3 x 106 cells) were used for determination of caspase-3 activity. Increase in apoptosis manifested by an elevation in caspase-3 levels was determined using a Caspase-3 kit from Millipore. Data are expressed as a percent of the maximum response (100%). Compounds of the invention dose-dependently induced apoptosis in MKN-45 cells manifested by an increase in caspase-3 activity.

[554] Results: The results are provided below as percentage induction @ 3 μΜ in Table 7.

Table 7 Cpd Apoptosis in MKN-45 cells) Ex 15 A Ex 52 A Ex 108 A 197 22257712

Ex 119 AEx 130 BEx 134 A B = &lt;50, A=&gt;50to100% [555] 7. Inhibition of HGF-induced Met phosphorylation in MDA-MB-231 cells: MDA-MB-231 is a breast cancer cell line having a high level of c-Met expression. Activation of Met kinase in these cells occurs only after the addition of its natural ligand, Hepatocyte Growth Factor (HGF). Upon binding to the extracellular domain of the enzyme, it triggers phosphorylation of tyrosine residues and regulates several downstream events such as cell proliferation. Cell proliferation assays were carried out using the high Met expressing cell line (MDA-MB-231) according to the following schedule: [556] Day 1: Cells were plated in 96-well plates in complete growth medium.

[557] Day 2: Media was replaced with starvation medium containing 0.04% BSA.

[558] Day 3: Inhibitors at the desired concentrations and HGF (50 ng/ml) were added.

[559] Day 5: Cell viability was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) dye reduction test.

[560] The compounds of the present invention tested potently inhibited HGF-induced Met phosphorylation in MDA-MB-231 cells thereby implicating their role in the modulation of the HGF/Met axis in breast cancer.

[561] Results: The results are provided below in Table 8 as IC50 values.

Table 8 Cpd HGF stimulated Met phosphorylation Ex 15 ++++ Ex 108 ++ Ex 119 = &lt; 10; ++ = &gt; 10 to &lt;50 nM Ex 130 Ex 134 [562] Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the 198 principles and applicatioNS of tHe present inveNtioN. It is THerefore to Be unDerstooD tHat numerous MoDiFicAtioNS may Be made to tHe illustrAtivE EMBoDiMents and tHat otHer arraNgeMENts may Be Devised witHout DepartiNg from tHe spirit and scope of tHe present inveNtioN as DescriBeD aBove and tHe cIaims. 222977/3 199